WO2003004027A1 - Substituted anilinic piperidines as mch selective antagonists - Google Patents

Substituted anilinic piperidines as mch selective antagonists Download PDF

Info

Publication number
WO2003004027A1
WO2003004027A1 PCT/US2002/021063 US0221063W WO03004027A1 WO 2003004027 A1 WO2003004027 A1 WO 2003004027A1 US 0221063 W US0221063 W US 0221063W WO 03004027 A1 WO03004027 A1 WO 03004027A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
phenyl
branched
alkyl
mmol
Prior art date
Application number
PCT/US2002/021063
Other languages
French (fr)
Inventor
Mohammad R. Marzabadi
John Wetzel
John E. Deleon
Yu Jiang
Chien-An Chen
Kai Lu
Bharat Lagu
Original Assignee
Synaptic Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA2004010518A priority Critical patent/UA75416C2/en
Priority to MXPA03011886A priority patent/MXPA03011886A/en
Priority to IL15969702A priority patent/IL159697A0/en
Priority to CA002454613A priority patent/CA2454613A1/en
Priority to BR0210869-0A priority patent/BR0210869A/en
Priority to AU2002316531A priority patent/AU2002316531B8/en
Priority to HU0401880A priority patent/HUP0401880A2/en
Priority to JP2003510038A priority patent/JP2004536104A/en
Priority to EP02746843A priority patent/EP1411942A4/en
Priority to KR10-2004-7000087A priority patent/KR20040027870A/en
Priority to NZ530221A priority patent/NZ530221A/en
Application filed by Synaptic Pharmaceutical Corporation filed Critical Synaptic Pharmaceutical Corporation
Priority to EA200400146A priority patent/EA005934B1/en
Priority to US10/345,063 priority patent/US7105544B2/en
Publication of WO2003004027A1 publication Critical patent/WO2003004027A1/en
Priority to IS7085A priority patent/IS7085A/en
Priority to NO20040028A priority patent/NO20040028L/en
Priority to US10/753,057 priority patent/US7199135B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • MCH Melanin-concentrating hormone
  • MCH (teleost fish) pituitaries (Kawauchi et al . , 1983). In fish the 17 amino acid peptide causes aggregation of melanin within the melanophores and inhibits the release of ACTH, acting as a functional antagonist of ⁇ -MSH.
  • Mammalian MCH (19 amino acids) is highly conserved between rat, mouse, and human, exhibiting 100% amino acid identity, but its physiological roles are less clear. MCH has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders (for reviews, see Baker, 1991; Baker, 1994; Nahon, 1994; Knigge et al . , 1996).
  • MCH is overexpressed in the hypothalamus of oh/oh mice compared with ob/+ mice, and that fasting further increased MCH mR ⁇ A in both obese and normal mice during fasting.
  • MCH also stimulated feeding in normal rats when injected into the lateral ventricles (Rossi et al . , 1997) .
  • MCH also has been reported to functionally antagonize the behavioral effects of ⁇ -MSH (Miller et al., 1993; Gonzalez et al, 1996; Sanchez et al .
  • MCH may serve as an integrative neuropeptide involved in the reaction to stress, as well as in the regulation of feeding and sexual activity (Baker, 1991; Knigge et al . , 1996) .
  • the ligand retained biological activity and exhibited specific binding to a variety of cell lines including mouse melanoma (B16-F1, G4F, and G4F-7) , PC12, and COS cells.
  • mouse melanoma B16-F1, G4F, and G4F-7)
  • PC12 PC12
  • COS cells C12
  • MCH methylcellulose
  • lateral hypothalamus a brain area implicated in the regulation of thirst and hunger
  • orexins A and B which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus (Sakurai et al . , 1998).
  • MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation (Herve and Fellman, 1997) ; after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA
  • MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis) (Ludwig et al . , 1998). Together these data suggest a role for endogenous MCH in the regulation of energy balance and response to stress, and provide a rationale for the development of specific compounds acting at MCH receptors for use in the treatment of obesity and stress-related disorders.
  • the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers (Bittencourt et al . , 1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it may be of some value to consider the involvement of this MCH system in movement disorders, such as Parkinson's disease and Huntingdon's Chorea in which extrapyr midal circuits are known to be involved.
  • the MCH gene may represent a good candidate for
  • MCH may regulate reproductive functions in male and female rats.
  • MCH transcripts and MCH peptide were found within germ cells in -testes of adult rats, suggesting that MCH may participate in stem cell renewal and/or differentiation of early spermatocytes (Hervieu et al . , 1996) .
  • MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual activity in female rats (Gonzalez et al . , 1996) .
  • MCH stimulated luteinizing hormone
  • anti- MCH antiserum inhibited LH release (Gonzalez et al . , 1997) .
  • the zona incerta which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the pre-ovulatory LH surge (MacKenzie et al . , 1984).
  • MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin.
  • MCH analogues may also be useful, in treating epilepsy.
  • MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats (McBride et al . , 1994), raising the possibility that MCH receptor antagonists may be beneficial for memory storage, and/or retention. A possible role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. Finally, MCH may participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume (Parkes, 1996) .
  • MCH may be an important peptide involved in the central control of fluid homeostasis in mammals.
  • MCH-1 G-protein coupled receptor
  • MCH-1 knockout mice Two groups have shown independently (Marsh et al, 2002; Chen et al, 2002) that the targeted disruption of the MCH-1 receptor gene (MCH-1 knockout) in mice results in animals that are hyperphagic but are lean and have decreased body mass relative to wild-type littermates. The decrease in body mass is attributed to an increase in metabolism. Each group demonstrated that the MCH-1 knockout mice are resistant to diet-induced obesity, and generally exhibit weights similar to. littermates maintained on regular chow.
  • MCHl antagonists are useful to treat obesity, depression, anxiety, as well as urinary disorders .
  • the term "antagonist” refers to a compound which binds to, and decreases the activity of, a receptor in the presence of an agonist.
  • activation may be measured using any appropriate second messenger system which is coupled to the receptor in a cell or tissue in which the receptor is expressed.
  • second messenger systems are adenylate cyclase, intracellular calcium mobilization, ion channel activation, guanylate cyclase and inositol phospholipid hydrolysis.
  • the term "agonist” refers to a compound which binds to, and increases activity of, a receptor as compared • with the activity of the receptor in the absence of any agonist.
  • MCHl human melanin-concentrating hormone-1
  • the synthesis of novel compounds which bind selectively to the cloned human melanin-concentrating hormone-1 (MCHl) receptor, compared to other cloned G-protein coupled receptors, and inhibit the activation of the cloned receptors as measured in in vi tro assays is disclosed.
  • the in vi tro receptor binding assays described hereinafter were performed using various cultured cell lines, each transfected with and expressing only a single cloned receptor.
  • the compounds of the present invention may also be used to treat abnormal conditions such as feeding disorders (obesity, bulimia and bulimia nervosa) , sexual/reproductive disorders, depression, anxiety, depression and anxiety, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, sleep disturbances, or any condition in which antagonism of an MCHl receptor may be beneficial.
  • feeding disorders ovalbumina, bulimia and bulimia nervosa
  • sexual/reproductive disorders depression, anxiety, depression and anxiety
  • epileptic seizure hypertension
  • cerebral hemorrhage congestive heart failure
  • sleep disturbances sleep disturbances
  • the compounds of the present invention may be used to reduce the body mass of a subject.
  • the compounds of the present invention may be used to treat urinary disorders .
  • This invention provides a compound having the structure:
  • Ri is hydrogen, straight chained or branched
  • R is straight-chained or branched C 3 -C 4 alkyl or cyclopropyl ;
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , straight chained or branched C -C alkyl;
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , -C0R 3 , -C0 2 R 3 , straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • X is O or NH
  • R is aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -COR 2 ,
  • R 3 is phenyl
  • A is H
  • R 2 is isopropyl
  • the compound has the structure:
  • compound has the structure:
  • Ri is hydrogen, straight chained or branched C ⁇ -C 7 alkyl; and wherein R 3 is aryl.
  • R 2 is isopropyl; and A is hydrogen.
  • the compound has the structure
  • the compound has the structure:
  • the present invention also provides a compound having the structure :
  • Ri is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -OCH 3 , phenoxy, fused cyclopentanyl, straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • R 2 is straight-chained or branched C ⁇ -C 4 alkyl or cyclopropyl; wherein A is -H, -F, -Cl, - Br, -CN, -N0 2 , straight chained or branched C ⁇ -C- 7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
  • n is an integer from 1 to 5 inclusive.
  • Ri is aryl optionally substituted with one or more -F, -Cl, -Br, -I or straight chained or branched C ⁇ -C 4 alkyl;
  • R 2 is isopropyl
  • n 2
  • the compound has the structure:
  • the compound has the structure
  • the compound has the structure:
  • Ri is thienyl; and wherein A is H.
  • R 2 is isopropyl
  • the compound has the structure:
  • the invention provides a compound having the structure:
  • each R is independently hydrogen, methyl or ethyl ; wherein R 2 is straight- chained or branched C 3 -C 4 alkyl or cyclopropyl;
  • R 3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, -N0 2 , straight chained or branched C ⁇ C 7 alkyl.
  • each A is independently -H, -F, -Cl, -Br, -CN, -N0 2 , -COR 3 , -C0 2 R 3 , straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • X is 0, NR 3 , CO or may be absent;
  • Y is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2/ straight chained or branched Q. -C ⁇ alkyl.
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R 2 is isopropyl.
  • the compound has the structure:
  • the compound has the structure:
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • A is -H, -F, -Cl, -Br.
  • R 2 is isopropyl; and A is hydrogen.
  • the compound has the structure:
  • This invention provides a compound having the structure:
  • Ri is hydrogen, straight chained or branched C ⁇ -C 7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , -OCH 3 , -C0 2 CH 3 , -CF 3 , phenyl, straight chained or branched C 1 -C 7 alkyl;
  • R 2 is straight-chained or branched C 3 -C 4 alkyl or cyclopropyl ;
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , -CORi, -C0 2 R ⁇ , straight chained or branched C 1. -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl .
  • each B is independently -H, -F, -Cl, -Br, -I, -CN, -N0 2 , -CORi, -C0 2 R ⁇ , - OCH 3 , -OCF 3 , -CF 3 , straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein the aryl, phenoxy or benzyloxy is optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , -C0R ⁇ , -C0 2 R ⁇ ,
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R x is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , straight chained or branched -0-j alkyl.
  • R 2 is isopropyl
  • the compound has the structure:
  • the compound has the structure:
  • This invention provides a compound having the structure:
  • Ri is hydrogen, straight chained or branched C ⁇ -C 7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , -CF 3 , -OCH 3 , straight chained or branched C ⁇ -C 3 alkyl;
  • R 2 is straight-chained or branched C 3 -C 4 alkyl or cyclopropyl ;
  • R 3 is -H, -F, -Cl, -Br, -I, -CN, -N0 2 , -CF 3 ,
  • R 4 is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -CF 3 , straight chained or branched -0 3 alkyl; wherein A is -H, -F, -Cl, -Br, -CN, -N0 2 , straight- chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
  • n is an integer from 2 to 4 inclusive.
  • R 3 is -H, -F, -Cl, -Br, -I, -CN, -N0 2 , -OCF 3 or -0CH 3 ;
  • R 4 is hydrogen or phenyl optionally substituted with one or more -F, -Cl or -CF 3 .
  • R x is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 ,
  • R 2 is isopropyl
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure
  • This invention provides a compound having the structure:
  • each Ri is independently hydrogen or CH 3 ;
  • R 2 is straight-chained or branched C ⁇ -C 4 alkyl or cyclopropyl ;
  • R 3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenenedioxy group or one or more -F or -Cl ; wherein A is -H, -F, -Cl, - Br, -CN, -N0 2 , straight chained or branched Cx-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl ;
  • X is (CH 2 ) 2 , COCH 2 or CONH;
  • R 3 is phenyl optionally' substituted with one or more -F;
  • X is CONH.
  • R 2 is methyl
  • the compound has the structure:
  • the compound has the structure:
  • each Y is independently hydrogen or -F.
  • the compound has the structure:
  • the compound has the structure:
  • R 3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl .
  • the compound has the structure:
  • each Y is independently hydrogen or -F.
  • the compound has the structure:
  • the compound is enantiomerically pure .
  • the compound is diastereomerically pure.
  • the compound is enantiomerically and diastereomerically pure.
  • This invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically amount of a compound of the invention and a pharmaceutically acceptable carrier.
  • the amount of the compound is from about 0.0lmg to about 500mg.
  • the amount of the compound is from about 0. lmg to about 60mg ' .
  • the amount of the compound is from about lmg to about 20mg.
  • the pharmaceutical composition consists of a carrier which is a liquid and the composition is a solution.
  • the pharmaceutical composition consists of a carrier which is a solid and the composition is a tablet.
  • the pharmaceutical composition consists of a carrier which is a gel and the composition is a suppository.
  • the invention also provides a process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of the invention and a pharmaceutically acceptable carrier.
  • This invention also provides the method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of the invention.
  • the therapeutically effective amount is between about 0.03 and about 1000 mg per day.
  • the therapeutically effective amount is between about 0.30 and about 300 mg per day.
  • the therapeutically effective amount is between about 1.0 and about 100 mg per day. In one embodiment, the disorder is depression.
  • the disorder is anxiety.
  • the disorder is obesity.
  • the disorder is urge incontinence.
  • the invention provides the method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.
  • the invention provides the method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims of the invention effective to treat the subject's depression.
  • the invention provides the method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's anxiety.
  • the invention provides the method of alleviating urge urinary incontinence in a subject suffering from an overactive bladder, which comprises administering to the subject an amount of the compound of the invention effective to alleviate the subject's urge urinary incontinence .
  • the invention provides the method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of the invention effective to induce weight loss in the subject.
  • the invention provides the method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of the invention effective to maintain such weight loss in the subject.
  • the invention provides the method of treating overactive bladder in a subject, which comprises administering to the subject an amount of a compound of any of the invention effective to treat the subject's overactive bladder.
  • the invention provides the method of treating a disorder in a subject, wherein the symptoms of the subject can be alleviated by treatment with an MCHl antagonist, wherein the MCHl antagonist is the compound of the invention.
  • the invention provides the method of alleviating the symptoms of a disor4der in a subject, which comprises administering to the subject an amount of an MCHl antagonist effective to alleviate the symptoms, wherein the MCHl antagonist is the compound of the invention.
  • This invention provides a compound having the structure:
  • each V is independently phthalimide, aryl, phenoxy or heteroaryl, wherein the aryl, phenoxy or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR 5 ; C0 2 R 5 ; -OCOR 5 ; -CON(R 5 ) 2 ; -N(R 5 )COR 5 ; CN; -N0 2 ; -N(R 5 ) 2 ; -OR 5 ; -SR 5 ; (CH 2 ) q OR 5 ; (CH 2 ) q R 5 ; (CH 2 ) q SR 5 ; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl ; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; aryl; phenoxy; C 3
  • each W is independently aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted ith one or more F; Cl; Br; I; COR 3 ; -OCOR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; -N(R 3 )COR 3 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q 0R 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; aryl; phenoxy; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluor
  • each R is independently -H; -F; straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -OCOR 3 ; -OR 3 ; or -N(R 3 )COR 3 ; -CON(R 3 ) 2 ;
  • each R 3 is independently -H; straight chained or branched C ⁇ -C-j alkyl, monofluoroalkyl or polyfluoroalkyl ; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ;
  • R 6 is. -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C-C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; -0C0R 3 ; -CON(R 3 ) 2 ; -N(R 3 )COR 3 ; aryl, benzyl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -OCOR 3 ; -CON(R 3 ) 2 ; -N(R 3 )
  • Z is CO, S0 2 or S0 2 NR 6 ;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is independently an integer from 0 to 5 inclusive;
  • each p is independently an integer from 1 to 7 inclusive;
  • q is an integer from 1 to 3 inclusive
  • cycloalkyl includes C 3 -C 7 cycloalky moities which may be substituted with one or more of the following: F; CN; -N0 ; straight chained or branched C x -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched Ci-C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 ' polyfluorocycloalkyl, C 5 -C cycloalkenyl, -N(R 3 ) 2 ; -OR 3 ; -NCOR 3 ; -C0R 3 ;
  • cycloalkenyl includes C 5 -C 7 cycloalkenyl moities which may be substituted with one or more of the following: -F; -Cl; -Br, -I; CN; -N0 2 ; straight chained or branched C ⁇ -C- 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C-j polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, -N (R 3 ) 2 ; -OR 3 ; -NCOR 3 ;
  • heteroaryl is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms.
  • heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazzolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl .
  • heteroaryl is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen.
  • heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo [b] furanyl , benzo [b] thiophenyl, indazolyl, benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo [b] thiazolyl, imidazo [2, 1-b] thiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1, 8-naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2,1,3 -benzothiazolyl .
  • heteroaryl also includes those chemical moieties recited above which may be substituted with one or more of the following: -F; -Cl; -Br, -I; CN; -N0 2 ; straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C 1 -C7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl, -N(R 3 ) 2 ,• -0R 3 ; -NC0R 3 ; -COR 3 ; -
  • the compound has the structure:
  • R 6 is straight chained or branched C ⁇ -C 7 alkyl; C 3 -C 7 cycloalkyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; aryl, benzyl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; -OR 3 ; -(CH 2 ) q OR 3 ; or straight chained or branched Ci-C 7 alkyl.
  • the compound has the structure:
  • At least one V is phenyl optionally substituted with one or more F; Cl ; Br; -OR 3 ; (CH 2 ) q OR 3 ; straight chained or branched Ci-C 7 alkyl; Cx-C? polyfluoroalkyl; or phenoxy.
  • the compound is :
  • the compound is;
  • the compound is:
  • the compound has the structure:
  • At least one V is phenyl optionally substituted with one or more F; Cl; Br; -OR 3 ; (CH 2 ) q OR 3 ; straight chained or branched C ⁇ -C 7 alkyl; C ⁇ -C 7 polyfluoroalkyl; or phenoxy.
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • the compound has the structure:
  • At least one V is phenyl optionally substituted with one or more F; Cl; Br; -OR 3 ; -C0R 3 ; (CH 2 ) q OR 3 ; straight chained or branched C ⁇ -C 7 alkyl; C ⁇ -C 7 polyfluoroalkyl; aryl or phenox .
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound has the structure:
  • At least one V is phenyl optionally substituted with one or more F; Cl; Br; -OR 3 ; (CH 2 ) q OR 3 ; straight chained or branched C 1 -C 7 alkyl; C 1 -C 7 polyfluoroalkyl; or phenoxy.
  • the compound is
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure
  • the compound has the structure :
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • Y is hydrogen and V is phthalimide.
  • R 6 is straight chained or branched Ci-C 7 alkyl; C 3 -C 7 cycloalkyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p 0R 3 ; aryl, benzyl or heteroaryl, optionally substituted with one or more F; Cl ; Br; I; -OR 3 ; -(CH 2 ) q OR 3 ; or straight chained or branched C 1 -C 7 alkyl.
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • the compound has the structure:
  • At least one V is phenyl or heteroaryl optionally substituted with one or more F; Cl ; Br; I; R 5 ; -OR 5 ; - (CH 2 ) q OR 5 ; -(CH 2 ) q R 5 ; straight chained or branched C ⁇ -C 7 alkyl; C ⁇ -C 7 monoflouroalkyl or polyflouroalkyl; or phenoxy.
  • the compound has the structure:
  • the compound has the structure:
  • V is phenyl which is optionally substituted with one or more F; Cl; Br; -0R 5 ; -(CH 2 ) q OR 5 ; -(CH 2 ) q R 5 ; straight chained or branched alkyl; C ⁇ -C 7 monoflouroalkyl or polyflouroalkyl ; or phenoxy.
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure
  • R 5 is straight chained or branched C ⁇ -C 7 alkyl; C 3 -C 7 cycloalkyl;
  • the compound has the structure:
  • the compound has the structure:
  • X is hydrogen and Y is carbazole optionally substituted with one or more F; Cl; Br; R 5 ; -0R 5 ; - (CH 2 ) q OR 5 ; -(CH 2 ) q R 5 ; straight chained or branched Ci - C 7 alkyl; or C 1 -C 7 monoflouroalkyl or poly louroalkyl; or phenoxy.
  • the compound has the structure :
  • the compound has the structure:
  • Y is hydrogen
  • V is an indole, which can be optionally substituted with one or more F; Cl; Br; R 5 ; -C0 2 R 5 ; -OR s ; -(CH 2 ) q 0R 5 ; -
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure':
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the present invention provides a compond having the srucuture :
  • each X is independently O or S;
  • each R is independently H; -(CH 2 ) t XR 3 ;
  • each t is independently an integer from 1 to 4 inclusive;
  • each R 3 is independently H; straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C 2 -C 7 alkenyl, or alkynyl; or C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl ; wherein R 4 is aryl, heteroaryl, C ⁇ -C 7 alkyl substituted with one or two aryl, or C 1 -C7 alkyl substituted with one or two heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F, Cl, Br, I,
  • n independently is an integer from 0 to 7 inclusive;
  • R 5 is H; aryl, C ⁇ -C 7 alkyl substituted with aryl, heteroaryl, or C -C alkyl substituted with heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F, Cl, Br, I, -CN, -N0 2 , -N(R 3 ) 2 , -COR 3 , - (CH 2 ) n XR3, - (CH 2 ) n C(X)NR 3 , - (CH 2 ) n C0 2 R 3 , straight chained or branched C 1 -C7 alkyl, monofluoroalkyl, polyfluoroalkyl or carboxamidoalkyl, or straight chained or branched C 2 -C 7 aminoalkyl, alkenyl or alkynyl, or C 3 -C 7 cycloalkyl or C ⁇ -C 7 cycloalkenyl;
  • R 5 and one R 2 on adjacent carbon atoms together may form aryl, heteroaryl, indane or tetrahydronaphthyl, C 3 - C 7 cycloalkyl, or heterocycloalkyl wherein one or two heteroatoms may be 0, N or S;
  • each V is independently aryl, phenoxy .or heteroaryl, wherein the aryl, phenoxy or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR 5 ; C0 2 R 5 ; ' -OCOR 5 ; -CON(R 5 ) 2 ; -N(R 5 )COR 5 ; CN; -N0 2 ; - N(R 5 ) 2 ; -OR 5 ; -SR 5 ; (CH 2 ) q OR 5 ; (CH 2 ) q SR 5 ; straight chained or branched C 1 -C 7 alkyl optionally substituted with - CON(R 5 ) 2 , -N(R 5 )C(0)R 3 or N(R 3 ) 2 , straight chained or branched monofluoroalkyl or polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, C 2 -
  • each R 6 is independently H; (CH 2 ) t XR 3 ; (CH 2 ) t C(X)NR 3 ; (CH 2 ) t N (R 3 ) C (X) R 3 ; (CH 2 ) t C0 2 R 3 ; (CH 2 ) t OCOR 3 ; straight chained or branched C ⁇ -C ⁇ alkyl optionally substituted with -CON(R 3 ) 2 or -NC(0)R 3 ; straight chained or branched C 2 -C 7 alkyl substituted with -N(R 3 ) 2 ; straight chained or branched C 2 -C 7 alkenyl or alkynyl; or C 3 -C 7 cycloalkyl or C 5 -C cycloalkenyl;
  • each R 7 is independently H; F; Cl; Br; I; -COR 3 ; - C0 2 R 3 ; -(CH 2 ) n XR 3 ; - (CH 2 ) n N (R 3 ) C (0) R 3 ; (CH 2 ) n C (X) N (R 3 ) 2 ; - (CH 2 ) ' n C0 2 R 3 ; -CN; -N0 2 ; -N(R 3 ) 2 ; straight chained or branched C x -C 7 alkyl, hydroxyalkyl , aminoalkyl, carboxamidoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C ⁇ alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or C 5 -
  • B is CO, S0 2 or S0 2 NR 6 ;
  • R 8 is -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -NR 3 C(0)R 3 ; -0R 3 ; -(CH 2 ) p 0R 3 ; - COR 3 ; -C0 2 R 3 ; -OCOR 3 ; -CON(R 3 ) 2 ; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -OCOR 3 ; -NR 3 C(0)R 3 ; -C0N(R 3 ) 2 ; CN;
  • each m independently is an integer from 0 to 3 inclusive;
  • C 2 -C 7 alkenyl wherein the C 2 -C 7 alkenyl may be unsubstituted or substituted with one or more Rg groups;
  • each R 9 is independently H; F; Cl; Br; I; • - (CH 2 ) m XR 3 ; (CH 2 ) m C(X)NR 3 ; (CH 2 ) m C0 2 R 3 ; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, or alkynyl; or C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; wherein R 10 is H; (CH 2 ) t XR 3 ; (CH 2 ) t C (X)NR 3 ; (CH 2 ) t C0 2 R 3 ; straight chained or branched C - 7 alkyl, carboxamidoalkyl; straight chained or branched C 2 -C 7 aminoalkyl
  • Y is S, O, or NR i0 ;
  • each p is independently an integer from 1 to 7 inclusive;
  • the compound has the following structure:
  • the compound has the structure :
  • the compound has the structure :
  • Z is:
  • Z is:
  • the compound has the structure:
  • the compound has the strucuture:
  • This invention provides a compound having the structure:
  • Ri is hydrogen, straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -CH 3 , -CF 3 , -COCH 3 , -C0 2 R 2 , phenyl, phenoxy or straight chained or branched C ⁇ -C 7 alkyl;
  • R 2 is straight-chained or branched C 3 -C 4 alkyl or cyclopropyl
  • R 3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , -COR 3 , -C0 2 R 3 , straight chained or branched C 1. -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • X is 0 or NH
  • n is an integer from 0 to 5 inclusive
  • R is aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -COCH 3 , -C0 2 R 2 , straight chained or branched C ⁇ -C 7 alkyl;
  • R 3 is phenyl
  • A is H
  • R 2 is isopropyl
  • X is NH
  • Ri is alkyl
  • n is 1 or 2.
  • X is O
  • R is 3 -acetyl phenyl
  • R 2 is isopropyl
  • R 3 is phenyl
  • n is 1.
  • the compound has the structure:
  • compound has the structure:
  • Ri is hydrogen, straight chained or branched C--C 7 alkyl; and wherein R 3 is aryl.
  • R 2 isopropyl
  • A is hydrogen
  • the compound has the structure:
  • the compound has the structure:
  • the present invention also provides a compound having the structure:
  • R x is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -OCH 3 , phenoxy, fused cyclopentanyl, straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; wherein R 2 is straight-chained or branched C ⁇ -C 4 alkyl or cyclopropyl ;
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , straight chained or branched C ⁇ C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • n is an integer from 1 to 5 inclusive.
  • R 3. is aryl optionally substituted with one or more -F, -Cl, -Br, -I or straight chained or branched C ⁇ -C 4 alkyl;
  • R 2 is isopropyl
  • n 2
  • n is 2 and R 2 is isopropyl.
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • R is thienyl; and wherein A is H.
  • R 2 is isopropyl
  • the compound has the structure:
  • the invention provides a compound having the structure:
  • each Ri is independently hydrogen, methyl or ethyl ;
  • R 2 is straight-chained or branched C 3 -C 4 alkyl or wherein R 2 is straight- chained or branched C 3 -C 4 alkyl or cyclopropyl;
  • R 3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, -N0 2 , straight chained or branched C ! -C 7 alkyl.
  • each A is independently -H, -F, -Cl, -Br, -CN, -N0 2 -COR 3 , -C0 2 R 3 , straight chained or branched Cx-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • X is 0, NR 3 , CO or may be absent;
  • Y is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , straight chained or branched ⁇ -0 7 alkyl.
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R 2 is isopropyl.
  • the compound has the structure;
  • the compound has the structure:
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • A is -H, -F, -Cl, -Br.
  • R 2 is isopropyl; and A is hydrogen.
  • the compound has the structure:
  • This invention provides a compound having the structure:
  • R ⁇ is hydrogen, straight chained or branched C ⁇ -C 7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , -OCH 3 , -C0 2 CH 3 , -CF 3 , phenyl, straight chained or branched C 1 -C 7 alkyl;
  • R 2 is straight-chained or branched C 3 -C alkyl or cyclopropyl
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , -CORi, -C0 2 R ⁇ , straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl.
  • each B is independently -H, -F, -Cl, -Br, -I,
  • W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • Ri is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , straight chained or branched C 1 -C 7 alkyl.
  • R 2 is isopropyl
  • the compound has the structure:
  • the compound has the structure:
  • This invention provides a compound having the structure:
  • R x is hydrogen, straight chained or branched C ⁇ -C 7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , -CF 3 , -OCH 3 , straight chained or branched C ⁇ -C 3 alkyl;
  • R 2 is straight-chained or branched C 3 -C 4 alkyl or cyclopropyl ;
  • R 3 is -H, -F, -Cl, -Br, -I, -CN, -N0 2 , -CF 3 , -OCH 3 , or straight chained or branched C ⁇ -C 3 alkyl, monofluoroalkyl ' or polyfluoroalkyl , or a phenyl ring fused to C ⁇ and C 7 of the indole moiety;
  • R is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N0 2 , -CF 3 , straight chained or branched C ⁇ -C 3 alkyl;
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • R 3 is - H, -F, -Cl, -Br, -I, -CN,
  • R 4 is hydrogen or phenyl optionally substituted with one or more -F, -Cl or -CF 3 .
  • R x is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N0 2 , -CF 3 , -OCH 3 or straight chained or branched C ⁇ -C 3 alkyl;
  • R 2 is isopropyl
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • This invention provides a compound having the structure:
  • each Ri is independently hydrogen or CH 3 ;
  • R 2 is straight-chained or branched C ⁇ -C 4 alkyl or cyclopropyl; wherein R 3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenenedioxy group or one or more -F or -Cl;
  • A is -H, -F, -Cl, -Br, -CN, -N0 2 , straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl;
  • X is (CH 2 ) 2 , COCH 2 or CONH;
  • R 3 is phenyl optionally substituted with one or more -F.
  • X is CONH.
  • R 2 is methyl
  • the compound has the structure:
  • the compound has the structure:
  • each Y is independently hydrogen or -F .
  • the compound has the structure:
  • the compound has the structure:
  • R 3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl .
  • the compound has the structure:
  • each Y is independently hydrogen or -F.
  • the compound has the structure:
  • the compound is enantiomerically pure.
  • the compound is diastereomerically pure.
  • the compound is enantiomerically and diastereomerically pure.
  • This invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically amount of a compound of the invention and a pharmaceutically acceptable carrier.
  • the amount of the compound is from about 0.0lmg to ahout 500mg.
  • the amount of the compound is from about 0. lmg to about 60mg.
  • the amount of the compound is from about lmg to about 20mg.
  • the pharmaceutical composition consists of a carrier which is a liquid and the composition is a solution.
  • the pharmaceutical composition consists of a carrier which is a solid and the composition is a tablet .
  • the pharmaceutical composition consists of a carrier which is a gel and the composition is a suppository.
  • This invention also provides the method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of the invention.
  • the therapeutically effective amount is between about 0.03 and about 1000 mg per day.
  • the therapeutically effective amount is between about 0.30 and about 300 mg per day.
  • the therapeutically effective amount is between about 1.0 and about 100 mg per day.
  • the disorder is depression. _
  • the disorder is anxiety.
  • the disorder is obesity.
  • the disorder is urge incontinence.
  • the invention provides the method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.
  • the invention provides the method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims of the invention effective to treat the subject's depression.
  • the invention provides the method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's anxiety.
  • the 'invention provides the method of alleviating urge urinary ' incontinence in a subject suffering from an overactive bladder, which comprises administering to the subject an amount of the compound of the invention effective to alleviate the subject's urge urinary incontinence.
  • the invention provides the method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of the invention effective to induce weight loss in the subject.
  • the invention provides the method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of the invention effective to maintain such weight loss in the subject.
  • the invention provides the method of treating overactive bladder in a subject, which comprises administering to the subj ect an amount of a compound of any of the invention effective to treat the subject'.s overactive bladder .
  • the invention provides the method of treating a disorder in a subj ect , wherein the symptoms of the subj ect can be alleviated by treatment with an MCHl antagonist, wherein the MCHl antagonist is the compound of the invention.
  • the invention provides the method of alleviating the symptoms of a disor4der in a subject, which comprises administering to the subject an amount . of an MCHl antagonist effective to alleviate the symptoms, ' wherein the MCHl antagonist is the compound of the invention
  • heteroaryl is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms.
  • heteroaryl groups include, but are not limited to, carbazole, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
  • heteroaryl is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen.
  • heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo [b] furanyl , benzo [b] thiophenyl , indazolyl , benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo [b] thiazolyl, imidazo [2, 1-b] thiazolyl,.
  • heteroaryl also includes those chemical moieties recited above which may be substituted with one or more of the following: -F, -Cl, -Br, -I, CN, -N0 2 , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 7 cycloalkenyl,
  • heteroaryl further includes the N-oxides of those chemical moieties recited above which include at least one nitrogen atom.
  • aryl is phenyl or naphthyl .
  • stereoisomers may include enantiomers, diastereomers, or E or Z alkene or imine isomers.
  • the invention also provides for stereoisomeric " mixtures, including racemic mixtures, diastereomeric mixtures, or E/Z isomeric mixtures.
  • Stereoisomers can be synthesized in pure form (N ⁇ gradi-,- M.; Stereoselective Synthesis, (1987) VCH Editor Ebel, H. and Asymmetric Synthesis, Volumes 3 ⁇ B 5, (1983) Academic Press, Editor Morrison, J.) or they' can be resolved by a variety of methods such as crystallization and chromatographic techniques (Jaques, J. ; Collet, A. ; ilen, S.; Enantiomer, Racemates, and Resolutions, 1981, John Wiley and Sons and Asymmetric Synthesis, Vol.
  • the compounds of the present invention may be present as enantiomers, diasteriomers, isomers or two or- more of the ' compounds may be present to form a racemic or diastereomeric mixture.
  • the compounds of the present invention are preferably 80% pure, more preferably 90% pure, and most preferably 95% pure. Included in this invention are pharmaceutically acceptable salts and complexes of all of the compounds described herein.
  • the acids and bases from which these salts are prepared include but are not limited to ' the acids and bases listed herein.
  • the acids include, but are not limited to, the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and boric acid.
  • the acids include > but are not limited to, the following organic acids: acetic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, maleic acid, citric acid, methanesulfonic acid, benzoic acid, glycolic acid, lactic acid and mandelic acid.
  • the bases include, but are not limited to ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine , trimethylamine, triethylamine, ethylenediamine, hydroxyethylamine, morpholine, piperazine and guanidine . This invention further provides for the hydrates and polymorphs of all of the compounds described herein.
  • the present invention includes within its scope prodrugs of the compounds of the invention.
  • prodrugs will be functional derivatives of the compounds of the invention which are readily convertible in vivo into the required compound.
  • administering shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after . administration to
  • the present invention further includes metabolites of the compounds of the present invention.
  • Metabolites include active species produced upon introduction of compounds of this invention into the biological milieu.
  • This invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
  • the amount of the compound is from about 0.01 mg to about 800 mg. In another embodiment, the amount of the compound is from about 0.01 mg to about 500 mg. In yet another embodiment, the amount of the compound is from about 0.1 mg to about 250 mg. In another embodiment, the amount of the compound is from about 0.1 mg to about 60 mg. In yet another embodiment, the amount of the compound is from about 1 mg to about 20 mg.
  • the carrier is a liquid and the composition is a solution. In another embodiment,- the carrier is a solid and the composition is a tablet. In another embodiment, the carrier is a gel and the composition is a capsule, suppository or a cream. In
  • the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.
  • the compound may be delivered to. ' 'the ' subject by means of a spray or inhalant .
  • This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceuticall acceptable, carrier.
  • This -invention- provides a process for making a pharmaceutical ' composition comprising combining - a - therapeutically ' e fective amount of the compound of . this - invention and a pharmaceutically acceptable carrier.
  • - -solid carrier can include one or more substances which may also act as .endogenous carriers (e.g. nutrient or micronutrient carriers), flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is lh admixture with the finely divided active ingredient.
  • ⁇ In tablets, - the active ingredient is mixed with a carrier -having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
  • the active ingredient can be dissolved or suspended in ' a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers or osmoregulators .
  • suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives/ preferably sodium carboxymethyl cellulose solution) , alcohols (including onohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils
  • the carrier can also be an oily ester such as ethyl oleate or isopropyl myristate.
  • Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
  • The- liquid carrier for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellent.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example,- intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
  • the compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
  • Carriers are intended to include , necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
  • the compound can be administered orally in- the form of a s$£ lile - solution ; ⁇ - or suspension, containing other solutes or suspending agents (for example, enough - saline or glucose to make the solution isotonic) , bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
  • solutes or suspending agents for example, enough - saline or glucose to make the solution isotonic
  • bile salts for example, enough - saline or glucose to make the solution isotonic
  • bile salts for example, enough - saline or glucose to make the solution isotonic
  • bile salts for example, enough - saline or glucose to make the solution isotonic
  • bile salts for example, enough - saline or glucose to
  • compositions suitable for oral administration include solid forms, such as pills, capsules, granu ⁇ s., tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
  • forms useful for parenteral administration include "sterile solutions, emulsions, and suspenions .
  • Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result i ⁇ a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.
  • a "therapeutically effective amount” is any amount of a compound which, when administered to a subject suffering from a disease against which the compounds are effective, causes reduction, remission, or regression of the disease.
  • a "subject” is a vertebrate, a mammal or a human.
  • depressive and anxiety disorders is for the purpose of illustrating the utility of the compounds of this invention.
  • the definitions of depressive and anxiety disorders given below are those listed in Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV; American Psychiatric Association, 1994a) or Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Revised (DSM-III-R; American Psychiatric Association, 1987) . Additional information regarding these disorders can be found in this reference, as well as the others cited below, all of which are incorporated herein by reference.
  • Depressive disorders include major depressive disorder and dysthymic disorder (American Psychiatric Association, 1994a; American Psychiatric Association, 1994b) .
  • Major depressive disorder is characterized by the occurrence of one or more major depressive episodes without manic or hypomanic episodes.
  • a major depressive episode is defined as a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks) ; it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation (Medical Economics Company, 2002) .
  • Dysthymic disorder involves a type of depression that is not severe enough to be called a major depressive episode, but that lasts much longer than major depressive disorder, without high phases.
  • HDRS Harmonic Scale
  • CGI Global Impressions
  • the compounds of the invention will be effective in inducing improvements in certain of the factors measured in these tests, such as the HDRS subfactor scores, including the depressed mood item, sleep disturbance factor and anxiety factor, and the CGI-Severity of Illness rating. It is also contemplated that the compounds of this invention will be effective in preventing relapse of major depressive episodes.
  • Anxiety disorders include panic disorder, agoraphobia with or without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder and generalized anxiety disorder. It is ⁇ contemplated that the compounds of this invention will be effective in treating any of all of these disorders in patients who have been diagnosed with these disorders.
  • Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable (American Psychiatric
  • the compounds of this invention will be effective in treating obsessions and compulsions in patients who have been diagnosed with obsessive compulsive disorder by administration of appropriate tests, which may include, but are not limited to any of the following: Yale Brown Obsessive Compulsive Scale (YBOCS) (Goodman, 1989) (for adults) , National Institute of Mental Health Global OCD Scale (NIMH GOCS) , CGI- Severity of Illness scale. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain of the factors measured in these tests, such as a reduction of several points in the YBOCS total score. It is also contemplated that the compounds of this- invention will be effective in preventing relapse of obsessive compulsive disorder.
  • YBOCS Yale Brown Obsessive Compulsive Scale
  • NIMH GOCS National Institute of Mental Health Global OCD Scale
  • CGI- Severity of Illness scale CGI- Severity of Illness
  • Panic disorder is characterized by recurrent unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks (American Psychiatric Association, 1994a) .
  • a panic attack is defined as a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself) ; fear of losing control; (11) fear of dying;
  • Panic disorder may or may not be associated with agoraphobia, or an irrational and often disabling fear of being out in public.
  • the compounds of this invention will be effective in treating panic disorder in patients who have been diagnosed with panic disorder on the basis of frequency of occurrence of panic attacks, or by means of the CGI-Severity of Illness scale. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain of the factors measured in these evaluations, such- as a reduction in frequency or elimination of panic attacks, an improvement in the CGI-Severity of Illness scale or a CGI-Global Improvement score of 1 (very much improved) , 2 (much improved) or 3 (minimally improved)-. It is also contemplated that the compounds of this invention will be effective in preventing relapse of panic disorder.
  • Social anxiety disorder also known as social phobia, is characterized by a marked and persistent fear of one or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others (American Psychiatric Association,
  • the compounds of this invention will be effective in treating social anxiety disorder in patients who have been diagnosed with social anxiety disorder by administration of any of the following tests: the Liebowitz Social Anxiety Scale (LSAS) , the CGI-Severity of Illness scale, the Hamilton Rating Scale for Anxiety (HAM-A) , the Hamilton Rating Scale for Depression (HAM-D) , the axis V Social and Occupational Functioning Assessment Scale of DSM-IV, the axis II
  • Generalized anxiety disorder is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control (American Psychiatric
  • the compounds of this invention will be effective in treating generalized anxiety disorder in patients who have been diagnosed with this disorder according to the diagnostic criteria described in DSM-IV. It is further contemplated that the compounds of the invention will be effective in reducing symptoms of this disorder, such as the following: excessive worry and anxiety, difficulty controlling worry, restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, or sleep disturbance . It is also contemplated that the compounds of this invention will be effective in preventing relapse of general anxiety disorder.
  • Post-traumatic stress disorder (PTSD) , as defined by DSM-III-R/IV (American Psychiatric Association, 1987, American Psychiatric Association, 1994a) , requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror.
  • DSM-III-R/IV American Psychiatric Association, 1987, American Psychiatric Association, 1994a
  • Symptoms that occur as a result of exposure to the traumatic event include re-experiencing of the event in the form of -intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger.
  • a PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
  • the compounds of this invention will be effective in treating PTSD in patients who have been diagnosed with PTSD by administration of any of the following tests: Clinician-Administered PTSD Scale Part 2 (CAPS) , the patient-rated Impact of Event Scale (IES)
  • the compounds of the invention will be effective in inducing improvements in the scores of the CAPS, IES, CGI-Severity of Illness or CGI-Global Improvement tests. It is also contemplated that the compounds of this invention will be effective in preventing relapse of PTSD.
  • the subject invention provides a method of treatment or management of the following indications: depressive disorders, anxiety disorders, eating/body weight disorders, and urinary disorders.
  • depressive disorders are major depressive disorder or dysthymic disorder.
  • anxiety disorders are panic disorder, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post- traumatic stress disorder, acute stress disorder or generalized anxiety disorder.
  • eating/body weight disorders are obesity, weight gain, bulimia, bulimia nervosa or anorexia nervosa.
  • urinary disorders include, but are not limited to urinary incontinence overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia or enuresis.
  • Overactive bladder and urinary urgency may or may not be associated with benign prostatic hyperplasia.
  • This invention provides a method of modifying the feeding behavior of a subject, which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject.
  • This invention also provides a method of treating an eating disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the eating disorder.
  • the eating disorder is obesity, bulimia, bulimia nervosa or anorexia nervosa.
  • the present invention further provides a method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.
  • This invention also provides a method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of the invention effective to induce weight loss in the subject.
  • This invention also provides a method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of the invention effective to maintain such weight loss in the subject.
  • the present invention also provides a method of treating depression in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression.
  • This invention also provides a method of treating anxiety in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's anxiety.
  • This invention also provides a method of treating depression and anxiety in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and anxiety.
  • This invention also provides a method of treating major depressive disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's major depressive disorder. This invention also provides .
  • a method of treating dysthymic disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's dysthymic disorder.
  • This invention also provides a method of treating obsessions and compulsions in a subject with obsessive compulsive disorder, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's obsessions and compulsions.
  • This invention also provides a method of treating panic disorder, with or without agoraphobia, in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's panic disorder.
  • This invention also provides a method of treating social anxiety disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat , the subject's social anxiety disorder.
  • This invention also provides a method of treating generalized anxiety disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's generalized anxiety disorder.
  • This invention also provides a method of treating post-traumatic stress disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's post-traumatic stress disorder.
  • the compounds of this invention will be effective in treating obesity, including weight loss and maintenance of weight loss in patients, who have been diagnosed with obesity by the one or more of the following measurements: an increased body mass index, increased waist circumference (an indicator of intra-adominal fat) , Dual Energy X-Ray Absorptiometry (DEXA) and nestal (android) fat mass. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain factors measured in these tests.
  • the compounds of this invention will be effective in treating urinary disorders in patients who have urge or mixed (with a predominance of urge) incontinence as evidenced by the number of unnecessary episodes per week, the number of unnecessary micturitions per day and a low volume voided per micturition. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain factors measured in these tests.
  • the present invention also provides a method of treating a subject suffering from bipolar I or II disorder, schizoaffective disorder, a cognitive disorder with depressed mood, a personality disorder, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder or sleepwalking disorder.
  • the present invention provides a method of treating overactive bladder with symptoms of urge urinary incontinence, urgency and/or frequency in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's overactive bladder.
  • This invention also provides a method of alleviating urge urinary incontinence in a subject suffering from overactive bladder, which comprises administering to the subject an amount of a compound of the invention effective to alleviate the subject's urge urinary incontinence.
  • This invention further provides a method of alleviating urinary urgency in a subject suffering from overactive bladder, which comprises administering to the subject an amount of a compound of the invention effective to alleviate the subject's urinary urgency.
  • this invention provides a method of alleviating urinary frequency in a subject suffering from overactive bladder, which comprises administering to the subject an amount of a compound of the invention effective to alleviate the subject's urinary frequency.
  • the present invention also provides a method of treating a subject suffering from a urinary disorder, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's urinary disorder.
  • the urinary disorder is urinary incontinence, overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia or enuresis.
  • the present invention provides a method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject an amount of an MCHl antagonist effective to alleviate the symptoms, wherein the MCHl antagonist is any of the compounds of the invention.
  • the subject is a vertebrate, a mammal, a human or a canine.
  • the compound is administered orally.
  • the compound is administered in combination with food.
  • the subject invention provides a method of treatment for the following indications: depression, anxiety, eating/body weight disorders, and urinary disorders.
  • eating/body weight disorders are obesity, bulimia, or bulimia nervosa.
  • urinary disorders include, but are not limited to, urinary incontinence, overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia, or enuresis. Overactive bladder and urinary urgency may or may not be associated with benign prostatic hyperplasia.
  • This invention provides, a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject.
  • This invention also provides a method of treating an eating disorder in a subject which comprises administering to the subject an amount of a compound of this invention effective to decrease the consumption of food by the subject.
  • the eating disorder is bulimia, obesity or bulimia nervosa.
  • the subject is a vertebrate, a mammal, a human or a canine .
  • the compound is administered in combination with food.
  • the present invention further provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subj ect .
  • the present invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's depression.
  • the present invention further provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's anxiety.
  • the present invention also provides a method of treating a subject suffering from depression and anxiety which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's depression and anxiety.
  • the present invention also provides a method of treating a subject suffering from major depressive disorder, dysthymic disorder, bipolar I and II disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, . narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, obsessive-compulsive disorder, panic disorder, with or without agoraphobia, posttraumatic stress disorder, social anxiety disorder, social phobia and generalized anxiety disorder.
  • the present invention also provides a method of treating a subject suffering from a urinary disorder which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's a urinary disorder.
  • the urinary disorder is urinary incontinence, overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia, or enuresis.
  • reaction mixture was cooled to -78 °C and tert-butyl 4-oxo-l-piperidinecarboxylate (Aldrich Chemical Company, 40.0 mmol) in THF (40 mL) was added dropwise to the reaction mixture and stirred for 30 minutes.
  • Tf 2 NPh (42.0 mmol, 15.0 g) in THF (40 mL) was added dropwise to the reaction mixture and stirred at °C overnight.
  • the reaction mixture was concentrated in vacuo, re-dissolved in hexanes : EtOAc (9:1), passed through a plug of alumina and the alumina plug was washed with hexanes : EtOAc (9:1). The combined extracts were concentrated to yield 16.5 g of the desired product that was contaminated with some starting Tf 2 NPh.
  • TERT-BUTYL N- (3- ⁇ 4- [3- (ACETYLAMINO) PHENYL] -1,2,3, 6-TETRAHYDRO-l-PYRIDINYL ⁇ PROPYL)
  • CARBAMATE A solution of Nl - [3- (l,2,3,6-tetrahydro-4- pyridinyl) phenyl] acetamide. HCl (8.24 mmol), tert-butyl N- (3 -bromopropyl) carbamate and potassium carbonate (33 mmol) in dry dioxane (30 mL) was heated at reflux temperature overnight.
  • PIPERIDINECARBOXYLATE A mixture tert-butyl 4- [3- (acetylamino)phenyl] -1, 2, 3 , 6-tetrahydro-l- pyridinecarboxylate (710 mg) and 5% Pd/C (100 mg) in EtOH (10 mL) was hydrogenated (balloon technique) at room temperature overnight. The reaction mixture was passed through a pad of Celite 545 and the pad of Celite was washed with ethanol.
  • Nl- [3- (4-PIPERIDYL) PHENYL] CETAMIDE A solution of HCl in dioxane (4N, 5 mL) was added to tert-butyl 4- [3- (acetylamino) phenyl] -1-piperidinecarboxylate (660 mg) in dry dichloromethane (15 mL) . The reaction mixture was stirred at room temperature overnight and concentrated in vacuo, giving the desired product. (550 mg) : mp 102-104 °C; X ⁇ .
  • TERT-BUTYL N- (3- ⁇ 4- [3- (ACETYLAMINO) PHENYL] PIPERIDIN ⁇ PROPYL)
  • CARBAMATE A solution of Nl - [3- (4-piperidyl) phenyl] acetamide (550 mg, 0.210 mmol), tert-butyl N- (3 -bromopropyl) carbamate (550 mg, 0.230 mmol), K 2 C0 3 (1.10 g, 0.890 mmol), diisopropylethyl amine (1.50 mL) and a few crystals of KI in dioxane (20 mL) was heated at reflux temperature for 2 days.
  • PYRIDINECARBOXYLATE According to the procedure used for the synthesis of tert-butyl 4- [3- (amino) phenyl] -1, 2, 3 , 6- tetrahydro-l-pyridinecarboxylate,a mixture of 2 M aqueous Na 2 C0 3 solution (2.2 mL) , tert-butyl 4- ⁇ [ (trifluoromethyl) sulfonyl] oxy ⁇ -1, 2, 3 , 6-tetrahydro-l- pyridine-carboxylate (0.5.00 g, 1.51 mmol), 3-nitrophenylboronic acid (0.353 g, 2.11 mmol), lithium chloride (0.191 g, 4.50 mmol) and tetrakis- triphenylphosphine palladium (0) (0.080 g, 0.075 mmol) in dimethoxyethane (5 mL) afforded 0.380g of the desired product .
  • TERT-BUTYL 3- (4- (3-NITR0PHENYL) -3 , 6-DIHYDR0-1 (2H) - PYRIDINYDPROPYLCARBAMATE: A mixture of 2.80 g (14.0 mmol) of 1, 2 , 3 , 6-tetrahydro-4- (3 -nitrophenyl) pyridine, 3.60 g (15.0 mmol) of tert-butyl
  • N- (3 -bromopropyl) carbamate 11.6 g (84.0 mmol) of K 2 C0 3 , 14.6 mL (84.0 mmol) of diisopropylethylamine and 0.78 g (2.00 mmol) of tetrabutylammonium iodide in 250 mL of 1,4-dioxane was heated at reflux temperature for 14 hours .
  • the reaction mixture was filtered and concentrated in vacuo.
  • the residue was dissolved in 100 mL of ethyl acetate and washed 3 X 50 mL of 5% aqueous NaOH solution, the organic layer was dried (MgS0 4 ) and concentrated in vacuo .
  • the residue was dissolved in 100 mL of anhydrous ethanol containing 0.50 g 10% Pd/C and the reaction mixture was stirred under a hydrogen balloon for 24 hours.
  • the reaction mixture was passed through a column of Celite 545 filtering agent, washed with ethanol, the filtrate was dried (MgS0 4 ) and concentrated in vacuo .
  • PYRIDINECARBOXYLATE To a 25-mL RB flask, equipped with a condensor, was added tert-butyl 4- ⁇ [ (trifluoromethyl) sulfonyl] oxy ⁇ -3, 6-dihydro-l (2H) - pyridinecarboxylate (1.0 g) , 4-nitrophenylboronic acid (0.71 g) , sodium carbonate (0.430 mL of 2M solution), lithium chloride (0.382 g) , tetrakis (friphenylphosphine) - palladium (0) (0.173 g) and ethylene glycol dimethyl ether (10 mL) . The reaction mixture was flushed with Argon three times, then the reaction mixture was heated to 100 °C for 3 hrs.
  • reaction mixture was diluted with methylene chloride (30 mL) and water
  • Nitrophenyl) -1, 2 , 3 , 6-tetrahydropyridine was prepared by a similar procedure to that used for the preparation of 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide using HCl gas and tert-Butyl 4- (4-Nitrophenyl) -3 , 6-dihydro- 1 (2H) -pyridinecarboxylate (130 mg) in dioxane (5.0 mL) at room temperature. The reaction -mixture was concentrated in vacuo to give the crude product (69.8 mg) which used in the next reaction without further purification.
  • 2-AMINO-2- (3, 4-DIFLUOROPHENYL) -ETHANOL Into a well- stirred suspension of LiAlH 4 (4.7 g, 0.125 mol) in THF (120 mL) in a 3-necked round bottom flask fitted with a condenser and a dropping funnel, was added a solution of amino- (3, 4-difluorophenyl) -acetic acid methyl ester (10.0 g, 0.05 mol) in THF (100 mL) dropwise at 0 °C. The resulting greenish brown suspension was heated at reflux temperature for 2 h.
  • the reaction mixture was cooled to 0 °C and then carefully quenched sequentially with 5 mL of water, 5 mL .of 3N NaOH followed by 15 mL of water.
  • the resulting suspension was filtered through a fritted glass funnel. To the filter cake was added 100 mL Et 2 0 and the suspension was heated at reflux temperature for 20 min. The suspension was filtered and the combined filtrates were dried over MgS0 4 , filtered and the solvent was removed in vacuo. 2 - Amino-2- (3, 4-difluorophenyl) -ethanol was obtained as a yellow glassy syrup which was used in the next step without further purification.
  • (+) -4- (3, 4-DIFLUOROPHENYL) -OXAZOLIDIN-2-ONE Into a well-stirred suspension of NaH (1.1 g, 45.8 mmol) in THF (40 mL) at R.T. was added a solution of [l-(3,5- difluorophenyl) -2-hydroxy- ethyl] -carbamic acid- tert- butyl ester (5.0 g, 18.3 mmol) in THF (20 mL) via a dropping funnel at room temperature. The resulting suspension was stirred for 3 h and then quenched carefully with 10 mL of water.
  • the ether layer was separated and the aqueous layer was extracted with more ether (4 X 200 mL) .
  • the combined extracts were dried with magnesium sulfate and the solvent evaporated.
  • the crude product was purified by column chromatography on silica gel using chloroform/methanol/2M ammonia in methanol (1000:20:10, 1000:40:20, 1000:80:40) as the eluent to give the product as an oil (6.5 g, 62% yield) which was used in the next step without further purification.
  • 1,3-OXAZOLIDINE-3-CARBOXYLATE Into a stirred suspension of sodium hydride (60% suspension in paraffin 203 mg,
  • the relative configurations of the cis and trans isomers were assigned on the basis of E NMR analysis of the respective p-nitrophenyloxycarbonyl derivatives.
  • For the trans isomer an NOE was observed between the protons of the C-5 methyl group and the proton at C-4. No NOE was observed between the protons at the C-4 and C-5 positions of this isomer, which was thus assigned trans stereochemistry.
  • For the cis isomer no NOE was observed between the protons of the C-5 methyl group and the proton at C-4. However, a NOE was observed between the protons at the C-4 and C-5 positions, leading us to assign this isomer cis stereochemistry.
  • Enantiomers of the diastereomers were separated by HPLC by using a Chiralcel OD column (20 x 250 mm) with 80% hexane/20% isopropyl alcohol/ 0.1 % diethylamine as the eluting system (12 mL/min) under isocratic conditions (U.V. 254 nm) .
  • (+) - tl- (3,4-DIFLUOROBENZYL) -2-HYDROXY-ETHYL] -CARBAMIC ACID-TERT-BUTYL ESTER A solution of di- tert-butyl dicarbonate (0.640 g, 2.90 mmol) in CHC1 3 (10 mL) was added in one portion to a solution of (+) -2-amino-3- (3, 4-difluoro) -phenyl-propan-1-ol (0.500 g, 2.62 mmol) in CHC1 3 (20 mL) at 0 °C and the resulting solution was stirred overnight at room temperature.
  • (+) -4- (3,4-DIFLUORO-BENZYL) -OXAZOLIDIN-2-ONE A solution of (+) - [1- (3, 4-difluorobenzyl) -2-hydroxy-ethyl] -carbamic acid- ert-butyl ester (1.00 g, 4.00 mmol) in THF (10 mL) was added via a dropping funnel to a stirring suspension of ' 95% NaH (0.12 g, 5.0 mmol) in THF (20 mL) at room temperature. The resulting suspension was stirred for 3 h and then quenched carefully with water (10 mL) .
  • PIPERIDINYL ⁇ PHENYL) -2-METHYLPROPANAMIDE A mixture of 0.0500 g (0.200 mmol) of 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide, 0.100 g (0.480 mmol) of 4-chloro-3' , 4' -dimethylbutyrophenone, 0.080 g (0.600 mmol) of K 2 C0 3 and 0.090 g (0.600 mmol) of Nal in 5 mL of DMF was heated at reflux temperature for 18 hours. The reaction mixture was filtered, the filtrate was poured into 5 mL of water and washed with 3 X 5 mL of ethyl acetate. The combined organic extracts were dried
  • PIPERIDINYL ⁇ PHENYL)METHAN ⁇ SULFONAMIDE Using Method II, the desired product was obtained.
  • X H NMR ' 400 MHz, CDC1 3 ) ⁇ 7.82-7.10 (m, 7H) , 3.41 (s, 3H) , 3.40-2.85 (m, 4H) , 2.82-2.35 (m, 5H) , 2.32 (s, 6H) , 2.22-1.80 (m, -6H) ; ESMS m/e : 429.3 (M + H) + .
  • PIPERIDINYL ⁇ PHENYL)ACETAMIDE Using Method III, the desired product was obtained. ⁇ NMR (400 MHz, CDC1 3 ) 6 7.90-6.80 (m, 8H) , 3.30-J ⁇ -.05 (m, 4H) , 2:70-2.45 (m, 3H) , 2.05 (s, 3H) , 1.98-1.65 (m, 8H) ; ESMS m/e : 444.0 (M + H) + .
  • PIPERIDINYL] PHENYL ⁇ -2-METHYLPROPANAMIDE A mixture of 3- methoxy-3 -phenyl-1-chloropropane (23.1 mg, 0.126 mmol), 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide (28.3 mg, 0.126 mmol), diisopropylethylamine (0.50 mL) and catalytic amount of tetrabutylammonium iodide in dioxane
  • PIPERIDINYL]PHENYL ⁇ PROPANAMIDE A mixture of 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide (28.3 mg, 0.100 mmol), 4-phenyl-1-chlorobutane (21.1 mg, 0.125 mmol-), diisopropylethylamine (0.50 mL) , catalytic amount of tetrabutylammonium iodide and dioxane (2.0 mL) was heated at reflux temperature for 3 days. The reaction mixture was concentrated and chromatographed using preparative TLC plates [2.5% of NH 3 (2.0 M in methanol) in CHCI 3 ] afforded the product, 2-methyl-N- ⁇ 3- [1-
  • METHYLPROPANAMIDE A mixture of 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide (28.3 mg, 0.100 mmol), 3- methoxybenzyl chloride (19.6 mg, 0.125 mmol), diisopropylethylamine (0.50 mL) , catalytic amount of tetrabutylammonium iodide and dioxane (2.0 mL) .
  • PIPERIDINYL ⁇ PHENYL) -2-METHYLPROPANAMIDE A mixture of 2- methyl -N- [3- (4-piperidinyl) phenyl] propanamide (28.3 mg, 0.100 mmol), 3 , 5-bis (trifluoromethyl) benzyl bromide (38.4 mg, 0.125 mmol), diisopropylethylamine (0.50 mL) , catalytic amount of tetrabutylammonium ⁇ iodide and dioxane (2.0 mL) .
  • the residue can either be washed with pentane (x3) and the combined pentane extracts were concentrated and chromatographed (silica with hexanes-EtOAc 8:1 as the eluent) to give the desired product (as described as a general procedure by: Srebnik, M.; Ramachandran, P.V.; Brown, H.C. J. Org. Chem. 1988, 53 , 2916-2920) . This procedure was performed on a smaller scale reaction and only a 40% yield of the product was realized.
  • PIPERIDINYL ⁇ PHENYL PROPANAMIDE: A mixture of N-(3- ⁇ l- [ (3R) -3-hydroxy-3-phenylpropyl] -4-piperidinyl ⁇ phenyl) -2- methylpropanamide (9.53 mg, 0.0250 mmol), phenol (4.70 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days.
  • PIPERIDINYL ⁇ PHENYL) - 2 -METHYLPROPANAMIDE A mixture of N- (3- ⁇ l- [ (3R) -3-hydroxy-3- phenylpropyl] -4- piperidinyl ⁇ phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 4-methoxyphenol (6.20 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.2 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days.
  • reaction mixture was poured into water (50 mL) and the aqueous layer was extracted with methylene chloride (3x20 mL) . The combined organic extracts were washed with brine (20 L) , dried over Na 2 S0 4 and concentrated under reduced pressure.
  • the hydrochloric salt was prepared by addition of a slight excess of 1 N HCl in ether (1.2 eq.) to a solution of the free base in dichloromethane. The solvent was removed under reduced pressure, the residue was washed with ether and dried under reduced pressure Anal. Calc. for C 24 H 32 N 2 O 2 +HCl+0.8H 2 0: C, 66.82; H, 8.08 N, 6.49; Cl, 8.22. Found: C, 66.90; H, 7.78; N, 6.63 Cl, 8.52.
  • PIPERIDINYL ⁇ PHENYL) -2-METHYLPROPANAMIDE A mixture of N- (3- ⁇ l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl ⁇ phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 4-fluorophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days.
  • PIPERIDINYL ⁇ PHENYL) -2-METHYLPROPANAMIDE A mixture of N- (3- ⁇ l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl ⁇ phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 4-bromophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days.
  • N-(3- ⁇ l-[(3S)-3- (3-METHOXYPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL ⁇ PHENYL) -2-METHYLPROPANAMIDE A mixture of N- (3- ⁇ l- [ (3R) -3 -hydroxy-3-phenylpropyl] -4- piperidinyl ⁇ phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 3 -methoxyphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days.

Abstract

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Description

SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS
BACKGROUND OF THE INVENTION
This application is a continuation-in-part of U.S. Serial No. 10/042,582, filed January 9, 2002, and of U.S. Serial No. 09/899,794, filed July 5, 2001, the contents of both of which are hereby incorporated by reference into the subject application.
Throughout this application, various publications are referenced in parentheses by author and year. Full citations for these references may be found at the end of the specification immediately preceding the sequence listings and the claims. The disclosure of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains. Melanin-concentrating hormone (MCH) is a cyclic peptide originally isolated from salmonid
(teleost fish) pituitaries (Kawauchi et al . , 1983). In fish the 17 amino acid peptide causes aggregation of melanin within the melanophores and inhibits the release of ACTH, acting as a functional antagonist of α-MSH. Mammalian MCH (19 amino acids) is highly conserved between rat, mouse, and human, exhibiting 100% amino acid identity, but its physiological roles are less clear. MCH has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders (for reviews, see Baker, 1991; Baker, 1994; Nahon, 1994; Knigge et al . , 1996). Its role in feeding or body weight regulation is supported by a recent Nature publication (Qu et al . , 1996) demonstrating that MCH is overexpressed in the hypothalamus of oh/oh mice compared with ob/+ mice, and that fasting further increased MCH mRΝA in both obese and normal mice during fasting. MCH also stimulated feeding in normal rats when injected into the lateral ventricles (Rossi et al . , 1997) . MCH also has been reported to functionally antagonize the behavioral effects of α-MSH (Miller et al., 1993; Gonzalez et al, 1996; Sanchez et al . , 1997); in addition, stress has been shown to increase POMC mRΝA levels while decreasing the MCH precursor preproMCH (ppMCH) mRΝA levels (Presse et al . , 1992). Thus MCH may serve as an integrative neuropeptide involved in the reaction to stress, as well as in the regulation of feeding and sexual activity (Baker, 1991; Knigge et al . , 1996) .
Although the biological effects of MCH are believed to be mediated by specific receptors, binding sites for MCH have not been well described. A tritiated ligand ( [3H] - MCH) was reported to exhibit specific binding to brain membranes but was unusable for saturation analyses, so neither affinity nor Braaχ were determined (Drozdz and Eberle, • 1995) . Radioiodination of the ■ tyrosine at position thirteen resulted in a ligand with dramatically reduced biological activity (see Drozdz and Eberle, 1995) . In contrast, the radioiodination of the MCH analogue [Phe13,Tyr19] -MCH was successful (Drozdz et al . , 1995) ; the ligand retained biological activity and exhibited specific binding to a variety of cell lines including mouse melanoma (B16-F1, G4F, and G4F-7) , PC12, and COS cells. In G4F-7 cells, the KD = O.llδnM and the
Bmax -1100 sites/cell. Importantly, the binding was not inhibited by α-MSH but was weakly inhibited by rat ANF
(Ki = 116 nM vs. 12 nM for native MCH) (Drozdz et al . ,
1995) . More recently specific MCH binding was reported in transformed keratinocytes (Burgaud et al . , 1997) and melanoma cells (Drozdz et al . , 1998), where photo- crosslinking studies suggest that the receptor is a membrane protein with an apparent molecular weight of 45-50 kDaltons, compatible with the molecular weight range of the GPCR superfamily of receptors. No radioautoradiographic studies of MCH receptor localization using this ligand have been reported as yet .
The localization and biological activities of MCH peptide suggest that the modulation of MCH receptor activity may be useful in a number of therapeutic applications. The role of MCH in feeding is the best characterized of its potential clinical uses. MCH is expressed in the lateral hypothalamus , a brain area implicated in the regulation of thirst and hunger (Grillon et al . , 1997); recently orexins A and B, which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus (Sakurai et al . , 1998). MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation (Herve and Fellman, 1997) ; after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA
(Bahjaoui-Bouhaddi et al . , 1994). Consistent with the ability of MCH to stimulate feeding in rats (Rossi et al., 1997) is the observation that MCH mRNA levels are upregulated in the hypothalami of obese ob/ob mice (Qu et al . , 1996), and decreased in the hypothalami of rats treated with leptin, whose food intake and body weight gains are also decreased (Sahu, 1998) . MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis) (Ludwig et al . , 1998). Together these data suggest a role for endogenous MCH in the regulation of energy balance and response to stress, and provide a rationale for the development of specific compounds acting at MCH receptors for use in the treatment of obesity and stress-related disorders.
In all species studied to date, a major portion of the neurons of the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers (Bittencourt et al . , 1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it may be of some value to consider the involvement of this MCH system in movement disorders, such as Parkinson's disease and Huntingdon's Chorea in which extrapyr midal circuits are known to be involved.
Human genetic linkage studies have located authentic hMCH loci on chromosome 12 (12q23-24) and the variant hMCH loci on chromosome 5 (5ql2-13) (Pedeutour et al . , 1994) . Locus 12q23-24 coincides with a locus to which autosomal dominant cerebellar ataxia type II (SCA2) has been mapped (Auburger et al . , 1992; Twells et al . , 1992) . This disease comprises neurodegenerative disorders, including an olivopontocerebellar atrophy. Furthermore, the gene for Darier's disease, has been mapped to locus 12q23-24 (Craddock et al . , 1993). Dariers' disease is characterized by abnormalities I keratinocyte adhesion and mental illnesses in some families. In view of the functional and neuroanatomical
• patterns of the MCH neural system in the rat and human brains, the MCH gene may represent a good candidate for
SCA2 or Darier's disease. Interestingly, diseases with high social impact have been mapped to this locus. Indeed, the gene responsible for chronic or acute forms of spinal muscular atrophies has been assigned to chromosome 5ql2-13 using genetic linkage analysis (Melki et al., 1990; estbrook et al . , 1992). Furthermore, independent lines of evidence support the assignment of a major schizophrenia locus to chromosome 5qll.2-13.3
(Sherrington et al . , 1988; Bassett et al . , 1988; Gilliam et al., 1989). The above studies suggest • that MCH may play a role in neurodegenerative diseases and disorders of emotion.
Additional therapeutic applications for MCH-related compounds are suggested by the observed effects of MCH in other biological systems. For example, MCH may regulate reproductive functions in male and female rats. MCH transcripts and MCH peptide were found within germ cells in -testes of adult rats, suggesting that MCH may participate in stem cell renewal and/or differentiation of early spermatocytes (Hervieu et al . , 1996) . MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual activity in female rats (Gonzalez et al . , 1996) . In ovariectomized rats primed with estradiol, MCH stimulated luteinizing hormone (LH) release while anti- MCH antiserum inhibited LH release (Gonzalez et al . , 1997) . The zona incerta, which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the pre-ovulatory LH surge (MacKenzie et al . , 1984). MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin. MCH analogues may also be useful, in treating epilepsy. In the PTZ seizure model, injection of MCH prior to seizure induction prevented seizure activity in both rats and guinea pigs, suggesting that MCH-containing neurons may participate in the neural circuitry underlying PTZ-induced seizure (Knigge and Wagner, 1997) . MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats (McBride et al . , 1994), raising the possibility that MCH receptor antagonists may be beneficial for memory storage, and/or retention. A possible role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. Finally, MCH may participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume (Parkes, 1996) .
Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, the results indicate that MCH may be an important peptide involved in the central control of fluid homeostasis in mammals.
The identification of a G-protein coupled receptor for MCH has recently been published (Chambers et al . , 1999; Saito et al . , 1999) . These groups identified MCH as the endogenous ligand for the human orphan G-protein coupled receptor SLC-1 (Lakaye et al . , 1998). The rat homologue of this receptor (now called MCH-1) was reported to be localized in regions of the rat brain associated with feeding behavior (e.g. dorsomedial and ventromedial hypothalamus) . The link between MCH-1 and the effects of MCH on feeding has been strengthened by recent reports on the phenotype of MCH-1 knockout mice. Two groups have shown independently (Marsh et al, 2002; Chen et al, 2002) that the targeted disruption of the MCH-1 receptor gene (MCH-1 knockout) in mice results in animals that are hyperphagic but are lean and have decreased body mass relative to wild-type littermates. The decrease in body mass is attributed to an increase in metabolism. Each group demonstrated that the MCH-1 knockout mice are resistant to diet-induced obesity, and generally exhibit weights similar to. littermates maintained on regular chow.
Finally, synthetic antagonist molecules for the MCH-1 receptor have now been described in the literature. Bednarek et al . (2002) have reported on the synthesis of high affinity peptide antagonists of MCH-1. In addition, a small molecule antagonist of MCH-1 has been described by Takekawa et al . (Takekawa et al . , 2002). This compound, T-226296, exhibits high affinity for the MCH-1 receptor (- 5-9 nM for rat and human MCH-1) , and was shown to inhibit food intake induced by the intracerebroventricular application of MCH. These data validate the strategy of using an MCH-1 receptor antagonist to treat obesity.
Furthermore, in our own studies, we have tested MCHl antagonists in several animal models that are well known as predictive for the efficacy of compounds in humans (Borowsky, et al . , in press; unpublished data) . These experiments indicate that MCHl antagonists are useful to treat obesity, depression, anxiety, as well as urinary disorders .
As used in this invention, the term "antagonist" refers to a compound which binds to, and decreases the activity of, a receptor in the presence of an agonist. In the case of a G-protein coupled receptor, activation may be measured using any appropriate second messenger system which is coupled to the receptor in a cell or tissue in which the receptor is expressed. Some specific, but by no means limiting, examples of well-known second messenger systems are adenylate cyclase, intracellular calcium mobilization, ion channel activation, guanylate cyclase and inositol phospholipid hydrolysis. Conversely, the term "agonist" refers to a compound which binds to, and increases activity of, a receptor as compared • with the activity of the receptor in the absence of any agonist. In one embodiment of this invention, the synthesis of novel compounds which bind selectively to the cloned human melanin-concentrating hormone-1 (MCHl) receptor, compared to other cloned G-protein coupled receptors, and inhibit the activation of the cloned receptors as measured in in vi tro assays is disclosed. The in vi tro receptor binding assays described hereinafter were performed using various cultured cell lines, each transfected with and expressing only a single cloned receptor.
Furthermore, the compounds of the present invention may also be used to treat abnormal conditions such as feeding disorders (obesity, bulimia and bulimia nervosa) , sexual/reproductive disorders, depression, anxiety, depression and anxiety, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, sleep disturbances, or any condition in which antagonism of an MCHl receptor may be beneficial. In addition, the compounds of the present invention may be used to reduce the body mass of a subject. Furthermore, the compounds of the present invention may be used to treat urinary disorders .
Summary of the Invention
This invention provides a compound having the structure:
Figure imgf000011_0001
wherein Ri is hydrogen, straight chained or branched
C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -CH3, -CF3, -COR2, -C02R2, phenyl, phenoxy or straight chained or branched Cx-C6 alkyl;
wherein R is straight-chained or branched C3-C4 alkyl or cyclopropyl ;
wherein R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, straight chained or branched C -C alkyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, -C0R3, -C02R3, straight chained or branched Cχ-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is O or NH; and
wherein n is an integer from 0 to 5 inclusive. In one embodiment, R is aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -COR2,
-C02R2/ straight chained or branched C1-C7 alkyl;
wherein R3 is phenyl;
wherein A is H; and
wherein X is O.
In one embodiment, R2 is isopropyl,
In one embodiment, the compound has the structure:
Figure imgf000012_0001
In one embodiment, compound has the structure:
Figure imgf000012_0002
In one embodiment, Ri is hydrogen, straight chained or branched Cι-C7 alkyl; and wherein R3 is aryl.
In one embodiment, R2 is isopropyl; and A is hydrogen. In one embodiment, the compound has the structure
Figure imgf000013_0001
In one embodiment, the compound has the structure:
Figure imgf000013_0002
The present invention also provides a compound having the structure :
Figure imgf000013_0003
wherein Ri is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -OCH3, phenoxy, fused cyclopentanyl, straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein R2 is straight-chained or branched Cι-C4 alkyl or cyclopropyl; wherein A is -H, -F, -Cl, - Br, -CN, -N02, straight chained or branched Cχ-C-7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
wherein n is an integer from 1 to 5 inclusive.
In one embodiment, Ri is aryl optionally substituted with one or more -F, -Cl, -Br, -I or straight chained or branched Cι-C4 alkyl; and
wherein A is H.
In one embodiment, R2 is isopropyl; and
wherein n is 2
In one embodiment, the compound has the structure:
Figure imgf000014_0001
In one embodiment, the compound has the structure
Figure imgf000014_0002
In one embodiment, the compound has the structure:
Figure imgf000015_0001
In one embodiment, Ri is thienyl; and wherein A is H.
In one embodiment, R2 is isopropyl,
In one embodiment, the compound has the structure:
Figure imgf000015_0002
The invention provides a compound having the structure:
Figure imgf000015_0003
wherein is
Figure imgf000015_0004
wherein each R is independently hydrogen, methyl or ethyl ; wherein R2 is straight- chained or branched C3-C4 alkyl or cyclopropyl;
wherein R3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, -N02, straight chained or branched Cι~C7 alkyl.
wherein each A is independently -H, -F, -Cl, -Br, -CN, -N02, -COR3, -C02R3, straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is 0, NR3, CO or may be absent; and
wherein Y is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02/ straight chained or branched Q. -Cη alkyl.
In one embodiment, W is
Figure imgf000016_0001
and wherein X is 0 or may be absent,
In one embodiment, R2 is isopropyl. In one embodiment, the compound has the structure:
Figure imgf000017_0001
In one embodiment, the compound has the structure:
Figure imgf000017_0002
In one embodiment, W is
Figure imgf000017_0003
In one embodiment, A is -H, -F, -Cl, -Br.
In one embodiment, R2 is isopropyl; and A is hydrogen.
In one embodiment, the compound has the structure:
Figure imgf000018_0001
This invention provides a compound having the structure:
Figure imgf000018_0002
wherein W is
wherein Ri is hydrogen, straight chained or branched Cχ-C7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -OCH3, -C02CH3, -CF3, phenyl, straight chained or branched C1-C7 alkyl;
wherein R2 is straight-chained or branched C3-C4 alkyl or cyclopropyl ;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, -CORi, -C02Rι, straight chained or branched C1.-C7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl .
wherein each B is independently -H, -F, -Cl, -Br, -I, -CN, -N02, -CORi, -C02Rι, - OCH3, -OCF3, -CF3, straight chained or branched Cx-C7 alkyl, monofluoroalkyl or polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein the aryl, phenoxy or benzyloxy is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -C0Rχ, -C02Rι,
-OCH3, -OCF3, -CF3 or straight chained or branched Cl -C3 alkyl.
In one embodiment, W is
Figure imgf000019_0001
In one embodiment, Rx is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, straight chained or branched -0-j alkyl.
In one embodiment, R2 is isopropyl.
In one embodiment, the compound has the structure:
Figure imgf000019_0002
In one embodiment, the compound has the structure:
Figure imgf000020_0001
This invention provides a compound having the structure:
Figure imgf000020_0002
wherein Ri is hydrogen, straight chained or branched Cι-C7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -CF3, -OCH3, straight chained or branched Cχ-C3 alkyl;
wherein R2 is straight-chained or branched C3-C4 alkyl or cyclopropyl ;
wherein R3 is -H, -F, -Cl, -Br, -I, -CN, -N02, -CF3,
-OCH3, or straight chained or branched C1-C3 alkyl, monofluoroalkyl or polyfluoroalkyl , or a- phenyl ring fused to C6 and C7 of the indole moiety;
wherein R4 is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -CF3, straight chained or branched -03 alkyl; wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight- chained or branched Cx-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
wherein n is an integer from 2 to 4 inclusive.
In one embodiment, R3 is -H, -F, -Cl, -Br, -I, -CN, -N02, -OCF3 or -0CH3; and
wherein R4 is hydrogen or phenyl optionally substituted with one or more -F, -Cl or -CF3.
In one embodiment, Rx is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N02,
-CF3, -OCH3 or straight chained or branched C1.-C3 alkyl;
In one embodiment, R2 is isopropyl.
In one embodiment, the compound has the structure:
Figure imgf000021_0001
In one embodiment, the compound has the structure:
Figure imgf000022_0001
In one embodiment, the compound has the structure
Figure imgf000022_0002
This invention provides a compound having the structure:
Figure imgf000022_0003
wherein each Ri is independently hydrogen or CH3;
wherein R2 is straight-chained or branched Cι-C4 alkyl or cyclopropyl ;
wherein R3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenenedioxy group or one or more -F or -Cl ; wherein A is -H, -F, -Cl, - Br, -CN, -N02, straight chained or branched Cx-C6 alkyl, monofluoroalkyl or polyfluoroalkyl ;
wherein X is (CH2)2, COCH2 or CONH;
In one embodiment, R3 is phenyl optionally' substituted with one or more -F; and
wherein A is hydrogen.
In one embodiment, X is CONH.
In one embodiment, R2 is methyl.
In one embodiment, the compound has the structure:
Figure imgf000023_0001
In one embodiment, the compound has the structure:
Figure imgf000023_0002
wherein each Y is independently hydrogen or -F.
In one embodiment, the compound has the structure:
Figure imgf000024_0001
In one embodiment, the compound has the structure:
Figure imgf000024_0002
In one embodiment, R3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl .
In one embodiment, the compound has the structure:
Figure imgf000024_0003
wherein each Y is independently hydrogen or -F. In one embodiment, the compound has the structure:
Figure imgf000025_0001
In one embodiment, the compound is enantiomerically pure .
In one embodiment, the compound is diastereomerically pure.
In one embodiment, the compound is enantiomerically and diastereomerically pure.
This invention also provides a pharmaceutical composition comprising a therapeutically amount of a compound of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the amount of the compound is from about 0.0lmg to about 500mg.
In one embodiment, the amount of the compound is from about 0. lmg to about 60mg'.
In one embodiment, the amount of the compound is from about lmg to about 20mg. In one embodiment, the pharmaceutical composition consists of a carrier which is a liquid and the composition is a solution.
In one embodiment, the pharmaceutical composition consists of a carrier which is a solid and the composition is a tablet.
In one embodiment, the pharmaceutical composition consists of a carrier which is a gel and the composition is a suppository.
The invention also provides a process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of the invention and a pharmaceutically acceptable carrier.
This invention also provides the method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of the invention.
In one embodiment, the therapeutically effective amount is between about 0.03 and about 1000 mg per day.
In one embodiment, the therapeutically effective amount is between about 0.30 and about 300 mg per day.
In one embodiment, the therapeutically effective amount is between about 1.0 and about 100 mg per day. In one embodiment, the disorder is depression.
In one embodiment, the disorder is anxiety.
In one embodiment, the disorder is obesity.
In one embodiment, the disorder is urge incontinence.
The invention provides the method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.
The invention provides the method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims of the invention effective to treat the subject's depression.
The invention 'provides the method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's anxiety.
The invention provides the method of alleviating urge urinary incontinence in a subject suffering from an overactive bladder, which comprises administering to the subject an amount of the compound of the invention effective to alleviate the subject's urge urinary incontinence . The invention provides the method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of the invention effective to induce weight loss in the subject.
The invention provides the method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of the invention effective to maintain such weight loss in the subject.
The invention provides the method of treating overactive bladder in a subject, which comprises administering to the subject an amount of a compound of any of the invention effective to treat the subject's overactive bladder.
The invention provides the method of treating a disorder in a subject, wherein the symptoms of the subject can be alleviated by treatment with an MCHl antagonist, wherein the MCHl antagonist is the compound of the invention.
The invention provides the method of alleviating the symptoms of a disor4der in a subject, which comprises administering to the subject an amount of an MCHl antagonist effective to alleviate the symptoms, wherein the MCHl antagonist is the compound of the invention. Detailed Description of the Invention
This invention provides a compound having the structure:
Figure imgf000029_0001
Figure imgf000030_0001
wherein each V is independently phthalimide, aryl, phenoxy or heteroaryl, wherein the aryl, phenoxy or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR5 ; C02R5; -OCOR5; -CON(R5)2; -N(R5)COR5; CN; -N02; -N(R5)2; -OR5; -SR5; (CH2)qOR5; (CH2)qR5; (CH2)qSR5; straight chained or branched Cι-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl ; straight chained or branched C2-C7 alkenyl, C2-C7 alkynyl; aryl; phenoxy; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl ;
wherein each W is independently aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted ith one or more F; Cl; Br; I; COR3; -OCOR3; C02R3; -CON(R3)2; -N(R3)COR3; CN; -N02; -N(R3)2; -OR3; -SR3; (CH2)q0R3; (CH2)qSR3; straight chained or branched Cι-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl, C2-C7 alkynyl; aryl; phenoxy; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl ; wherein X is hydrogen or - OR3, provided that when X is -OR3 the V geminal to X cannot be phthalimide;
wherein Y is hydrogen, =0 (carbonyl oxygen) , 0R3, OV, COV, =NNHV, =NNR5, NZR5, NZV, NCONV (ureas) , NCONRs, NR3, carbazole, indole or phthalimide;
wherein each R is independently -H; -F; straight chained or branched Cx-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; -N(R3)2; -N02; -CN; -C02R3; -OCOR3; -OR3; or -N(R3)COR3; -CON(R3)2;
wherein each R3 is independently -H; straight chained or branched Cλ-C-j alkyl, monofluoroalkyl or polyfluoroalkyl ; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
wherein each R5 is -H; -N02; -N3; -CN; straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -0R3; -(CH2)pOR3; -COR3; -C02R3;
-OCOR3; -CON(R3)2; -N(R3)C0R3; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; C0R6; C02R3 ; -OCOR3; -CON(R3)2; -N(R3)COR3; CN; -N02; -N(R3)2; -OR6; -SRS; (CH2)qOR6; (CH2)qSR6; straight chained or branched Cι-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl, C2-C7 alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl ;
wherein R6 is. -H; straight chained or branched Cα-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -OR3; -(CH2)pOR3; -C0R3; -C02R3; -0C0R3; -CON(R3)2; -N(R3)COR3; aryl, benzyl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR3; C02R3; -OCOR3; -CON(R3)2; -N(R3)COR3, CN; -N02; -N(R3)2; -OR3; -SR3; (CH2)q0R3; (CH2)qSR3; straight chained or branched Cι-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; aryl; benzyl; straight chained or branched C2-C7 alkenyl, C2-C7 alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
wherein Z is CO, S02 or S02NR6;
wherein each m is independently an integer from 0 to 3 inclusive;
wherein each n is independently an integer from 0 to 5 inclusive;
wherein each p is independently an integer from 1 to 7 inclusive; and
wherein q is an integer from 1 to 3 inclusive;
or a pharmaceutically acceptable salt thereof. As used in the present invention, the term "cycloalkyl" includes C3-C7 cycloalky moities which may be substituted with one or more of the following: F; CN; -N0 ; straight chained or branched Cx-C7 alkyl, straight chained or branched Cι-C7 monofluoroalkyl, straight chained or branched Ci-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl; C3-C7 cycloalkyl, C3-C7 monofluorocycloalkyl, C3-C7 ' polyfluorocycloalkyl, C5-C cycloalkenyl, -N(R3)2; -OR3; -NCOR3; -C0R3; -C0R3; -C0N(R3)2 or (CH2)p-0- (CH3)m-CH3.
In the present invention, the term "cycloalkenyl" includes C5-C7 cycloalkenyl moities which may be substituted with one or more of the following: -F; -Cl; -Br, -I; CN; -N02; straight chained or branched Cχ-C-7 alkyl, straight chained or branched Cχ-C7 monofluoroalkyl, straight chained or branched Cχ-C-j polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl; C3-C7 cycloalkyl, C3-C7 monofluorocycloalkyl, C3-C7 polyfluorocycloalkyl, C5-C7 cycloalkenyl, -N (R3) 2; -OR3; -NCOR3; -COR3; -C02R3; -CON(R3)2 or (CH2) p-0- (CH3) ra-CH3.
As used in the present invention, the term "heteroaryl" is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms. Examples of heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazzolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl .
In addition, the term "heteroaryl" is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen. Examples of such heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo [b] furanyl , benzo [b] thiophenyl, indazolyl, benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo [b] thiazolyl, imidazo [2, 1-b] thiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1, 8-naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2,1,3 -benzothiazolyl .
The term "heteroaryl" also includes those chemical moieties recited above which may be substituted with one or more of the following: -F; -Cl; -Br, -I; CN; -N02; straight chained or branched Cι-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched Cι-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl; C3-C7 cycloalkyl, C3-C7 monofluorocycloalkyl, C3-C7 polyfluorocycloalkyl, C5-C7 cycloalkenyl, -N(R3) 2,• -0R3; -NC0R3; -COR3; -C02R3; CON(R3)2 or (CH2)p-0-(CH3)m-CH3.
In still another embodiment of the above described invention, the compound has the structure:
Figure imgf000035_0001
In a further embodiment of the instant invention, R6 is straight chained or branched Cι-C7 alkyl; C3-C7 cycloalkyl; -N(R3)2; -OR3; -(CH2)pOR3; aryl, benzyl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; -OR3; -(CH2)qOR3; or straight chained or branched Ci-C7 alkyl.
In an embodiment of the present invention, the compound has the structure:
Figure imgf000036_0001
In a further embodiment of the present invention, at least one V is phenyl optionally substituted with one or more F; Cl ; Br; -OR3; (CH2)qOR3; straight chained or branched Ci-C7 alkyl; Cx-C? polyfluoroalkyl; or phenoxy.
In one embodiment of the present invention, the compound is :
Figure imgf000036_0002
In one embodiment, the compound is;
Figure imgf000036_0003
In one embodiment, the compound is:
Figure imgf000037_0001
In another embodiment of the present invention, the compound has the structure:
Figure imgf000037_0002
In a further embodiment of the present invention, at least one V is phenyl optionally substituted with one or more F; Cl; Br; -OR3; (CH2)qOR3; straight chained or branched Cι-C7 alkyl; Cι-C7 polyfluoroalkyl; or phenoxy.
In another embodiment of the present invention, the compound is
Figure imgf000037_0003
In one embodiment , the compound is
Figure imgf000038_0001
In a further embodiment of the present invention, the compound has the structure:
Figure imgf000038_0002
In another embodiment of the present invention, at least one V is phenyl optionally substituted with one or more F; Cl; Br; -OR3; -C0R3; (CH2) qOR3 ; straight chained or branched Cι-C7 alkyl; Cι-C7 polyfluoroalkyl; aryl or phenox .
In yet another embodiment of the present invention, the compound is
Figure imgf000039_0001
In one embodiment, the compound is
Figure imgf000039_0002
In one embodiment, the compound is
Figure imgf000039_0003
In one embodiment, the compound is
Figure imgf000039_0004
In one embodiment, the compound is
Figure imgf000040_0001
In one embodiment, the compound is
Figure imgf000040_0002
In an embodiment of the present invention, the compound has the structure:
Figure imgf000040_0003
-
In a further embodiment of the present invention, at least one V is phenyl optionally substituted with one or more F; Cl; Br; -OR3; (CH2)qOR3; straight chained or branched C1-C7 alkyl; C1-C7 polyfluoroalkyl; or phenoxy. In yet another embodiment of the present invention, the compound is
Figure imgf000041_0001
In one embodiment, the compound has the structure:
Figure imgf000041_0002
In one embodiment, the compound has the structure:
Figure imgf000041_0003
In one embodiment, the compound has the structure
Figure imgf000041_0004
In one embodiment , the compound has the structure :
Figure imgf000042_0001
In one embodiment, the compound has the structure:
Figure imgf000042_0002
In one embodiment, the compound has the structure:
Figure imgf000042_0003
In one embodiment, the compound has the structure:
Figure imgf000042_0004
In one embodiment, the compound has the structure:
Figure imgf000043_0001
In an additional embodiment of the present invention, Y is hydrogen and V is phthalimide.
In an additional embodiment of the present invention, R6 is straight chained or branched Ci-C7 alkyl; C3-C7 cycloalkyl; -N(R3)2; -OR3; -(CH2)p0R3; aryl, benzyl or heteroaryl, optionally substituted with one or more F; Cl ; Br; I; -OR3; -(CH2)qOR3; or straight chained or branched C1-C7 alkyl.
In a further embodiment of the present invention, the compound is
Figure imgf000043_0002
In one embodiment, the compound has the structure:
Figure imgf000043_0003
In one embodiment of the compound, at least one V is phenyl or heteroaryl optionally substituted with one or more F; Cl ; Br; I; R5; -OR5; - (CH2) qOR5; -(CH2)qR5; straight chained or branched Cι-C7 alkyl; Cι-C7 monoflouroalkyl or polyflouroalkyl; or phenoxy.
In one embodiment, the compound has the structure:
Figure imgf000044_0001
In one embodiment, the compound has the structure:
Figure imgf000044_0002
In one embodiment of the compound, V is phenyl which is optionally substituted with one or more F; Cl; Br; -0R5; -(CH2)qOR5; -(CH2)qR5; straight chained or branched
Figure imgf000044_0003
alkyl; Cι-C7 monoflouroalkyl or polyflouroalkyl ; or phenoxy.
In one embodiment, the compound has the structure:
Figure imgf000044_0004
In one embodiment, the compound has the structure:
Figure imgf000045_0001
In one embodiment, the compound has the structure:
Figure imgf000045_0002
In one embodiment, the compound has the structure:
Figure imgf000045_0003
In one embodiment, the compound has the structure
Figure imgf000045_0004
In one embodiment of the compound, R5 is straight chained or branched Cι-C7 alkyl; C3-C7 cycloalkyl;
-N(R6)2; -OR6; - (CH2) qOR6; -CH(RS)2; -(CH2)qRs ; or aryl, benzyl or heteroaryl, wherein the aryl, benzyl or heteroaryl is optionally .substituted with one or more F; Cl; I; Rs ; -N(Rε)2; -ORe; -(CH2)qOR6; -(CH2)qR&; or Straight chained or branched Cι-C7 alkyl . In one embodiment, the compound has the structure:
Figure imgf000046_0001
In one embodiment, the compound has the structure:
Figure imgf000046_0002
In one embodiment of the compound, X is hydrogen and Y is carbazole optionally substituted with one or more F; Cl; Br; R5; -0R5; - (CH2) qOR5; -(CH2)qR5 ; straight chained or branched Ci - C7 alkyl; or C1-C7 monoflouroalkyl or poly louroalkyl; or phenoxy.
In one embodiment , the compound has the structure :
Figure imgf000046_0003
In one embodiment, the compound has the structure:
Figure imgf000046_0004
In one embodiment of the compound, Y is hydrogen and
V is an indole, which can be optionally substituted with one or more F; Cl; Br; R5; -C02R5; -ORs; -(CH2)q0R5; -
(CH2)qR5; straight chained or branched Ci - C7 alkyl; Cι-C7 monoflouroalkyl or polyflouroalkyl; or phenoxy on the 1,
2, 3, 4 , 5, 6 or 7 positions.
In one embodiment, the compound has the structure:
Figure imgf000047_0001
In one embodiment, the compound has the structure:
Figure imgf000047_0002
In one embodiment, the compound has the structure':
Figure imgf000047_0003
In one embodiment, the compound has the structure:
Figure imgf000047_0004
In one embodiment, the compound has the structure:
Figure imgf000048_0001
In one embodiment, the compound has the structure:
Figure imgf000048_0002
In one embodiment, the compound has the structure:
Figure imgf000048_0003
In one embodiment, the compound has the structure:
Figure imgf000048_0004
In one embodiment, the compound has the structure:
Figure imgf000048_0005
In one embodiment, the compound has the structure:
Figure imgf000049_0001
In one embodiment, the compound has the structure:
Figure imgf000049_0002
In one embodiment, the compound has the structure:
Figure imgf000049_0003
In one embodiment, the compound has the structure:
Figure imgf000049_0004
In one embodiment, the compound has the structure:
Figure imgf000050_0001
In one embodiment, the compound has the structure:
Figure imgf000050_0002
The present invention provides a compond having the srucuture :
Figure imgf000051_0001
wherein each X is independently O or S;
wherein q is 1 or 2;
wherein each R is independently H; -(CH2)tXR3;
- (CH2) tC (X)N(R3) 2; - (CH2) tC02R3 ; -C02R3; straight chained or branched C1-C7 alkyl optionally substituted with -N(R3)2; -CON(R3)2 or -N (R3) C (0) R3; straight chained or branched C2-C alkenyl, or alkynyl; or C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
wherein each t is independently an integer from 1 to 4 inclusive;
wherein each R3 is independently H; straight chained or branched Cι-C7 alkyl, straight chained or branched C2-C7 alkenyl, or alkynyl; or C3-C7 cycloalkyl or C5-C7 cycloalkenyl ; wherein R4 is aryl, heteroaryl, Cι-C7 alkyl substituted with one or two aryl, or C1-C7 alkyl substituted with one or two heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F, Cl, Br, I,
-CN, -N02, -N(R3)2, -C0R3, -(CH2)nXR3, - (CH2) nC (X) NR3, -(CH2)nN(R3)C(X)R3, - (CH2)nC02R3, - (CH2) nOCOR3 , straight chained or branched C1-C7 alkyl, monofluoroalkyl OR polyfluoroalkyl or straight chained or branched C2-C7 aminoalkyl, alkenyl or alkynyl, or C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
wherein each n independently is an integer from 0 to 7 inclusive;
wherein R5 is H; aryl, Cι-C7 alkyl substituted with aryl, heteroaryl, or C -C alkyl substituted with heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F, Cl, Br, I, -CN, -N02, -N(R3)2, -COR3, - (CH2)nXR3, - (CH2)nC(X)NR3, - (CH2) nC02R3, straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl or carboxamidoalkyl, or straight chained or branched C2-C7 aminoalkyl, alkenyl or alkynyl, or C3-C7 cycloalkyl or CΞ-C7 cycloalkenyl;
where R5 and one R2 on adjacent carbon atoms together may form aryl, heteroaryl, indane or tetrahydronaphthyl, C3- C7 cycloalkyl, or heterocycloalkyl wherein one or two heteroatoms may be 0, N or S;
wherein Ri is
Figure imgf000053_0001
wherein- each V is independently aryl, phenoxy .or heteroaryl, wherein the aryl, phenoxy or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR5; C02R5; ' -OCOR5; -CON(R5)2; -N(R5)COR5; CN; -N02; - N(R5)2; -OR5; -SR5; (CH2)qOR5; (CH2)qSR5; straight chained or branched C1-C7 alkyl optionally substituted with - CON(R5)2, -N(R5)C(0)R3 or N(R3)2, straight chained or branched monofluoroalkyl or polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, C2-C7 alkynyl; phenoxy; or C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
wherein each R6 is independently H; (CH2)tXR3; (CH2)tC(X)NR3; (CH2) tN (R3) C (X) R3 ; (CH2) tC02R3 ; (CH2)tOCOR3; straight chained or branched Cχ-Cη alkyl optionally substituted with -CON(R3)2 or -NC(0)R3; straight chained or branched C2-C7 alkyl substituted with -N(R3)2; straight chained or branched C2-C7 alkenyl or alkynyl; or C3-C7 cycloalkyl or C5-C cycloalkenyl;
where each R7 is independently H; F; Cl; Br; I; -COR3; - C02R3; -(CH2)nXR3; - (CH2) nN (R3) C (0) R3; (CH2) nC (X) N (R3) 2; - (CH2)' nC02R3; -CN; -N02 ; -N(R3)2; straight chained or branched Cx-C7 alkyl, hydroxyalkyl , aminoalkyl, carboxamidoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-Cη alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or C5-C7 cycloalkenyl, wherein the alkyl, aminoalkyl, carboxamidoalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be substituted with one or more aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more of F, Cl, Br, I, -(CH2)nXR3, -C0R3, - (CH2) nC (X) N (R3) 2, - (CH2) nC02R3, - CN, -N02, - (CH2)nN(R3)C(0)R3; -N(R3)2, -S02R3, straight chained or branched Ci-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, straight chained or branched C2-C7 alkenyl or alkynyl, or C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or CΞ-C7 cycloalkenyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more of F, Cl, Br, I, -(CH2)nXR3, -C0R3, - (CH2) nC (X) N (R3) 2
- ( CH2) nC02R3 , - (CH2) nN (R3 ) C (0) R3 ; -CN, -N02 ,
-N(R3)2, -S0R3, straight chained or branched Cχ-C-7 alkyl, straight chained or branched Cχ-C7 monofluoroalkyl or polyfluoroalkyl, straight chained or branched C2-C7 alkenyl or alkynyl, or C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or C5-C7 cycloalkenyl ;
wherein B is CO, S02 or S02NR6;
wherein R8 is -H; straight chained or branched Cχ-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -NR3C(0)R3; -0R3; -(CH2)p0R3; - COR3; -C02R3; -OCOR3; -CON(R3) 2; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR3; C02R3; -OCOR3; -NR3C(0)R3; -C0N(R3)2; CN; -N02; - N(R3)2; -OR3; -SR3; (CH2)qOR3; (CH2)qSR3; straight chained or branched Ci-C7 alkyl optionally substituted with - CON(R3)2, -NR3C(0)R3 or -N(R3)2; straight chained or branched monofluoroalkyl, polyfluoroalkyl; straight chained or branched C2-C7 alkenyl, C2-C7 alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
wherein each m independently is an integer from 0 to 3 inclusive;
wherein Z is 55
Figure imgf000056_0001
Figure imgf000057_0001
or C2-C7 alkenyl, wherein the C2-C7 alkenyl may be unsubstituted or substituted with one or more Rg groups;
wherein each R9 is independently H; F; Cl; Br; I; • - (CH2)mXR3; (CH2)mC(X)NR3; (CH2) mC02R3 ; straight chained or branched Cι-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl, or alkynyl; or C3-C7 cycloalkyl or C5-C7 cycloalkenyl; wherein R10 is H; (CH2)tXR3; (CH2) tC (X)NR3; (CH2) tC02R3; straight chained or branched C - 7 alkyl, carboxamidoalkyl; straight chained or branched C2-C7 aminoalkyl, alkenyl, or alkynyl; or C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
wherein Y is S, O, or NRi0;
wherein each p is independently an integer from 1 to 7 inclusive;
or a pharmaceutically acceptable salt thereof.
In a further embodiment of the present invention, the compound has the following structure:
Figure imgf000058_0001
In an additional embodiment of the present invention, the compound has the structure :
Figure imgf000059_0001
In an additional embodiment of the present invention, the compound has the structure :
Figure imgf000059_0002
In one embodiment of the present invention, Z is:
Figure imgf000059_0003
In one embodiment of the present invention, Z is:
Figure imgf000060_0001
In an additional embodiment of the present .invention, the compound has the structure:
Figure imgf000060_0002
In one embodiment of the present invention, the compound has the strucuture:
Figure imgf000060_0003
This invention provides a compound having the structure:
Figure imgf000061_0001
wherein Ri is hydrogen, straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -CH3, -CF3, -COCH3, -C02R2, phenyl, phenoxy or straight chained or branched Cχ-C7 alkyl;
wherein R2 is straight-chained or branched C3-C4 alkyl or cyclopropyl;
wherein R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more
-F, -Cl, -Br, -I, -CN, -N02, straight chained or branched Cx-C6 alkyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, -COR3, -C02R3, straight chained or branched C1.-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is 0 or NH;
wherein n is an integer from 0 to 5 inclusive;
In one embodiment, R is aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -COCH3, -C02R2, straight chained or branched Cχ-C7 alkyl;
wherein R3 is phenyl;
wherein A is H; and
wherein X is 0.
In one embodiment, R2 is isopropyl.
In a preferred embodiment, X is NH, Ri is alkyl and n is 1 or 2.
In the most preferred embodiment, X is O, R is 3 -acetyl phenyl, R2 is isopropyl, R3 is phenyl and n is 1.
In one embodiment, the compound has the structure:
Figure imgf000062_0001
In one embodiment, compound has the structure:
Figure imgf000062_0002
In one embodiment, Ri is hydrogen, straight chained or branched C--C7 alkyl; and wherein R3 is aryl.
In one embodiment, R2.is isopropyl; and A is hydrogen.
In one embodiment, the compound has the structure:
Figure imgf000063_0001
In one embodiment, the compound has the structure:
Figure imgf000063_0002
The present invention also provides a compound having the structure:
Figure imgf000063_0003
wherein Rx is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -OCH3, phenoxy, fused cyclopentanyl, straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; wherein R2 is straight-chained or branched Cι-C4 alkyl or cyclopropyl ;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight chained or branched Cι~C7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
wherein n is an integer from 1 to 5 inclusive.
In one embodiment, R3. is aryl optionally substituted with one or more -F, -Cl, -Br, -I or straight chained or branched Cχ-C4 alkyl; and
wherein A is H.
In one embodiment, R2 is isopropyl; and
wherein n is 2
In a preferred embodiment, n is 2 and R2 is isopropyl.
In one embodiment, the compound has the structure:
Figure imgf000064_0001
In one embodiment, the compound has the structure:
Figure imgf000064_0002
In one embodiment, the compound has the structure:
Figure imgf000065_0001
In one embodiment, R is thienyl; and wherein A is H.
In one embodiment, R2 is isopropyl.
In one embodiment, the compound has the structure:
Figure imgf000065_0002
The invention provides a compound having the structure:
Figure imgf000065_0003
wherein W is
Figure imgf000065_0004
wherein each Ri is independently hydrogen, methyl or ethyl ;
wherein R2 is straight-chained or branched C3-C4 alkyl or wherein R2 is straight- chained or branched C3-C4 alkyl or cyclopropyl;
wherein R3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, -N02, straight chained or branched C!-C7 alkyl.
wherein each A is independently -H, -F, -Cl, -Br, -CN, -N02 -COR3, -C02R3, straight chained or branched Cx-C6 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is 0, NR3, CO or may be absent; and
wherein Y is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, straight chained or branched ^-07 alkyl.
In one embodiment, W is
Figure imgf000066_0001
and wherein X is O or may be absent.
In one embodiment, R2 is isopropyl. In one embodiment, the compound has the structure;
Figure imgf000067_0001
In one embodiment, the compound has the structure:
Figure imgf000067_0002
In one embodiment, W is
Figure imgf000067_0003
In one embodiment, A is -H, -F, -Cl, -Br.
In one embodiment, R2 is isopropyl; and A is hydrogen.
In one embodiment, the compound has the structure:
Figure imgf000067_0004
This invention provides a compound having the structure:
wherein
Figure imgf000068_0001
wherein Rτ is hydrogen, straight chained or branched Cι-C7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -OCH3, -C02CH3, -CF3, phenyl, straight chained or branched C1-C7 alkyl;
wherein R2 is straight-chained or branched C3-C alkyl or cyclopropyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, -CORi, -C02Rι, straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl.
wherein each B is independently -H, -F, -Cl, -Br, -I,
-CN, -N02, -CORi, -C02Rι, -0CH3, -0CF3, -CF3, straight chained or branched C -C7 alkyl, monofluoroalkyl or polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein the aryl, phenoxy or benzyloxy is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -CORi, -C02Rι, -OCH3, -OCF3, -CF3 or straight chained or branched Cl -C3 alkyl.
In one embodiment, W is
Figure imgf000069_0001
In one embodiment, Ri is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, straight chained or branched C1-C7 alkyl.
In one embodiment, R2 is isopropyl.
In one embodiment, the compound has the structure:
Figure imgf000069_0002
In one embodiment, the compound has the structure:
Figure imgf000069_0003
This invention provides a compound having the structure:
Figure imgf000070_0001
wherein Rx is hydrogen, straight chained or branched Cχ-C7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -CF3, -OCH3, straight chained or branched Cχ-C3 alkyl;
wherein R2 is straight-chained or branched C3-C4 alkyl or cyclopropyl ;
wherein R3 is -H, -F, -Cl, -Br, -I, -CN, -N02, -CF3, -OCH3, or straight chained or branched Cχ-C3 alkyl, monofluoroalkyl ' or polyfluoroalkyl , or a phenyl ring fused to Cε and C7 of the indole moiety;
wherein R is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -CF3, straight chained or branched Cχ-C3 alkyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight chained or branched Cχ-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
wherein n is an integer from 2 to 4 inclusive. In one embodiment, R3 is - H, -F, -Cl, -Br, -I, -CN,
N02/ -OCF3 or -OCH3; and
wherein R4 is hydrogen or phenyl optionally substituted with one or more -F, -Cl or -CF3.
In one embodiment, Rx is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -CF3, -OCH3 or straight chained or branched Cχ-C3 alkyl;
In one embodiment, R2 is isopropyl.
In one embodiment, the compound has the structure:
Figure imgf000071_0001
In one embodiment, the compound has the structure:
Figure imgf000071_0002
In one embodiment, the compound has the structure:
Figure imgf000071_0003
This invention provides a compound having the structure:
Figure imgf000072_0001
wherein each Ri is independently hydrogen or CH3;
wherein R2 is straight-chained or branched Cχ-C4 alkyl or cyclopropyl; wherein R3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenenedioxy group or one or more -F or -Cl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight chained or branched Cχ-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is (CH2)2, COCH2 or CONH;
In one embodiment, R3 is phenyl optionally substituted with one or more -F; and
wherein A is hydrogen.
In one embodiment, X is CONH.
In one embodiment, R2 is methyl.
In one embodiment, the compound has the structure:
Figure imgf000073_0001
In one embodiment, the compound has the structure:
Figure imgf000073_0002
wherein each Y is independently hydrogen or -F .
In one embodiment, the compound has the structure:
Figure imgf000073_0003
In one embodiment, the compound has the structure:
Figure imgf000073_0004
In one embodiment, R3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl .
In one embodiment, the compound has the structure:
Figure imgf000074_0001
wherein each Y is independently hydrogen or -F.
In one embodiment, the compound has the structure:
Figure imgf000074_0002
In one embodiment, the compound is enantiomerically pure.
In one embodiment, the compound is diastereomerically pure.
In one embodiment, the compound is enantiomerically and diastereomerically pure.
This invention also provides a pharmaceutical composition comprising a therapeutically amount of a compound of the invention and a pharmaceutically acceptable carrier.
In one embodiment, the amount of the compound is from about 0.0lmg to ahout 500mg.
In one embodiment, the amount of the compound is from about 0. lmg to about 60mg.
In one embodiment, the amount of the compound is from about lmg to about 20mg.
In one embodiment, the pharmaceutical composition consists of a carrier which is a liquid and the composition is a solution.
In one embodiment, the pharmaceutical composition consists of a carrier which is a solid and the composition is a tablet .
In one embodiment, the pharmaceutical composition consists of a carrier which is a gel and the composition is a suppository.
The invention also- provides a process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of the invention and a pharmaceutically acceptable
'carrier.
This invention also provides the method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of the invention.
In one embodiment, the therapeutically effective amount is between about 0.03 and about 1000 mg per day.
In one embodiment, the therapeutically effective amount is between about 0.30 and about 300 mg per day.
In one embodiment, the therapeutically effective amount is between about 1.0 and about 100 mg per day.
In one embodiment, the disorder is depression. _
In one embodiment, the disorder is anxiety.
In one embodiment, the disorder is obesity.
In one embodiment, the disorder is urge incontinence.
The invention provides the method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.
The invention provides the method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims of the invention effective to treat the subject's depression. The invention provides the method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's anxiety. ' "
The 'invention provides the method of alleviating urge urinary ' incontinence in a subject suffering from an overactive bladder, which comprises administering to the subject an amount of the compound of the invention effective to alleviate the subject's urge urinary incontinence.
The invention provides the method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of the invention effective to induce weight loss in the subject.
The invention provides the method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of the invention effective to maintain such weight loss in the subject.
The invention provides the method of treating overactive bladder in a subject, which comprises administering to the subj ect an amount of a compound of any of the invention effective to treat the subject'.s overactive bladder .
The invention provides the method of treating a disorder in a subj ect , wherein the symptoms of the subj ect can be alleviated by treatment with an MCHl antagonist, wherein the MCHl antagonist is the compound of the invention.
The invention provides the method of alleviating the symptoms of a disor4der in a subject, which comprises administering to the subject an amount . of an MCHl antagonist effective to alleviate the symptoms, ' wherein the MCHl antagonist is the compound of the invention
As used in the present invention, the term "heteroaryl" is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms. Examples of heteroaryl groups include, but are not limited to, carbazole, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
In addition, the term "heteroaryl" is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen. Examples of such heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo [b] furanyl , benzo [b] thiophenyl , indazolyl , benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo [b] thiazolyl, imidazo [2, 1-b] thiazolyl,. cinnolinyl, quinazolinyl, quinoxalinyl, 1, 8-naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2,1,3 -benzothiazolyl . The term "heteroaryl" also includes those chemical moieties recited above which may be substituted with one or more of the following: -F, -Cl, -Br, -I, CN, -N02, straight chained or branched Cχ-C7 alkyl, straight chained or branched Cχ-C7 monofluoroalkyl, straight chained or branched Cχ-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl; C3-C7 cycloalkyl, C3-C7 monofluorocycloalkyl, C3-C7 polyfluorocycloalkyl, C5-C7 cycloalkenyl,
The term "heteroaryl" further includes the N-oxides of those chemical moieties recited above which include at least one nitrogen atom.
In the present invention, the term "aryl" is phenyl or naphthyl .
The invention provides for each pure stereoisomer of any of the compounds described herein. Such stereoisomers may include enantiomers, diastereomers, or E or Z alkene or imine isomers. The invention also provides for stereoisomeric " mixtures, including racemic mixtures, diastereomeric mixtures, or E/Z isomeric mixtures. Stereoisomers can be synthesized in pure form (Nόgradi-,- M.; Stereoselective Synthesis, (1987) VCH Editor Ebel, H. and Asymmetric Synthesis, Volumes 3 ■ B 5, (1983) Academic Press, Editor Morrison, J.) or they' can be resolved by a variety of methods such as crystallization and chromatographic techniques (Jaques, J. ; Collet, A. ; ilen, S.; Enantiomer, Racemates, and Resolutions, 1981, John Wiley and Sons and Asymmetric Synthesis, Vol.
2, 1983, Academic Press, Editor Morrison, J) .
In addition the compounds of the present invention may be present as enantiomers, diasteriomers, isomers or two or- more of the ' compounds may be present to form a racemic or diastereomeric mixture.
The compounds of the present invention are preferably 80% pure, more preferably 90% pure, and most preferably 95% pure. Included in this invention are pharmaceutically acceptable salts and complexes of all of the compounds described herein. The acids and bases from which these salts are prepared include but are not limited to' the acids and bases listed herein. The acids, include, but are not limited to, the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and boric acid. The acids include> but are not limited to, the following organic acids: acetic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, maleic acid, citric acid, methanesulfonic acid, benzoic acid, glycolic acid, lactic acid and mandelic acid. The bases include, but are not limited to ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine , trimethylamine, triethylamine, ethylenediamine, hydroxyethylamine, morpholine, piperazine and guanidine . This invention further provides for the hydrates and polymorphs of all of the compounds described herein.
The present invention includes within its scope prodrugs of the compounds of the invention. In general, such prodrugs will be functional derivatives of the compounds of the invention which are readily convertible in vivo into the required compound. Thus, in the present invention, the term "administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after . administration to
" the patient. Conventional procedures for the selection. and preparation of suitable prodrug derivatives are -• described, for example, in Design of Prodrugs, ed. H.. ι Bundgaard, Elsevier, 1985.
" ' ■ The present invention further includes metabolites of the compounds of the present invention. Metabolites include active species produced upon introduction of compounds of this invention into the biological milieu.
This invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. In one embodiment, the amount of the compound is from about 0.01 mg to about 800 mg. In another embodiment, the amount of the compound is from about 0.01 mg to about 500 mg. In yet another embodiment, the amount of the compound is from about 0.1 mg to about 250 mg. In another embodiment, the amount of the compound is from about 0.1 mg to about 60 mg. In yet another embodiment, the amount of the compound is from about 1 mg to about 20 mg. In a further, embodiment, the carrier is a liquid and the composition is a solution. In another embodiment,- the carrier is a solid and the composition is a tablet. In another embodiment, the carrier is a gel and the composition is a capsule, suppository or a cream. In
■ ■ a further embodiment the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.
In yet a further embodiment, the compound may be delivered to.' 'the ' subject by means of a spray or inhalant .
This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceuticall acceptable, carrier.
.This -invention- provides a process for making a pharmaceutical ' composition comprising combining - a - therapeutically 'e fective amount of the compound of. this - invention and a pharmaceutically acceptable carrier.
- -solid carrier can include one or more substances which may also act as .endogenous carriers (e.g. nutrient or micronutrient carriers), flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders', the carrier is a finely divided solid which is lh admixture with the finely divided active ingredient.
■In tablets, - the active ingredient is mixed with a carrier -having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in ' a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers or osmoregulators . Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives/ preferably sodium carboxymethyl cellulose solution) , alcohols (including onohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils
(e.g. fractionated coconut oil and arachis oil) . .For
• parenteral administration, the carrier can also be an oily ester such as ethyl oleate or isopropyl myristate.
Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The- liquid carrier for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellent.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example,- intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. Carriers are intended to include, necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. The compound can be administered orally in- the form of a s$£ lile - solution ;■- or suspension, containing other solutes or suspending agents (for example, enough - saline or glucose to make the solution isotonic) , bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
The compound can also be administered orally either in liquid, or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granuϊs., tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include "sterile solutions, emulsions, and suspenions .
Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result iξ a need to adjust dosages, including subject age, weight, gender, diet, and time of administration. In the subject application a "therapeutically effective amount" is any amount of a compound which, when administered to a subject suffering from a disease against which the compounds are effective, causes reduction, remission, or regression of the disease. In a subject application, a "subject" is a vertebrate, a mammal or a human.
This invention provides a method of treating a subject suffering from an abnormality wherein the abnormality is alleviated by decreasing the activity of an MCHl receptor which comprises administering to the subject an amount of a compound of the invention which is an MCHl receptor antagonist effective to treat the subject=s abnormality.
In separate embodiments, the abnormality is a regulation of a steroid or pituitary hormone disorder, an epinephrine release disorder, a gastrointestinal disorder,- a cardiovascular disorder, an electrolyte balance disorder, hypertension, diabetes, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder such as Alzheimer=s disease, a sensory modulation and transmission disordex-, a motor coordination disorder, a sensory integration disorder, . a motor integration disorder, a dopaminergic function disorder such as Parkinson=s disease, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder such as depression and anxiety, a stress-related disorder, a fluid-balance disorder, a seizure disorder, pain, psychotic behavior such as schizophrenia, morphine tolerance, opiate addiction, migraine or a urinary disorder such as urinary incontinence.
The following description of depressive and anxiety disorders is for the purpose of illustrating the utility of the compounds of this invention. The definitions of depressive and anxiety disorders given below are those listed in Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV; American Psychiatric Association, 1994a) or Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Revised (DSM-III-R; American Psychiatric Association, 1987) . Additional information regarding these disorders can be found in this reference, as well as the others cited below, all of which are incorporated herein by reference.
Depressive disorders include major depressive disorder and dysthymic disorder (American Psychiatric Association, 1994a; American Psychiatric Association, 1994b) . Major depressive disorder is characterized by the occurrence of one or more major depressive episodes without manic or hypomanic episodes. A major depressive episode is defined as a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks) ; it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation (Medical Economics Company, 2002) . Dysthymic disorder involves a type of depression that is not severe enough to be called a major depressive episode, but that lasts much longer than major depressive disorder, without high phases.
It is contemplated that the compounds of this invention will be effective in treating depression in patients who have been diagnosed with depression by administration of any of the following tests: Hamilton Depression Rating
Scale (HDRS) , Hamilton depressed mood item, Clinical
Global Impressions (CGI) -Severity of Illness. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain of the factors measured in these tests, such as the HDRS subfactor scores, including the depressed mood item, sleep disturbance factor and anxiety factor, and the CGI-Severity of Illness rating. It is also contemplated that the compounds of this invention will be effective in preventing relapse of major depressive episodes.
Anxiety disorders include panic disorder, agoraphobia with or without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder and generalized anxiety disorder. It is ■ contemplated that the compounds of this invention will be effective in treating any of all of these disorders in patients who have been diagnosed with these disorders. Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable (American Psychiatric
Association, 1994a) . The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.
It is contemplated that the compounds of this invention will be effective in treating obsessions and compulsions in patients who have been diagnosed with obsessive compulsive disorder by administration of appropriate tests, which may include, but are not limited to any of the following: Yale Brown Obsessive Compulsive Scale (YBOCS) (Goodman, 1989) (for adults) , National Institute of Mental Health Global OCD Scale (NIMH GOCS) , CGI- Severity of Illness scale. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain of the factors measured in these tests, such as a reduction of several points in the YBOCS total score. It is also contemplated that the compounds of this- invention will be effective in preventing relapse of obsessive compulsive disorder.
Panic disorder is characterized by recurrent unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks (American Psychiatric Association, 1994a) . A panic attack is defined as a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself) ; fear of losing control; (11) fear of dying;
(12) paresthesias (numbness or tingling sensations) ;
(13) chills or hot flushes. Panic disorder may or may not be associated with agoraphobia, or an irrational and often disabling fear of being out in public.
It is contemplated that the compounds of this invention will be effective in treating panic disorder in patients who have been diagnosed with panic disorder on the basis of frequency of occurrence of panic attacks, or by means of the CGI-Severity of Illness scale. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain of the factors measured in these evaluations, such- as a reduction in frequency or elimination of panic attacks, an improvement in the CGI-Severity of Illness scale or a CGI-Global Improvement score of 1 (very much improved) , 2 (much improved) or 3 (minimally improved)-. It is also contemplated that the compounds of this invention will be effective in preventing relapse of panic disorder.
Social anxiety disorder, also known as social phobia, is characterized by a marked and persistent fear of one or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others (American Psychiatric Association,
1994a) . Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress.
The avoidance, anxious anticipation, or distress in the feared situation (s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment .
It is contemplated that the compounds of this invention will be effective in treating social anxiety disorder in patients who have been diagnosed with social anxiety disorder by administration of any of the following tests: the Liebowitz Social Anxiety Scale (LSAS) , the CGI-Severity of Illness scale, the Hamilton Rating Scale for Anxiety (HAM-A) , the Hamilton Rating Scale for Depression (HAM-D) , the axis V Social and Occupational Functioning Assessment Scale of DSM-IV, the axis II
(ICD-10) World Health Organization Disability
Assessment, Schedule 2 (DAS-2) , the Sheehan Disability
Scales, the Schneier Disability Profile., the World
Health Organization Quality of Life-lOO (WHOQOL-100) , or other tests as described in Bobes, 1998, which is incorporated herein by reference. It is further contemplated that the compounds of the invention will be effective in inducing improvements as measured by these tests, such as the a change from baseline in the
Liebowitz Social Anxiety Scale (LSAS) , or a CGI- Global
Improvement score of 1 (very much improved) , 2 (much improved) or 3 (minimally improved) . It is also contemplated that the compounds of this invention will be effective in preventing relapse of social anxiety disorder.
Generalized anxiety disorder is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control (American Psychiatric
Association, 1994a) . It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. The diagnostic criteria for this disorder are described in further detail in DSM-IV, which is incorporated herein by reference (American Psychiatric Association, 1994a) .
It is contemplated that the compounds of this invention will be effective in treating generalized anxiety disorder in patients who have been diagnosed with this disorder according to the diagnostic criteria described in DSM-IV. It is further contemplated that the compounds of the invention will be effective in reducing symptoms of this disorder, such as the following: excessive worry and anxiety, difficulty controlling worry, restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, or sleep disturbance . It is also contemplated that the compounds of this invention will be effective in preventing relapse of general anxiety disorder.
Post-traumatic stress disorder (PTSD) , as defined by DSM-III-R/IV (American Psychiatric Association, 1987, American Psychiatric Association, 1994a) , requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include re-experiencing of the event in the form of -intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
It is contemplated that the compounds of this invention will be effective in treating PTSD in patients who have been diagnosed with PTSD by administration of any of the following tests: Clinician-Administered PTSD Scale Part 2 (CAPS) , the patient-rated Impact of Event Scale (IES)
(Medical Economics Company, 2002, p. 2752) . It is further contemplated that the compounds of the invention will be effective in inducing improvements in the scores of the CAPS, IES, CGI-Severity of Illness or CGI-Global Improvement tests. It is also contemplated that the compounds of this invention will be effective in preventing relapse of PTSD.
In a preferred embodiment, the subject invention provides a method of treatment or management of the following indications: depressive disorders, anxiety disorders, eating/body weight disorders, and urinary disorders. Examples of depressive disorders are major depressive disorder or dysthymic disorder. Examples of anxiety disorders are panic disorder, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post- traumatic stress disorder, acute stress disorder or generalized anxiety disorder. Examples of eating/body weight disorders are obesity, weight gain, bulimia, bulimia nervosa or anorexia nervosa. Examples of urinary disorders include, but are not limited to urinary incontinence overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia or enuresis. Overactive bladder and urinary urgency may or may not be associated with benign prostatic hyperplasia.
This invention provides a method of modifying the feeding behavior of a subject, which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention also provides a method of treating an eating disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the eating disorder. In an embodiment of the present invention, the eating disorder is obesity, bulimia, bulimia nervosa or anorexia nervosa.
The present invention further provides a method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention also provides a method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of the invention effective to induce weight loss in the subject. This invention also provides a method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of the invention effective to maintain such weight loss in the subject.
The present invention also provides a method of treating depression in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression. This invention also provides a method of treating anxiety in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's anxiety. This invention also provides a method of treating depression and anxiety in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and anxiety. This invention also provides a method of treating major depressive disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's major depressive disorder. This invention also provides . a method of treating dysthymic disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's dysthymic disorder. This invention also provides a method of treating obsessions and compulsions in a subject with obsessive compulsive disorder, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's obsessions and compulsions. This invention also provides a method of treating panic disorder, with or without agoraphobia, in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's panic disorder. This invention also provides a method of treating social anxiety disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat , the subject's social anxiety disorder. This invention also provides a method of treating generalized anxiety disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's generalized anxiety disorder. This invention also provides a method of treating post-traumatic stress disorder in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's post-traumatic stress disorder.
It is contemplated that the compounds of this invention will be effective in treating obesity, including weight loss and maintenance of weight loss in patients, who have been diagnosed with obesity by the one or more of the following measurements: an increased body mass index, increased waist circumference (an indicator of intra-adominal fat) , Dual Energy X-Ray Absorptiometry (DEXA) and trucal (android) fat mass. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain factors measured in these tests.
It is contemplated that the compounds of this invention will be effective in treating urinary disorders in patients who have urge or mixed (with a predominance of urge) incontinence as evidenced by the number of unnecessary episodes per week, the number of unnecessary micturitions per day and a low volume voided per micturition. It is further contemplated that the compounds of the invention will be effective in inducing improvements in certain factors measured in these tests.
The present invention also provides a method of treating a subject suffering from bipolar I or II disorder, schizoaffective disorder, a cognitive disorder with depressed mood, a personality disorder, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder or sleepwalking disorder. The present invention provides a method of treating overactive bladder with symptoms of urge urinary incontinence, urgency and/or frequency in a subject, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's overactive bladder. This invention also provides a method of alleviating urge urinary incontinence in a subject suffering from overactive bladder, which comprises administering to the subject an amount of a compound of the invention effective to alleviate the subject's urge urinary incontinence. This invention further provides a method of alleviating urinary urgency in a subject suffering from overactive bladder, which comprises administering to the subject an amount of a compound of the invention effective to alleviate the subject's urinary urgency. Additionally, this invention provides a method of alleviating urinary frequency in a subject suffering from overactive bladder, which comprises administering to the subject an amount of a compound of the invention effective to alleviate the subject's urinary frequency.
The present invention also provides a method of treating a subject suffering from a urinary disorder, which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's urinary disorder. In some embodiments the urinary disorder is urinary incontinence, overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia or enuresis. The present invention provides a method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject an amount of an MCHl antagonist effective to alleviate the symptoms, wherein the MCHl antagonist is any of the compounds of the invention.
In an embodiment of the invention, the subject is a vertebrate, a mammal, a human or a canine. In another embodiment, the compound is administered orally. In yet another embodiment, the compound is administered in combination with food.
This invention will be better understood from the Experimental Details In a preferred embodiment, the subject invention provides a method of treatment for the following indications: depression, anxiety, eating/body weight disorders, and urinary disorders. Examples of eating/body weight disorders are obesity, bulimia, or bulimia nervosa. Examples of urinary disorders include, but are not limited to, urinary incontinence, overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia, or enuresis. Overactive bladder and urinary urgency may or may not be associated with benign prostatic hyperplasia.
This invention provides, a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention also provides a method of treating an eating disorder in a subject which comprises administering to the subject an amount of a compound of this invention effective to decrease the consumption of food by the subject. In an embodiment of the present invention, the eating disorder is bulimia, obesity or bulimia nervosa. In an embodiment of the present invention, the subject is a vertebrate, a mammal, a human or a canine . In a further embodiment , the compound is administered in combination with food.
The present invention further provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subj ect .
The present invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's depression. The present invention further provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's anxiety. The present invention also provides a method of treating a subject suffering from depression and anxiety which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's depression and anxiety.
The present invention also provides a method of treating a subject suffering from major depressive disorder, dysthymic disorder, bipolar I and II disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, . narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, obsessive-compulsive disorder, panic disorder, with or without agoraphobia, posttraumatic stress disorder, social anxiety disorder, social phobia and generalized anxiety disorder.
The present invention also provides a method of treating a subject suffering from a urinary disorder which comprises administering to the subject an amount of a compound of this invention effective to treat the subject's a urinary disorder. In some embodiments, the urinary disorder is urinary incontinence, overactive bladder, urge incontinence, urinary frequency, urinary urgency, nocturia, or enuresis.
This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
Experimental Section
I. Synthetic Methods for Examples
General Methods: All reactions (except for those done by parallel synthesis reaction arrays) were performed under an Argon atmosphere and the reagents, neat or in appropriate solvents, were transferred to the reaction vessel via syringe and cannula techniques . The parallel synthesis reaction arrays were performed in vials
(without an inert atmosphere) using J-KEM heating shakers (Saint Louis, MO) . Anhydrous solvents were purchased from Aldrich Chemical Company and used as received. The examples described in the patent were named using ACD/Name program (version 2.51, Advanced Chemistry Development Inc., Toronto, Ontario, M5H2L3 , Canada) . Unless otherwise noted, the 1H spectra were recorded at 300 and 400 MHz (QE Plus and Brύker respectively) with tetramethylsilane as internal standard, s = singlet; d = doublet; t = triplet; q = quartet; p = pentet; sext; sept; br = broad; m = multiplet. Elemental analyses were performed by Robertson Microlit Laboratories, Inc. Unless otherwise noted, mass spectra were obtained using low-resolution electrospray (ESMS) and MH+ is reported. Thin-layer chromatography (TLC) was carried out on glass plates precoated with silica gel 60 F254 (0.25 mm, EM Separations Tech.). Preparative • thin-layer chromatography was carried out on glass sheets precoated with silica gel GF (2 mm, Analtech) . Flash column chromatography was performed on Merck silica gel 60 (230 - 400 mesh) . Melting points (mp) were determined in open capillary tubes on a Mel-Temp apparatus and are uncorrected.
Piperidine Side Chain Intermediates
TERT-BUTYL 4-{ [ (TRIFLUOROMETHYL) SULFONYL] OXY}-1,2,3,6 -TETRAHYDRO-1-PYRIDINECARBOXYLATE: Ώ-Butyl lithium (17.6 mL, 44.2 mmol, 2.5 M in hexanes) was added to a solution of diisopropyl amine (96.2 mL, 44.2 mmol) in 40 mL of dry THF at 0 °C and stirred for 20 minutes. The reaction mixture was cooled to -78 °C and tert-butyl 4-oxo-l-piperidinecarboxylate (Aldrich Chemical Company, 40.0 mmol) in THF (40 mL) was added dropwise to the reaction mixture and stirred for 30 minutes. Tf2NPh (42.0 mmol, 15.0 g) in THF (40 mL) was added dropwise to the reaction mixture and stirred at °C overnight. The reaction mixture was concentrated in vacuo, re-dissolved in hexanes : EtOAc (9:1), passed through a plug of alumina and the alumina plug was washed with hexanes : EtOAc (9:1). The combined extracts were concentrated to yield 16.5 g of the desired product that was contaminated with some starting Tf2NPh.
XH NMR (400 MHz, 400 MHz, CDC13) δ 5.77 (s, 1 H) , 4.05 (dm, 2 H, J=3.0 Hz), 3.63 (t, 2 H, J=5.7 Hz), 2.45 (m, 2 H) , 1.47 (s, 9 H) .
TERT-BUTYL 4- [3- (AMINO) PHENYL] -1,2,3, 6-TETRAHYDRO-1- PYRIDINECARBOXYLATE: A mixture of 2 M aqueous Na2C03 solution (4.2 mL) , tert-butyl 4- { [ (trifluoromethyl) sulfonyl] oxy} -1,2,3, 6-tetrahydro- 1-pyridine-carboxylate (0.500 g, 1.51 mmol), 3-aminophenylboronic acid hemisulfate (0.393 g, 2.11 mmol), lithium chloride (0.191 g, 4.50 mmol) and tetrakis- friphenylphosphine palladium (0) (0.080 g, 0.075 mmol) in dimethoxyethane
(5 mL) was heated at reflux temperature for 3 hours, under an inert atmosphere (an initial degassing of the mixture is recommended to prevent the formation of friphenylphosphine oxide) . The organic layer of the cooled reaction mixture was separated and the aqueous layer was washed with ethyl acetate (3X) . The combined organic extracts were dried and concentrated in vacuo . The crude product was chromatographed (silica, hexanes : EtOAc : dichloromethane (6:1:1) with 1% added isopropylamine to protect the BOC group from hydrolysis) to give 0.330 g of the desired product in 81% yield. 1H NMR (400 MHz, CDC13) δ 7.12 (t, 1H, J= 7.60 Hz), 6.78 (d, 1H, J= 8.4 Hz), 6.69 (t, 1H, J= 2.0 Hz), 6.59 (dd, 1H, J= 2.2, 8.0 Hz), 6.01 (m, 1H) , 4.10 - 4.01 (d, 2H, J= 2.4 Hz), 3.61 (t, 2H, J= 5.6 Hz), 2.52 - 2.46 (m, 2H) , 1.49 (s, 9H) ; ESMS m/e : 275.2 (M + H) + . Anal. Calc . for C16H24N2O2 : C, 70.04; H, 8.08; N, 10.21. Found: C, 69.78; H, 7.80; N, 9.92.
TERT-BUTYL 4- [3- (AMINO) PHENYL] -1-P PER DINECARBOXYLATE:
A mixture of 3.10 g of tert-butyl 4- (3-aminophenyl) - 1 , 2 , 3 , 6-tetrahydropyridine-l-carboxylate (11.3 mmol) and 1.0 g of 10% Pd/C in 200 mL of ethanol was hydrogenated at room temperature using the balloon method for 2 days. The reaction mixture was filtered and washed with ethanol. The combined ethanol extracts were concentrated in vacuo and the residue was chromatographed on silica (dichloromethane: methanol 95:5 with 1% isopropylamine added to protect the BOC group from hydrolysis) to give 2.63 g of the desired product (84%). 1H NMR (400 MHz, CDC13) δ 7.10 (t, 1H, J= 7.60 Hz), 6.62 (d, 1H, J= 8.4 Hz), 6.60 - 6.59 (m,
2H) , 4.27 - 4.18 (m, 2H) , 3.62 - 3.58 (m, 2H) , 2.80 -
2.72 (m, 2H) , 2.62 - 2.59 (m, 1H) , 1.89 - 1.52 (m, 4H) ,
1.49 (s, 9H) ; ESMS m/e : 277.2 (M + H) + .
TERT-BUTYL 4- [3- (ACETYLAMINO) PHENYL] -1, 2, 3, 6-TETRAHYDRO-
1-PYR D NECARBOXYLATE: A mixture of saturated aqueous
Na2C03 solution (25 mL) , tert-butyl
4- { [ (trifluoromethyl) sulfonyl] oxy} -1,2,3, 6-tetrahydro- 1-pyridine-carboxylate (20 mmol) ,
3-acetamidophenylboronic acid (30 mmol) and tetrakis- triphenylphosphine palladium (0) (1.15 g) and dimethoxyethane (40 mL) was heated at reflux temperature overnight. The organic layer of the cooled reaction mixture was separated and the aqueous layer was washed with ethyl acetate (3X) . The combined organic extracts were dried and concentrated in vacuo . The crude product was chromatograghed, giving the desired product: 1H NMR (CDC13) δ 8.11 (br s, 1 H) , 7.57 (br s, 1 H) , 7.41 (br d , 1 H, J=7.8 Hz), 7.25 (apparent t, 1 H, J=7.8 Hz), 7.08 (br d, 1 H, J=7.8 Hz), 5.99 (br s, 1 H) , 4.03 (br m, 2 H, J=2.7 Hz), 3.59 (t, 2 H, J=5.7 Hz), 2.46 (m, 2 H, ) , 2.16 (s, 3 H) , 1.49 (s, 9 H) .
Nl- [3- (1,2,3, 6-TETRAHYDRO-4-PYRIDINYL) PHENYL] CETAMIDE:
A solution of 4 M HCl in dioxane (10 mL) was added to tert-butyl 4- [3- (acetylamino) phenyl] -1,2,3, 6-tetrahydro- 1-pyridinecarboxylate (8.25 mmol) in dichloromethane (30 L) . The reaction mixture was stirred at room temperature overnight, concentrated in vacuo, giving the desired product as the hydrochloride salt (2.1 g) : 1H NMR (CDC13) δ 7.41-7.00 (m, 4 H) , 6.10 (br, 1 H) , 3.55 (m, 2 H) , 3 . 16 (t , 2 H, J - 5 . 7 Hz ) , 2 . 44 (m, 2 H) , 2 . 19
( s , 3 H) .
TERT-BUTYL N- (3 -BROMOPROPYL) CARBAMATE: Prepared from 3-bromopropylamine hydrobromide and BOC20 in the presence of base in dichloromethane, 9.89 mmol: 1H NMR (CDC13) δ 5.07 (br, 1 H) , 3.31 (t, 2 H, J=6.6 Hz), 3.12 (apparent br q, 2 H, J=6.0 Hz), 1.92 (p, 2 H, J=6.6 Hz), 1.30 (s, 9H) .
TERT-BUTYL N- (3-{4- [3- (ACETYLAMINO) PHENYL] -1,2,3, 6-TETRAHYDRO-l-PYRIDINYL}PROPYL) CARBAMATE: A solution of Nl - [3- (l,2,3,6-tetrahydro-4- pyridinyl) phenyl] acetamide. HCl (8.24 mmol), tert-butyl N- (3 -bromopropyl) carbamate and potassium carbonate (33 mmol) in dry dioxane (30 mL) was heated at reflux temperature overnight. The solids were removed by filtration, the solution was concentrated in vacuo and the product was chromatograghed, giving the desired product (110 mg) . XH NMR (CDC13) δ 7.65 (s, 1 H) , 6.98 (s, 1 H) , 7.45 (d, 1 H, J=7.8 Hz), 7.16 (apparent t, 1 H, J=7.8 Hz), 7.1θ" (d, 1 H, J=7.8 Hz), 6.02 (s, 1 H) , 5.23 (b,' l"H), 3.40 (b, 2 H) , 3.30-1.80 (m, 10 H) , 2.18 (s, 3 H) , 1.45 (s, 9 H) .
Nl-{3- [1- (3-AMINOPROPYL) -1, 2, 3 , 6-TETRAHYDRO-4- PYRIDINYL] PHENYL}ACETAMIDE : A 1:1 solution of TFA:CH2C12 (5 mL) was added to tert-butyl N- (3 -{4- [3- (acetylamino) phenyl] -1,2 , 3 , 6-tetrahydro-l- pyridinyl}propyl) carbamate in dichloromethane (5 mL) . The resulting solution was stirred at room temperature for 1-3 days, saturated NaHC03 was added until pH > 6, the organic layer was separated, and dried in vacuo, giving the desired product (45 g) : XH NMR (CDC13) δ
7.68 (br, 1 H) , 7.35 (dm, 1 H, J=7.8 Hz) , 7.25 (apparent t, 1 H, J=7.8 Hz), 7.15 (dm, 1 H, J=7.8 Hz), 6.12 (m, 1
H) , 3.22 (m, 2 H) , 3.03 (t, 2 H, J=7.3 Hz), 2.78 (t, 2 H, J=5.5 Hz) , 2.70-2.50 (m, 4 H) , 2.10 (s, 3 H) , 1.87
(p, 2 H, J=7.3 Hz) .
TERT-BUTYL 4- [3- (ACETYLAMINO) PHENYL] -1-
PIPERIDINECARBOXYLATE : A mixture tert-butyl 4- [3- (acetylamino)phenyl] -1, 2, 3 , 6-tetrahydro-l- pyridinecarboxylate (710 mg) and 5% Pd/C (100 mg) in EtOH (10 mL) was hydrogenated (balloon technique) at room temperature overnight. The reaction mixture was passed through a pad of Celite 545 and the pad of Celite was washed with ethanol. The combined ethanol extracts were concentrated and chromatograghed, giving the desired product (660 mg) : XH NMR (CDC13) δ 7.80 (s, 1 H) ,- 7.41-7.20 (m, 3 H) , 6.94 (d, l.H, J=7.5 Hz), 4.21 (m, 2 H) , 2.75 (m, 2 H) , 2.62 (m, 1 H) , 2.16 (s, 3 H) , 1.78 (m, 2 H) , 1.56 (m, 2 H) , 1.48 (s, 9 H) .
Nl- [3- (4-PIPERIDYL) PHENYL] CETAMIDE: A solution of HCl in dioxane (4N, 5 mL) was added to tert-butyl 4- [3- (acetylamino) phenyl] -1-piperidinecarboxylate (660 mg) in dry dichloromethane (15 mL) . The reaction mixture was stirred at room temperature overnight and concentrated in vacuo, giving the desired product. (550 mg) : mp 102-104 °C; XΗ. NMR (CDCl3) δ 2.02 (d, J=13.2 Hz, 2H) , 2.11-2.45 (m, 5H) , 2.67-2.77 (m, 1H) , 3.00-3.10 (m, 2H) , 3.51 (d, J=10.5 Hz, 2H) , 6.94 (d, J=7.5 Hz, 1H) , 7.20-7.46 (m, 3H) , 7.60 (s, 1H) ; Anal. Calcd. For C13H19N2OC1+0.86 CH2C12: C, 50.78; H, 6.37; N, 8.55. Found: C, 50.80; H, 7.55; N, 7.01. TERT-BUTYL N- (3-{4- [3- (ACETYLAMINO) PHENYL] PIPERIDINθ}PROPYL) CARBAMATE : A solution of Nl - [3- (4-piperidyl) phenyl] acetamide (550 mg, 0.210 mmol), tert-butyl N- (3 -bromopropyl) carbamate (550 mg, 0.230 mmol), K2C03 (1.10 g, 0.890 mmol), diisopropylethyl amine (1.50 mL) and a few crystals of KI in dioxane (20 mL) was heated at reflux temperature for 2 days. The precipitated salts were removed by filtration, concentrated in vacuo and the crude product was chromatographed, giving the desired product (340 mg) : XH NMR (CDC13) δ 8.15 (s, 1 H) , 7.47-7.44 (m, 2 H) , 7.22 (t, 1 H, J=7.8 Hz), 6.94 (d, 1 H, J=7.8 Hz), 5.53 (b, 1 H) , 3.23 (b, 6 H) , 2.80-1.60 (m, 9 H) , 2.20 (s, 3 H) , 1.45 (s, 9 H) .
Nl-{3- tl- (3-AMINOPROPYL) -4-PIPERIDYL] PHENYL} CETAMIDE:
TFA (1.0 mL) was added to a solution of tert-butyl N-(3-{4-[3-
(acetylamino) phenyl] piperidino}propyl) carbamate (340 mg) in dry dichloromethane (10 mL) and stirred at room temperature for 5 h. A 10% aqueous solution of KOH was added to the reaction mixture until pH > 6 and then the dichloromethane was removed in vacuo . The aqueous layer was frozen and lyophilized to give a solid, which was extracted with methanol . Removal of the solvent gave the desired product (120 mg) as an oil: λ NMR (CDC13) δ 7.23-7.16 (apparent t, 1H, J=7.5 Hz), 6.95-6.92 (m, 1H) , 3.03-2.99 (m, 2H) , 2.77-2.73 (t, 2H, J = 6 . 6 Hz), 2.50- 1.60 (m, 10 H) , 2.13 (s, 3 H) . TERT-BUTYL 4- (3-NITROPHENYL) -3 , 6-DIHYDRO-l (2H) -
PYRIDINECARBOXYLATE: According to the procedure used for the synthesis of tert-butyl 4- [3- (amino) phenyl] -1, 2, 3 , 6- tetrahydro-l-pyridinecarboxylate,a mixture of 2 M aqueous Na2C03 solution (2.2 mL) , tert-butyl 4-{ [ (trifluoromethyl) sulfonyl] oxy} -1, 2, 3 , 6-tetrahydro-l- pyridine-carboxylate (0.5.00 g, 1.51 mmol), 3-nitrophenylboronic acid (0.353 g, 2.11 mmol), lithium chloride (0.191 g, 4.50 mmol) and tetrakis- triphenylphosphine palladium (0) (0.080 g, 0.075 mmol) in dimethoxyethane (5 mL) afforded 0.380g of the desired product . XH NMR (400 MHz, CDC13) δ 8.23 (s, 1H) , 8.11 (d, 1H, J=8.0 Hz), 7.69 (d, 1H, J=8.0 Hz), 7.51 (t, 1H, J=8.0 Hz), 6.20 (m, 1H) , 4.17-4.08 (m, 2H) , 3.67 (t, 2H, J=5.6 Hz), 2.61-2.52 (m, 2H) , 1.50 (s, 9H) ; ESMS m/e : 249.1 (M + H - C4H8) + .
l,2,3,6-TETRAHYDR0-4- (3-NITROPHENYL) PYRIDINE: Into a stirred solution of 5.00 g (16.0 mmol) of tert-butyl 1,2,3, 6-tetrahydro-4- (3-nitrophenyl)pyridine-l- carboxylate in 100 ml of 1,4-dioxane at 0°C was bubbled HCl gas for 10 minutes. The reaction mixture was allowed to warm to room temperature and the bubbling of the HCl gas was continued for an additional 1 hour. The solvent was removed in vacuo, the residue was dissolved in 50. mL of water and was neutralized by the addition of KOH pellets. The aqueous solution was extracted with 3 X 80 mL of dichloromethane and the combined organic extracts were dried (MgS04) , filtered and concentrated in vacuo. The residue was purified by column chromatography (silica, 9 : 1 , dichloromethane : methanol + 1% isopropyl amine) to afford 2.85 g
(87.5% yield) of the desired product: XH NMR (400 MHz,
CDC13) δ 8.24 (s, 1H) , 8.09 (d, 1H, J=8.4 Hz), 7.71 (d,
1H, J=8.0 Hz), 7.49 (t, 1H, J=8.0 Hz), 6.35-6.25 (m, 1H), 3.58 (apparent q, 2H, J=3.0 Hz), 3.14 (t, 2H, J=5.6
Hz) , 2.54-2.46 (m, 2H) .
TERT-BUTYL 3- (4- (3-NITR0PHENYL) -3 , 6-DIHYDR0-1 (2H) - PYRIDINYDPROPYLCARBAMATE: A mixture of 2.80 g (14.0 mmol) of 1, 2 , 3 , 6-tetrahydro-4- (3 -nitrophenyl) pyridine, 3.60 g (15.0 mmol) of tert-butyl
N- (3 -bromopropyl) carbamate, 11.6 g (84.0 mmol) of K2C03, 14.6 mL (84.0 mmol) of diisopropylethylamine and 0.78 g (2.00 mmol) of tetrabutylammonium iodide in 250 mL of 1,4-dioxane was heated at reflux temperature for 14 hours . The reaction mixture was filtered and the filtrate was dried (MgS04) , concentrated in vacuo and the residue was purified by column chromatography (silica, 9:1, dichloromethane: methanol + 1% isopropyl amine) to afford 4.35 g (85.7% yield) of the desired product: E NMR (400 MHz, CDC13) δ 8.24 (t, 1H, J=1.9 Hz), 8.09 (dd, 1H, J=1.9, 8.0 Hz), 7.70 (apparent d, 1H, J=8.0 Hz), 7.49 (t, 1H, J=8.0 Hz), 6.23 (m, 1H) , 3.29-3.18 (m, 4H) , 2.75 (t, 2H, J=5.6 Hz), 2.64-2.54 (m, 4H) , 1.82-1.70 (m, 2H) , 1.44 (s, 9H) ; ESMS m/e : 362.2 (M + H) + .
3- (4- (3 -NITROPHENYL) -3, 6-DIHYDR0-1 (2H) -PYRIDINYL) -1- PROPANAMINE: Into a stirred solution of 4.35 (12.0 mmol) of tert-butyl 3- (4- (3 -nitrophenyl) -3 , 6-dihydro-l (2H) - pyridinyDpropylcarbamate in 100 ml of 1,4-dioxane at 0°C was bubbled HCl gas for 10 minutes. The reaction mixture was allowed to warm to room temperature and the bubbling was continued for an additional 1 hour. The solvent was removed in vacuo, the residue was dissolved in 50 mL of water and was neutralized by the addition of
KOH pellets. .The aqueous solution was extracted with 3 X 80 mL of dichloromethane, the combined organic extracts were dried (MgS04) , filtered and concentrated in vacuo. The residue was purified by column chromatography (silica, 9 : 1 , dichloromethane : methanol + 1% isopropyl amine) to afford 3.05 g (97.0% yield) of the desired product: E NMR (400 MHz, CDC13) δ 8.24 (t, 1H, J=1.8 Hz), 8.09 (dd, 1H, J=1.8, 8.2 Hz), 7.69 (dd, 1H, J=1.8, 8.2 Hz), 7.48 (t, 1H, J=8.2 Hz), 6.24 (m, 1H) , 3.21 (d, 2H, J=3.6 Hz), 2.84 (t, 2H, J=6.6 Hz), 2.75 (t, 2H, J=5.8 Hz), 2.64-2.54 (m, 4H) , 1.76 (m, 2H) ; ESMS m/e : 262.2 (M + H) + ; Anal . Calc . for Cι4H19N302 (0.06 CHC13) : C, 62.90; H, 7.16; N, 15.65. Found: C, 63.20; H, 7.16; N, 15.65.
METHYL (4S) -3- [ ({3- [4- (3-AMIN0PHENYL) -1- PIPERIDINYL] PR0PYL>AMIN0) CARBONYL] -4- (3,4-
DIFLUOROPHENYL) -6- (METHOXYMETHYL) -2-0X0-1,2,3,4- TETRAHYDR0-5-PYRIMIDINECARB0XYLATE: A mixture of 3.02 g (6.33 mmol) 5-methyl 1- (4-nitrophenyl) (6S) -6- (3 , 4- difluorophenyl) -4- (methoxymethyl) -2-oxo-3 , 6-dihydro- 1, 5 (2H) -pyrimidinedicarboxylate, 1.50 g (5.80 mmol) of 3- (4- (3-nitrophenyl) -3 , 6-dihydro-l (2H) -pyridinyl) -1- propanamine, 7.94 g (75.5 mmol) of K2C03 and 1.00 mL of methanol in 200 mL dichloromethane (under argon) was stirred at room temperature for 1 hour. The reaction mixture was filtered and concentrated in vacuo. The residue was dissolved in 100 mL of ethyl acetate and washed 3 X 50 mL of 5% aqueous NaOH solution, the organic layer was dried (MgS04) and concentrated in vacuo . The residue was dissolved in 100 mL of anhydrous ethanol containing 0.50 g 10% Pd/C and the reaction mixture was stirred under a hydrogen balloon for 24 hours. The reaction mixture was passed through a column of Celite 545 filtering agent, washed with ethanol, the filtrate was dried (MgS04) and concentrated in vacuo . The residue was purified, by column chromatography (silica, 9.5 : 0.5 , dichloromethane : methanol + 1% isopropyl amine) to afford 1.65 g (52.0% yield) of the desired product: XH NMR (400 MHz, CDC13) δ 7.80 (s, 1H) , 7.22-7.02 ■ (m, 2H) , 6.95 (t, J = 8.70 Hz, 1H) , 6.63-6.44 (m, 4H) , 4.56 (Abq, 2H) , 3.62 (s, 3H) , 3.33 (s, 3H) , 3.32-3.20 (m, 4H) , 2.96 (br s, 2H) , 2.33 (t, J = 7.50 Hz, 2H) , 2.11-1.94 (m, 3H) , 1.81-1.64 (m, 4H) ; ESMS m/e : 572.3 (M + H)+;
TERT-BUTYL 4- [3- (ISOBUTYRYLAMINO) PHENYL] -3 , 6-DIHYDR0- 1(2H) -PYRIDINECARBOXYLATE: Into a solution of 4.00 g (16.0 mmol) of tert-butyl 4- (3-aminophenyl) -3 , 6-dihydro- 1 (2H) -pyridinecarboxylate and 5.60 mL (32.0 mmol) of diisopropylethylamine in 100 mL dichloromethane was slowly added 1.90 mL (19.0 mmol) of isobutyryl chloride. The reaction mixture was stirred at room temperature for 2 hours, washed with water, dried (MgS04) , and concentrated in vacuo . The residue was purified by column chromatography (silica, 50 : 46 : 3 : 1, hexanes : dichloromethane : methanol : isopropyl amine) to afford 2.90 g (52.0% yield) of the desired product: 1H NMR (400 MHz, CDC13) δ 7.69 (s, 1 H) , 7.34 (d, 1 H, J=7.8 Hz), 7.27 (t, 1H, J=7.8 Hz), 7.11 (d, 1H, J=7.8 Hz), 6.04 (s, 1H) , 4.05 (s, 2H) , 3.62 (apparent t, 2 H, J=4.9 Hz), 2.51 (m, 3H) , 1.49 (s, 9H) , 1.25 (d, 6H, J=7.4 Hz); ESMS m/e : 345.5 (M + H) + . Anal. Calc . for C2oH28N203 + 0 . 175 CHC13 : C , 66 . 33 ; H, 7 . 77 ; N , 7 . 67 .
Found : C , 66 . 20 ; H , 7 . 41 ; N , 7 . 88
TERT-BUTYL 4- [3- (ISOBUTYRYLAMINO) PHENYL] -1 -PIPERIDINECARBOXYLATE: A mixture of 2.90 g (8.40 mmol) of tert-butyl 4- [3- (isobutyrylamino) phenyl] -3 , 6-dihydro- 1 (2H) -pyridinecarboxylate and 0.80 g of 10% yield Pd/C in 100 mL of ethanol was stirred under a hydrogen balloon for 24 hours. The reaction mixture was passed through a column of Celite 545 filtering agent, the filtrate was dried (MgS04) and concentrated in vacuo .
The residue .was purified by column chromatography
(silica, 9.5 : 0.5 , dichloromethane : methanol + 1% isopropyl amine) to afford 2.40 g (84.0% yield) of the desired product: X NMR (400 MHz, CDC13) δ 7.49-7.44 (m, 2H) , 7.24 (t, 1H, J=7.6 Hz), 6.93 (d, 1H, J=7.6 Hz), 4.20-4.10 (m, 2H) , 2.86-2.45 (m, 4H) , 1.86-1.75 (m, 4H) , 1.48 (s, 9H) , 1.24 (d, 6H, J=6.8 Hz); ESMS m/e : 345.2 (M + H)+; Anal. Calc. for C20H3o 2θ3+0.3H20 : C, 68.27; H, 8.77; N, 7.96. Found: C, 68.25; H, 8.54; N, 7.84.
2-METHYL-W- [3- (4-PIPERIDINYL) PHENYL] PROPANAMIDE: Into a stirred solution of 2.20 (6.50 mmol) of tert-butyl 4- [3- (isobutyrylamino) phenyl] -1-piperidinecarboxylate in 100 ml of 1,4-dioxane at 0 °C was bubbled HCl gas for 10 minutes . The reaction mixture was allowed to warm to room temperature and the bubbling of the HCl gas was continued for 1 hour. The solvent was removed in vacuo, the residue was dissolved in 50 mL of water and was neutralized by the addition of KOH pellets. The aqueous solution was extracted with 3 X 80 mL of dichloromethane, the combined organic extracts were dried (MgS04) , filtered and concentrated in vacuo. The residue was purified by column chromatography
(silica, 9 : 1 , dichloromethane : methanol + 1% isopropyl amine) to afford 0.700 g (46.0% yield) of the desired product: XH NMR (400 MHz, CDC13) δ 7.47 (s, 1H) , 7.40 (d, 1H, J=7.8 Hz), 7.24 (t, 1H, J=7.8 Hz), 7.00 (d,
1H, J=7.8 Hz), 3.23-3.14 (m, 5H) , 2.82-2.57 (m, 4H) ,
1.20 (d, 6H, J=6.8 Hz); ESMS m/e : 247.2 (M + H)+; The hydrochloride salt was used for the combustion analysis:
Anal. Calc. for C15H22N2O+HCl+0.15 CHC13 : C, 60.51; H, 7.76; N, 9.32. Found: C, 60.57; H, 7.83; N, 8.88.
3- (4 -PIPERIDINYL) NILINE: A solution of 4 M HCl in dioxane (25 mL) was added to tert-butyl 4- [3- (amino) phenyl] -1-piperidinecarboxylate (2.60 g, 9.00 mmol) in dichloromethane (250 mL) . The reaction mixture was stirred at room temperature overnight, concentrated in vacuo, and the residue was dissolved in water (50 mL) . The mixture was nuetralized using KOH pellets and extracted with methylene chloride (3 X 50 mL) . The combined organic extracts were dried (MgS04) , concentrated and chromatographed to give the desired product (1.03 g) . XE NMR (400 MHz, CDC13) δ 7.01 (t, 1H, J=7.6 Hz), 6.62-6.54 (m, 3H) , 3.16 (br d, 2H, J=10.3 Hz), 2.75 (dt, 2H, J=2.7, 12.3 Hz), 2.56 (tt, 1H, J=3.6, 12.3 Hz), 1.81 (br d, 2H, J=12.3 Hz), 1.65 (dq, 2H, J=4.0, 12.3 Hz); ESMS m/e : 177.2 (M + H) + .
TERT-BUTYL 4- (4-NITROPHENYL) -3 , 6-DIHYDRO-1 (2H) -
PYRIDINECARBOXYLATE: To a 25-mL RB flask, equipped with a condensor, was added tert-butyl 4- { [ (trifluoromethyl) sulfonyl] oxy}-3, 6-dihydro-l (2H) - pyridinecarboxylate (1.0 g) , 4-nitrophenylboronic acid (0.71 g) , sodium carbonate (0.430 mL of 2M solution), lithium chloride (0.382 g) , tetrakis (friphenylphosphine) - palladium (0) (0.173 g) and ethylene glycol dimethyl ether (10 mL) . The reaction mixture was flushed with Argon three times, then the reaction mixture was heated to 100 °C for 3 hrs.
After cooling to room temperature, the reaction mixture was diluted with methylene chloride (30 mL) and water
(30 mL) and the organic layer was separated. The aqueous layer was extracted with methylene chloride (3x20 mL) and the combined organic extracts were washed with sat NH4C1 (20 mL) and brine (20 mL) , dried over MgS04 and concentrated under reduced pressure. The residue was purified by chromatography (6 : l=hexane: ethyl acetate with 1% NH3) to afford the product (0.55 g, 59.9%) as a yellow oil. The compound is not stable at room temperature and should be used as promptly as practical: λE NMR (400 MHz, CDC13) δ 8.20 (d, 2H, J=8.6 Hz), 7.51 (d, 2H, J=8.6 Hz), 6.24 (m, 1H) , 4.13 (m, 2H) , 3.67 (apparent t, 2H, J=5.5 Hz), 2.55 (m, 2H) , 1.49 (s, 9H) .
4- (4-NITROPHENYL) -1, 2, 3 , 6-TETRAHYDROPYRIDINE: 4- (4-
Nitrophenyl) -1, 2 , 3 , 6-tetrahydropyridine was prepared by a similar procedure to that used for the preparation of 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide using HCl gas and tert-Butyl 4- (4-Nitrophenyl) -3 , 6-dihydro- 1 (2H) -pyridinecarboxylate (130 mg) in dioxane (5.0 mL) at room temperature. The reaction -mixture was concentrated in vacuo to give the crude product (69.8 mg) which used in the next reaction without further purification.
Oxazolidinone Intermediates: AMINO- (3 , 4-DIFLUOROPHENYL) -ACETONITRILE: Through a solution of 3,4-difluorobenzaldehyde (25.0 g, 0.176 mol) in MeOH (500 mL) in a round bottom flask, was bubbled ammonia gas for two hours at room temperature . The flask was then cooled to 0 °C and trimethylsilyl cyanide was then added slowly. The reaction mixture was stirred for 2 h, at which time TLC analysis indicated that the reaction was complete (Rf = 0.35, 3:2 hexane/EtOAc) . The solvent was removed in vacuo and the residue was subjected to flash column chromatography on silica gel to obtain the desired product, which was used in the next step without purification.
AMINO- (3, 4-DIFLUOROPHENYL) -ACETIC ACID METHYL ESTER:
Into a well-stirred solution of amino- (3,4- difluorophenyl) -acetonitrile (22.0 g, 0.130 mol), a solution of HCl in MeOH (200 mL) was added at room temperature. The resulting yellow solution was stirred at room temperature for 10 h and was heated at reflux temperature for 1.5 h. After cooling, the solvent was removed in vacuo and the resulting yellow solid was dissolved in water (200 mL) . The aqueous solution was then carefully basified with 20% NaOH solution to pH 9. The aqueous layer was extracted with CH2C12 (3 x 100 mL) . The organic layer was separated and dried over Na2S04, filtered and the solvent was removed in vacuo to obtain the desired product which was used in the next step without purification.
2-AMINO-2- (3, 4-DIFLUOROPHENYL) -ETHANOL: Into a well- stirred suspension of LiAlH4 (4.7 g, 0.125 mol) in THF (120 mL) in a 3-necked round bottom flask fitted with a condenser and a dropping funnel, was added a solution of amino- (3, 4-difluorophenyl) -acetic acid methyl ester (10.0 g, 0.05 mol) in THF (100 mL) dropwise at 0 °C. The resulting greenish brown suspension was heated at reflux temperature for 2 h. The reaction mixture was cooled to 0 °C and then carefully quenched sequentially with 5 mL of water, 5 mL .of 3N NaOH followed by 15 mL of water. The resulting suspension was filtered through a fritted glass funnel. To the filter cake was added 100 mL Et20 and the suspension was heated at reflux temperature for 20 min. The suspension was filtered and the combined filtrates were dried over MgS04, filtered and the solvent was removed in vacuo. 2 - Amino-2- (3, 4-difluorophenyl) -ethanol was obtained as a yellow glassy syrup which was used in the next step without further purification.
[1- (3, 4-DIFLUOROPHENYL) -2-HYDROXY-ETHYL] -CARBAMIC ACID- TERT-BUTYL ESTER: Into a solution of 2-amino-2- (3 , 4- difluorophenyl) -ethanol (8.6 g, 49.7 mmol) in CHC13 (150 mL) at 0 °C was added a solution of di -tert-butyl dicarbonate (11.4 g, 52.0 mmol) in CHC13 (50 mL) in one portion and the resulting solution was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was subjected to column chromatography on silica gel (2:1 hexane-EtOAc followed by EtOAc) to obtain [1- (3, 4-difluorophenyl) -2-hydroxy-ethyl] -carbamic acid- tert-butyl ester as a white solid (10.0 g, 74% yield) .
(+) -4- (3, 4-DIFLUOROPHENYL) -OXAZOLIDIN-2-ONE: Into a well-stirred suspension of NaH (1.1 g, 45.8 mmol) in THF (40 mL) at R.T. was added a solution of [l-(3,5- difluorophenyl) -2-hydroxy- ethyl] -carbamic acid- tert- butyl ester (5.0 g, 18.3 mmol) in THF (20 mL) via a dropping funnel at room temperature. The resulting suspension was stirred for 3 h and then quenched carefully with 10 mL of water. The biphasic mixture was extracted with 100 mL of Et20, washed with brine, filtered and the solvent was removed in vacuo. The gummy residue thus obtained was purified by column chromatography over silica gel (Rf = 0.15, 3:2 hexane- EtOAc) to obtain 4- (3 , 5-difluorophenyl) -oxazolidin-2-one as a white flaky solid (2.8 g, 77% yield). M.P. 81-83 °C; ^Η NMR (300 MHz, CDCl3) δ 7.23-7.03 (m, 3H),...6.08. (br s, 1H) , 4.94 (dd, J=6.6 Hz, J=8.7 Hz, 1 H) , 4.73 (t, J=8.7 Hz, 1 H) , 4.13 (dd, J=6.6 Hz, J=8.7 Hz, 1 H) . The enantiomers were separated by HPLC on a Chiralcel OD (20 x 250 mm) column using 80% hexane/20% isopropyl alcohol as the eluting system at 12.0 mL/min (U.V. 254 nm) . The retention times for the two isomers were 16.19 min and 20.08 min respectively.
4-NITROPHENYL (4S) -4- (3 , 4-DIFLUOROPHENYL) -2-0X0-1, 3- OXAZOLIDINE-3-CARBOXYLATE: Into a suspension of NaH (0.14 g, 5.30 mmol) in 20 mL of anhydrous THF under argon, a solution of (+) -4- (3 , 4-difluorophenyl) - oxazolidin-2-one (0.88 g, 4.42 mmol) in THF was added dropwise (dropping funnel) . The resulting suspension was stirred at room temperature for 30 min. This suspension was then added dropwise via -cannula into another round bottom flask containing a solution of 4- nitrophenylchloroformate (1.11 g, 5.30 mmol) in 25 mL of THF and cooled at -78 °C over a period of 15 min. The stirring was continued for 2 h after which the solvent ■was removed and the residue was purified by column chromatography on silica gel with 1:1 hexane/CH2Cl2 followed by CH2C12 (Rf= 0.4, CH2C12) to obtain the desired product as a white solid (1.55 g, 86% yield) .
Similarly, following the above procedure, 4- (3,5- difluorophenyl) -2-oxo-oxazolidine-3-carboxylic acid-4- nitro-phenyl ester and 4- (3 , 4, 5-trifluorophenyl) -2-oxo- oxazolidine-3-carboxylic acid-4-nitro-phenyl ester were obtained by substituting 3 , 4-diflourobenzaldehyde in the first step with 3 , 5-diflourobenzaldehyde or 3,4,5- triflourobenzaldehyde, respectively. The oxazolidinone enantiomers were resolved by HPLC on a Chiralcel OD column (as in the previous example) and the 4-nitrophenyl carbamates were prepared using 4-nitrophenyl ' chloroformate .
4-NITROPHENYL (4S) -4- (3, 5-DIFLUOROPHENYL) -2-0X0-1,3- OXAZOLIDINE-3 -CARBOXYLATE: Following the procedure for the synthesis of 4- (3 , 4-difluorophenyl) -2-oxo- oxazolidine-3-carboxylic acid-4-nitro-phenyl ester, 3,5- diflourobenzaldehyde yielded the desired product. E NMR (400 MHz, CDC13) δ 8.26 (d, 2H, J= 9.3 Hz), 7.33
- 6.81 (m, 5H) , 5.41 (dd, 1H, J=4.1, 8.7 Hz), 4.81 (t,
1H, J=9.3 Hz), 4.33 (dd, 1H, J=4.1, 9.3 Hz); Anal. Calc. for C16H10F2N2O6+0.2EtOAc: C, 52.84; H, 3.06; N, 7.34. Found: C, 53.26; H, 2.83; N, 7.73
4-NITROPHENYL (4S) -2-0X0-4- (3 , 4, 5-TRIFLUOROPHENYL) -1,3- OXAZOLIDINE-3-CARBOXYLATE: Following the procedure for the synthesis of 4- (3 , 4-difluorophenyl) -2-oxo- oxazolidine-3-carboxylic acid-4-nitro-phenyl ester, 3 , 4, 5-triflourobenzaldehyde yielded the desired product. H NMR (400 MHz, CDC13) δ 8.27 (d, 2H, J=9.0 Hz) ,
7.31 (d, 2H, J=9.0 Hz) , 7.11-7.02 (m, 2H) , 5.37 (dd, 1H,
J=4.1, 9.0 Hz) , 4.81 (apparent t, 1H, J=9.0 Hz) , 4.33
(dd, 1H, J=4.1, 9.0 Hz) ; Anal. Calc. for Cι6H9F3N2θ6: C, 50.27; H, 2.37; N, 7.33. Found: C, 50.56; H, 2.50; N,
7.49.
1- (3 , 4-DIFLUOROPHENYL) -2-METHYL-2-HYDROXYPROPYLAMINE: .
Into a well-stirred solution of methyl 2-amino-2- (3, 4- difluorophenyl) cetate (10.5 g, 52.19 mmol) in anhydrous ether (200 mL) at 0 °C a solution of methylmagnesium bromide (3 M, 87 mL, 261 mmol) in ether was added over 10 minutes. The reaction mixture was stirred at 0 °C for 2.5 h and allowed to warm to room temperature. After 12 h, the reaction mixture was carefully poured onto a mixture of ice (300 g) and saturated aqueous ammonium chloride (50 g) . The ether layer was separated and the aqueous layer was extracted with more ether (4 X 200 mL) . The combined extracts were dried with magnesium sulfate and the solvent evaporated. The crude product was purified by column chromatography on silica gel using chloroform/methanol/2M ammonia in methanol (1000:20:10, 1000:40:20, 1000:80:40) as the eluent to give the product as an oil (6.5 g, 62% yield) which was used in the next step without further purification.
4- (3, 4-DIFLUOROPHENYL) -5, 5-DIMETHYL-2-OXO-OXAZOLIDINE: A mixture of 1- (3 , 4-difluorophenyl') -2-methyl-2- hydroxypropylamine (3.00 g, 14.9 mmol) and carbonyldiimidazole (2.418 g, 14.9 mmol) in dichloromethane (150 L) was heated at reflux temperature for 36 h and the solvent evaporated. The residue was purified by column chromatography on silica gel using chloroform/ethyl acetate (9:1) to give the product as a viscous oil which solidified on standing
(1.80 g, 50% yield) . The product was used in the next step without further characterization.
4-NITROPHENYL 4- (3, 4-DIFLUOROPHENYL) -5, 5-DIMETHYL-2-OXO-
1,3-OXAZOLIDINE-3-CARBOXYLATE: Into a stirred suspension of sodium hydride (60% suspension in paraffin 203 mg,
1.4 eq.) in THF (20 mL) at 0 °C, a solution of 4- (3,4- difluorophenyl) -5, 5-dimethyl-2-oxo-oxazolidine (870 mg, 3.622 mmol) in THF (5 mL) was added followed by stirring for 30 minutes. This suspension was added to a solution of 4-nitrophenyl chloroformate (950 mg, 4.71 mmol) in THF (20 mL) at -78 °C under argon and the stirring was continued for 2 h. It was slowly warmed to room temperature and after 4 h the solvent was evaporated. The residue was mixed with dichloromethane (150 mL) , washed with 0.05 N sodium hydroxide (3 X 10 mL) , and dried (sodium sulfate) . The solvent was evaporated and the residue was purified by column chromatography on silica gel using chloroform/ethyl acetate (9:1) as the eluent to give the product as a white powder (860 mg, 59% yield) . lηΑ NMR (400 MHz, CDC13) δ 8.24 (d, 2H, J=9 Hz), 7.29 - 6.97 (m, 5H) , 5.04 (s, 1H) , 1.09 (s, 6H) ; Anal. Calc. for C18H14F2N2O6+0.2% H20: C, 54.61; H, 3.67; N, 7.08. Found: C, 54.89; H, 3.59; N, 7.41.
(3 , 4-D FLOUROPHENYL) - (DIPHENYLMETHYLENE) ETHANAMINE: Into a solution of 3 , 4-difluorobenzylamine (9.8 g, 69 mmol) and benzophenone (13.0 g, 71.0 mmol) in toluene
(200 mL) was added a catalytic amount of BF3.0Et2 and the resulting solution was heated at reflux temperature for 12 h. The reaction mixture was concentrated in vacuo, yielding an oil (21 g, >95%) , which was characterized by NMR analysis and subjected to the following reaction without any further purification. λE NMR (CDC13) δ 4.57 (s, 2H) , 7.80-6.80 (m, 13H) .
1- (3,4-DIFLOUROPHENYL) -1-
[(DIPHENYLMETHYLENE)AMINO]PROPAN-2-OL: Into a solution of the benzhydrylindene- (3 , 4-difluoro-benzyl) -amine (21 g, 69 mmol) in 250 ml of dry THF was added tert- butyllithium (1.7 M, 60 ml) dropwise and the resulting solution was stirred at -78 °C for 0.5 h. To the solution was added acetaldehyde (10 ml, 180 mmol) in 100 ml of THF and the solution was stirred at -78 °C for 2 h and 25 °C for 1 h. The reaction mixture was quenched by addition of brine. The reaction mixture was diluted with 500 ml of Et20 and washed with brine. The organic layer was dried over Na2S04 and concentrated in vacuo to give an oil, which was taken to the next step without any further purification. H NMR (CDC13) δ 1.04 (d, 3H) , 2.77 (broad s. 1H) , 4.08(m, 1H) , 4.15 (d, 1H) , 7.80-6.80 (m, 13H) .
1-AM NO-l- (3,4-DIFLUORO-PHENYL) -PR0PAN-2-0L: A solution of crude product from the previous procedure and MeONH2.HCl (10 g, 120 mmol) was diluted in 200 ml of MeOH and stirred for 12 h. The reaction mixture was concentrated in vacuo, yielding an oily residue, which was re-dissolved in 200 ml of EtOAc and washed with brine. The organic layer was concentrated in vacuo to produce an oily mixture, which was subjected to column chromatography [5% NH3 (2.0 M in MeOH) in CHC13] to yield the desired product (8.8 g, 68% yield from 3,4- difluorobenzylamine) as a mixture of diastereomers. E NMR (CDCI3) (~ 4:1 mixture of the diastereomers) δ
1.02 (d, J=6.0 Hz, 3 H) , 1.04 (d, J=6.3 Hz, 3 H) , 2.10
(br, 6 H) , 3.56-3.69 (m, 2 H) , 3.88-3.92 (m, 2 H) , 7.02- 7.17 (m, 6 H) .
[1- (3, 4-DIFLUOROPHENYL) -2-HYDROXY- ROPYL] -CARBAMIC AC D- TERT-BUTYL ESTER: Into a solution of 1-amino- 1- (3, 4- difluorophenyl) -propan-2-ol (13.1 g, 70.1 mmol) in CHC13 (150 mL) at 0 °C was added a solution of di - ert-butyl dicarbonate (19.3 g, 87.6 mmol) in CHC13 (50 mL) in one portion and the resulting solution was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was subjected to column chromatography. on silica gel (2:1 hexane-EtOAc followed by EtOAc) to obtain [1- (3 , 4-difluorophenyl) -2-hydroxy-propyl] - carbamic acid- tert-butyl ester as a viscous oil (18.4 g, 91% yield). XH NMR (CDC13) (~ 4:1 mixture of the diastereomers) δ 1.05 (d, J=6.6 Hz, 3 H) , 1.25 (d, J=6.0 Hz, 3 H) , 1.41 (br, 20 H) , 3.92-4.19 (br, 2 H) , 4.45- 4.60 (m, 2 H) , 5.41-5.49 (br, 2 H) , 7.02-7.17 (m, 6 H) .
4- (3, 4-DIFLUOROPHENYL) -5-METHYL-OXAZOLIDIN-2-ONE: Into a well-stirred solution of [1- (3 , 4-difluorophenyl) -2- hydrox -propyl] -carbamic acid- ert-butyl ester (0.43 g, 1.5 mmol) in THF (20 mL) was added 95% NaH (0.09 g, 3.8 mmol) at room temperature. When the reaction was carried out on a larger (> 5 g) scale, 1.0 equivalent of KH and 1.5 eq. of NaH was used as the base. The resulting suspension was stirred for 3 h at about 35 °C
(warm water bath) and then quenched carefully with ice.
The biphasic mixture was extracted with 100 mL of EtOAc, washed with brine, dried over Na2S04, filtered and the solvent was removed in vacuo . The two diastereomers were separated by column chromatography over silica gel (First isomer: 0.16 g, Rf = 0.6, 3:1 hexane-EtOAc; second isomer: 0.18 g, Rf = 0.5, 3:1 hexane-EtOAc) . NOE experiments suggested that the first diastereomer had the methyl and the aryl group in trans configuration while the second diastereomer had cis relationship between the two groups . The λE NMR spectrum for the trans diastereomer is as follows. ^Η NMR (CDC13) δ 1.49 (d, J = 6.0 Hz, 3H) , 4.37 (dq, J = 6.0 Hz, J =
7.2 Hz, 1H) , 4.45 (d, J = 7.2 Hz, 1H) , 6.63 (br s, 1H) ,
7.08-7.28 (m, 3H) .
The 1H NMR spectrum for the cis diastereomer is as follows. XH NMR (CDC13) δ 0.96 (d, J = 6.6 Hz, 3H) , 4.91 (d, J = 8.1 Hz, 1H) , 4.99 (dq, J = 6 . 6 Hz, J = 8.1 Hz, 1H) , 6.63 (br s, 1H) , 7.08-7.28 (m, 3H) .
4- (3, -DIFLUOROPHENYL) -5-METHYL-2-OXO-OXAZOLIDINE-3- CARBOXYLIC ACID-4-NITRO-PHENYL ESTER : Into a solution of one of the two diastereomers of 4- (3,4- difluorophenyl) -5-methyl-oxazolidin-2-one (0.97 g, 4.55 mmol) in 60 mL THF was added a solution of n- butyllithium in hexane (3.06 mmol, 4.9 mmol) dropwise via a syringe under argon atmosphere at -78 °C . The resulting yellow solution was stirred at -78 °C for 40 min. This solution was then added dropwise via a cannula into another round bottom flask .containing a solution of 4-nitrophenylchloroformate (1.03 g, 5.1 mmol) in 60 mL of THF, cooled at -78 °C, over a period of 15 min. After five minutes, the flask was removed from the cooling bath and stirring was continued for 1 h. The reaction mixture was quenched by adding ice and it was extracted with EtOAc. The organic extracts were washed with brine and the organic layer was dried over
Na2S0 . The solvent was removed after filtration and the residue was purified by column chromatography on silica gel with 1:1 hexane/CH2Cl2 followed by CH2C12 to give the desired product.
The relative configurations of the cis and trans isomers were assigned on the basis of E NMR analysis of the respective p-nitrophenyloxycarbonyl derivatives. For the trans isomer, an NOE was observed between the protons of the C-5 methyl group and the proton at C-4. No NOE was observed between the protons at the C-4 and C-5 positions of this isomer, which was thus assigned trans stereochemistry. For the cis isomer, no NOE was observed between the protons of the C-5 methyl group and the proton at C-4. However, a NOE was observed between the protons at the C-4 and C-5 positions, leading us to assign this isomer cis stereochemistry. The vicinal coupling constants of the C-4 protons of cis (J = 7.8 Hz) and trans (J = 5.1 Hz) are also consistent with the values reported for similar oxazolidinones, and were thus helpful in making the stereochemical assignments (Dondoni, A.; Perrone, D.; Semola, T. Synthesis 1995, 181) .
Enantiomers of the diastereomers were separated by HPLC by using a Chiralcel OD column (20 x 250 mm) with 80% hexane/20% isopropyl alcohol/ 0.1 % diethylamine as the eluting system (12 mL/min) under isocratic conditions (U.V. 254 nm) .
In order to assign the absolute configurations at the stereogenic centers of the oxazolidinone rings, a new synthetic route was designed which employed an enantiomerically pure substrate derived from the chiral pool. Commercially available (S) -(+) -methyl lactate was converted into its pyrrolidine amide according to the method of Martin et al (Martin, R.; Pascual, 0.; Romea,
P.; Rovira, R. ; Urpi, F . ; Vilarrasa, J. Tetrahedron
Lett. 1997, 38, 1633) . Following the protection of the hydroxy group of (2S) -1-oxo-l- (1-pyrrolidinyl) -2- propanol to a TBDMS group, treatment of tert- butyl (dimethyl) silyl (IS) -l-methyl-2-oxo-2- (1- pyrrolidinyl) ethyl ether with 3 , 4-difluorophenyllithium yielded (2S) -2-{ [tert-butyl (dimethyl) silyl] oxy} -1- (3,4- difluorophenyl) -1-propanone as the sole product, which was then converted to (2S) -2- { [tert- butyl (dimethyl) silyl] oxy} -1- (3 , 4-difluorophenyl) -1- propanone oxime. Reduction of the (2S) -2- { [tert- butyl (dimethyl) silyl] oxy} -1- (3 , 4-difluorophenyl) -1- propanone oxime with LiAlH4, N-acylation, and base induced cyclization provided oxazolidinone diastereomers, which were separated by flash column chromatography. The enantiomeric purity of these isomers was confirmed by chiral HPLC analysis and their relative configurations were assigned by comparison of their """H NMR spectra with those of the racemic isomers.
As the absolute configuration at C-5 of the lactic acid derived oxazolidinone described above is (S) , the C-4 center in trans compounds also has the (S) configuration. Accordingly, the. absolute configurations for the stereogenic centers in the cis compounds are assigned accordingly (4R, 5S) . 4-NITROPHENYL (4S,5R)-4- (3, 4-DIFLUOROPHENYL) -5-
METHYL-2-OXO-1,3 -OXAZOLIDINE-3 -CARBOXYLATE: XH NMR (400
MHz, CDC13) δ 8.25 (d, 2H, J=8.8 Hz), 7.30 - 6.99 (m,
5H) , 5.35 (d, 1H, J=7.7 Hz), 5.07 (apparent quintet, 1H) , 1.17 (d, 3H, J=6.5 Hz); Anal. Calc. for
C17Hι2F2N2O6+0.5H2O: C, 52.72; H, 3.38; N, 7.23. Found: C,
53.09; H, 3.19; N, 7.50.
( + ) -2-AMINO-3- (3,4-DIFLUORO) -PHENYL- PROPAN-1-OL: ( + ) - 3 , 4-difluorophenyl alanine (1.0 g, 5.0 mmol) was added in small portions to a stirring suspension of LiAlH4 (0.480 g, 12.5 mmol) in THF (30 mL) at 0 °C . The resulting gray suspension was then heated at reflux for 2 h. The reaction mixture was cooled to 0 °C and then carefully quenched sequentially with water (0.5 mL) , 3 N
NaOH (0.5 mL) , and water (1.50 mL) . The resulting suspension was filtered through a fritted glass funnel.
" Ether (50 mL) was added to the filter cake and the suspension was heated at reflux temperature for 20 min. The suspension was filtered and was combined with the previous filtrate. The combined organics were dried over MgS04, filtered and the solvent was removed in vacuo. 2-Amino-3- (3 , 4-difluoro) -phenyl-propan-1-ol was obtained as a white solid (0.500 g, 100%) which was used in the next step without further purification.
(+) - tl- (3,4-DIFLUOROBENZYL) -2-HYDROXY-ETHYL] -CARBAMIC ACID-TERT-BUTYL ESTER: A solution of di- tert-butyl dicarbonate (0.640 g, 2.90 mmol) in CHC13 (10 mL) was added in one portion to a solution of (+) -2-amino-3- (3, 4-difluoro) -phenyl-propan-1-ol (0.500 g, 2.62 mmol) in CHC13 (20 mL) at 0 °C and the resulting solution was stirred overnight at room temperature. The solvent was removed in vacuo and the residue was chromatographed (2:1 hexane-EtOAc, followed by EtOAc), giving (+)-[l-(3,4-difluorobenzyl) -2-hydroxy-ethyl] - carbamic acid- tert-butyl ester as a white solid (0.640 g, 99%) .
(+) -4- (3,4-DIFLUORO-BENZYL) -OXAZOLIDIN-2-ONE: A solution of (+) - [1- (3, 4-difluorobenzyl) -2-hydroxy-ethyl] -carbamic acid- ert-butyl ester (1.00 g, 4.00 mmol) in THF (10 mL) was added via a dropping funnel to a stirring suspension of ' 95% NaH (0.12 g, 5.0 mmol) in THF (20 mL) at room temperature. The resulting suspension was stirred for 3 h and then quenched carefully with water (10 mL) . The biphasic mixture was extracted with Et20 (50 mL) , washed with brine, filtered and the solvent was removed in vacuo. The resulting gummy residue was purified by column chromatography (Rf = 0.25, 3:2 hexane-EtOAc) , to give the desired product as a white solid (0.320 g, 76%) .
(+) -4- (3,4-DIFLUORO-BENZYL) -OXAZOLIDIN-2-ONE-3- CARBOXYLIC ACID-4-NITRO-PHENYL ESTER: A solution of (+) - 4- (3 , -difluoro-benzyl) -oxazolidin-2-one (0.210 g, 1.0 mmol) in THF (10 mL) was added dropwise via a dropping funnel to a stirring suspension of NaH (30.0 mg, 1.30 mmol) in anhydrous THF (10 mL) under argon. The resulting suspension was stirred at room temperature for 30 min. This suspension was then added .dropwise via cannula to a solution of 4-nitrophenylchloroformate (0.300 g, 1.50 mmol) in THF (20 mL) at -78 °C over 15 min. Stirring was continued for 2 h after which the solvent was removed and the residue was purified by column chromatography (1:1 hexane/CH2Cl2, followed by CH2C12; Rf= 0.4, CH2C12) , to give the desired product as a yellow solid (0.350 g, 82%) .
Similarly, following the above procedure, 4-nitrophenyl 4- (4-fluorobenzyl) -2-oxo-l, 3 -oxazolidine-3 -carboxylate was obtained by substituting (+) -3 , 4-diflourophenyl alanine with p-fluorophenyl alanine:
4-NITROPHENYL 4- (4-FLUOROBENZYL) -2-0X0-1, 3 -OXAZOLIDINE- 3 -CARBOXYLATE: ^H NMR (400 MHz, CDC13) δ 8.32 (d, 2H, J=9.3 Hz), 7.42 (d, 2H, J=8.9 Hz), 7.24-6.99 (m, 4H) , 4.69 - 4.59 (m, 1H) , 4.35 (t, 1H, J=8.6 Hz), 4.23 (dd, 1H, J=2.7, 9.3 Hz), 3.37 (dd, 1H, J=3.8, 13.6 Hz), 2.94 (dd, 1H, J=9.3, 13.6 Hz); Anal.- Calc. for Cι7H13FN2Os : C, 56.67; H, 3.64; N, 7.77. Found: C, 56.94; H, 3.76; N, 7.71.
2- [6- (4-PHENYL-l-PIPERIDINYDHEXYL] -1H-ISOINDOLE-
1,3 (2H) -DIONE: To the 500 ml RB-flask was added 4- phenylpiperidine hydrochloride (5 g, 25 mmol) , N- (6- bromohexyl) phthalimide (15.5 g, 50 mmol), N,N- diisopropylethylamine (21.8 ml, 125 mmol), tetrabutylammonium iodide (0.2 g) , and dioxane (250 ml) at room temperature. The reaction mixture was stirred at 100 °C for 72 h. 'The solvent was removed in vacuo and the crude product was purified by flash chromatography
(98:2 = Chloroform : 2N -ammonia in methanol) to afford
7.67 g of the desired product (77% yield) :• 1H NMR (400
MHz, CDC13) 6 7.78-7.79 (m, 2H) , 7.74-7.65 (m, 2H) , 7.32- 7.14 (m, 5H) , 3.69 (t, 2H, J=7.35 Hz), 3.06 (d, 2H, J=11.0 Hz), 2.49 (quintet, 1H, J=7.6 Hz), 2.36 (t, 2H, J=7.6 Hz), 2.02 (t, 2H, J=12.5 Hz), 1.82 (br s, 4H) , 1.69 (t, 2H, J=6.3 Hz), 1.54 (br s, 2H) , 1.37 (br s, 4H) ; ESMS m/e: 391.3 (M + H)+; Anal. Calc . for
C25H30N2O2+0.2H2O: C, 76.19; H, 7.77; N, 7.11. Found: C,
76.14; H, 7.38; N, 7.13.
METHOD I. General procedure for the Preparation of the substituted 4- [4- (3-aminophenyl) -1-piperidinyl] -1- (phenyl) -1-butanones: A mixture of 4- (3- aminophenyDpiperidine (2.0 mmol), 2.4 mmol of the appropriate substituted phenyl butyryl chloride (e.g. 4- chloro-4' -phenoxybutyrophenone, 4-chloro-3' , ' - dimethylbutyrophenone, 4-chloro-4' -chlorobutyrophenone, γ-chlorobutyrophenone, 4-chloro-3' ,4' - dimethoxybutyrophenone) , 3.0 mmol of K2C03, and 10 mg of 18-crown-6 in 5 mL of toluene were heated at 110 °C for 2.5 days. The reaction mixture was concentrated and chromatographed on silica (5% methanol in dichloromethane) to give the desired compound:
4- [4- (3-AMINOPHENYL) -1-PIPERIDINYL] -1- (4-PHENOXYPHENYL) - 1-BUTANONE: Using Method I, the desired product was obtained. 305 mg; ESMS m/e : 415.4 (M + H)+.
4- [4- (3-AMINOPHENYL) -1-PIPERIDINYL] -1- (3,4- DIMETHYLPHENYL) -1-BUTANONE: Using Method I, the desired product was obtained. 320 mg; ESMS m/e : 351.3 (M + H)+.
4- [4- (3-AMINOPHENYL) -1-PIPERIDINYL] -1- (4-CHLOROPHENYL) - 1-BUTANONE: Using Method I, the desired • product was obtained. 500 mg; Anal. Calc for C21H25ClN2O+0.3H20: C, 69.62; H, 7.12; N, 7.73. Found: C, 69.63; H, 7.34; N, 7.60; ESMS m/e : 357.3 (M + H)+. 4- [4- (3-AMINOPHENYL) -1- PIPERIDINYL] -1-PHENYL-l-
BUTANONE: Using Method I, the desired product was obtained. 250 mg; Anal. Calc for C2ιH26N2O+0.2H20: C,
77.36; H, 8.16; N, 8.59. Found: C, 77.55; H, 8.12; N, 8.75; ESMS m/e : 323.3 (M + H) + .
4- [4- (3-AMINOPHENYL) -1-PIPERIDINYL] -1- (2,4- DIMETHOXYPHENYL) -l-BUTANONE: Using Method I, the desired product was obtained. 330 mg; Anal. Calc for C23H3oN2θ3+0.5H20: C, 70.56; H, 7.98; N, 7.16. Found: C, 70.69; H, 7.87; N, 6.99; ESMS m/e : 383.3 (M + H)+.
METHOD II . General Procedure for the Acylation or Sulfonylation of the Substituted 4- [4- (3-Aminophenyl) -1- piperidinyl] -1- (4-phenyl) -1-butanones: A mixture of 1 equivalent of a substituted 4- [4- (3-aminophenyl) -1- piperidinyl] -1- (4-phenyl) -1-butanone, 1.5 equivalent of an acid chloride or a sulfonyl chloride, and 5 equivalents of diisopropylethylamine, in dichloromethane was stirred at room temperature for two days. The reaction mixture was applied to a preparative TLC plate and eluted with dichloromethane: methanol (15:1, containing 1% isopropyl amine) to give the desired product .
METHOD III. General procedure for the Preparation of the substituted 4-N- (3-{l- [4- (phenyl) -4-oxobutyl] -4- piperidinyl}phenyl) aceta ides: A mixture -of N- [3- (4- piperidinyl) phenyl] acetamide (1.0 eq) and an aryl substituted chlorobutyrophenone (2.0 eq) , K2C03 (5.0 eq) , diisopropylethylamine (3.0 eq) and tetrabutylammonium iodide (cat. 5-10%) in dioxane (0.5 to 1.0 M) were heated at reflux temperature for 16 h. The reaction mixture was filtered and concentrated in vacuo.
The crude product was chromatographed using silica preparative TLC (chloroform : methanol containing 0.5% isopropyl amine) to give the desired product.
Example 1
N-(3-{l-[4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. ^Η NMR (CDC13) δ 7.75 (s, 1H) , 7.71 (d, 1H, J=7.6 Hz) , 7.45 (d, 2H, J=7.2 Hz) ,
7.35 (s, 1H) , 7.26-7.22 (m, 2H) , 6.93 (d, 1H, J=7.6 Hz) , 3.24-3.21 (m, 2H) , 3.04 (t, 2H, J=7.0 Hz) , 2.67-2.63 (m, 2H) , 2.59-2.48 (m, 1H) , 2.32 (s, 6H) , 2.30-2.27 (m, 2H) , 2.18 (s, 3H) , 2.14-2.06 (m, 2H) , 2.00-1.80 (m, 4H) ; ESMS m/e : 393.3 (M + H)+.
Example 2
N- (3-{l- [4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE : A mixture of 0.0500 g (0.200 mmol) of 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide, 0.100 g (0.480 mmol) of 4-chloro-3' , 4' -dimethylbutyrophenone, 0.080 g (0.600 mmol) of K2C03 and 0.090 g (0.600 mmol) of Nal in 5 mL of DMF was heated at reflux temperature for 18 hours. The reaction mixture was filtered, the filtrate was poured into 5 mL of water and washed with 3 X 5 mL of ethyl acetate. The combined organic extracts were dried
(MgS04) , concentrated in vacuo and purified by preparative TLC (silica; 9.5 : 0.5, dichloromethane : methanol + 1% isopropyl amine) to afford 0.067 g (80.0% yield) of the desired product: λE NMR (400 MHz, CDC13) δ 7.72 (d, 1H, J=8.0 Hz), 7.44 (s, 1H) , 7.38 (d, 1H, J=8.0 Hz), 7.23-7.20 (m, 2H) , 7.16 (s, 1H) , 6.95 (d, 1H, J=6.8 Hz), 3.13-3.11 (m, 2H) , 3.02 (t, 2H, J=7.0 Hz),
2.56-2.40 (m, 4H) , 2.32 (s, 6H) , 2.17-2.15 (m, 2H) ,
2.04-1.78 (m, 6H) , 1.25 (d, 6H, J=6.8 Hz); ESMS m/e :
421.3 (M + H)+.
Example 3
N-(3-{l-[4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)CYCLOHEXANECARBOXAMIDE: Using Method
II, the desired compound was obtained. 1H NMR (400 MHz, CDC13) δ 7.80-6.81 (m, 7H) , 3.41-3.00 (m, 4H) , 2.95-2.41
" (m, 4H) , 2.32 (s, 6H) , 2.22-1.05 (m, 18H) ; ESMS m/e :
461.4 (M + H)+.
Example 4 N- (3-{l- [4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2-PHENYLACETAMIDΞ : Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.85-7.65 (m, 2H) , 7.45-6.92 (m, 10H) , 3.76 (s, 2H) , 3.10-2.90 (m, 4H) , 2.50-2.35 (m, 3H) , 2.32 (s, 6H) , 2.10-1.85 (m, 4H) , 1.80-1.60 (m, 4H) ; ESMS m/e : 469.4 (M + H) + .
Example 5
N-(3-{l-[4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) -2- (3 -METHOXYPHENYL) ACETAMIDE : Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.76-7.65 (m, 2H) , 7.38-7.12 (m, 6H) , 6.95- 6.80 (m, 3H) , 3.82 (s, 3H) , 3.70 (s, 2H) , 3.10-2.90 (m, 4H) , 2.50-2.38 (m, 3H) , 2.32 (s, 6H) , 2.10-1.85 (m, 4H) , 1.80 -1.60 (m, 4H) ; ESMS m/e : 499.4 (M + H) + .
Example 6 N- (3-{l- [4- (3,4- DIMETHYLPHENYL) -4-
OXOBUTYL] -4-PIPERIDINYL}PHENYL) -2-METHOXYACETAMIDE:
Using Method II, the desired product was obtained. λE NMR (400 MHz, CDC13) δ 7.80-7.75 (m, 2H) , 7.50-7.38 (m, 2H) , 7.34-6.90 (m, 3H) , 4.00 (s, 2H) , 3.51 (s, 3H) , 3.30-2.95 (m, 4H) , 2.70-2.50 (m, 3H) , 2.32 (s, 6H) , 2.15 -1.80 (m, 8H) ; ESMS m/e : 423.3 (M + H) + .
Example 7 N- (3-{l- [4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)METHANΞSULFONAMIDE: Using Method II, the desired product was obtained. XH NMR' (400 MHz, CDC13) δ 7.82-7.10 (m, 7H) , 3.41 (s, 3H) , 3.40-2.85 (m, 4H) , 2.82-2.35 (m, 5H) , 2.32 (s, 6H) , 2.22-1.80 (m, -6H) ; ESMS m/e : 429.3 (M + H)+.
Example 8
N-(3-{l-[4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)ETHANESULF0NAMIDE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.75 (s, 1H) , 7.71 (d, 1H, J=7.6 Hz), 7.30-7.09 (m, 4H) , 7.02 (d, 1H, J=7.2 Hz), 3.36-3.05 (m, 6H) , 2.77- 2.52 (m, 3H) , 2.32 (s, 6H) , 2.15-1.82 (m, 8H) , 1.37 (t, 3H, J=7.4 Hz); ESMS m/e : 443.3 (M + H) +
Example 9
N-(3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.92 (d, 2H, J=8.8 Hz) , 7.55-7.40 (m, 3H) , 7.35 (s, 1H) ,
7.22 (t, 1H, J=8.0 Hz) , 6.92 (d, 1H, J=8.0 Hz) , 3.30- 3.27 (m, 2H) , 3.09 (t, 2H, J=7.0 Hz) , 2.76-2.39 (m, 5H) , 2.20 (s, 3H) , 2.17-1.85 (m, 6H) ; ESMS m/e : 399.3
(M + H)\
Example 10 N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Using Method II, the desired product was obtained. ^Η NMR (400 MHz, CDC13) δ 7.93 (d, 2H, J=8.6 Hz), 7.45 (d, 2H, J=8.6 Hz), 7.39 (d, 1H, J=7.2 Hz), 7.32 (s, 1H) , 7.24 (t, 1H, J=7.8 Hz), 6.94 (d, 1H, J=8.4 Hz), 3.21-3.18 (m, 2H) , 3.05 (t, 2H, J=7.0 Hz), 2.64-2.51 (m, 4H) , 2.28-1.86 (m, 8H) , 1.26 (d, 6H, J=6.8 Hz); ESMS m/e : 427.3 (M + H) + .
Example 11 N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)CYCLOHEXANECARBOXAMIDE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.93 (d, 2H, J=8.4 Hz), 7.55-7.19 (m, 5H) , 6.93 (d, 1H, J=7.6 Hz), 3.25-3.00 (m, 4H) , 2.65-2.45 (m, 4H) , 2.30-1.50 (m, 18H) ; ESMS m/e : 467.3 (M + H) + .
Example 12
N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2-PHENYLACETAMIDE: Using Method II, the desired product was obtained. XH NMR (400 MHz, CDC13) δ 7.92 (d, 2H, J=8.4 Hz), 7.46-7.26 (m, 9H) , 7.20 (t, 1H, J=7.6 Hz), 6.92 (d, 1H, J=7.6 Hz), 3.75 (s, 2H) , 3.15-3.13 (m, 2H) , 3.03 (t, 2H, J=7.0 Hz), 2.64-2.46 (m, 3H) , 2.22-1.60 (m, 8H) ; ESMS m/e : 475.3 (M + H) + .
Example 13
N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2- (3-METHOXYPHENYD CETAMIDE: Using Method II, the desired product was obtained. 1H
NMR (400 MHz, CDC13) δ 7.92 (d, 2H, J=8.4 Hz), 7.44 (d, 2H, J=8.4 Hz) 7.38 (s, IH) , 7.35-7.25 (m, 3H) , 7.19 (t, IH, J=7.8 Hz) , -6.94-6.86 (m, 3H) , 3.81 (s, 3H) , 3.72 (s, 2H) , 3.12-3.09 (m, 2H) , 3.02 (t, 2H, J=6.8 Hz), 2.57- 2.44 (m, 3H) , 2.20-1.60 (m, 8H) ; ESMS m/e : 505.3 (M + H) + .
Example 14 N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHOXYACETAM DE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.93 (d, 2H, J=8.4 Hz), 7.50-7.25 (m, 5H) , 6.98 (d, IH, J=7.8 Hz), 4.01 (s, 2H) , 3.57 (s, 3H) , 3.30-3.15 (m, 2H) , 3.06 (t, 2H, J=6.8 Hz), 2.70-2.50 (m, 3H) , 2.35-1.80 (m, 8H) ; ESMS m/e : 429.3 (M + H)+.
Example 15
N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL)METHANESULF0NAMIDE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.95-6.96 (m, 8H) , 3.48 (s, 3H) , 3.28-2.90 (m, 6H) , 2.80-2.57 (m, 3H) , 2.38-1.86 (m, 6H) ; ESMS m/e : 435.2 (M + H)+.
Example 16
N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)ETHANESULF0NAMIDE: Using' Method II, the' desired product was obtained. 1H NMR (400 MHz,- CDCI3) δ 7.93 (d, 2H, J=8.2 Hz), 7.45 (d, 2H, J=8.2 Hz), 7.30-7.08 (m, 3H) , 6.99 (d, IH, J=7.6 Hz), 3.26-3.02 (m, 6H) , 2.69-2.45 (m, 3H) , 2.32-1.75 (m, 8H) , 1.36 (t, 3H, J=7.4 Hz); ESMS m/e : 449.3 (M + H) + . Example 17
N-{3- [1- (4-OXO-4-PHENYLBUTYL) -4-
PIPERIDINYL] PHENYL}ACETAMIDE : Using Method III, the desired product was obtained. λE NMR (400 MHz, CDC13) δ 8.10-6.80 (m, 9H) , 3.40-2.95 (m, 4H) , 2.85-2.20 (m, 3H) , 2.19 (s, 3H) , 2.15-1.70 (m, 8H) ; ESMS m/e : 365.3 (M + H) + .
Example 18
2-METHYL-N-{3- [1- (4-OXO-4-PHENYLBUTYL) -4- PIPERIDINYL]PHENYL}PROPANAMIDE: Using Method II, the desired product was obtained. λE NMR (400 MHz, CDC13) δ 7.99 (d, 2H, J=7.4 Hz), 7.57 (t, IH, J=7.4 Hz), 7.48 (t, 2H, J=7.4 Hz), 7.45-7.20 (m, 2H) , 7.24 (t, IH, J=8.0 Hz), 6.94 (d, IH, 8.0 Hz), 3.24-3.21 (m, 2H) , 3.09 (t, 2H, J=7.0 Hz), 2.57-2.25 (m, 4H) , 2.31-1.84 (m, 8H)-, 1.26 (d, 6H, J=7.2 Hz); ESMS m/e : 393.3 (M + H) + .
Example 19
N-{3- [1- (4-OXO-4-PHENYLBUTYL) -4-PIPERIDINYL] PHENYL}-2- PHENYLACETAMIDE : Using Method II, the desired product was obtained. ^Η NMR (400 MHz, CDC13) δ 7.98 (d, 2H, J=7.6 Hz), 7.65-7.15 (m, 11H) , 6.92 (d, 2H, J=7.2 Hz), 3.74 (s, 2H) , 3.20-2.95 (m, 4H) , 2.65-2.40 (m, 3H) , 2.25-1.70 (m, 8H) ; ESMS m/e : 441.3 (M + H) + .
Example 20
2- (3-METHOXYPHΞNYL) -N-{3- [1- (4-OXO-4-PHENYLBUTYL) -4- PIPERIDINYL] PHENYL}ACETAMIDE : Using Method II, the desired product was obtained. XH NMR (400 MHz, CDC13) δ 7.98 (d, 2H, J=7.6 Hz), 7.56 (t, IH, J=7.62 Hz), 7.46 (t, 2H, J=7.6 Hz), 7.40 (s, IH) , 7.37-7.26 (m, 2H) , 7.19 (t, IH, J=7.8 HZ) , 6.94- 6.86 (m, 3H) , 3.81 (s,
3H) , 3.71 (s, 3H) , 3.12-3.03 (m, 4H) , 2.57-2.44 (m, 3H) ,
2.16-1.77 (m, 8H) ; ESMS m/e : 471.3 (M + H) + .
Example 21
N- (3-{l- [4- (2,4-DIMETHOXYPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. XE NMR (400 MHz, CDC13) δ 7.82 (d, IH, J=8.8 Hz), 7.54 (d, IH, J=7.6 Hz), 7.33 (s, IH) , 7.22 (t, IH, J=7.6 Hz), 6.93 (d, IH, J=7.6 Hz), 6.53 (d, IH, J=8.8 Hz), 6.46 (s, IH) , 3.90 (s, 3H) , 3.86 (s, 3H) , 3.48-3.27 (m, 2H) , 3.05 (t, 2H, J=6.8 Hz), 2.90-2.68 (m, 2H) , 2.65-2.38 (m, 3H) , 2.25 -(s, 3H) , 2.18-1.80 (m, 6H) ; ESMS m/e : 425.3 (M + H) + .
Example 22
N- (3-{l- [4- (2,4-DIMETHOXYPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.98 (d, IH, J=8.6 Hz), 7.41-7.37 (m, 2H) , 7.24 (t, IH, J=7.8 Hz), 6.96 (d, IH, J=7.8 Hz), 6.54 (d, IH, J=8.6 Hz), 6.46 (s, IH) , 3.89 (s, 3H) , 3.86 (s, 3H) , 3.11-3.08 (m, 2H) , 2.98 (t, 2H, J=7.2 Hz), 2.53-2.46 (m, 4H) , 2.13-1.79 (m, 8H) , 1.25 (d, 6H, J=6.8 Hz); ESMS m/e : 453.3 (M + H) + .
Example 23
N- (3-{l- [4- (2,4-DIMETHOXYPHENYL) -4-OXOBUTYL]-4- PIPERIDINYL}PHENYL) -2-PHENYLACETAMIDE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.85 (m, 12H) , 3.89 (s, 3H) , 3.86 (s, 3H) , 3.74
(s, 2H) , 3.22-2.90 (m, 4H) , 2.64-2.40 (m, 3H) , 2.25-1.70
(m, 8H) ; ESMS m/e : 501.3 (M + H)+. Example 24
N- (3-{l- [4- (2,4-DIMETHOXYPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -2- (3-METH0XYPHENYL)ACETAMIDE:Using ■ Method II, the desired product was obtained. 1H NMR (400
MHz, CDC13) δ 7.82 (d, IH, J=8.8 Hz) , 7.48-7.15 (m, 5H) ,
6.95-6.80 (m, 3H) , 6.58-6.45 (m, 2H) , 3.89 (s, 3H) , 3.86
(s, 3H) , 3.81 (s, 3H) , 3.72 (s, 2H) , 3.25-2.95 (m, 4H) ,
2.65-2.40 (m, 3H) , 2.30-1.95 (m, 4H) , 1.93-1.72 (m, 4H) ; ESMS m/e : 531.3 (M + H)+.
Example 25
N- (3-{l- [4-0X0-4-(4-PHEN0XYPHENYL)BUTYL] -4-
PIPERIDINYL}PHENYL)ACETAMIDE: Using Method II, the desired product was obtained.
^Η NMR (400 MHz, CDCl3) δ 8.15-6.75 (m, 13H) , 3.30-2.80 (m, 4H) , 2.75-2.10 (m, 5H) , 2.03 (s, 3H) , 2.00-1.60 (m, 6H) ; ESMS m/e : 457.3 (M + H)+. Example 26 2-METHYL-N- (3-{l- [4-0X0-4- (4-PHEN0XYPHENYL) BUTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.96 (d, 2H, J=8.8 Hz), 7.43-7.15 (m, 6H) , 7.10-6.93 (m, 5H) , 3.42-2.95 (m, 4H) , 2.80-2.45 (m, 4H) , 2.20-1.80 (m, 8H) , 1.14 (d, 6H, J=6.8 Hz); ESMS m/e : 485.4 (M + H) + .
Example 27
2- (3-METHOXYPHENYL) -N- (3-{l- [4-0X0-4- (4-
PHENOXYPHENYL) BUTYL] -4 -PIPERIDINYL}PHENYL) ACETAMIDE : Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.97 (d, 2H,~ J=8.8 Hz), 7.41-7.18 (m, 7H) , 7.08-6.99 (m, 5H) , 6.94-6.87 (m, 3H) , 3.82 (s, 3H) , 3.70 (s, 2H) , 3.10-2.95 (m, 4H) , 2.55-2.40 (m, 3H) , 2.15-1.95 (m, 4H) , 1.81- 1.70 (m, 4H) ; ESMS m/e :
563.4 (M + H)+.
Example 28 N' - (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) -N,N-DIMETHYLSULFAMIDE: Using Method II, the desired product was obtained. H NMR (400 MHz, CDC13) δ 7.93 (d, 2H, J=8.8 Hz), 7.44 (d, 2H, J=8.8 Hz), 7.27 (s, IH) , 7.25-7.10 (m, 2H) , 6.94 (d, IH, J=7.6 Hz), 3.30-3.10 (m, 2H) , 3.04 (t, 2H, J=6.8 Hz), 2.83 (s, 6H) , 2.68-2.45 (m, 3H) , 2.30-1.75 (m, 8H) ; ESMS m/e : 464.3 (M + H) + .
Example 29 N- (3-{l- [4-0X0-4- (2-THIENYL) BUTYL] -4-
PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.90-6.78 (m, 7H) , 3.22-2.88 (m, 4H) , 2.69-2.25 (m, 5H) ,
2.02 (s, 3H) , 2.00-1.64 (m, 6H) ; ESMS m/e : 371.2 (M + H)+.
Example 30
N- (3-{l- [4- (4-ISOPROPYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. λE NMR (400 MHz, CDC13) δ
8.00-6.78 (m, 8H) , 3.15-2.98 (m, 4H) , 2.77-2.15 (m, 4H) ,
2.03 (s, 3H) , 2.00-1.62 (m, 8H) , 0.927 (d, 6H, J=6.0 Hz) ; ESMS m/e : 407.3 (M + H)+.
Example 31
N-(3-{l-[4- (4-METHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.90-6.80 (m, 8H) , 3.10- 2.45 (m, 7H) , 2.32 (S,
3H) , 2.02 (s, 3H) , 2.01-1.68 (m, 8H) ; ESMS m/e : 379.3
(M + H) + .
Example 32
N- (3-{l- [4- (4-BROMOPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL)ACETAMIDE: Using Method III, the desired product was obtained. ^Η NMR (400 MHz, CDC13) 6 7.90-6.80 (m, 8H) , 3.30-J§-.05 (m, 4H) , 2:70-2.45 (m, 3H) , 2.05 (s, 3H) , 1.98-1.65 (m, 8H) ; ESMS m/e : 444.0 (M + H) + .
EXAMPLE 33
N-(3-{l-[4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) -2-PROPANESULFONAMIDE : Using Method II, the desired product was obtained. 1H NMR (400 MHz, CDC13) δ 7.75 (s, IH) , 7.71 (d, IH, J=7.6 Hz), 7.27-7.00 (m, 5H) , 3.32-3.24 (m, 3H) , 3.10-3.02 (m, 2H) , 2.78-2.50 (m, 3H) , 2.32 (s, 6H) , 2.19-1.84 (m, 8H) , 1.39 (d, 6H, J=6.8 Hz); ESMS m/e : 4"*-.4 (M + H) + .
Example 34
N- (3-{l- [4-0X0-4- (4-PHENOXYPHENYDBUTYL] -4- PIPERIDINYL}PHENYL) -2-PROPANESULFONAMIDE: Using Method II, the desired product was obtained. λE NMR (400 MHz, CDC13) δ 7.97 (d, 2H, J=7.6 Hz), 7.44 (t, 2H, J=7.6 Hz), 7.27-7.00 (m, 9H) , 3.35-2.96 (m, 5H) , 2.69-2.45 (m, 3H) , 2.14-1.79 (m, 8H) , 1.39 (d, 6H, J=6.8 Hz); ESMS m/e : 521.4 (M + H)+.
Example 35 -
N- (3-{l- [3- (4-CHLOROPHENYL) -3-METHOXYPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 3- methoxy-3- (p- chlorophenyl) -1- chloropropane (27.4 mg, 0.125 mmol), 2-methyl-N- [3- (4-^ • piperidinyl) phenyl] propanamide (28.3 mg, 0.125 mmol), diisopropylethylamine (0.50 mL) and catalytic amount of tetrabutylammonium iodide in dioxane (2.0 mL) was stirred at 90 °C for 72 hrs. The reaction mixture was concentrated to a small volume and chromatographed using preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave N- (3- {l- [3- (4-chlorophenyl) -3- methoxypropyl] -4-piperidinyl}phenyl) -2-methylpropanamide (39.5 mg, 73.8% yield) as a thick oil: 1H NMR δ 7.48 (S, 1 H) , 7.34-7.3 (m, 2H) , 7.25 (m, 4H) , 6.96 (d, IH, J=7.4 Hz), 4.20 (apparent dd, IH, J=5.9, 7.6 Hz), 3.2 (s, 3H) , 3.04 (d, IH, J=10.1 Hz), 2.99 (d, IH, J=10.1 Hz), 2.49 (h, 4H, J=6.6 Hz), 2.20-2.10 (m, 4H) , 1.82 (m, 4H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e : 429.4 (M + H) + .
Example 36
N- (3-{l- [6- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2- YL) HEXYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: The synthetic method is the same as described for 2- [6- (4- phenyl-1-piperidinyl) hexyl] -lH-isoindole-1, 3 (2H) -dione . N- (3- {l- [6- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2- yl) hexyl] -4-piperidinyl}phenyl) -2-methylpropanamide: 506 mg (56% yield); 1H NMR (400 MHz, CDC13) δ 7.86-7.80 (m, 2H) , 7.73-7.68 (m, 2H) , 7.44 (s, IH) , 7.37 (d, IH, J=8.3 Hz), 7.22 (t, IH, J=7.7'Hz), 6.96 (d, IH, J=7.7 Hz), 3.69 (t, 2H, J=7.2 Hz), 3.01 (apparent d^ 2H, J=11.3 Hz), 2.58-2.40 (m, 2H) , 2.33 (m, 2H) 1.98 (dt, 2H, J=3.2, 11.3 Hz), 1.84-1.64 (m, 4H) , 1.51 (q, 2H, J=7.1 Hz), 1.43-1.30 (m, 6H) , 1.24 (d, 6H, J=6.8 Hz); ESMS m/e: 476.4 (M + H)+. Example 37
N-{3- [1- (3-METHOXY-3-PHENYLPROPYL) -4-
PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE: A mixture of 3- methoxy-3 -phenyl-1-chloropropane (23.1 mg, 0.126 mmol), 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide (28.3 mg, 0.126 mmol), diisopropylethylamine (0.50 mL) and catalytic amount of tetrabutylammonium iodide in dioxane
(2.0 mL) was stirred at 90 °C for 72 hrs. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave N- {3- [1- (3-methoxy-3- phenylpropyl) -4-piperidinyl] phenyl} -2-methylpropanamide
(45.4 mg, 91.2% yield) as a thick oil: XH NMR (400 MHz,
CDC13) δ 7.45 (S, 1 H) , 7.34-7.25 (m, 5H) , 7.25 (m, 2H) ,
6.96 (d, IH, J=7.4 Hz), 4.20 (apparent dd, IH, J=5.9, 7.6 Hz), 3.2 (s, 3H) , 3.04 (d, IH, J=10.1 Hz), 2.99 (d, IH, J=10.lHz), 2.49 (apparent sept, partially hidden, 4H, J=6.6 Hz), 2.3-2. l(m, 4H) , 1.82 (m, 4H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e: 395.4 (M + H) + .
Example 38
N- (3-{l- [4- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2-
YL) BUTYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: The synthetic method is the same as described for 2- [6- (4- phenyl-1-piperidinyl) hexyl] -lH-isoindole-1, 3 (2H) -dione. N- (3-{l- [4- (l,3-dioxo-l,3-dihydro-2H-isoindol-2- yl)butyl] -4-piperidinyl }phenyl) -2-methylpropanamide: 664 mg (74% yield); XE NMR (400 MHz, CDC13) δ 7.87-7.78 (m, 2H) , 7.76-7.64 (m, 2H) , 7.47 (s, IH) , 7.39 (d, IH, J=7.6 Hz), 7.21 (t, IH, J=8.1 Hz), 6.94 (d, IH, J=7.6 Hz), 3.72 (t, 2H, J=6.8 Hz), 3.37-3.22 (m, 2H) , 3.0 (apparent d, 2H, J=10.7 Hz), 2.75 (q, 2H, J=7.0 Hz), 2.64-2.33 (m, 4H) , 1.99 (dt, 2H, J=2.6, 11.7 Hz), 1.86-1.65 (m, 2H) , 1.63-1.50 (m, 2H) , 1.23 and 1,21 (two d, 6H, J=5.5 Hz); ESMS m/e: 448.4 (M + H)+; Anal. Calc. for
C27H34N3Clθ3 + 0.4H2O: C, 66.02; H, 7.14; N, 8.55. Found: C,
66.07; H, 6.78; N, 8.65.
Example 39
N- (3-{l- [4- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2-
YL) BUTYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: The synthetic method is the same as described for 2- [6- (4- phenyl-1-piperidinyl) hexyl] -lH-isoindole-1, 3 (2H) -dione. N- (3-{l- [5- (l,3-dioxo-l,3-dihydro-2H-isoindol-2- yl) pentyl] -4-piperidinyl}phenyl) -2-methylpropanamide : 614 mg (64% yield); ^Η NMR (400 MHz, CDC13) δ 7.87-7.8 (m, 2H) , 7.76-7.68 (m, 2H) , 7.48 (s, IH) , 7.41 (d, IH, J=7.6 Hz), 7.21 (t, IH, J=7.6 Hz), 6.95 (d, IH, J=7.6 Hz), 3.69 (t, 2H, J=7.2 Hz), 3.39-3.28 (m, 2H) , 3.02 (apparent d, 2H, J=11.6 Hz), 2.78 (q, 2H, J=7.2 Hz), 2.64-2.52 (m, IH) , 2.52-2.40 (m, IH) , 2.40-2.31 (m, 2H) , 2.01 (dt, 2H, J=3.7, 11.1 Hz), 1.85-1.64 (m, 2H) , 1.58 (q, 2H, J=7.6 Hz), 1.45-1.32 (m, 2H) , 1.23 (d, 6H, J=6.9 Hz) ; ESMS m/e: 462.4 (M + H)+; Anal. Calc. for
C28H3SN3C103 : C, 67.52; H, 7.29; N, 8.44. Found: C, 67.04; H, 7.06; N, 8.38.
Example 40 2-METHYL-N-{3- [1- (4-PHENYLBUTYL) -4-
PIPERIDINYL]PHENYL}PROPANAMIDE: A mixture of 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide (28.3 mg, 0.100 mmol), 4-phenyl-1-chlorobutane (21.1 mg, 0.125 mmol-), diisopropylethylamine (0.50 mL) , catalytic amount of tetrabutylammonium iodide and dioxane (2.0 mL) was heated at reflux temperature for 3 days. The reaction mixture was concentrated and chromatographed using preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHCI3] afforded the product, 2-methyl-N- {3- [1-
(4-phenylbutyl) -4-piperidinyl] phenyl}propanamide (9.50 mg, 25.1% yield) as a thick oil: XH NMR δ 7.37 (s, IH) ,
7.29 (apparent d, IH,. J=7.9 Hz), 7.18 (m, 3H) , 7.11 (m, 3H), 6.90 (apparent d, IH, J=7.9 Hz), 3.02 (d, 2H, J=6.8
Hz), 2.41 (m, 4H, partially hidden), 2.01 (m, 2H) , 1.78
(m, 4H) , 1.57 " (m, 4H) , 1.18 (d, 6H, J=7.7 Hz); ESMS m/e :
379.4 (M + H)+.
Example 41
N- (3-{l- [3- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2-
YL) PROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
The synthetic method is the same as described for 2- [6- (4-phenyl-l-piperidinyl) hexyl] -lH-isoindole-1, 3 (2H) - dione. N- (3- {l- [3- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2- yl) propyl] -4-piperidinyl}phenyl) -2-methylpropanamide :
810 mg (93% yield); XH NMR (400 MHz, CDC13) δ 7.87-7.82
(m, 2H) , 7.73-7.68 (m, 2H) , 7.57 (s, IH) , 7.36 (d, IH,
, J=8.5 Hz), 7.18 (t, IH, J=7.7 Hz), 6.79 (d, IH, J=7.1 Hz), 3.78 (t, 2H, J=6.8 Hz), 3.06 (quintet, 2H, J=6 Hz), 2.95 (apparent d, 2H, J=12.2 Hz), 2.58-2.31 (m, 4H) , 1.96-1.83 (m, 2H) , 1.70 (apparent d, 2H, J=12.1 Hz), 1.52 (dt, 2H, J=3.5, 12.5 Hz), 1.03 (d, 6H, J=6.5 Hz); ESMS m/e: 434.4 (M + H) X
Example 42
N- (3-{l- [ (3S) -3-HYDROXY-3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A' mixture of (S) -(-) -3-chloro-l-phenyl-1-propanol (0.426 g, 2.50 mmol, 99%ee) , 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide (0.565 g, 2.00 mmol), diisopropylethylamine (1.29 g, 10.0 mmol), dioxane (5.0 mL) and catalytic amount of tetrabutylammonium iodide was stirred at 90 °C for 72 hrs. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (306 mg,
39.3 % yield) as a thick oil: XH NMR (400 MHz, CDC13) δ 7.46 (S, 1 H) , 7.42 (d, 4H, J=8.1 Hz), 7.35 (m, 1 H) ,
7.30 (d, 1 H, J=8.0 Hz), 7.23 (t, IH, J=8.1 Hz), 7.12
(s, IH) , 6.96 (apparent dd, IH, J=8.0 Hz), 5.0 (apparent dd, IH, J=4.4, 8.3 Hz), 3.18 (apparent dd, 2H, J=2.5,
12.5 Hz), 2.74 (m, 2 H) , 2.50 (m, 2H) , 2.3-2.1 (m, 6H) , 1.8 (m, 2H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e: 389.2 (M
+ H) + .
Example 43
N- (3-{l- [3-METHOXY-3- (4 -METHYLPHENYL) ROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of
3-methoxy-3- (p-tolyl) -1-chloropropane (24.9 mg, 0.126 mmol) , 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide
(28.3 mg, 0.126 mmol), diisopropylethylamine (0.50 mL) and catalytic amount of tetrabutylammonium iodide in dioxane (2.0 mL) was stirred at 90 °C for 72 hrs.
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (10.9 mg, 21.2 % yield) as a thick oil: 1H NMR
(400 MHz, CDCI3) δ 7.44 (s, 1 H) , 7.38 (m, IH) , 7.3-7.1 (m, 5 H) , 6.96 (d, IH, J=7.4 Hz), 4.18 (apparent dd, IH, J=5.6, 7.9 Hz), 3.24" (d, IH, J=8.2 Hz), 3.2 (s, 3H) , 3.11 (m, 2H, J=10.1Hz), 2.49 (m, 4H) , 2.35 (s, 3H) , 2.3- 2.1 (m, 3H) , 1.92 (d, 4H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e: 409.4 (M + H) + .
Example 44
N- {3 - [ 1 - (3 - ISOPROPOXY- 3 - PHENYLPROPYL) - 4 -
PIPERIDINYL] PHENYL} - 2 -METHYLPROPANAMIDE : A mixture of 3 - isopropyl-3' -phenyl- 1- chloropropane (26.6 mg,
0.126 mmol), 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide (28.3 mg, 0.126 mmol), diisopropylethylamine (0.50 mL) and catalytic amount of tetrabutylammonium iodide in dioxane (2.0 mL) was stirred at 90 °C for 72 hrs. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (14.1 mg, 26.5% yield) as a thick oil: E NMR (400 MHz, CDC13) δ 7.46 (s, IH) , 7.43-7.37 (m, 2H) , 7.33 (m, 3H) , 7.23 (m, 2H) , 6.95 (d, IH, J=8.4 Hz), 4.46 (apparent dd, IH, J=5.0, 8.3 Hz), 3.49 (apparent sept, IH, J=7.1 Hz), 3.10 (s, 2H) , 2.70 (m, 2H) , 2.52 (apparent sept, partially hidden, 4H, J=6.6 Hz), 2.30-2.10 (m, 2H) , 1.90-1.80 (d, 4H) , 1.25 (d, 6H, J=7.1 Hz), 1.15 (d, 3H, J=6.4 Hz), 1.08 (d, 3H, J=6.4 Hz); ESMS m/e : 423.4 (M + H)+.
Example 45
N- (3-{l- [4, 4-BIS (4 -FLUOROPHENYL) BUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of
4,4-bis (4-fluoro-phenyl) -1-chloro-butane (39.0 mg, 0.126 mmol) , 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide
(28.3 mg, 0.126 mmol), diisopropylethylamine (0.50 L) and catalytic amount of tetrabutylammonium iodide in dioxane (2.0 mL) was stirred at 90 °C for 72 hrs.
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (15.9 mg, 25.2 % yield) as a thick oil: 1H NMR
(400 MHz, CDC13) δ 8.02 (s, IH) , 7.41 (s, IH) , 7.3-7.15 (m, 4H) , 7.10 (m, 3H) , 6.89 (apparent t, 5H) , 3.81 (t, IH, J=7.8 Hz), 3.30 (s, IH) , 2.91 (d, IH, J=12,5 Hz), 2.80 (m, IH) , 2.40 (m, 2H) , 2.31 (t, IH, J=8.0 Hz), 1.93 (apparent q, 3H, J=8.0 Hz), 1.72 (m, 3H) , 1.40 (m, 2H) , 1 . 20 (m, 2H) , 1 . 15 ( d, 6H , J=8 . 1 Hz) ; ESMS /e 491 . 4
(M + H) +
EXAMPLE 46 N-{3- [1- (3-METHOXYBENZYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE: A mixture of 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide (28.3 mg, 0.100 mmol), 3- methoxybenzyl chloride (19.6 mg, 0.125 mmol), diisopropylethylamine (0.50 mL) , catalytic amount of tetrabutylammonium iodide and dioxane (2.0 mL) .
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] afforded the desired product (10.2 mg, 27.9% yield) as a yellow solid: 1H NMR
(400 MHz, CDC13) δ 7.46 (s, IH) , 7.35 (apparent d, IH, J=8.3 Hz), 7.27-7.21 (m, 2H) , 6.95 (apparent t, 3H,
J=6.9 Hz), 6.82 (apparent dd, IH, J=2.4, 8.3 Hz), 3.84
(m, 3H) , 3.56 (s,' 2H) , 3.05 (d, 2H, J=10.5 Hz), 2.51
(apparent sept, partially hidden, 4H, J=7.2 Hz), 2.13
(apparent t, 2H, J=9.7 Hz), 1.88 (m, 2H) , 1.25 (d, 6H, J=6.7 Hz); ESMS m/e : 367.3 (M + H) + .
Example 47
N- (3-{l- [3,5-BIS (TRIFLUOROMETHYL) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 2- methyl -N- [3- (4-piperidinyl) phenyl] propanamide (28.3 mg, 0.100 mmol), 3 , 5-bis (trifluoromethyl) benzyl bromide (38.4 mg, 0.125 mmol), diisopropylethylamine (0.50 mL) , catalytic amount of tetrabutylammonium ■ iodide and dioxane (2.0 mL) . Chromatography using silica preparative TLC plates [2.5% of ΝH3 (2.0 M in methanol) in CHC13] gave the desired product (12.2 mg, 25.8% yield) as a thick oil: λE NMR (400 MHz, CDC13) δ 7.83 (s, 2H) , 7.77 (s, IH) , 7.53 (s, IH) , 7.30-7.21 (m, 2H) , 7.16 (s, IH) , 6.98 (apparent d, IH, J=7.6 Hz), 3.62 (s, 2H) ,
2.94 (d, 2H, J=9.4 Hz), 2.51 (apparent sept, partially hidden, 2H, J=6.6 Hz), 2.14 (m, 2H) , 1.82 (m, 4H) , 1.25
(d, 6H, J=6.6 Hz); ESMS m/e: 473.2 (M + H)+.
Example 48
N- (3-{l- [ (3R) -3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE
Method A
4-{ [ (1R) -3-chloro-l-phenylpropyl] oxy}-1,2- dimethoxybenzene: A mixture of 3 ,4-dimethoxyphenol (4.07 g, 26.4 mmol), (S) - (-) -3-chloro-phenyl-1-propanol (4.50 g, 26.4 mmol, 99%ee, Aldrich Chemical Co.), triphenylphosphine (6.92 g, 26.4 mmol) and diethyl azodicarboxylate (4.59 g, 26.4 mmol) in THF (110 mL) was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo. At this point, the residue can either be washed with pentane (x3) and the combined pentane extracts were concentrated and chromatographed (silica with hexanes-EtOAc 8:1 as the eluent) to give the desired product (as described as a general procedure by: Srebnik, M.; Ramachandran, P.V.; Brown, H.C. J. Org. Chem. 1988, 53 , 2916-2920) . This procedure was performed on a smaller scale reaction and only a 40% yield of the product was realized.
Alternatively, on a larger scale (26.4 mmol), the crude product was triturated with a small amount of dichloromethane and the precipitated triphenylphosphine oxide was filtered. The filtrate was concentrated and the crude product was chromatographed to give the desired product as a thick yellow oil (7.30 g, 88.9% yield): 1H NMR (400 MHz, CDC13) δ 7.39-7.32 (m, 4H) ,
7.20 (m, IH) , 6.64 (d, IH, J=8.7 Hz), 6.51 (d, IH, J=2.7
Hz), 6.30 (dd, IH, J=2.7, 8.7 Hz), 5.27 (apparent dd,
IH, J=4.5, 8.7 Hz), 3.79 (s, 3H) , 3.77 (s, 3H) , 3.61 (m, IH) , 2.45 (m, 1 H) , 2.20 (m, IH) , 1.80 (s, IH) ; ESMS m/e : 307.11 (M+H) + .
N- (3-{l- [ (3R) -3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of potassium carbonate (321 mg, 2.32 mmol), sodium iodide
(522 mg, 3.48 mmol), 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide (570 mg, 2.32 mmol) and
4-{ [ (1R) -3-chloro-l-phenylpropyl] oxy} -1,2- dimethoxybenzene (712 mg, 2.32 mmol) in DMF (5.0 mL) was stirred at 100 °C for 3 hrs, at which time TLC indicated that the reaction was complete. The reaction mixture was poured into water (50 mL) and the aqueous layer was extracted with methylene chloride (3x30 mL) . The combined organic extracts were washed with brine (30 mL) , dried over MgS04 and concentrated under reduced pressure. The crude product was purified by Prep-TLC plates [2.5% of ΝH3 (2.0 M in methanol) in CHC13] to afford the product (970 mg, 90.1%) as a thick oil.
Method B
Into a 25-mL RB-flask was added triphenylphosphine (9.80 mg, 0.0375 mmol), diethyl azodicarboxylate (5.22 mg, 0.0300 mmol), N- (3- {l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 3,4-dimethoxyphenol (7.70 mg, 0.050 mmol) and THF (1.0 mL) at room temperature. The reaction mixture was stirred at room temperature overnight (16 hrs) . The solvent was removed under reduced pressure and the residue was purified by preparative TLC plates
[2.5% of NH3 (2.0 M in methanol) in CHC13] to afford the desired product (4.4 mg, 34.1 % yield) as a thick oil: XE
NMR (400 MHz, CDC13) δ 7.46 (s, 1 H) , 7.40-7.30 (m, 4H) , 7.25 (m, 3H) , 6.97 (d, IH, J=7.8 Hz), 6.64 (d, IH, J=9.1
Hz), 6.51 (d, IH, J=2.6 Hz), 6.29 (d, IH, J=2.6, 9.1
Hz), 5.20 (apparent dd, IH, J=4.4, 8.5 Hz), 3.80 (s,
3H) , 3.77 (s, 3H) , 3.23 (m, 2H) , 2.77 (m, 2 H) , 2.5 (m,
2H) , 2.3-2. Km, 6H) , 1.80 (m, 2H) , 1.25 (d, 6H, J=7.9 Hz); ESMS m/e : 517.4 (M + H) + .
Example 49
2-METHYL-N- (3-{l- [ (3S) -3-PHENOXY-3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of N-(3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide (9.53 mg, 0.0250 mmol), phenol (4.70 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (2.7 mg, 23.6 % yield) as a thick oil: XH NMR δ 7.46 (s, 2H) , 7.40-7.30 (m, 4H) , 7.25 (m, 3 H) , 7.20 (m, 2H) , 6.97 (apparent d, IH, J=7.4 Hz), 6.89 (apparent tt, IH, J=0.8, 7.6 Hz), 6.84 (apparent dt, IH, J=0.8, 8.0 Hz), 5.20 (apparent dd, IH, J=4.4, 8.5 Hz), 3.35 (m, 2H) , 2.91 (m, 2H) , 2.60 (m, 2H) , 2.30- 2.10 (m, 6H) , 1.90 ( , 2H) , 1.25 (d, 6H, J=7.9 Hz); ESMS m/e : 457.4 (M + H)+;
Example 50
N- (3 - { l- [ (3 S) - 3 - (4 -METHOXYPHENOXY) -3 -PHENYLPROPYL] -4 -
PIPERIDINYL}PHENYL) - 2 -METHYLPROPANAMIDE : A mixture of N- (3-{l- [ (3R) -3-hydroxy-3- phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 4-methoxyphenol (6.20 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.2 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days.
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (4.6 mg, 37.9 % yield) as a thick oil. λE NMR (400 MHz, CDC13) δ 7.38-7.14 (m, 8H) , 6.90 (apparent d, IH, J=7.7 Hz), 6.72-6.46 (m, 4H) , 5.09 (apparent dd, IH, J=4.8, 8.1 Hz), 3.64 (s, 3H) , 3.18 (m, 2H) , 2.73 (m, 2H) , 2.50 (m, 2H) , 2.37-1.72 (m, 8H) , 1.25 (d, 6H, J=7.4 Hz); ESMS m/e: 487.4 (M + H) + .
Example 51
N-(3-{l-[(3S)-3- (3-CHLOROPHENOXY) -3 -PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3 -hydroxy- 3 -phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 3-chlorophenol (6.40 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days. Chromatography using' silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (4.9 mg, 40.0 % -yield) as a thick oil: XH NMR
(400 MHz, CDC13) δ 7.39 (s, IH) , 7.35-7.10 '(m, 7H) , 7.02
(t, IH, J=8.0 Hz), 6.90 (d, IH, J=7.6 Hz), 6.84-6.75 (m, 2H) , 6.65 (m, IH) , 5.09 (apparent dd, IH, J=4.99, 8.1 Hz), 3.10 (m, 2H) , 2.60 (m, 2H) , 2.50 (m, 2H) , 2.30-1.70 (m, 8H) , 1.18 (d, 6H, J=6.8 Hz); ESMS m/e : 491.4 (M + H) + . Example 52
N- (3-{l- [(3S) -3- (4-CHLOROPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 4-chlorophenol (6.40 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (3.3 mg, 26.9 % yield) as a thick oil: E NMR δ 7.36 (s, IH) , 7.35-7.22 (m, 7H) , 7.12 (m, 2H) , 6.97 (apparent d, IH, J=7.2 Hz), 6.77 (m, 2H) , 5.23 (m, IH) , 3.18 (m, 2H) , 2.70 (m, 2H) , 2.50 (m, 2H) , 2.40-1.80 (m, 8H) , 1.25 (d, 6H, J=6.8 Hz); ESMS m/e 491.4 (M + H) + .
Example 53 2-METHYL-N- [3- (l-{ (3S) -3-PHENYL-3- [4- (TRIFLUOROMETHYL) PHENOXY] PROPYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: A mixture of N-(3-{l-
[ (3R) -3-hydroxy-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide (9.53 mg, 0.0250 mmol), 4- trifluoromethylphenol (8.100 mg, 0.050 mmol), triphenylphosphine (9.8 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (5.10 mg, 38.9 % yield) as a thick oil: 1H NMR δ 8.06 (s, IH) , 7.49 (s, IH) , 7.44 (apparent d, 2H, J= .6 Hz), 7.38-7.30 (m, 4H) , 7.30-7.20 (m, 3H) , 6.96 (apparent d, IH, J=7.6 Hz), 6.91 (apparent d, 2H,
J=8.6 Hz), 5.34 (m, IH) , 3.19 (m, 2H) , 2.72 (m, 2H) ,
2.53 (m, 2H) , 2.40-1.80 (m, 8H) , 1.25 (d, 6H, J=6.8 Hz);
ESMS m/e : 525.4 (M + H)+.
Example 54
N-(3-{l-[(3R)-3- (2,5-DIFLUOROPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N-
(3-{l- [(3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl }phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 2 , 5-difluorophenol (6.50 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3- (2.0 M in methanol) in CHC13] gave the desired product (3.60 mg, 29.3 % yield) as a thick oil: XH NMR δ
7.46 (s, IH) , 7.40-7.32 (m, 4H) , 7.31-7.20 (m, 2H) , 7.17
(s, IH) , 7.01-6.92 (m, 2H) , 6.65-6.42 (m, 2H) , 5.27 (m, IH) , 3.13 (m, 2H) , 2.64 (m, 2H) , 2.51 (m, 2H) , 2.28-1.80 (m, 8 H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e 493.4 (M + H) + .
Example 55 N- (3-{l- [(3R) -3- (3, 4-D CHLOROPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N-
(3-{-l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 3,4-dichlorophenol (8.20 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days.
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (5.20 mg, 39.7 % yield) as a thick oil: XE NMR
(CDC13) δ 7.70-7.63 ( , 2H) , 7.55 (m, IH) , 7.47-7.43 (m,
3H) , 7.40-7.19 (m, 3H) , 7.00-6.50 (m, 2H) , 6.69 (dd, IH, J=2.2, 8.8 Hz), 5.25 (m, IH) , 3.20 (m, 2H) , 2.70 (m,
2H) , 2.53 (m, 2H) , 2.40-2.20 (m, 4H) , 2.10-1.80 (m, 4H) ,
1.25 (d, 6H, J=7.1 Hz); ESMS m/e : 525.4 (M + H) + .
Example 56 2-METHYL-N- (3-{l- [ (3R) -3 -PHENOXY-3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of N-(3-{l-
[(3S) -3-hydroxy-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide (9.53 mg, 0.0250 mmol), phenol (4.70 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.0 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (4.1 mg, 36.0 % yield) as a thick oil: 2H NMR (400 MHz, CDCl3) δ 7.45 (s, IH) , 7.40-7.15 (m, 10H) , 6.97 (d, IH, J=7.6 Hz), 6.88-6.82 (m, 2H) ,
5.26 (m, IH) , 3.18 (m, 2H) , 2.75 (m, 2H) , 2.53 (m, 2H) , 2.40-2.10 (m, 4H) , 2.10-1.80 (m, 4H) , 1.25 (d, 6H, J=6.9 Hz); ESMS m/e: 457.4 (M + H) + .
Example 57
N- (3-{l- [ (3R) -3 -HYDROXY-3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE
Method A
Into a 25-mL RB-flask was added (R) - (+) -3-chloro-l- phenyl-1-propanol (0.545 g, 3.19 mmol, 99%ee, Aldrich Chemical Co.), 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide (0.748 g, 3.04 mmol), potassium carbonate (0.420 g, 3.04 mmol) and sodium iodide (0.684 g, 4.56 mmol) and DMF (6.0 mL) at room temperature. After stirring at 100 °C for 3 hrs, the TLC showed the reaction was complete . The reaction mixture was poured into water (50 mL) and the aqueous layer was extracted with methylene chloride (3x20 mL) . The combined organic extracts were washed with brine (20 L) , dried over Na2S04 and concentrated under reduced pressure. The residue was purified by flash chromatography (1:1= hexane: ethyl acetate with 1% isopropylamine) to afford the desired product (1.09 g, 94.3 % yield) as light-yellow solid: λE NMR (400 MHz, CDC13) δ 8.10 (S, IH) , 7.46-7.35 (m, 6H) , 7.27 (m, 2H) , 6.98 (apparent d, IH, J=7.6 Hz), 5.02 (apparent dd, IH, J=4.4, 8.1 Hz), 3.18 (apparent dd, 2H, J=2.5, 12.5 Hz), 2.74 (m, 2 H) , 2.50 (m, 2H) , 2.30-2.10 (m, 6H) , 1.80 (m, 2H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e: 381.2 (M + H) + .
The hydrochloric salt was prepared by addition of a slight excess of 1 N HCl in ether (1.2 eq.) to a solution of the free base in dichloromethane. The solvent was removed under reduced pressure, the residue was washed with ether and dried under reduced pressure Anal. Calc. for C24H32N2O2+HCl+0.8H20: C, 66.82; H, 8.08 N, 6.49; Cl, 8.22. Found: C, 66.90; H, 7.78; N, 6.63 Cl, 8.52.
Method B Into a 25-mL RB-flask was added (R) - (+) -3-chloro-l- phenyl-1-propanol (0.426 g, 2.50 mmol), 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide (0.565 g, 2.00 mmol), diisopropylethylamine (1.29 g, 10.0 mmol), dioxane (5.0 mL) and catalytic amount of tetrabutylammonium iodide at room temperature . After stirring at 90 °C for 72 hrs, the reaction mixture was poured into water (50 mL) and the aqueous layer was extracted with methylene chloride (3x20 mL) . The combined organic extracts were washed with brine (20 mL) , dried over Na2S04 and concentrated under reduced pressure. The residue was purified by preparative TLC plates (1 : 5 : 100=isopropylamine:methanol : ethyl acetate) to afford the desired product (0.260 g, 34.2 % yield) as light-yellow solid.
Example 58 N- (3-{l- [ (3S) -3- (4-CYANO-PHEONXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: N-(3-{l-[(3S)-
3- (4-cyanophenoxy) -3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide
A mixture of N- (3- {l- [ (3R) -3 -hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 4-cyanophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (4.70 mg, 71.3 % yield) as a thick oil: LH NMR (400 MHz, CDC13) δ 7.54
(m, 2H) , 7.48 (d, 2H, J=8.4 Hz), 7.30-7.20 '(m, 3H) , 7.20
(m, 3H) , 6.97 (apparent d, IH, J=8.4 Hz), 6.92 (apparent d, 2H, J=8.4 Hz), 5.36 (apparent dd, IH, J=3.9, 7.6 Hz), 3.12 (m, 2H) , 2.61 (m, 2H) , 2.53 (apparent sept, partially hidden, 2H, J=7.6 Hz), 2.30-2.10 (m, 6H) , 1.82 (m, 2H) , 1 . 25 (d, 6H , J=6 . 8 Hz) ; ESMS m/e : 482 . 2
(M + H) + .
Example 59 N- (3-{l- [ (3S) -3- (4-FLUOROPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 4-fluorophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (4.20 mg, 64.7% yield) as a thick oil: E 'NMR (400 MHz, CDC13) δ 7.40 (m, 2H) , 7.30-7.20 (m, 5H) , 7.20 (m, 3H) , 6.97 (apparent d, IH, J=7.7 Hz), 6.87 (m, IH) , 6.76 ( , IH) , 5.26 (apparent dd, IH, J=4.0, 8.1 Hz), 3.09 (m, 2H) , 2.66 (m, 2H) , 2.51 (m, 2H) , 2.3-2.1 (m, 6H) , 1.82 (m, 2H) , 1.25 (d, 6H, overlapped); ESMS m/e: 475.2 (M + H) + .
Example 60
N- (3-{l- [ (3S) -3- (4-BROMOPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 4-bromophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] the desired product (0.70 mg, 9.6% yield) as a thick oil: E NMR (400 MHz, CDC13) δ 8.06 (s, IH) , 7.48 (m, 2H) , 7 . 30 - 7 . 20 (m, 5H) , 7 . 20 (m, 3H) , 6 . 97
(apparent d, IH, J=8.5 Hz), 6.73 (apparent d, 2H, J=8.5
Hz), 5.22 (apparent dd, IH, J=4.9, 7.8 Hz), 3.15 (m,
2H) , 2.65 (m7 2H) , 2.51 (apparent sept, partially hidden, 2H, J=7.6 Hz), 2.30-2.10 (m, 6H) , 1.82 (m, 2H) ,
1.25 (d, 6H, J=6.8 Hz); ESMS m/e : 535.1 (M + H) + .
Example 61
N-(3-{l-[(3S)-3- (3-METHOXYPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3- {l- [ (3R) -3 -hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 3 -methoxyphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (3.1 mg, 46.6 % yield) as a thick oil: E NMR (400 MHz, CDC13) δ 7.47 (d, IH, J=6.7 Hz), 7.42 (s, IH) , 7.3-7.20 (m, 3H) , 7.20 (m, 3H) , 7.07 (t, IH, J=8.4 Hz), 6.97 (apparent d, IH, J=6.7 Hz), 6.40 (m, 3H) , 5.27 (apparent dd, IH, J=5.3, 8.0 Hz), 3.74 (s, 3H) , 3.38 (m, 2H) , 2.93 (m, 2H) , 2.61 (s, IH) , 2.53 (apparent sept, partially hidden, IH, J=6.5 Hz), 2.30-2.10 (m, 6H) , 1.82 (m, 2H) , 1.25 (d, 6H, J=6. Hz); ESMS m/e : 487.3 (M + H) + .
Example 62
N- (3-{l- [ (3S) -3- (4-CYANO-2-METHOXYPHENOXY) -3- PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
A mixture of N- (3- {l- [ (3R) -3 -hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol) , 2-methoxy-4-cyanophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF
(0.50 mL) was stirred at room temperature for 3 days.
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (5.50 mg, 76.5 % yield) as a thick oil: 1H NMR
(400 MHz, CDC13) δ 7.51 (s, IH) , 7.38 (s, IH) , 7.37 (d,
2H, J=2.4 Hz), 7.20 (m, 4H) , 7.10 (d, IH, J=2.4 Hz),
7.08 (s, IH) , 6.99 (apparent d, IH, J=8.3 Hz), 6.76 (apparent d, IH, J=8.3 Hz), 5.43 (apparent dd, IH, J=5.1, 8.0 Hz), 3.91 (s, 3H) , 3.34 (m, 2H) , 2.63 (m, 2H) , 2.63 (s, IH) , 2.53 (apparent sept, partially hidden, IH,' J=7.7 Hz), 2.30-2.10 (m, 6H) , 1.82 (m, 2H) , 1.28 (d, 6H, J=6.8 Hz); ESMS m/e: 512.2 (M + H) + .
Example 63
N- (3-{l- [ (3S) -3- (5-ACETYL-2-METHOXYPHENOXY) -3- PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3- {l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl }phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol) , 2-methoxy-5-acetylphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL)
' ' was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (1.60 mg, 22.2 % yield) as a thick oil: λE NMR
(400 MHz, CDC13) δ 7.52 (d, 2H, J=2.4 Hz),' 7.3-7.2 (m,
5H) , 7.20 (m, 3H) , 6.97 (apparent d, IH, J=6.7 Hz), 6.69 (apparent d, IH, J=8.0 Hz), 5.47 (apparent dd, IH, J=4.3, 7.8 Hz), 3.95 (s, 3H) , 3.38 (m, 2H) , 2.93 (m, 2H) , 2.61 (s, IH) , 2.53 (apparent sept, partially hidden, IH, J=7.6 Hz), 2.50 (s, 3H) , 2.30-2.10 (m, 6H) , 1 . 82 (m, 2H) , 1 . 25 (d, 6H , J=6 . 8 Hz ) ; ESMS m/e : 529 . 6
(M + H) X
Example 64 N-(3-{l-[(3R)-3- (2-ACETYLPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.2 mg, 0.0137 mmol), 2-acetylphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (1.70 mg, 24.9 % yield) as a thick oil: XE NMR (400 MHz, CDC13) δ 7.65 (m, IH) , 7.55 (s, IH) , 7.30-7.20 (m, 5H) , 7.20 (m, 3H) , 6.97 (m, 2H) , 6.76 (apparent d, IH) , 5.49 (apparent dd, IH, J=4.3, 8.0 Hz), 3.38 (m, 2H) , 2.93 (m, 2H) , 2.71 (s, 3H) , 2.60 (s, IH) , 2.53 (apparent sept, partially hidden, IH, J=7.6 Hz), 2.30-2.10 (m, 6H) , 1.82 (m, 2H) , 1.25 (d, 6H, J=6.9 Hz); ESMS m/e : 498.8 (M+) .
Example 65
N- [3- (l-{ (3R) -3- [2-FLUORO-5- (TRIFLUOROMETHYL) PHENOXY] -3- PHENYLPROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
A mixture of N- (3- {l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol) , 2-fluoro-5-trifluoromethylphenol • (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (2.50 mg, 33.7 % yield) as a thick oil: XH
NMR (400 MHz, CDC13) δ 8.07 (s, IH) , 7.67 (m, IH) , 7.54 ( , IH) , 7.45 (m, 2H) , 7.30-7.10 (m, 6H) , 7.14 (d, IH, J=7.4 Hz) , 6.97 (apparent d, IH, J=7.7 Hz) , 5.37 (apparent dd, IH, J=5.0, 8.5 Hz) , 3.4 (m, 2H) , 2.8 (m,
2H) , 2.6 (s, IH) , 2.53 (apparent sept, partially hidden, IH, J=7.4 Hz) , 2.30-2.10 (m, 6H) , 1.80 (m, 2H) , 1.25 (d, 6H, J=7.1 Hz, overlapped) ; ESMS m/e: 542.6 (M+) , 543.54 (M + H) + .
Example 66
N-[3-(l-{(3S)-3- [2-FLUORO-5- (TRIFLUOROMETHYL) PHENOXY] -3- PHENYLPROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl }phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol) , 2-fluoro-5-trifluoromethylphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (3.00 mg, 40.4% yield) as a thick oil: ^Η NMR
(400 MHz, CDC13) δ 8.06 (s, IH) , 7.67 (m, 2H) , 7.55 (m,
2H) , 7.50-7.40 (m, 3H) , 7.30-7.10 (m, 3H) , 7.17 (d, IH, J=8.9 Hz), 7.07 (apparent d, IH, J=6.7 Hz), 6.97
(apparent d, IH, J=7.8 Hz), 5.37 (apparent dd, IH,
J=4.2, 8.1 Hz), 3.37 (m," 2H) , 2.93 (m, 2H) , 2.63 (s,
IH) , 2.50 (apparent sept, partially hidden, IH, J=7.9
Hz), 2.30-2.10 (m, 6H) , 1.85 (m, 2H) , 1.25 (d, 6H, J=6.9 Hz); ESMS m/e 542.7 (M + H)+.
Example 67 N-(3-{l- C(3S)-3-(2,5- DIFLUOROPHENOXY) -3-
PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
A mixture of N- (3- {l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 2 , 5-difluorophenol (100 mg) , triphenylphosphine
(30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (2.70 mg, 40.1 % yield) as a thick oil: λE NMR (400 MHz, CDC13) δ 7.46. (s,
IH) , 7.40-7.30 (m, 4H) , 7.20 (m, 2H) , 7.17 (s, IH) , 6.97
(m, 2H) , 6.58 (m, IH) , 6.51 (m, IH) , 5.27 (apparent dd,
IH, J=5.1, 8.2 Hz), 3.13 (apparent d, J=9.7 Hz,- 2H) , 2.64 (m, 2H) , 2.51 (m, 2H) , 2.34 (apparent sept, partially hidden, J=7.1 Hz, IH) , 2.17 (m, 3H) , 1.90-1.80
(m, 4H) , 1.25 (d, 6H, J=7.1 Hz); ESMS m/e : 493.1 (M +
H) + .
Example 68.
N-(3-{l-[(3R)-3- (3-CHLOROPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 3-chlorophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography usin silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (2.4 mg, 35.8% yield) as a thick oil: ^Η NMR (400 MHz, CDC13) δ 7.30 (m, 2H) , 7.30-7.20 (m, 3H) , 7.20 (m, 3H) , 6.90 (apparent d, IH, J=7.7 Hz), 6.71 (apparent d, IH, J=2.9 Hz), 6.69 (apparent t, IH, J=2.9 Hz), 6.67 (apparent t, IH,
J=2.9 Hz), 6.65 (apparent d, IH, J=2.9 Hz), 5.09
(apparent dd, IH, J=4.8, 8.1 Hz), 3.18 (m, 2H) , 2.73 (m,
2H) , 2.50 (apparent sept, partially hidden, 2H, J=7.1 Hz), 2.30-2.10 (m, 6H) , 1.89 (m, 2H) , 1.25 (d, 6H, overlapped); ESMS m/e: 491.1 (M + H) + .
Example 69 (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLPROPYL 1-NAPHTHOATE: Into a 25-mL RB-flask was added N- (3-{l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol) , 1-naphthalenecarbonyl chloride (100 mg) , diisopropylethylamine (0.30 mL) in THF (0.50 mL) at room temperature. After stirring for 16 hrs at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified using preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (4.70 mg, 71.3 % yield) as a thick oil: ^H NMR (400 MHz, CDC13) δ 8.90 (d, IH, J=8.'9 Hz), 8.28 (apparent dd, IH, J=1.5, 7.2 Hz), 8.03 (d, IH, J=8.7 Hz), 7.88 (dm, 2H, J=8.7 Hz), 7.60- 7.48 (m, 7H) , 7.40-7.32 (m, 3H) , 7.25 (m, IH) , 6.90 (apparent d, IH, J=7.4 Hz), 6.18 (apparent dd, IH, J=5.7, 7.8 Hz), 3.42 (m, 2H) , 2.84 (m, 2H) , 2.53 (m, 2H) , 2.44 (apparent sept, partially hidden, 4H, J=7.5 Hz), 2.30-2.10 (m, 2H) , 1.82 (m, 2H) , 1.25 (d, 6H, J=6.8 Hz); ESMS m/e: 535.6 (M + H) + .
Example 70
N- (3 - {l- [ (3S) - 3 - (3 -ACETYLPHENOXY) - 3 - PHENYLPROPYL] - 4 - PIPERIDINYL}PHENYL) - 2 -METHYLPROPANAMIDE : A mixture of N- ( 3 - { l - [ (3R) - 3 -hydroxy- 3 -phenylpropyl] -4 - piperidinyl }phenyl) -2- methylpropanamide (5.20 mg, 0.0137 mmol), 2-acetylphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days .
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave .the desired product (1.50 mg, 22.0% yield) as a thick oil: XE NMR
(400 MHz, CDC13) δ 7.65 (m, IH) , 7.55 (s, IH) , 7.30-7.20 (m, 5H) , 7.20 (m, 3H) , 6.97 (m, 2H) , 6.76 (apparent d,
IH) , 5.49 (apparent dd, IH, J=4.3, 8.0 Hz), 3.38 (m,
2H) , 2.93 (m, 2H) , 2.75 (s, 3H) , 2.53 (apparent sept, partially hidden, 2H, J=7.6 Hz), 2.30-2.10 (m, 6H) , 1.92
(m, 2H) , 1.25 (d, 6H, J=6.9 Hz); ESMS m/e : 498.81 (M+) , 499.6 (M + H)X
Example 71
N- (3-{l- [ (3S) -3- (2-FLUOROPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 2-fluorophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (3.5 mg, 53.9% yield) as a thick oil: 1H NMR (400 MHz, CDC13) δ 8.07 (s, IH) , 7.65 (m, IH) , 7.41 (s, IH) , 7.40-7.10 (m, 5H) , 7.05 (m, 2H) , 6.97 (apparent d, IH, J=8.7 Hz), 6.86 (m, 2H) , 6.79 (apparent dt, IH, J=2.4, 7.9 Hz), 5.31 (apparent dd, IH, J=4.5, 8.0 Hz), 3.39 (m, 2H) , 2.97 (m, 2H) , 2.53 (apparent sept, partially hidden, 2H, J=7.5 Hz), 2.3-2.1 (m, 6H) , 1.92 (m, 2H) , 1.25 (d, 6H, J=6.7 Hz) ;
ESMS m/e: 475.7 (M + H) + .
Example 72 (4S) -N- (3 -{4- [3- (ACETYLAMINO) PHENYL] -1-
PIPERIDINYL}PROPYL) -4- (3 , 5-DIFLUOROPHENYL) -2-0X0-1,3- OXAZOLIDINE-3 -CARBOXAMIDE
Method: Into a 20 ml vial was added Nl- {3- [1- (3- aminopropyl) -4 -piperidyl] phenyl }acetamide (15 mg, 0.054 mmol) , (4S) -4- (3, 5-difluorophenyl) -2-oxo-oxazolidine-3- carboxylic acid-4-nitro-phenyl ester (39.3 mg, 1.08 mmol, 2 eq) and dichloromethane with 0.6% of methanol (3 ml) at room temperature. After stirring at room temperature for 3 hrs, the reaction mixture was filtered, and purified by preparative silica TLC (19:1 = chloroform : methanol) to afford the desired product (18.3 mg, 68% yield); 1H NMR (400 MHz, CDC13) δ 8.09 (br s, IH) , 7.40 (d, IH, J=8.0 Hz), 7.36-7.28 (m, 2H) , 7.24 (t, IH, J=8.0 Hz), 6.99 (d, IH, J=8.0 Hz), 6.86-6.82 (m, 2H) , 5.41 (dd, IH, J=4.1, 9.0 Hz), 4.72 (t, IH, J=9.0 Hz), 4.22 (dd, IH, J=3.9, 9.1 Hz), 3.42-3.29 (m, 2H) ; 3.02 (d, 2H J=ll.l Hz), 2.52-2.38 (m, 3H) , 2.16 (s, 3H) , 2.08-1.98 (m, 2H) , 1.86-1.70 (m, 6H) ; ESMS m/e: 501.2 (M + H) + ; Anal. Calc. for C2SH3oF2N4θ4+0.5H20: C, 60.64; H,
6.18; N, 10.88. Found: C, 60.67; H, 5.79; N, 10.86.
Example 73
The synthetic method is the same as described for the synthesis of (4S) -N- (3- {4- [3- (acetylamino) phenyl] -1- piperidinyl}propyl) -4- (3, 5-difluorophenyl) -2-oxo-l, 3- oxazolidine- 3 -carboxamide . (4S)-N-(3-{4-[3- (ACETYLAMINO) PHENYL] -1-
PIPERIDINYL}PROPYL) -2-0X0-4- (3,4,5-TRIFLUOROPHENYL) -1,3-
OXAZOLIDINE-3-CARBOXAMIDE: 18.8 mg (67% yield); XE NMR
(400 MHz, CDC13) δ 8.09 (br s, IH) , 7.41-7.20 (m, 3H) , 7.02-6.91 (m, 3H) , 5.37 (dd, IH, J=3.8 , 8.9 Hz), 4.71
(t, IH, J=9 Hz), 4.21 (dd, IH, J=4, 9.3 Hz), 3.43-3.27
(m, 2H) , 3.02 (d, 2H, J=11.0 Hz), 2.53-2.37 (m, 3H) ,
2.16 (s, 3H) , 2.08-1.97 (m, 2H) , 1.85-1.69 (m, 6H) ; ESMS m/e: 519.2 (M + H)+; Anal. Calc. for C26H29F3N4θ4+0.5H20: C, 59.20; H, 5.73; N, 10.62. Found: C, 59.40; H, 5.35;
N, 10.65.
Example 74
The synthetic method is the same as described for the synthesis of (4S) -N- (3- {4- [3- (acetylamino) phenyl] -1- piperidinyl}propyl) -4- (3 , 5-difluorophenyl) -2-oxo-l, 3- oxazolidine-3 -carboxamide .
N- (3-{4- [3- (ACETYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -4- (3, 4-DIFLUOROPHENYL) -5, 5-DIMETHYL-2-OXO-1, 3 -OXAZOLIDINE- 3 -CARBOXAMIDE: 19.6 mg (68% yield); 1H NMR (400 MHz, CDC13) δ 8.18 (t, IH, J=5.9 Hz), 7.41 (d, IH, J=8.8 Hz), 7.33 (s, IH) , 7.27-7.14 (m, 2H) , 7.02-6.88 (m, 3H) , 5.04 (s, IH) , 3.34 (qm, 2H, J=6.3 Hz), 3.02 (dm, 2H, J=10.9 Hz), 2.53-2.38 (m, 3H) , 2.16 (s, 3H) , 2.07-1.96 (m, 2H) , 1.87-1.69 (m, 6H) , 1.62 (s, 3H) , 1.02 (s, 3H) ; ESMS m/e: 529.3 (M + H)+; Anal. Calc. for C28H34F2 4θ4 : C, 63.62; H, 6.48; N, 10.60. Found: C, 63.15; H, 6.27; N 10.48.
Example 75
The synthetic method is the same as described for the synthesis of (4S) -N- (3- {4- [3- (acetylamino) phenyl] -1- piperidinyl}propyl) -4- (3 , 5-difluorophenyl) -2- oxo-1 , 3 -oxazolidine-3 -carboxamide .
(4S,5R)-N- (3 -{4- [3- (ACETYLAMINO) PHENYL] -1- PIPERIDINYL}PROPYL) -4- (3 , 4-DIFLUOROPHENYL) -5-METHYL-2-
OXO- 1,3 -OXAZOLIDINE-3 -CARBOXAMIDE: 20.5 mg (74% yield); λE NMR (400 MHz, CDCl3) δ 8.14 (t, IH, J=5.5 Hz), 7.40 (d, IH, J=7.8 Hz), 7.37-6.89 (m, 6H) , 5.35 (d, IH, J=7.5 Hz), 5.02-4.93 (m, IH) , 3.41-3.25 (m, 2H) , 3.02 (d, 2H, J=10.8 Hz), 2.53-2.37 (m, 3H) , 2.16 (s, 3H) , 2.07 (m, 2H) , 1.89-1.68 (m, 6H) , 1.04 (d, 3H, J=6.4 Hz); ESMS m/e: 515.3 (M + H)+; Anal. Calc. for C27H32F2 4θ4+0.5H20 : C, 61.94; H, 6.35; N, 10.70. Found: C, 61.90; H, 6.13; N, 10.64.
Example 76
The synthetic method is the same as described for the synthesis of (4S) -N- (3- {4- [3- (acetylamino) phenyl] -1- piperidinyl}propyl) -4- (3 , 5-difluorophenyl) -2-oxo-l , 3- oxazolidine-3 -carboxamide.
Ν- (3-{4- [3- (ACETYLAMINO) PHENYL] -1-PIPERIDINYL}PR0PYL) -4- ( -FLUOROBENZYL) -2 -OXO-1,3-OXAZOLIDINE-3 -CARBOXAMIDE :
17.4 mg (65% yield); λE NMR (400 MHz, CDC13) δ 8.08 (t, IH, J=5.6 Hz), 7.4 (d, IH, J=7.2 Hz), 7.34 (s, IH) , 7.28-7.14 (m, 3H) , 7.05-6.95 (m, 3H) , 4.69-4.60 (m, IH) , 4.26 (t, IH, J=8.8 Hz), 4.15 (dd, IH, J=3.2, 9 Hz), 3.43 (q, 2H, J=6.2 Hz), 3.3 (dm IH, J=13.6 Hz), '3.04 (dm, 2H, J=ll Hz), 2.87 (dd, IH, J=9.3, 14.4 Hz), 2.53-2.42 (m, 3H) , 2.16 (s, 3H) , 2.09-1.99 (m, 2H) , 1.87-1.65 (m, 6H) ; ESMS m/e: 497.3 (M + H)+; Anal. Calc. for C27H33FN4O4+0.5H2O: C, 64.14; H, 6.78; N, 11.08. Found: C, 64.26; H, 6.39; N, 11.12. Example 77
2-METHYL-N- (3-{l- [ (3R) -3- (2-NITROPHENOXY) -3-
PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of N-(3-{l-[(3S)-3 -hydroxy-3 -phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 2-nitrophenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (2.37 mg, 34.5% yield) as a -thick oil: 1H NMR (400 MHz, CDC13) δ 7.84 (d, IH) , 7.90 (m, IH) , 7.45 (m IH) , 7.30-7.20 (m, 5H) , 7.20 (m, 2H) , 6.98 (m, 2H) , 6.89 (apparent d, IH, J=7.7 Hz), 5.62 (apparent dd, IH, J=4.1, 8.9 Hz), 3.10 (m, 2H) , 2.60 (m, 2H) , 2.53 (m, 2H) , 2.30-2.10 (m, 6H) , 1.90 (m, 2H) , 1.25 (d, 6H, overlapped); ESMS m/e : 502.3 (M + H)+.
Example 78
N- (3-{l- [ (3S) -3- ( [1,1' -BIPHENYL] -4-YLOXY) -3- PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 4-phenylphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography -using silica preparative TLC plates [2.5% of • NH3 (2.0 M in methanol) in CHC13] gave the desired product (3.00 mg, 41.2% yield) as a thick oil: XH NMR (400 MHz, CDCl3) δ 8.06 (s, IH) , 7.48 (m, 2H) , 7.40-7.30 (m, 8H) , 7.30-7.25 (m, 4H) , 6.97 (apparent d, IH, J=7.6 Hz), 6.91 (apparent d, 2H, J=8.7 Hz), 5.34 (apparent dd, IH, J=4.4, 8.0 Hz), 3.40
(m, 2H) , 2.98 (m, 2H) , 2.53 (apparent sept, partially hidden, IH, J=8.1 Hz), 2.44 (m, IH) , 2.30-2.10 (m, 6H) ,
1.93 (d, 2H) , 1.26 (d, 6H, J=6.9 Hz); ESMS m/e : 533.4 (M + H)+.
Example 79
2-METHYL-N- (3-{l- [ (3R) -3- (3-NITROPHENOXY) -3-
PHENYLPROPYL] - 4-PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of N-(3-{l-
[ (3S) -3 -hydroxy-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide (5.20 mg, 0.0137 mmol), 3-nitrophenol
(100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days.
Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (2.80 mg, 40.8 % yield) as a thick oil: 1H NMR
(400 MHz, CDC13) δ 7.76 (dm, IH) , 7.71 (t, IH, J=l .8 Hz), 7.50-7.40 (m, 2H) , 7.40-7.25 (m, 7H) , 7.17 (apparent dd, IH, J=2.4, 8.2), 6.97 (apparent d, IH, J=7.7 Hz), 5.45 (apparent dd, IH, J=5.0, 8.1 Hz), 3.45 (m, 2H) , 2.89 (m, 2H) , 2.53 (apparent sept, partially hidden, 2H, J=8.3 Hz), 2.30-2.10 (m, 6H) , 1.92 (m, 2H) , 1.25 (d, 6H, J=6.8 Hz); ESMS m/e : 502.3 (M + H) + .
Example 80
N- (3-{l- [ (3S) -3- (2-ETHOXYPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 2-ethoxyphenol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] gave the desired product (1.16 mg, 15.5% yield) as a thick oil: XE NMR (400 MHz, CDC13) δ 8.06 (s, IH) ,
7.52 (s, IH) , 7.40-7.33 (m, 4H) , 7.30-7.20 (m, 3H) , 6.97
(apparent d, IH, J=7.7 Hz), 6.88 (m, 2H) , 6.68 (m, 2H) ,
5.21 (m, IH) , 4.11 (q, 2H, J=7.3 Hz), 3.37 (m, 2H) , 2.71
(m, 2H) , 2.53 (apparent sept, partially hidden, 2H, J=7.6 Hz), 2.30-2.10 (m, 6H) , 1.89 (m, 2H) , 1.49 (t, 3H,
J=7.3 Hz), 1.25 (d, 6H, J=6.8. Hz) ; ESMS m/e : 501.4 (M +
H) + .
Example 81 2-METHYL-N- (3-{l- [ (3S) -3- (1-NAPHTHYLOXY) -3-
PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE : A mixture of N- (3- {l- [ (3R) -3 -hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.20 mg, 0.0137 mmol), 1-naphthol (100 mg) , triphenylphosphine (30.0 mg, 0.115 mmol) and diethyl azodicarboxylate (7.42 mg, 0.0426 mmol) in THF (0.50 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHCI3] gave the desired product (4.30 mg, 66.2% yield) as a thick oil: XH NMR (400 MHz, CDC13) δ 8.06 (s, IH) , 7.72 (d, IH, J=8.5 Hz), 7.59 (d, IH, J=8.5 Hz), 7.5 (m, 2H) , 7.45-7.30 (m, 6H) , 7.25 (m, 3H) , 7.17 (apparent dd, IH, J=2.6, 9.0 Hz), 7.01 (apparent d, IH, J=2.6 Hz), 6.97 (apparent d, IH, J=7.9 Hz), 5.46 (apparent dd, IH, J=4.5, 8.1 Hz), 3.12 (m, 2H) , 2.61 (m, 2H) , 2.53 (apparent sept, partially hidden, 2H, J=7.9 Hz), 2.30- 2.10 (m, 6H) , 1.90 (m, 2H) , 1.25 (d, 6H, J=7.3 Hz, overlapped); ESMS m/e : 507.2 (M + H) + . Example 82
N- (3-{l- [ (3S) -3- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2- YL) -3-PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE
Step 1:
2- [(IS) -3-CHLORO-l-PHENYLPROPYL] -Iff-ISO NDOLE-1, 3 (2H) -
DIONE: According to the general procedure descibed in Srebnik, M. ; Ram chandran, P.V.; Brown, H.C. J. Org. Chem . 1988, 53 , 2916-2920, a mixture of phthalimide (0.147 g, 1.0 mmol), (R) - (+) -3-chloro-phenyl-l-propanol (0.171 g, 1.0 mmol), triphenylphosphine (0.262 g, 1.0 mmol) and diethyl azodicarboxylate (0.174 g, 1.0 mmol) in 5.0 mL of THF was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo . The residue was washed with pentane (x3) and the combined pentane extracts were concentrated and chromatographed (silica with hexanes-EtOAc 8:1 as the eluent) to give the desired product (0.121 g, 50.2 %) as a yellow solid: XE NMR (400 MHz, CDCl3) δ 7.82 (apparent dd, 2H, J=2.9 Hz), 7.70 (apparent dd, 2H, J=2.9 Hz), 7.56 (m, 2H) , 7.39-7.27 (m, 3H) , '5.64 (apparent dd, IH, J=7.0, 9.2 Hz), 3.57 (m, 2H) , 3.05 (m, IH) , 2.82 (apparent sept, IH, J=7.0 Hz); ESMS m/e : 300.13 (M+H)+.
Step 2:
N- (3-{l- [ (3S) -3- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2- YL) -3-PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE : A mixture of potassium carbonate (29.2 mg, 0.211 mmol), sodium iodide (47.5 mg,
0.317 mmol), 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide (51.8 mg, 0.211 mmol) 2-
[ (IS) -3-chloro-l-phenylpropyl] -lH-isoindole-1, 3 (2H) - dione (63.1 mg, 0.211 mmol) in DMF (5.0 mL) was stirred at- 100 °C for 3 hrs, at which time TLC indicated that the reaction was complete. The reaction mixture was poured into water (50 mL) and the aqueous layer was extracted with methylene chloride (3x30 mL) . The combined organic extracts were washed with brine (30 mL) , dried over MgS04 and concentrated under reduced pressure. The crude product was purified by Prep-TLC plates [2.5% of ΝH3 (2.0 M in methanol) in CHC13] to give the desired product (74.1 mg, 77.1 %) as a thick oil: NMR (400 MHz, CDC13) δ 7.83 (apparent dd, 2H, J=2.9 Hz), 7.69 (apparent dd, 2H, J=2.9 Hz), 7.56 (apparent dt, 3H, J=2.9, 7.3 Hz), 7.33 (m, 4H) , 7.21 (t, IH, J=7.8 Hz), 7.09 (s, IH) , 6.81 (apparent d, IH, J=7.8 Hz), 5.49 (apparent dd, IH, J=5.5, 9.5 Hz), 2.98 (d, IH, J=9.5 Hz), 2.87 (m, 2H) , 2.50 (apparent sept, IH, J=6.7 Hz), 2.40-2.35 (m, 4H) , 1.94 (m, 2H) , 1.70-1.50 (m, 4H) , 1.25 (d, 6H, J=7.9 Hz); ESMS m/e : 510.37 (M+H)+.
Example 83 2-METHYL-N- (3-{l- [ (3S) -3- (4-PHENOXYPHENOXY) -3- PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE
STEP 1:
4-{ [ (IS) -3-CHLORO-l-PHENYLPROPYL]OXY}- (4-
PHENOXY) BENZENE: A mixture of 4-phenoxyphenol (1.86 g, 10.0 mmol), (R) - (-) -3-chloro-phenyl-1-propanol (1.70 g, 10.0 mmol), triphenylphosphine (2.62 g, 10.0 mmol), diethyl azodicarboxylate (1.57 mL, 10.0 mmol) in
5.0 mL of THF was stirred at room temperature for 24 h.
The reaction mixture was concentrated in vacuo . The residue was washed with pentane (x3) and the combined pentane extracts were concentrated and chromatographed
(silica with hexanes-EtOAc 97:3 as the eluent) to give the desired product as a thick oil which solidified on standing (2.51 g, 75.7 %) : 1H NMR (400 MHz, CDC13) 6 7.4-
7.23 (m, 7H) , 7.03 (apparent t, IH, J=7.3 Hz), 6.91 (apparent dm, 2H, J=7.8 Hz), 6.93 (apparent q, 4H, J=7.8
Hz), 5.31 (apparent dd, IH, J=4.5, 8.6 Hz), 3.82 (m,
IH) , 3.62 (apparent quintet, IH, J=5.6 Hz), 2.47 (m,
IH) , 2.20 (m, IH) .
Step 2:
2-METHYL-N- (3-{l- [ (3S) -3- (4-PHENOXYPHENOXY) -3- PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide (65.5 mg, 0.266 mmol), 4-
{ [ (IS) -3-chloro-l-phenylpropyl] oxy}- (4-phenoxy) benzene
(0.100 mg, 0.296 mmol), potassium carbonate (40.9 mg,
0.296 mmol) and sodium iodide (67.0 mg, 0.444 mmol) in
DMF (1.0 mL) at 100 °C for 3 hours. The reaction mixture was poured into water (50 mL) and the aqueous layer was extracted with methylene chloride (3x30 mL) . The combined organic extracts were washed with brine (30 mL) , dried over MgS04 and concentrated under reduced pressure. The crude product was purified by Prep-TLC plates [2.5% of ΝH3 (2.0 M in methanol) in CHC13] to give the desired product (0.109 g, 74.6 %) as a thick oil: E
NMR (400 MHz, CDC13) δ 7.48 (s, IH) , 7.40-7.30 (m, 4H) ,
7.20-7.10 (m, 6 H) , 7.09 (s, IH) , 6.99 (apparent d, IH, j=7.8 Hz), 6.98 (apparent t, IH, J=7.8 Hz), 6.93
(apparent d, 2H, J=8.4 Hz), 6.84 (m, 2H) , 5.20 (apparent dd, IH, J=4.4, 8.5 Hz), 3.03 (m, 2H) , 2.51 (m, 4H) , 2.24
(apparent sept, IH, =7.8 Hz), 2.20-2.10 (m, 3H) , 1.90 (m, 4H) , 1.25 (d, 6H, J=7.9 Hz); ESMS m/e: 549.41 (M+H)+; Anal. Calc. for C36H4oN203: C, 78.80; H, 7.35; N, 5.11. Found: C, 78.58; H, 7.48; N, 5.09.
Example 84 N- (4-{l- [(3R)-3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE
Step 1:
1- [ (3R) -3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] -4- (4-
NITROPHENYL) -1, 2,3 , 6-TETRAHYDROPYRIDINE: A mixture of potassium carbonate (24.0 mg, 0.174 mmol), sodium iodide
(39.0 mg, 0.260 mmol), 4- (4-nitrophenyl) -1, 2 , 3 , 6- tetrahydropyridine (35.4 mg, 0.174 mmol) and 4-{[(lR)-3- chloro-1-phenylpropyl] oxy} -1, 2-dimethoxybenzene (53.4 mg, 0.174 mmol) in DMF (0.5 mL) was stirred at 100 °C for
3 hrs, at which time TLC indicated that the reaction was complete. The reaction mixture was poured into water
(5.0 mL) and the aqueous layer was extracted with methylene chloride (3x30 mL) . The combined organic extracts were washed with brine (30 mL) , dried over MgS04 and concentrated under reduced pressure. The crude product was purified by Prep-TLC plates
[1: l=hexane: ethyl acetate with 1% NH3] afforded the product (63.1 mg, 76.6 %) as a yellow oil. The product was used in next reaction without further purification.
Step 2: 4-{l- [ (3R) -3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}ANILINE: A 25-mL RB flask, equipped with a hydrogen-filled balloon, was charged with l-[(3R)-3- (3, 4-dimethoxyphenoxy) -3-phenylpropyl] -4- (4- nitrophenyl) -1,2, 3, 6-tetrahydropyridine (63.0 mg, 0.133 mmol), palladium on carbon (5.0 mol-eq%, 0.00665 mmol, 7.04 mg) and ethanol (2.0 mL) at room temperature. After 1 hr the reaction mixture was filtered through a plug of Celite 545 and concentrated under reduced pressure. The crude product (54.1 mg, 89.4%) was used in next reaction without further purification.
STEP 3
N- (4-{l- [ (3R) -3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 4- {l- [ (3R) -3- (3, 4-dimethoxyphenoxy) -3-phenylpropyl] -4- piperidinyl}aniline (5.31 mg, 0.0119 mmol), isobutyryl chloride (2.08 mg, 0.019 mmol), N,N- diisopropylethylamine (8.40 mg, 0.0650 mmol) in methylene chloride (1.0 mL) was stirred at room temperature for 24 hours. The reaction mixture was concentrated and chromatographed using a preparative TLC plate [2.5% of NH3 (2.0 M in methanol) in CHC13] to give the product (3.5 mg, 56.5 %) as a thick oil: λE NMR (400 MHz, CDC13) δ 7.38 (d, IH, J=8.6 Hz), 7.30-7.20 (m, 4H) , 7.20(m, IH) , 7.11 (d, 2H, J=8.6 Hz), 7.04 -(s, IH) , 6.57 (d, IH, J=8.3 Hz), 6.44 (d, IH, J=2.6 Hz), 6.22 (dd, IH, J=2.6, 8.3 Hz), 5.09 (apparent dd, IH, J=4.4, 8.1 Hz), 3.72 (s, 3H) , 3.70 (s, 3H) , 3.08 (m, 2H) , 2.57 (m, 2 H) , 2.43 (apparent sept, partially hidden, 2H, J=6.8 Hz), 2.30-2.10 (m, 6H) , 1.80 (m, 2H) , 1.25 (d, 6H,
J=7.9 Hz); ESMS m/e: 517.3 (M+H) + .
Example 85
N- (3-{l- [ (3S) -3- (3-ACETYLPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Into a 25-mL RB-flask was added triphenylphosphine (9.80 mg, 0.0375 mmol), diethyl azodicarboxylate (5.22 mg, 0.0300 mmol), N- (3-{l- [ (3R) -3 -hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 3-hydroxyacetophenone (100 mg) and THF (1.0 mL) at room temperature. The reaction mixture was stirred at room temperature overnight (16 hrs) . The solvent was removed under reduced pressure and the residue was purified by preparative TLC plates [2.5% of NH3 (2.0 M in methanol) in CHC13] to afford the desired product (2.73 mg, 39.9%) as a thick oil: E NMR (CDC13) δ 7.70-7.64 (m, 2H) , 7.54 (m, 2H) , 7.49-7.44 (m, 6H) , 7.25 (m, IH) , 7.05 (d, IH, J=8.3 Hz), 6.96 (apparent d, IH, J=7.7 Hz), 5.34 (apparent dd, IH, J=4.8, 8.2 Hz), 3.15 (m, 2H) , 2.67 (m, 2H) , 2.52 (s, 3H) , 2.53 (apparent sept, partially hidden, 2H, J=7.6 Hz), 2.30-2.10 (m, 6H) , 1.89 (m, 2H) , 1.25 (d, 6H, J=6.9 Hz); ESMS /e: 499.4 (M + H) + .
Scheme A. Synthesis of tert-Butyl 4-(3-arninophenyl)-1-piperidinecarboxylate
Figure imgf000177_0001
Figure imgf000177_0002
a. n-BuLi, diisopropylamine, THF, PhN(Tf)2, -78 °C to room temperature, 81% b. 3-aminophenylboronic acid hemisulfate, LiCI, tetrakis-triphenylphosphine -palladium (0), Na2C03, DME-H20, reflux, 81% c. 10% Pd/C, ethanol, H2, room temperature, balloon method, 84%
Scheme B1. A General Synthesis of the MCH Antagonists
or p-N02
Figure imgf000178_0001
Figure imgf000178_0002
Scheme B2. A General Synthesis of the MCH Antagonists
Figure imgf000178_0003
X = C, S(=0) halide = Cl, Br Scheme C1. Specific Examples of the Syntheses of the MCH Antagonists
Figure imgf000179_0001
Scheme C2. Specific Examples of the Syntheses of the MCH Antagonists
Figure imgf000179_0002
Figure imgf000179_0003
commercially available
Figure imgf000179_0005
Figure imgf000179_0004
Scheme D1. Specific Examples of the Syntheses of the MCH Antagonists
Figure imgf000180_0001
Scheme D2. Specific Examples of the Syntheses of the MCH Antagonists
Figure imgf000180_0002
Scheme E: General Synthesis of the MCH Antagonists
Figure imgf000181_0001
Figure imgf000181_0002
a. dioxane, diisopropylethylamine, Bu4NI, reflux or DMF, Ki, Na2C03, 90-100 °C or toluene, 110 °C, 18-cro n-6 b. diisopyropylethylamine, dichloromethane
X = S(=0), C
R1 = Aromatic, substituted aromatic or heterocyciic
R2 = aliphatic oraromatic
Scheme F. General Synthesis of the MCH Antagonists
R-halide;
Figure imgf000182_0001
If R = (CH2)nCHOH-Ar, then,
Figure imgf000182_0002
or e other enan omer stereochemistry
acid chloride, Hunig's base
Figure imgf000182_0004
retention of the absolute stereochemistry
Figure imgf000182_0003
Scheme G. General Synthesis of the MCH Antagonists
Figure imgf000183_0001
phthalimide
Figure imgf000183_0002
Bu4NI, or Kl; dioxane, toluene, or or DMF; heat
Figure imgf000183_0003
Scheme H: Synthesis of Oxazolidinones
a
ArCHO A -
NC NH2 Me02C NH2
Figure imgf000184_0001
Ar = 3,4-difluorophenyl, 3,5-difluorophenyl or 3,4,5-trifluorophenyl
Scheme I: Synthesis of gem-Dialkyl Substituted Oxazolidinones
Figure imgf000185_0001
a. methyl magnesium bromide, THF; b. N,N-carbonyldiimidazole, DCM; c. NaH, THF, p-nitrophenylch!oroformate; d. an amine such as N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}acetamide
Scheme J: Synthesis and Chiral Resolution of Oxazolidinones
Figure imgf000185_0002
a (a) f-BuLi, THF, RCHO (b) CH3ONH2.HCI, MeOH, 50-68% over 2 steps (c) Boc20, CHCI3, >90% (d) NaH.THF, 76-92% (e) separate diastereomers by column chromatography and separate enantiomers by chiral phase HPLC, 10-16% (f) n-BuLi, THF, 4-nitrophenylchloroformate, -75% (g) THF, >80%, an amine such as N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}acetamide Scheme K: Synthesis Oxazolidinones from Amino Acids
Figure imgf000186_0001
a. LAH, THF; b. (BOC)20, CHCI3; c. NaH, THF; d. p-nitrophenylchloroformate, NaH, THF; h. an amine such as N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}acetamide
Ar = aromatic such as 4-fluorophenyl or 3,4-difluorophenyl
Scheme L: Determination of the Absolute Stereochemistry of the Di-Substituted Oxazolidinones Using Lactic Acid Derivatives
Figure imgf000187_0001
Figure imgf000187_0002
Figure imgf000187_0003
a. pyrrolidine, methanol, heat; b. t-butyldimethylsilyi chloride; c. LAH, ether, reflux d. (BOC)20, chloroform; e. NaH, THF; h. silica gel chromatography
For more details, See: Lagu, B.; Wetzel, J. M.; Forray, C; Patane, M. A.; Bock, M. G. "Determination of the Relative and Absolute Stereochemistry of a Potent α A Selective Adrenoceptor Antagonist" Bioorg. Med. Chem. Lett. 2000, 10, 2705.
Figure imgf000188_0001
Figure imgf000188_0003
Figure imgf000188_0002
n=2, R1=H, R2=Ph, R3=H n=5, R1=H, R2=H, R3=5-O e n=1, R1=H, R2=Ph, R3=H n=4, R1=H, R2=H, R3=5-0Me
Scheme N
Figure imgf000189_0001
Example
Figure imgf000189_0002
R1=6-CI, R2=H R1=H, R2=4'-tolyl
Scheme P
Figure imgf000190_0001
Example
Figure imgf000190_0002
Scheme O
Figure imgf000191_0001
R1=H, R2=4'-Me
Scheme Q
Figure imgf000191_0002
Example
Figure imgf000191_0003
Scheme R
Figure imgf000192_0001
Example
Figure imgf000192_0002
EXPERIMENTAL SECTION
The following additional abbreviations are used: HOAc, acetic acid; DMF, N, AT-dimethylformamide; EtOAc, ethyl acetate; MeOH, methanol; ΝMP, l-methyl-2-pyrrolidinone; TEA, triethylamine; THF, tetrahydrofuran; All solvent ratios are volume/volume unless stated otherwise.
1- (4-METHYLPHEΝYL) IH-INDOLE: A mixture of 1-H-indole (58.5 mg, 0.500 mmol), 1- (iodo) -4-methylbenzene (0.218 g, 1.00 mmol), copper powder (32.0 mg, 0.500 mmol), and K2C03 (0.138 g, 1.00 mmol) in 1-methyl-2 -pyrrolidinone (1 mL) was heated at 150 °C for 12 h under argon. The resulting mixture was diluted with H20 (6 mL) . The aqueous layer was extracted with CH2C12 (3 X 10 mL) . The combined organic extracts were washed with brine (10 mL) , dried over MgS04, and concentrated in vacuo . The residue was purified by preparative TLC using EtOAc/hexane (1:4) to give the desired product (82 mg, 79%) . ^Η NMR (400 MHz, CDCl3) δ 7.67 (d, IH, J = 7.7 Hz), 7.52 (d, IH, J = 7.4 Hz), 7.38 (d, 2H, J = 8.4 Hz), 7.34-7.29 (m, 3H) , 7.21 (t, IH, J = 7.0 Hz), 7.15 (t, IH, J = 7.0 Hz), 6.66 (d, IH, 3.3 Hz), 2.43 (s, 3H) ; ESMS /e : 208.0 (M + H)+.
Example 86
N- (3-{l- [ (6-CHLORO-1H-INDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A solution of 2 -methyl -N- [3- (4-piperidinyl) phenyl] propanamide (0.369 g, 1.50 mmol) and 37 wt % aqueous formaldehyde (30.0 mg, 1.50 mmol) in 1 mL of HOAc : dioxane (1:4) was added to 6-chloro-1-H-indole (0.152 g, 1.00 mmol) and the reaction mixture was stirred for 12 h at room temperature. The resulting mixture was diluted with
H20 (10 mL) . The aqueous layer was extracted with CH2C12
(3 X 100 mL) . The combined organic extracts were washed with brine (10 mL) , dried over MgS0 , and concentrated in vacuo. The residue was purified by preparative TLC on silica using 5% of NH3 (2.0 M in methanol) in CH2C12 to give the desired product (79 mg, 42%) . 1H NMR (400 MHz,
CDC13) δ 9.14 (s, IH) , 8.04 (s, IH) , 7.52 (t, 2H, J" = 8.1
Hz), 7.35 (d, 2H, J = 13.3 Hz), 7.18 (t, IH, J = 7.9 Hz), 7.09 (dd, IH, J = 1.9, 8.5 Hz), 6.85 (d, IH, J =
7.4 Hz), 5.18 (s, IH) , 4.01 (s, 2H) , 2.55 (septet, IH, J
= 6.8 Hz), 2.48-2.34 (m, 3H) , 2.08-1.95 (m, 4H) , 1.78
(d, 2H, J = 12.8 Hz), 1.22 (d, 6H, J = 6.8 Hz); ESMS m/e : 410.1 (M + H)+.
Example 87
2-METHYL-N- [3- (l-{ [1- (4-METHYLPHENYL) -1H-INDOL-3-
YL] METHYL} -4 -PIPERIDINYL) PHENYL] PROPANAMIDE: According to the procedure used for the synthesis of N- ( 3 - { l - [ ( 6 - chloro-lH-indol-3-yl) methyl] -4 -piperidinyl }phenyl) -2- methylpropanamide, 1- (4-methylphenyl) -IH-indole (0.207 g, 1.00 mmol) provided 2 -methyl -N- [3- (1- { [1- (4- methylphenyl) -lH-indol-3-yl] methyl} -4- piperidinyl) phenyl] propanamide (0.441 g, 78%). ^Η ΝMR (400 MHz, CDC13) δ 7.90 (s, IH) , 7.73 (d, IH, J = 7.2 Hz), 7.58-7.51 (m, 2H) , 7.43-7.36 (m, 3H) , 7.35-7.29 ( , 3H) , 7.26-7.15 (m, 3H) , 6.89 (d, IH, J = 7.7 Hz), 4.07 (s, 2H) , 3.36 (d, 2H, J = 11.6 Hz), 2.59-2.39 (m, 6H) , 2.55 (sept, IH, J = 6.7 Hz), 2.10-1.98 (m, 2H) , 1.83 (d, ' 2H, J" = 12.9 Hz), 1.23 (d, 6H, J = 6.9' Hz); ESMS m/e -. 466.2 (M + H)+. 2- [ (IS) -3-CHLORO-l- PHENYLPROPYL] - 1H-
ISOINDOLE-1,3 (2JT) -DIONE: Triphenylphosphine (5.25 g,
20.0 mmol) and diethyl azodicarboxylate (3.58 g, 20.0 mmol) were added to a solution of (1R) -3-chloro-l-
5 phenyl-1-propanol (3.42 g, 20.0 mmol) and phthalimide
(2.94 g, 20.0 mmol) in THF (100 mL) . The reaction mixture was stirred for 4 h at room temperature. The solvent was removed under reduced pressure and the residue was triturated with pentane (3 X 50 mL) . The
10 combined pentane fractions were concentrated in vacuo and the crude product was purified by chromatography on silica using EtOAc/hexane (3:97) to give the desired product (4.40 g, 74%). XH NMR (400 MHz, CDC13) δ 7.82
(d, IH, J = 5.7 Hz), 7.81 (d, IH, J" = 5.5 Hz), 7.70 (d,
15 IH, J = 5.4 Hz), 7.69 (d, IH, J = 5.8 Hz), 7.55 (d, 2H, J = 7.2 Hz), 7.38-7.28 (m, 3H) , 5.64 (dd, IH, J = 6.8, 9.2 Hz), 3.56 (t, 2H, J = 6.4 Hz), 3.11-3.02 (m, IH) , 2.85-2.75 (m, IH) ; ESMS m/e : 300.1 (M + H) + .
20 N- (3-{l- [ (3S) -3- (l,3-DIOXO-l,3-DIHYDRO-2H-ISOINDOL-2- YL) -3-PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE : A mixture of 2- [ (IS) -3-chloro-l- phenylpropyl] -lH-isoindole-1, 3 (2H) -dione (4.50 g, 15.0 mmol) , 2 -methyl -N- [3- (4-piperidinyl) phenyl] propanamide
25 (4.26 g, 15.0 mmol), K2C03 (4.16 g, 30.0 mmol), and Νal
(3.40 g, 20.0 mmol) in DMF (40 mL) was stirred at 90 °C for 12 hrs. The reaction mixture was diluted with water
(50 mL) , extracted with CH2C12 (3 X 50 mL) , and the combined organic extracts were washed with brine (50
'30 mL) , dried over MgS04, and concentrated under reduced pressure. The residue was purified by chromatography on silica using 5% of ΝH3 (2.0 M in methanol) in CH2C12 to give the desired product (5.10 g, 74%). XH NMR (400 MHz, CDCI3) δ 7.83 (d, IH, J = 5.5 Hz), 7.82 (d, IH, J =
5.5 Hz), 7.71 (d, IH, J = 5.5 Hz), 7.70 (d, IH, J = 5.4
Hz), 7.56 (d, 2H, J = 7.1 Hz), 7.35-7.27 (m, 5H) , 7.22
(t, IH, J = 7.5 Hz), 7.09 (s, IH) , 6.81 (d, IH, J = 7.8 Hz), 5.49 (dd, IH, J = 5.5, 9.6 Hz), 2.97 (d, IH, J =
10.1 Hz), 2.92-2.82 (m, 2H) , 2.44 (sept, IH, J = 6.7
Hz), 2.40-2.29 (m, 3H) , 2.00-1.83 (m, 2H) , 1.79-1.39 (m,
5H) , 1.26 (d, 6H, J = 6.9 Hz); ESMS m/e : 510.4 (M + H) + .
N- (3-{l- [ (3S) -3-AMINO-3-PHENYLPROPYLJ -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of N- (3-{l- [ (3S) -3- (l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl) - 3-phenylpropyl] -4-piperidinyl}phenyl) -2 - methylpropanamide (4.60 g, 9.06 mmol) and hydrazine (3.62 g, 72.4 mmol) in ethanol (150 mL) was refluxed for 12 h. The resulting white precipitate was filtered out and the filtrate was concentrated under vacuum. The residue was washed with CH2Cl2/EtOAc (1:1, 3 X 50 mL) and the combined organic fractions were concentrated in vacuo to give the desired product (2.90 g, 95%). 1H ΝMR (400 MHz, CDCI3) δ 7.45 (s, IH) , 7.39-7.30 (m, 6H) , 7.29- 7.19 (m, 2H) , 6.95 (d, IH, J = 7.2), 4.01 (t, IH, J = 6.8 Hz), 3.04 (t, 2H, J = 10.6 Hz), 2.62-2.30 (m, 6H) , 2.05-1.70 (m, 8H) , 1.24 (d, 6H, J = 6.8 Hz); ESMS m/e : 380.4 (M + H)+.
Example 88
2 -METHYL-N- (3 - { l- [ (3S) - 3 - PHEΝYL- 3 -
(PROPIONYLAMINO) PROPYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: According to the procedure used for the synthesis of N- (3- {l- [ (3S) -3- (acetylamino) -3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide, N- (3-{l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl }phenyl) -2-methylpropanamide
(11.0 mg, 0.0280 mmol) and propionyl chloride (3.80 mg,
0.0420 mmol) provided 2 -methyl -N- (3- {l- [ (3S) -3-phenyl-3- (propionylamino) propyl] -4-piperidinyl}phenyl)propanamide (12 mg, 97% yield) . ^Η ΝMR (400 MHz, CDC13) δ 8.05 (s, IH) , 7.59 (s, IH) , 7.40-7.20 (m, 7H) , 6.96 (s, IH) , 5.19-5.12 (m, IH) , 3.18 (d, 1 H, J = 12.0 Hz), 2.99 (d, IH, J = 10.4 Hz), 2.93-2.86 (m, IH) , 2.61-2.40 (m, 3H) , 2.38-2.23 (m, 3H) , 2.19-1.75 (m, 8H) , 1.25 (d, 6H, J = 6.9 Hz), 1.22-1.08 (m, 3H) ; ESMS m/e : 436.4 (M + H) X
Example 89
N- {3 - [1- ( (3S) -3-{ [ (4-FLUOROPHENYL) ACETYL] AMINθ}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL} -2 -METHYLPROPANAMIDE :
A mixture of N- (3- {l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (11.0 mg, 0.0280 mmol) and (4-fluorophenyl) acetyl chloride (7.20 mg, 0.0420 mmol) in THF (5 mL) was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was purified by preparative TLC using Hexane: EtOAc (2:1) to give the desired product (13 mg, 90% yield) . XE NMR (400 MHz, CDC13) δ 7.89 (d, IH, J = 8.4 Hz), 7.59 (s, IH) , 7.31- 6.93 ( , 13H) , 5.13 (q, IH, J = 6.0 Hz), 3.56 (s, 2H) , 3.07 (d, IH, J = 11.7 Hz), 2.91 (d, IH, J = 11.0 Hz), 2.62-2.42 (m, 2H) , 2.40-2.30 (m, IH) , 2.12-1.54 (m, 9H) , 1.24 (d, 6H, J = 6.7 Hz); ESMS m/e : 515.3 (M + H) + . Example 90
N- (3-{l- [3-(l/2-DIPHENYL-lH-INDOL-3-YL)PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 1, 1-diphenylhydrazine hydrochloride (10.3 mg, 0.0470 mmol) , 2 -methyl-N- {3- [1- (5-oxo-5-phenylpentyl) -4- piperidinyl] phenyl}propanamide (14.7 mg, 0.0362 mmol), ZnCl2 (14.85 mg, 0.109 mmol), and HOAc (0.5 mL) was heated for 4 h at 80 °C. The resulting crude mixture was diluted with water (10 mL) , the aqueous layer was neutralized with saturated K2C03 and extracted with CH2C1
(3 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using 5% of ΝH3 (2.0 M in methanol) in CH2C12 to give the desired product N- (3- {l- [3- (1, 2- diphenyl -lH-indol- 3 -yl) propyl] -4-piperidinyl Jphenyl) -2- methylpropanamide (4.1 mg, 37%) . λE ΝMR (400 MHz, CDCl3) δ 7.71-7.65 (m, IH) , 7.42 (d, IH, J = 7.4 Hz), 7.39 (s, IH) , 7.36-7.15 (m, 15H) , 6.94 (d, IH, J = 7.8 Hz), 3.12 (d, 2H, J = 11.2 Hz) , 2.90 (t, 2H, J = 7.8 Hz) ,
2.59-2.45 (m, 3H) , 2.19-1.91 (m, 7H) , 1.82 (d, 2H, J = 13.5 Hz), 1.24 (d, 6H, J = 6.9 Hz); ESMS m/e : 555.3 (M + H) + .
Example 91
N- (3-{l- [3- (5-METHOXY-2-PHEΝYL-1H-IΝDOL-3-YD ROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: According to the procedure used for the synthesis of N- (3-{l- [3- (l,2-diphenyl-lH-indol-3-yl) propyl] -4- piperidinyl}phenyl) -2-methylpropanamide, 2 -methyl-N- {3- [1- (5-oxo-5-phenylpentyl) -4- piperidinyl] phenyl }propanamide (15.6 mg, 38.2 mmol), and 1- (4 -methoxyphenyl) hydrazine hydrochloride (8.00 mg, 0.0458 mmol) provided N- (3- {l- [3- (5-methoxy-2- phenyl-lH-indol-3 -yl) propyl] -4-piperidinyl }phenyl) -2- methylpropanamide (3.9 mg, 20%). 1H ΝMR (400 MHz, CDC13) δ 8.06 (S, IH) , 7.55.(d, 2H, J = 7.4 Hz), 7.43-7.39 (m, 3H) , 7.38-7.35 (m, 2H) , 7.27-7.19 (m, 3H) , 7.08 (d, IH,
J = 7.4 Hz), 6.94 (d, IH, J = 1 . 6 Hz), 6.87 (dd, IH, J =
4.0, 6.6 Hz), 3.88 (s, 3H) , 3.80-3.69 (m, IH) , 2.99 (d,
2H, J = 11.7 Hz), 2.89 (t, 2H, J = 7.3), 2.55-2.39 (m,
4H) , 2.02-1.88 (m, 3H) , 1.82-1.68 - (m, 4H) , 1.24 (d, 6H, J = 6.9 Hz); ESMS m/e : 510.3 (M + H) + .
Example 92
N- (3-{l- [4- (5-METHOXY-2-PHEΝYL-1H-IΝDOL-3-YDBUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: According to the procedure used for the synthesis of N- (3- {l- [3- (1, 2- diphenyl-lH-indol-3 -yl) propyl] -4-piperidinyl }phenyl) -2- methylpropanamide, 2 -methyl-N- {3- [1- (6-oxo-6- phenylhexyl) -4-piperidinyl] phenyl}propanamide (14.3 mg, 0.0339 mmol) and 1- (4-methoxyphenyl) hydrazine hydrochloride (7.10 mg, 0.0407 mmol) provided N- ( 3 - { l-
[4- (5-methoxy-2-phenyl-lH-indol-3-yl)butyl] -4- piperidinyl}phenyl) -2-methylpropanamide (5.8 mg, 33%).
1H ΝMR (400 MHz, CDCl3) δ 7.95 (d, 2H, J = 7.8 Hz), 7.61-
7.15 (m, 11H) , 6.97 (d, IH, J = 7.0 Hz), 3.88 (s, 3H) , 3.09 (d, 2H, J = 11.3 Hz), 2.99 (t, 2H, J = 7.0 Hz), 2.55-2.35 (m, 4H) , 2.12-1.70 (m, 6H) , 1.68-1.52 (m, 2H) , 1.48-1.34 (m, 2H) , 1.25 (d, 6H, J = 6.7 Hz); ESMS m/e : 524.3 (M + H)+.
Example 93
2 -METHYL-N- (3-{l- [ (1-PHEΝYL-1H-INDOL-3 -YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: According to the procedure used for the synthesis of N- ( 3 - { l - [3 - ( l , 2 - diphenyl-iH-indol-3- yl) propyl] -4- piperidinyl}phenyl) -2-methylpropanamide, N- { 3 - [1- (3,3- dimethoxypropyl ) -4-piperidinyl] phenyl } -2 - methylpropanamide (15.2 mg, 0.0436 mmol) and 1,1- diphenylhydrazine hydrochloride (11.6 mg, 0.0524 mmol) provided 2 -methyl-N- (3-{l- [ (1-phenyl-lH-indol-3- yl) methyl] -4-piperidinyl }phenyl) propanamide (11 mg,
56%). λE ΝMR (400 MHz, CDCl3) δ 7.79 (d, IH, J" = 7.8
Hz), 7.57 (d, IH, J" = 7.7 Hz), 7.54-7.47 (m, 4H) , 7.43- 7.32 (m, 4H) , 7.25-7.16 (m, 4H) , 6 . 95 (d, IH, J = 7.8
Hz), 3.87 (s, 2H) , 2.53-2.47 (m, 2H) , 2.21 (dt, 2H, J =
3.0, 10.5 Hz), 2.12-1.77 (m, 6H) , 1.24 (d, 6H, J = 6.9
Hz); ESMS m/e : 451.3 (M + H) + .
Example 94
2 -METHYL-N- (3-{l- [ (4E) -4-PHEΝYL-4- (2- PYRIDINYLHYDRAZONO) BUTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: According to the procedure used for the synthesis of N- (3- {l- [3- (1, 2- diphenyl-lH-indol-3-yl) propyl] -4-piperidinyl}phenyl) -2- methylpropanamide, 2 -methyl -N- {3- [1- (4-oxo-4- phenylbutyl) -4-piperidinyl] phenyl }propanamide (8.70 mg, * 0.0223 mmol) and 2-hydrazinopyridine (2.92 mg, 0.0268 mmol) provided 2 -methyl -N- (3- {l- [ (4E) -4 -phenyl-4- (2-. pyridinylhydrazono) butyl] -4- piperidinyl}phenyl) propanamide (2.5 mg, 24%). XH ΝMR (400 MHz, CDC13) δ 7.97 (d, IH, J = 8.6 Hz), 7.85 (d, IH, J = 7.3 Hz), 7.64-7.27 (m, 9H) , 7.09 (d, ' IH, J = 8.0 Hz) , 6.97 (d, IH, J" = 8.4 Hz) , 6.73 (q, IH, J" = 6.6 Hz) , 3.52-3.48 (m, 2H) , 3.20-3.10 (m, 2H) , 2.85-1.75 (m, 13H) , 1.26 (d, 6H, J = 6.8 Hz); ESMS m/e : 484.4 (M + H) + . Example 95
N- (3-{l- [3-(5-METHOXY-lH-IΝDOL-3-YL)PROPYL]-4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: According , to the procedure used for the synthesis of N- (3- {l- [3- (1, 2- diphenyl-lH-indol-3 -yl) propyl] -4-piperidinyl }phenyl) -2- methylpropanamide , N- (3-{l- [4- (1, 3-dioxolan-2-yl) butyl] - 4-piperidinyl}phenyl) -2-methylpropanamide (23.5 mg, 0.0628 mmol) and^T _ . l- (4-methoxyphenyl) hydrazine hydrochloride (13.2 mg, 0.0774 mmol) provided N- ( 3 - { l - [3- (5-methoxy-lH-indol-3-yl) propyl] -4- piperidinyl}phenyl) -2-methylpropanamide (11 mg, 42%). 1H ΝMR (400 MHz, CDCl3) δ 7.86 (s, IH) , 7.45 (s, IH) , 7.32 (d, IH, J = 8.4 Hz), 7.28-7.21 (m, 2H) , 7.10 (s, IH) , 7.05 (d, IH, J = 2.3 Hz), 7.00-6.91 (m, 2H) , 6.85 (dd, IH, J = 2.7, 9.0 Hz), 3.87 (s, 3H) , 3.06 (d, 2H, J" = 11.6 Hz), 2.75 (t, 2H, J = 7.2 Hz), 2.55-2.42 (m, 4H) , 2.08-1.90 (m, 4H) , 1.88-1.74 (m, 4H) , 1.25 (d, 6H, J = 6.9 Hz); ESMS m/e : 434.2 (M + H) + .
Figure imgf000201_0001
TERT-BUTYL 4- [3- (PROPIOΝYLAMIΝO) PHENYL] -1-
PIPERIDINECARBOXYLATE : Propionyl chloride (5.53 g, 0.0597 mol) was added dropwise to a solution of tert- butyl 4- (3-aminophenyl) -1-piperidinecarboxylate (15.0 g, 0.0543 mol) and TEA' (16.5 g, 0.163 mol) in THF (200 mL) and the mixture was stirred at room temperature for 3 h. Water (50 mL) was added- to the reaction mixture, the aqueous layer was extracted with CH2C12 (3 X-100 mL) , and the combined organic extracts were washed with brine (50 mL) , dried over Na2S04 and concentrated under reduced pressure. The residue vjjβs- purified by chromatography on silica using hexane/EtOAc (10:1) to afford the product (18.8 g, 99%). XH NMR (400 MHz, CDC13) δ 7.48 (s, IH) , 7.34-7.21 (m, 3H) , 6.93 (d, IH, J" = 7.4 Hz) , 2.77
(t, 2H, J" = 11.5 Hz) , 2.68-2.58 (m, IH) , 2.38 (q, 2H, J"
= 7.6 Hz) , 1.87-1.67 (m, 4H) , 1.67-1.54 (m, 2H) , 1.48
(s, 9H) , 1.25 (t, 3H, J = 7.5 Hz) ; ESMS m/e: 333.4 (M + H) + .
N- [3- (4-PIPERIDINYL) PHENYL] PROPANAMIDE: Into a stirred solution of tert-butyl 4- [3- (propionylamino) phenyl] -1- piperidinecarboxylate (18.8 g, 0.0543 mmol) in dioxane (100 mL) at 5 °C was bubbled HCl gas for 2 h. The solvent was removed in vacuo, the residue was dissolved in water (100 mL) and neutralized by adding 10% KOH aqueous solution. The aqueous layer was extracted (3 X 200 mL) with a mixture of CHC13/isopropyl alcohol (3:1), and the combined organic layers were washed with brine
(100 mL) , dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica using 5% of NH3 (2.0 M in methanol) in CH2C12 to afford the desired product (12.6 g, 99%). 1H NMR (400 MHz, CDCl3) δ 7.44 (s, IH) , 7.32 (d, IH, J" = 7.2 Hz), 7.28-7.21 (m, IH) , 7.09 (s, IH) , 6.97 (d, IH, J = 7.6 Hz), 3.18 (d, 2H, J = 12.6 Hz), 2.73 (dt, 2H, J" = 2.2, i'l.2 Hz), 2.65-2.57 (m, IH) , 2.38 (q, 2H, J" = 7.4 Hz), 1.83 (d, 2H, J" = 12.1 Hz), 1.70-1.61 (m, 3H) , 1.25 (t, 3H, J = 7.5 Hz); ESMS m/e: 233.1 (M + H) + .
TERT-BUTYL 4-{3- [ (CYCLOPROPYLCARBONYL) AMINO] PHENYL}-1- PIPERIDINECARBOXYLATE : According to the procedure used for the synthesis of tert-butyl 4- [3- (propionylamino) phenyl] -1-piperidinecarboxylate, tert- butyl 4- (3-aminophenyl) -1-piperidinecarboxylate (16.47 g 0.0596 mol) and cyclopropanecarbonyl chloride (6.27 g, 0.0597 mol) provided the tert-butyl 4-{3-
[ (cyclopropylcarbonyl) amino] phenyl} -1- piperidinecarboxylate (18.1 g, 100%). E NMR (400 MHz, CDC13) δ 7.55-7.46 (m, 2H) , 7.29-7.21 (m, 2H) , 6.96-6.89 (m, IH) , 2.79 (t, 2H, J" = 12.1 Hz), 2.68-2.58(m, IH) , 1.84 (d, 2H, J = 12.6 Hz), 1.83-1.76 (m, 4H) , 1.48 (s, 9H) , 1.19-1.12 (m, IH) , 1.09-1.05 (m, 2H) , 0.89-0.75 (m, 2H) ; ESMS m/e : 345.5 (M + H) + .
N- [3- (4 -PIPERIDINYL) HENYL] CYCLOPROPANECARBOXAMIDE :
According to the procedure used for the synthesis of N- [3- (4-piperidinyl) phenyl] propanamide, tert-butyl 4-{3- [ (cyclopropylcarbonyl) amino] phenyl} -1- piperidinecarboxylate (18.9 g, 0.0543 mol) provided N- [3- (4-piperidinyl) phenyl] cyclopropanecarboxamide (13.2 g, 100 %) . 1H ΝMR (400 MHz, CDC13) δ 7.46 (s, IH) , 7.36- 7.22 (m, 3H) , 7.23 (d, IH, J = 6.9 Hz), 3.17 (d, 2H, J = 11.9 Hz), 2.72 (dt, 2H, J = 2.6, 12.2 Hz), 2.65-2.55 (m, IH) , 1.82 (d, 2H, J = 13.9 Hz), 1.63 (dt, 3H, J" = 4.1, 12.5 Hz), 1.53-1.45 (m, IH) , 1.11-1.06 (m, 2H) , 0.87- 0.81 (m, 2H) ; ESMS m/e : 245.03 (M + H) + .
1- (6 -CHLOROHEXYL) -IH-INDOLE: To a mixture of NaH (0.249 g, 10.0 mmol) in DMF (5 mL) at 0 °C was added a solution of 1-H-indole (0.585 g, 5.00 mmol) in DMF (2 mL) . The reaction mixture was stirred for 30 minutes and warmed up to room temperature. Then l-bromo-6-chlorohexane (0.998 g, 5.00 mmol) was added dropwise by syringe and the reaction mixture was stirred overnight. The reaction mixture was diluted with EtOAc (30 mL) , washed with water (3 X 10 mL) , dried over MgS04, concentrated in vacuo and purified by chromatography using hexane/EtOAc (97.5:2.5) to give the desired product (0.900 g, 76 %) . E NMR (CDCI3) δ 7.76-7.54 (m, IH) , 7.47-6.96 (m,
4H) , 6.60-6.34 (m, IH) , 4.13 (t, 2H, J = 6.8 Hz) , 3.50 (t, 2H, J = 5.6 Hz) , 1.98-1.79 (m, 2H) , 1.79-1.64 (m, 2H) , 1.54-1.17 (m, 4H) .
1- (5-CHLOROPENTYL) -Iff-INDOLE: According to the procedure used for the synthesis of 1- (6-chlorohexyl) -lH-.indole, 1-H-indole (0.585 g, 5.00 mmol) and l-bromo-5- chloropentane (0.928 g, 5.00 mmol) gave the desired product (0.890 g, 80%). E NMR (CDCl3) δ 7.76-7.51 (m, IH) , 7.44-6.96 (m, 4H) , 6.60-6.38 (m, IH) , 4.11 (t, 2H, J = 6.8 Hz), 3.47 (t, 2H, J = 6.4 Hz), 1.97-1.79 (m, 2H) , 1.79-1.61 (m, 2H) , 1.58-1.32 (m, 2H) .
Example 96
N- (3-{l- [6- (Iff- NDOL-1-YL) HEXYL] -4-PIPERIDINYL}PHENYL) - 2-METHYLPROPANAMIDE: 1- (6-Chlorohexyl) -IH-indole (23.6 mg, 0.100 mmol), 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide (24.6 mg, 0.100 mmol), K2C03 (27.6 mg, 0.200 mmol), al (22.5 mg, 0.150 mmol) and DMF (1.00 mL) were combined and stirred overnight at 100 °C. The reaction mixture was cooled to room temperature and the crude material was purified by preparative TLC using 5 % of ΝH3 (2.0 M in methanol) in - CH2C12 to give the desired product as a yellow solid (40 mg, 90%). XH NMR (400 MHz, CDCl3) δ 8.08-6.52 (m, 11H) , 4.17 (t, 2H, J = 7.2 Hz), 3.26 (d, 2H, J" = 11.6 Hz), 2.74-2.52 (m, 4H) , 2.44-2.28 (m, 2H) , 2.20-2.02 (m, 2H) , 1.98-1.82 (m,4H), 1.78-1.62 (m, 2H) , 1.43-1.28 (m, 4H) , 1.28 (d, 6H, J = 6.8 Hz) ; ESMS m/e: 446.5 (M + H)+. Example 97
N- (3-{l- [5- (Iff-INDOL-1-YL) PENTYL] -4-PIPERIDINYL}PHENYL) -
2-METHYLPROPANAMIDE: Prepared as above, using 1- (5- chloropentyl) -IH-indole (22.2 mg, 0.100 mmol), 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide (24.6 mg, 0.100 mmol), K2C03 (27.6 mg, 0.200 mmol), al (23.0 mg, 0.150 mmol) and DMF (1.00 mL) , giving the desired product as a yellow oil (36 mg, 81%) . XE ΝMR (400 MHz, CDCl3) δ
8.08-6.52 (m, 11H) , 4.19 (t, 2H, J = 7.2 Hz), 3.26-3.10 (m, 2H) , 2.71-2.55 (m, 2H) , 2.55-2.42 (m, 2H) , 2.35-2.12
(m, 2H) , 2.12-1.80 (m, 6H) , 1.80-1.57 (m, 2H) , 1.51-1.34
(m, 2H) , 1.31 (d, 6H, J" = 6.8 Hz); ESMS m/e : 432.2 (M +
H) + .
Example 98
N- (4-{l- [ (9-ETHYL- 9H-CARBAZOL-3-YL) METHYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: According to the procedure used for the synthesis of N- (3- {l- [4- (4- CHLOROPHEΝOXY) BENZYL] -4 -PIPERIDINYL} PHENYL) -2- METHYLPROPANAMIDE (Example 108) N- (3- {l- [3- (1 , 2- diphenyl-lH-indol-3 -yl) propyl] -4 -piperidinyl }phenyl) -2- methylpropanamide, 9-ethyl-9H-carbazole-3-carbaldehyde
(22.3 mg, 0.100 mmol) and 2 -methyl -N- [4- (4- piperidinyl) phenyl] propanamide (24.6 mg, 0.100 mmol) provided N- (4- {l- [ (9-ethyl-9H-carbazol-3-yl) methyl] -4- piperidinyl }phenyl) -2-methylpropanamide . The product was obtained as a white crystalline solid (20 mg, 44%) . ^-H ΝMR (400 MHz, CDC13) δ 8.21-7.09 (m, 12H) , 4.38 (q, 2H, J = 7.2 Hz), 3.81 (s, 2H) , 3.25-3.03 (m, 2H) , 2.60-2.38 (m, 2H) , 2.31-2.09 (m, 2H) , 1.98-1.69 (m, 4H) , 1.44 (t, 3H, J = 7.2 Hz), 1.23 (d, 6H, J = 6.8 Hz); ESMS m/e : 454.3 (M + H)+. Example 99
N- (3 - { l - [ (9 -ETHYL- 9ff-CARBAZOL- 3 -YL) METHYL] -4 -
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: According to the procedure used for the synthesis of N- (3- {l- [4- (4- CHLOROPHEΝOXY) BENZYL] -4 -PIPERIDINYL} PHENYL) -2-
METHYLPROPANAMIDE (Example 108) N- (4- {l- [ (9-ethyl-9H- carbazol-3-yl) methyl] -4-piperidinyl }phenyl) -2- methylpropanamide, 9-ethyl - 9H-carbazole-3 -carbaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide afforded N- (3- {l- [ (9-ethyl- 9H-carbazol-3 -yl) methyl] -4- piperidinyl}phenyl) -2-methylpropanamide (37 mg, 95%) . λE ΝMR (400 MHz, CDC13) δ 8.24-6.29 (m, 12H) , 4.37 (q, 2H, J" = 7.2 Hz), 3.82 (s, 2H) , 3.23-3.06 (m, 2H) , 2.65- 2.38 (m, 2H) , 2.31-2.11 (m, 2H) , 2.01-1.73 (m, 4H) , 1.43 (t, 3H, J" = 7.2 Hz), 1.25 (d, 6H, J = 4.0 Hz); ESMS m/e 454.3 (M + H)+.
Example 100
N- [3- (l-{ [1- (4-METHOXYPHEΝYL) -lff-INDOL-5-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: According to the procedure used for the synthesis of 1- (4- methylphenyl) IH -indole, N- {3- [1- (lH-indol-5-ylmethyl) - 4-piperidinyl] phenyl} -2-methylpropanamide (37.5 mg, 0.100 mmol) and l-iodo-4-methoxybenzene (46.8 mg, 0.200 mmol) gave the desired product (27 mg, 56%) . 1H ΝMR (400 MHz, CDC13) δ 7.70-6.58 (m, 14H) , 3.88 (s, 3H) , 3.67 (s, 2H) , 3.14-3.01 (m, 2H) , 2.57-2.41 (m, 2H) , 2.25-2.01 (m, 2H) , 1.93-1.69 (m, 4H) , 1.24 (d, 6H, J" = 7.2 Hz); ESMS m/e: 482.2 (M + H) + .
Example 101
N- [3- (l-{ [1- (4-FLUOROPHENYL) -lff-INDOL-5-YL] METHYL} -4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: According to the procedure used for the synthesis of 1- (4- methylphenyl) IH-indole, N- {3- [1- (lH-indol-5-ylmethyl) -4- piperidinyl] phenyl} -2-methylpropanamide (37.5 mg, 0.100 mmol) and 1-fluoro-4-iodobenzene (44.4 mg, 0.200 mmol) gave the desired product (21 mg, 45%) . ^Η ΝMR (400 MHz,
CDC13) δ 7.71-6.60 (m, 14H) , 3.69 (s, 2H) , 3.19-2.99 (m,
2H) , 2.62-2.41 (m, 2H) , 2.22-2.07 (m, 2H) , 1.94-1.70 (m,
4H) , 1.24 (d, 6H, J = 6.-8 Hz); ESMS m/e : 470.2 (M + H) + .
Example 102
METHYL-4- [5- ({4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- IPERIDINYL}METHYL) -Iff-INDOL-1-YL] BENZOATE: According to the procedure used for the synthesis of 1- (4- methylphenyl) IH-indole, N- { 3 - [1- (lff-indol-5-ylmethyl) - 4-piperidinyl] phenyl} -2-methylpropanamide (37.5 mg, 0.100 mmol) and methyl 4-iodobenzoate (52.4 mg, 0.200 mmol) gave the desired product (11 mg, 22%) . 1H ΝMR (400 MHz, CDCI3) δ 8.31-6.64 (m, 14H) , 3.96 (s, 3H) , 3.67 (s, 2H) , 3.16-2.96 (m, 2H) , 2.57-2.41 (m, 2H) , 2.18-2.02 (m, 2H) , 1.91-1.73 (m, 4H) , 1.24 (d, 6H, J" = 6.8 Hz); ESMS m/e : 510.2 (M + H) + .
Example 103
2 -METHYL-N- [3- (l-{ [1- (3-METHYLPHEΝYL) -Iff-INDOL-5- YL]METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: According to the procedure used for the synthesis of 1- (4- methylphenyl) IH-indole, N- { 3 - [1- (lH-indol-5-ylmethyl) -4- piperidinyl] phenyl} -2-methylpropanamide (37.5 mg, 0.100 mmol) and l-iodo-3-methylbenzene (43.6 mg, 0.200 mmol) gave the desired product (28 mg, 60%) . ^Η ΝMR (400 MHz, CDCI3) δ 7.68-6.60 (m, 14H) , 3.66 (s, 2H) , 3.16-2.96 (m, 2H) , 2.59-2.44 (m, 2H) , 2.44 (s, 3H) , 2.18-2.01 (m, 2H) , 1.91-1.68 (m, 4H) , 1.24 (d, 6H, J = 6.8 Hz); ESMS m/e : 466.2 (M + H) + .
Example 104 N- {3 - [l- (3-{ [(4-CHLORO-3-
ΝITROPHEΝYL) SULFOΝYL] AMIΝθ}PROPYL) -4-
PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE: A mixture of N- {3 [1- (2-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide (10.0 mg, 0.0350 mmol), 4-chloro-3- nitrobenzenesulfonyl chloride (9.90 mg, 0.0380 mmol), and TEA (7.00 mg, 0.0700 mmol) in THF (2 mL) was stirred for 12 h at room temperature . The crude product was purified by preparative TLC (CH2Cl2/MeOH/isopropyl amine = 19:1:0.2) to give the desired product (16 mg, 86%). 1H ΝMR (400 MHz, CDC13) δ 8.45-8.38 (m, IH) , 8.02 (d, IH, J = 8.4 Hz), 7.72 (d, IH, J" = 8.8 Hz), 7.48-7.40 (m, 3H) , 7.29-7.24 (m, 2H) , 6.96 (d, IH, J" = 7.5 Hz), 3.17-3.09 (m, 4H) , 2.63-2.48 (m, 4H) , 2.15 (t, 2H, J" = 11.8 Hz), 1.96-1.72 (m, 6H) , 1.25 (d, 6H, J = 6.9 Hz); ESMS m/e 523.2 (M + H)+.
Example 105
N- [3- (l-{5- [4- (3 ,4-DIFLUOROPHENYL) -2-0X0-1, 3 -OXAZOLIDIN-
3-YL] PENTYL} -4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: A mixture of 3- (5-bromopentyl) -4- (3, 4-difluorophenyl) - l,3-oxazolidin-2-one (38.0 mg, 0.110 mmol), 2 -methyl -N-
[3- (4-piperidinyl) phenyl]-propanamide (26.0 mg, 0.100 mmol), al (23.0 mg, 0.150 mmol), and K2C03 (14.0 mg,
0.100 mmol) in DMF (2 mL) was heated for 1 h at 50°C. The crude product was purified by preparative TLC using CH2Cl2/MeOH/isopropyl amine (19:1:0.2) to give the desired product (21 mg, 41%) . 1H ΝMR (400 MHz, CDC13) δ 7.49 (s, IH) , 7.39-7.32 (m, 2H) , 7.26-7.20 (m, 2H) , 7.18-7.11 (m, IH) , 7.10- 7.03 (m, IH) , 6.96 (d, IH,
J = 7.6 Hz), 4.80-4.73 (m, IH) , 4.62 (t, IH, J" = 7.9
Hz), 4.09-4.04 (m, IH) , 3.51-3.42 (m, IH) , 3.03 (d, 2H,
J = 11.7 Hz), 2.82-2.72 (m, IH) , 2.51-2.42 (m, 2H) , 2.32 (t, 2H, J = 7.9 Hz), 2.11 (s, IH) , 2.03-1.97 (m, 2H) ,
1,85-1.70 (m, 4H) , 1.49 (m, 4H) , 1.31-1.27 (m, IH) , 1.24
(d, 6H, J" = 6.9 Hz); ESMS m/e : 514.4 (M + H) + .
Example 106 3- (2,6-DICHLOROPHENYL) -N- (5-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}PENTYL) -5-METHYL- 4-ISOXAZOLECARBOXAMIDE: A mixture of 3- (2, 6- dichlorophenyl) -4-formyl-5-isoxazolecarbonyl chloride (69.0 mg, 0.250 mmol), N- {3- [1- (5-aminopentyl) -4- piperidinyl] phenyl} -2 -ethylpropanamide (44.0 mg, 0.150 mmol), TEA (30.0 mg, 0.300 mmol) in THF (2 mL) was stirred for 12 h at room temperature. The crude product was purified by preparative TLC using CH2Cl2/MeOH/ isopropyl amine (19:1:0.2) to give the desired product (52 mg, 67%). E ΝMR (400 MHz, CDC13) δ 7.52-7.49 (m, 2H) , 7.49-7.41 (m, 2H) , 7.39-7.31 (m, 2H) , 7.29-7.21 (m, 2H) , 6.92 (d, IH, J" = 7.6 Hz), 3.25-3.11 (m, 5H) , 2.81- 2.74 (m, 4H) , 2.58-2.44 (m, 4H) , 2.30-2.19 ( , 2H) , 1.93- 1.78 (m, 4H) , 1.56-1.44 (m, 2H) , 1.31-1.28 (m, 2H) , 1.24 (d, 6H, J = 6 . 6 Hz); ESMS m/e : 585.2 (M + H) + .
Example 107
N- [3 - (l- {2 - [ (DIPHENYLACETYL) MINO] ETHYL} -4-- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: A mixture of N- {3 [1- (2-aminoethyl) -4-piperidinyl] phenyl} -2- methylpropanamide (20.0 mg, 0.0700 mmol), diphenylacetyl chloride (23.0 mg, 0.110 mmol), and TEA (20.0 mg, 0.140 mmol) in THF (2 mL) was stirred overnight at 23 °C. The crude product was purified by preparative TLC using
CH2Cl2/Me0H/isopropyl amine (19:1:0.2) to give the desired product (8.0 mg, 47%). XH NMR (400 MHz, CDC13) δ
7.53 (s, IH) ,• 7.37-7.20 (m, 13H) , 6.97-6.92 (m, IH) , 6.67 (s, IH) , 4.98 (s, IH) , 3.43 (q, 2H, J = 5.9 Hz),
2.90 (d, 2H, J = 11.6 Hz), 2.57-2.42 (m, 4H) , 2.11 (t,
2H, J = 10.4 Hz), 1.75 (d, 2H, J = 12.4 Hz), 1.70-1.58
(m, 2H) , 1.25 (d, 6H, J = 6.7 Hz); ESMS m/e : 484.2 (M +
H) + .
Example 108
N-(3-{l~[4- (4 -CHLOROPHENOXY) BENZYL] -4-
PIPERIDINYL}PHENYL) -2 -METHYLPROPANAMIDE : 4 - (4- chlorophenoxy) benzaldehyde (0.119' g, 0.510 mmol) and 2- methyl -N- [3- (4-piperidinyl)phenyl] propanamide (0.126 g, 0.510 mmol) were mixed in 1, 2-dichloroethane (5 mL) and then treated with sodium triacetoxyborohydride (0.424 g, 2.00 mmol) and HOAc (0.03 mL, 0.5 mmol). The mixture was stirred overnight at room temperature. The reaction mixture was neutralized with saturated ΝaHC03 aqueous solution and the aqueous layer was extracted with CH2C12
(3 X 10 mL) . The combined organic layers were washed with brine, dried over MgS04, concentrated in vacuo, and purified by preparative TLC using 5% of NH3 (2.0 M in methanol) in CH2C12 to give the desired product (53 mg, 23%). XH NMR (400 MHz, CDC13) δ 7.50 (s, IH) , 7.34-7.19 (m, 7H) , 6.98-6.87 (m, 5H) , 3.50 (s, 2H) , 2.98 (d, 2H, J = 11.8 Hz), 2.58-2.44 (m, 2H) , 2.10-1.98 (m, 2H) , 1.83- 1.76 (m, 4H) , 1.24 (d, 6H, J = .8 Hz); ESMS m/e : 463.2 (M + H)+.
Example 109 N- { 3 - [1- ( {2 , 5 -DIMETHYL- l- [3 -
(TRIFLUOROMETHYL) PHENYL] -Iff-PYRROL-3 -YL}METHYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by the procedure described in example 108, substituting 2,5- dimethyl-1- [3- (trifluoromethyl) phenyl] -lH-pyrrole-3- carbaldehyde (0.136 g, 0.510 mmol) for 4- (4- chlorophenoxy) benzaldehyde . 1H NMR (400 MHz,- CDC13) δ
7.69-7.56 (m, 2H) , 7.53-7.32 (m, 4H) , 7.28-7.18 (m, 2H) ,
6.99 (s, IH) , 5.98 (s, IH) , 3.43 (s, 2H) , 3.16-3.06 (m, 2H) , 2.57-2.42 (m, 2H) , 2.07-1.95 (m, 8H) , 1.89-1.76 (m,
4H) , 1.24 (d, 6H, J" = 6.8 Hz); ESMS m/e : 498.2 (M + H) + .
Example 110
N-(3-{l-[4- (3,4-DIFLUOROPHENOXY)BENZYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by the procedure described in example 108, substituting 4- (3,4- difluorophenoxy) benzaldehyde (0.119 g, 0.510 mmol) for 4- (4-chlorophenoxy) benzaldehyde. 1H NMR (400 MHz, CDC13) δ 7.52 (s, IH) , 7.32 (d, 2H, J = 8.4 Hz), 7.28-7.21 (m, 2H) , 7.14-7.06 (m, 2H) , 6.98-6.94 (m, 3H) , 6.86-6.79 (m, IH) , 6 . 76-6 . 69 (m, IH) , 3.51 (s, 2H) , 2.99 (d, 2H, J = 11.7 Hz), 2.55-2.44 (m, 2H) , 2.12-2.02 (m, 2H) , 1.86- 1.74 (m, 4H) , 1.25 (d, 6H, J = 7.0 Hz); ESMS m/e : 465.2 (M + H) + .
Example 111
N- (3-{l- [(5-CHLORO-3-METHYL-l-PHENYL-lff-PYRAZOL-4- YL) METHYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by the procedure described in example 108, substituting 5-chloro-3-methyl-l-phenyl-lH-pyrazole-4- carbaldehyde (0.113 g, 0.510 mmol) for 4- (4- chlorophenoxy) benzaldehyde . ^Η NMR (400 MHz, CDC13) δ 7.62-7.19 (m, 9H) , 6.97 (s, IH) , 3.43 (s, 2H) , 3.08-2.98 (m, 2H) , 2.58-2.43 (m, 2H) , 2.39-2.32 (m, 3H) ,
2.18-1.71 (m, 6H) , 1.24 (d, 6H, J" = 6.9 Hz); ESMS m/e :
451.2 (M + H)+.
Example 112
N- (3-{l- [4- (3, 4-DICHLOROPHENOXY) BENZYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by the procedure described in example 108, substituting 4- (3,4- dichlorophenoxy) benzaldehyde (0.136 g, 0.510 mmol) for 4- (4-chlorophenoxy) benzaldehyde. XE NMR (400 MHz, CDC13) δ 7.53 (s, IH) , 7.36-7.18 (m, 6H) , 7.08 (d, IH, J = 1.8 Hz), 6.96 (d, 3H, J = 6.8 Hz), 6.84 (dd, IH, J" = 2.8, 8.9 Hz), 3.51 (s, 2H) , 2.99 (d, 2H, J = 11.5 Hz), 2.55- 2.42 (m, 2H) , 2.12-2.02 (m, 2H) , 1.84-1.73 (m, 4H) , 1.24 (d, 6H, J" = 7.0 Hz); ESMS m/e: 497.1 (M + H) + .
Example 113
2-METHYL-#- (3-{l- [ (2-PHENYL-Iff-IMIDAZOL-4 -YL) METHYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by the procedure described in example 108, substituting 2- phenyl-lH-imidazole-4-carbaldehyde (88.0 mg, 0.510 mmol) for 4- (4-chlorophenoxy) benzaldehyde. 1H NMR (400 MHz, CDC13) δ 7.92 (d, 2H, J" = 7.4 Hz), 7.65-7.31 (m, 6H) , 7.28-7.18 (m, 2H) , 7.12-7.05 (m, IH) , 6.95-6.88 (m, IH) , 3.69 (s, 2H) , 3.17-3.05 (m, 2H) , 2.62-2.45 (m, 2H) , 2.28-2.18 (m, 2H) , 1.88-1.70 (m, 4H) , 1.25 (d, 6H, J" = 6.8 Hz); ESMS m/e : 403.2 (M + H) "X
Example 114 N- (3-{l- [4- (DIPHEΝYLAMIΝO) BENZYL] -4-PIPERIDINYL}PHENYL) - 2-METHYLPROPANAMIDE: Prepared by the procedure described in example 108, substituting 4- (diphenylamino) benzaldehyde (0.139 g, 0.510 mmol) for 4- (4 - chlorophenoxy) benzaldehyde. XE NMR (400 MHz, CDC13) δ 7.49 (s, IH) , 7.39-6.92 (m, 18H) , 3.49 (s, 2H) , 3.02- 2.99 (m, 2H) , 2.59-2.43 (m, 2H) , 2.15-2.03 (m, 2H) , 1.92-1.76 (m, 4H) , 1.23 (d, 6H, J = 6.8 Hz); ESMS m/e 504.2 (M + H)+.
Example 115
N- [3- (l-{ [4-BROMO-l- (4-CHLOROBENZYL) -lff-PYRAZOL-5- YL] METHYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by the procedure described in example 108, substituting 4-bromo-l- (4-chlorobenzyl) -lff-pyrazole-5- carbaldehyde (0.153 g, 0.510 mmol) for 4- (4- chlorophenoxy) benzaldehyde. XE NMR (400 MHz, CDC13) δ 7.41 (s, IH) , 7.36 (d, IH, J = 8.8 Hz), 7.34-7.30 (m, 3H) , 7.29-7.26 (m, IH) , 7.22 (t, IH, J = 7.8 Hz), 7.16 (d, 2H, J = 8.6 Hz), 6.95 (d, IH, J = 7.5 Hz), 5.24 (s, 2H) , 3.61 (s, 2H) , 3.09 (d, 2H, " = 11.9 Hz), 2.55-2.42 (m, 2H) , 2.19 (dt, 2H, J = 4.4, 11.4 Hz), 1.89-1.76 (m, 4H) , 1.24 (d, 6H, J" = 6.7 Hz); ESMS m/e : 529.1 (M + H) + .
1- (3- [{ (1R) -3-CHLORO-PHENYLPROPYL]OXY}PHΞNYL)ETHANONE:
Azodicarboxylate (5.37 g, 0.0310 mol) was added to a solution of triphenylphosphine (8.09 g, 0.0308 mol), 1S- 3 -chloro-1-phenyl-1-propanol (4.20 g, 0.031 mol) and, 1-
(3-hydroxyphenyl) ethanone in THF (150 mL) . The reaction mixture was stirred for 4' days at 23 °C. The solvent was removed under reduced pressure and the residue was triturated with ether/hexane (1:2, (3 X 100 mL) . The combined organic fractions were concentrated in vacuo and the crude product was purified by chromatography using EtOAc/hexane (1:14) to give the desired product (6.55 g, 74%). E NMR (400 MHz, CDC13) δ 7.48-7.31 (m, 6H) , 7.26 (t, 2H, J = 8.2 Hz), 7.04 (d, IH, J = 8.1
Hz), 5.44 (dd, IH, ι7 = 4.4, 8.1 Hz), 3.83-3.74 (m, IH) ,
3.63-3.56 (m, IH) , 2.51 (s, 3H) , 2.51-2.45 (m, IH) ,
2.29-2.17 (m, IH) ; ESMS m/e : 289.0 (M + H)+.
Example 116
N- (3-{l- [ (3R) -3- (3-ACETYLPHENOXY) -3-PHENYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 1-
(3-{ [ (1R) -3-chloro-l-phenylpropyl] oxy}phenyl) ethanone (58.5 mg, 0.200 mmol), 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide (56.8 mg, 0.200 mmol), Νal (34.0 mg, 0.200 mmol) and K2C03 (55.5 mg, 0.400 mmol) in DMF (1 mL) was stirred at 100 °C for 3 h. The solvent was removed under reduced pressure and the residue was purified by chromatography on silica using 5 % of ΝH3 (2.0 M in methanol) in CH2C12 to give the desired product (98 mg, 98%). XE NMR (400 MHz, CDCl3) δ 8.01 (s, IH) , 7.49-7.21 (m, 11H) , 7.09-7.03 (m, IH) , 6 . 96 (d, IH, J = 7.9 Hz) , 5.32 (dd, IH, J" = 5.0 , 7.9 Hz) , 3.08-2.98 (m, 2H) , 2.57-2.43 (m, 6H) , 2.11-1.72 (m, 9H) , 1.25 (d, 6H, J" = 6.8 Hz); ESMS m/e : 499.4 (M + H) + .
Procedures :
Procedure A (see also example 48) N- (3 - {l- t (3R) - 3 - (3,4-DIMETHOXYPHEΝOXY) -3-PHEΝYLPROPYL] - 4 -PIPERIDINYL}PHENYL) -2 -METHYLPROPANAMIDE :
Method A
4-{ [(1R) -3-CHLORO-l-PHENYLPROPYL]OXY}-l,2- DIMETHOXYBENZENE: A mixture of 3,4-dimethoxyphenol (4.07 g, 26.4 mmol), (S) -(-) -3-chloro-phenyl-1-propanol (4.50 g, 26.4 mmol, 99% ee, Aldrich Chemical Co.), triphenylphosphine (6.92 g, 26.4 mmol) and diethyl azodicarboxylate (4.59 g, 26.4 mmol) in THF (110 mL) was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo . At this point, the residue can either be washed with pentane and the combined pentane extracts were concentrated and chromatographed with hexane: EtOAc (8:1) as the eluent to give the desired product (as described as a general procedure by: Srebnik, M.; Ramachandran, P.V.; Brown, H.C. J". Org. Chem . 1988, 53 , 2916-2920) . This procedure was performed on a smaller scale reaction and only a 40% yield of the product was realized.
Alternatively, on a larger scale (26.4 mmol), the crude product was triturated with a small amount of dichloromethane and the precipitated triphenylphosphine oxide was filtered. The filtrate was concentrated and the crude product was chromatographed to give the desired product as a thick yellow oil (7.30 g, 88.9% yield): XE NMR (400 MHz, CDCl3) δ 7.39-7.32 (m, 4H) , 7.20
(m, IH) , 6.64 (d, IH, J = 8.7 Hz), 6.51 (d, IH, J = 2.7
Hz), 6.30 (dd, IH, J = 2.7, 8.7 Hz), 5.27 .(apparent dd,
IH, J = 4.5, 8.7 Hz), 3.79 (s, ,3H), 3.77 (s, 3H) , 3.61 (m, IH) , 2.45 (m, 1 H) , 2.20 (m, IH) , 1.80 (s, IH) ; ESMS m/e: 307.1 (M + H) + . N- (3-{l- [(3R)-3- (3,4- DIMETHOXYPHENOXY) -3-
PHENYLPROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
A mixture of potassium carbonate (321 mg, 2.32 mmol), sodium iodide (522 mg, 3.48 mmol), 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide (570 mg, 2.32 mmol) and 4-{ [ (1R) -3-chloro-l-phenylpropyl] oxy} -1,2- dimethoxybenzene (712 mg, 2.32 mmol) in DMF (5.00 mL) was stirred at 100 °C for 3 h, at which time TLC indicated that the reaction was complete. The reaction mixture was poured into water (50 L) and the aqueous layer was extracted with methylene chloride (3 x 30 mL) . The combined organic extracts were washed with brine (30 mL) , dried over MgS04 and concentrated under reduced pressure. The crude product was purified by Preparatory TLC [2.5% of ΝH3 (2.0 M in methanol) in CHC13] to afford the product (970 mg, 90.1%) as a thick oil.
Method B
Into a 25-mL RB-flask was added triphenylphosphine (9.80 mg, 0.0375 mmol), diethyl azodicarboxylate (5.22 mg, 0.0300 mmol), N- (3- {l- [ (3S) -3-hydroxy-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide (9.53 mg, 0.0250 mmol), 3,4-dimethoxyphenol (7.70 mg, 0.0500 mmol) and THF (1.00 mL) at room temperature. The reaction mixture was stirred at room temperature overnight (16 h) . The solvent was removed under reduced pressure and the residue was purified by preparative TLC plates [2.5% of ΝH3 (2.0 M in methanol) in CHC13] to afford the desired product (4.40 mg, 34.1 % yield) as a thick oil: 1H NMR (400 MHz, CDC13) δ 7.46 (s, 1 H) , 7.40-7.30 (m, 4H) , 7.25
(m, 3H) , 6.97 (d, IH, J = 7.8 Hz), 6.64 (d, IH, J = 9.1
Hz), 6.51 (d, IH, J = 2.6 Hz), 6.29 (d, IH, J = 2.6,
9.1 Hz), 5.20 (apparent dd, IH, J = 4.4, 8.5 Hz), 3.80 (s, 3H) , 3.77 (s, 3H) , 3.23 (m, 2H) , 2.77 (m,
2H) , 2.5 (m, 2H) , 2.3-2.1 (m, 6H) , 1.80 (m, 2H) , 1.25
(d, 6H, J = 7.9 Hz) ; ESMS m/e: 517.4 (M + H) + .
Procedure B (see also example 49)
2-METHYL-N- (3-{l- [ (3S) -3-PHEΝOXY-3-PHEΝYLPROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of N-(3-{l- [ (3R) -3-hydroxy-3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide (9.53 mg, 0.0250 mmol), phenol (4.70 mg, 0.050 mmol), triphenylphosphine (9.80 mg, 0.0375 mmol) and diethyl azodicarboxylate (5.22 mg, 0.0300 mmol) in THF (1.00 mL) was stirred at room temperature for 3 days. Chromatography using silica preparative TLC plates [2.5% of ΝH3 (2.0 M in methanol) in CHC13] gave the desired product (2.70 mg, 23.6 % yield) as a thick oil: 1H NMR δ 7.46 (s, 2H) , 7.40-7.30 (m, 4H) , 7.25 (m, 3H) , 7.20 (m, 2H) , 6.97 (apparent d, IH, J = 7.4 Hz), 6.89 (apparent tt, IH, J = 0.8, 7.6 Hz), 6.84 (apparent dt, IH, J = 0.8, 8.0 Hz), 5.20 (apparent dd, IH, J = 4.4, 8.5 Hz), 3.35 (m, 2H) , 2.91 (m, 2H) , 2.60 (m, 2H) , 2.30-2.10 (m, 6H) , 1.90 (m, 2H) , 1.25 (d, 6H, J = 7.9 Hz); ESMS /e: 457.4 (M + H)+;
Procedure C
Scheme O
Figure imgf000218_0001
R- H, R2=4'-Me
1- (4-METHYLPHENYL) IH-INDOLE: A mixture of 1-H-indole (58.5 mg, 0.500 mmol), l-iodo-4-methylbenzene (0.218 g, 1.00 mmol), copper powder (32.0 mg, 0.500 mmol), and K2C03 (0.138 g, 1.00 mmol) in 1-methyl-2 -pyrrolidinone (1.00 mL) was heated at 150 °C for 12 h under argon. The resulting mixture was diluted with H20 (6 mL) . The aqueous layer was extracted with CH2C12 (3 X 10 mL) . The combined organic extracts were washed with brine (10 mL) , dried over MgS04, and concentrated in vacuo . The residue was purified by preparative TLC using EtOAc :hexane (1:4) to give the desired product (82.0 mg,
79.0 lE NMR (400 MHz, CDC13) b 1 . 61 (d, IH, J = 7.7
Hz), 7.52 (d, IH, J = 7.4 Hz), 7.38 (d, 2H, J = 8.4 Hz), 7.34-7.29 (m, 3H) , 7.21 (t, IH, J = 7.0 Hz), 7.15 (t, IH, J = 7.0 Hz), 6.66 (d, IH, J = 3.3 Hz), 2.43 (s, 3H) ; ESMS m/e : 208.0 (M + H)+.
Procedure D (see also example 86)
Scheme N
Figure imgf000219_0001
Example
Figure imgf000219_0002
R- δ-CI, R2=H Rl=H, R2=4'-tolyl
N- (3-{l- [(6-CHLORO-1H-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A solution of 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide (0.369 g, 1.50 mmol) and 37 wt % aqueous formaldehyde (30.0 mg, 1.50 mmol) in 1.00 mL of HOAc : dioxane (1:4) was added to 6-chloro-l-H-indole (0.152 g, 1.00 mmol) and the reaction mixture was stirred for 12 h at room temperature. The resulting mixture was diluted with H20
(10 mL) . The aqueous layer was extracted with CH2C12 (3
X 100 mL) . The combined organic extracts were washed with brine (10 mL) , dried over MgS04, and concentrated in vacuo. The residue was purified by preparative TLC plates using 5% of ΝH3 (2.0 M in methanol) in CH2C12 to give the desired product (79.0 mg, 42.0 %): 1H NMR (400 MHz, CDC13) δ 9.14 (s, IH) , 8.04 (s, IH) , 7.52 (t, 2H, J = 8.1 Hz), 7.35 (d, 2H, J = 13.3 Hz), 7.18 (t, IH, J = 7.9 Hz), 7.09 (dd, IH, J = 1.9, 8.5 Hz), 6.85 (d, IH, J = 7.4 Hz), 5.18 (s, IH) , 4.01 (s, 2H) , 2.55
(septet, IH, J = 6.8 Hz) , 2.48-2.34 (m, 3H) , 2.08-1.95
(m, 4H) , 1.78 (d, 2H, J = 12.8 Hz), 1.22 (d, 6H, J = 6.8
Hz) ; ESMS m/e:- 410.1 (M + H) + .
Procedure E (see also example 90)
Figure imgf000220_0001
Figure imgf000220_0003
Figure imgf000220_0002
n=2, R-pH, R2=Ph, R3=H n=5, Rι=H, R2=H, R3=5-OM n=1,R1=H, R2=Ph, R3=H n=4, Rι=H, R2=H, R3=5-OM
N- (3-{l- [3- (l,2-DIPHEΝYL-lH-IΝDOL-3-YL) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 1, 1-diphenylhydrazine hydrochloride (10.3 mg, 0.0470 mmol) , 2-methyl-N- {3- [1- (5-oxo-5-phenylpentyl) -4- piperidinyl] phenyl}propanamide (14.7 mg, 0.0362 mmol), ZnCl2 (14.8 mg, 0.109 mmol), and HOAc (0.500 mL) was heated for 4 h at 80 °C. The resulting crude mixture was diluted with water (10 mL) , the aqueous layer was neutralized with saturated K2C03 (10 mL) and extracted with CH2C12 (3 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC plates using 5% of NH3 (2.0 M in methanol) in CH2C12 to give the desired product N-(3-{l-
[3- (1, 2-diphenyl-lH-indol-3-yl)propyl] -4- piperidinyl}phenyl) -2-methylpropanamide (4.10 mg, 37.0 %) : XE ΝMR (400 MHz, CDC13) δ 7.71-7.65 (m, IH) , 7.42 (d, IH, J = 7.4 Hz), 7.39 (s, IH) , 7.36-7.15 (m, 15H) , 6.94
(d, IH, J = 7.8 Hz), 3.12 (d, 2H, J = 11.2 Hz), 2.90 (t, 2H, J = 7.8 Hz), 2.59-2.45 (m, 3H) , 2.19-1.91 (m, 7H) , 1.82 (d, 2H, J = 13.5 Hz), 1.24 (d, 6H, J = 6.9 Hz); ESMS m/e: 555.3 (M + H) + .
Procedure F (see also example 108)
Scheme R
R..CHO +
Figure imgf000221_0001
Example
Figure imgf000221_0002
N-(3-{l-[4- (4 -CHLOROPHEΝOXY) BENZYL] -4-
PIPΞRIDINYL} PHENYL) -2-METHYLPROPANAMIDE: A solution of 4- (4-chlorophenoxy) benzaldehyde (0.119 g, 0.510 mmol) and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide
(0.126 g, 0.510 mmol) in 1, 2-dichloroethane (5.00 mL) was treated with sodium triacetoxyborohydride
(0.424 g, 2.00 mmol) and HOAc (0.0300 L, 0.500 mmol) at room temperature. The mixture was stirred overnight at room temperature. The reaction mixture was neutralized with saturated NaHC03 aqueous solution (10 mL) and the aqueous layer was extracted with CH2C12 (3 x 10 mL) . The combined organic layers were washed with brine, dried over MgS04, concentrated in vacuo and purified by preparative TLC plates using 5% of NH3 (2.0 M in methanol) in CH2C12 to give the desired product (53.0 mg, 23.0 %): E NMR (400 MHz, CDCl3) δ 7.50 (s, IH) , 7.34- 7.19 (m, 7H) , 6.98-6.87 (m, 5H) , 3.50 (s, 2H) , 2.98 (d, 2H, J = 11.8 Hz), 2.58-2.44 (m, 2H) , 2.10-1.98 (m, 2H) , 1.83-1.76 (m, 4H) , 1.24 (d, 6H, J = 6.8 Hz); ESMS m/e: 463.2 (M + H) + .
Procedure G (see also example 116)
Scheme F
R-halide; diisopropylethylamine
Figure imgf000222_0001
Figure imgf000222_0002
N- (3-{l- [ (3R) -3- (3-ACETYLPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A mixture of 1- (3- { [ (1R) -3-chloro-l-phenylpropyl] oxy}phenyl) ethanone (58.5 mg, 0.200 mmol), 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide (56.8 mg, 0.200 mmol), al (34.0 mg, 0.200 mmol) and K2C03 (55.5 mg, 0.400 mmol) in DMF (1.00 mL) was stirred at 100 °C for 3 h. The solvent was removed under reduced pressure and the residue was purified by chromatography on silica using 5 % of NH3 (2.0 M in methanol) in CH2C12 to give the desired product (98.0 mg, 98.0 %) : E NMR (400 MHz, CDGl3) δ 8.01 (s, IH) , 7.49-7.21 (m, 11H) , 7.09-7.03 (m, IH) , 6.96 (d, IH, J = 7.9 Hz), 5.32 (dd, IH, J = 5.0, 7.9 Hz), 3.08-2.98 (m, 2H) , 2.57-2.43 (m, 6H) , 2.11-1.72 (m, 9H) , 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e 499.4 (M + H) + .
Scheme S
Figure imgf000223_0001
Procedure H
Figure imgf000223_0002
2-METHYL-N- (3-{l- [3- (1-METHYL-1H-IΝDOL-3-YL) PROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: A mixture of N- (3 - { l- [4- (1, 3-dioxolan-2-yl)butyl] - 4-piperidinyl}phenyl) -2- methylpropanamide (100 mg, 0.270 mmol), 1-methyl-l- phenylhydrazine (106 mg, 0.870 mmol), ZnCl2 (119 mg, 0.870 mmol), and HOAc (1.00 mL) was heated for 12 h at 80 °C. The resulting crude mixture was diluted with water (20 mL) , the aqueous layer was neutralized with saturated K2C03 solotion (10 mL) and extracted with CH2C12 (3 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using 3 % of NH3 (2.0 M in methanol) in CH2C12 to give the desired product 2 -methyl-N- (3- {l- [3- (1-methyl- IH- indol -3 -yl) propyl] -4- piperidinyl }phenyl) propanamide (20.7 mg, 18.7 %) : XH ΝMR (400 MHz, CDC13) δ 7.60 (d, IH, J = 8.1 Hz), 7.45 (s, IH) , 7.35 (d, IH, J = 7.4 Hz), 7.26-7.24 (m, 4H) , 7.09 (t, IH, J = 7.3 Hz), 6.97 (d, IH, J = 7.3 Hz), 6.86 (s, IH) , 3.75 (s, 3H) , 3.11 (d, 2H, J = 11.6 Hz), 2.79 (t, 2H, J = -7.3 Hz), 2.51-2.50 (m, 4H) , 2.12-1.81 (m, 8H) , 1.25 (d, 6H, J = 7.1 Hz); Anal. Calcd for C27H35Ν3O+0.225CHCl3: C, 73.57; H, 7.99; N, 9.45. Found: C, 73.93; H, 7.90; N, 9.23; ESMS m/e 418.2 (M + H)+.
Procedure I
Scheme T
Figure imgf000224_0001
Figure imgf000225_0001
7- (2-FLUOROPHENYL) -IH-INDOLE: A mixture of 2- fluorophenylboronic acid (83.4 mg, 0.600 mmol), 7-bromo- 1H-indole (98.0 mg, 0.500 mmol), LiCI (42.0 mg, 1.00 mmol), Na2C03 (2.0 M, 0.100 mL) , Pd(PPh3)4 (115 mg, 0.100 mmol) and DME (2.00 mL) was heated at 75 °C for 12 h under Argon. The resulting crude mixture was diluted with water (40 mL) , the aqueous layer was extracted with CH2C12 (3 X 20 mL) . The combined organic layers were washed with brine (30 mL) , dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by preparative TLC using hexane: EtOAc (8:1) to give the desired product 7- (2-fluorophenyl) -IH-indole (108 mg, 100 %) : E NMR (400 MHz, CDC13) 8.21 (br s, IH) , 7.71 (dm, IH, J = 7.3), 7.55 (dt, IH, J = 7.3, 1.6 Hz), 7.39 (m, 1 H) , 7.30-7.19 (m, 5H) , 6.62 (dd, IH, J = 2.1-3.3 Hz); ESMS /e: 211.9 (M + H) + .
Procedure J
Scheme U
Figure imgf000225_0002
Figure imgf000226_0001
5- ( -METHYLPHENOXY) -IH-INDOLE: A mixture of 5-bromo-lH- indole (98.0 mg, 0.500 mmol) , p-cresol (108 mg, 1.00 mmol) , Cu (32.0 mg, 0.500 mmol) , K2C03 (138 mg, 1.00 mL) and DMF (1.00 mL) was heated at 160 °C for 12 h. The resulting crude mixture was diluted with water (40 mL) , the aqueous layer was extracted with CH2C12 (3 X 20 mL) .
The combined organic layers were washed with brine (30 mL) , dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by preparative TLC using hexane.-EtOAc (4:1) to give the desired product 5-
(4-methylphenoxy) -IH-indole (57.5 mg, 51.5 %) : ESMS m/e:
224.0 (M + H)+.
Procedure K
Figure imgf000226_0002
Scheme AN
Figure imgf000227_0001
N- (3-{l- [7- (2-FLUOROPHENYL) -7-OXOHEPTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: A 50-mL round- bottom flask was charged with a solution of 7-chloro-l-oxo-1 (2 -fluorophenyl) heptane (2.42 g, 10.0 mmol), 2-methyl-N- [3- (4-piperidyl) phenyl] propanamide
(2.46 g, 10.0 mmol), K2C03 (2.76 g, 20.0 mmol) and Νal
(2.25 g,' 15.0 mmol) in DMF (25.0 mL) . The mixture was stirred for 10 min at 25 °C and then heated at 100 °C for
12 h, cooled to 25 °C and diluted with EtOAc (100 mL) .
The reaction mixture was washed with water (4 X 50 mL) and the aqueous layer was extracted with EtOAc (100 mL) .
The organic layers were washed with brine (50 mL) , dried over MgS04, concentrated in vacuo and the crude product was purified by chromatography (EtOAc :MeOH 97:3) to give the desired product (3.70 g, 82.0 %) .
Procedure L
Figure imgf000228_0001
Scheme AN
Figure imgf000228_0002
N- (3 - {l- [7 - (2-FLUOROPHENYL) -7-HYDROXYHEPTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: To a 50-mL round-bottomed flask charged with N- (3- {l- [7- (2- fluorophenyl) -7-oxoheptyl] -4-piperidinyl }phenyl) -2 - methylpropanamide (5.0 mmol) and methanol (20 mL) was added NaBH4 (7.5 mmol) at 0 °C in an ice-bath. The reaction mixture was warmed to 25 °C and stirred for 2 h. The reaction was monitored by TLC (EtOAc:MeOH 95:5) . If necessary, another 5.0 mmol of NaBH4 was added to the reaction mixture and the reaction mixture was refluxed for 1 h. The reaction was quenched with water (5.0 mL) and diluted with EtOAc (10 mL) . The organic layer was separated, washed with saturated NaHC03 solution (10 mL) , dried over MgS04 and concentrated in vacuo . The crude product was purified by chromatography
(EtOAc :MeOH 97:3) to give the desired product (90%) .
Procedure M
Scheme A
Figure imgf000229_0001
Step 1: If reacted individually, a solution of the amine or aniline (1.00 eq) , diisopropylethylamine or TEA (2.00 eq) and an electrophile (1.50 eq) in CH2C12 was stirred for 24 h at 23 °C. The solvent was removed in vacuo and the crude product was chromatographed (silica) to give the final product.
Figure imgf000229_0002
TERT-BUTYL 4-{3- [ (4-CHLOROBUTANOYL) MINO] PHENYL}-1- PIPERIDINECARBOXYLATE (3.32 g, 87.4 %) was synthesized according to Scheme A and Procedure M: 1H NMR (400 MHz, CDC13) δ 7.55 (s, IH) , 7.47 (s, IH) , 7.37 (m, IH) , 7.28 (m, IH) , 6.97 (d, IH, J = 7.6 Hz), 3.89 (t, IH, J = 6.4 Hz), 3.74 (m, 2H) , 2.79- 2.75 (m, 4H) , 2.64 (m,
2H) , 1.88-1.77 (m, 4H) , 1.60-1.59 (m, 4H) , 1.48 (s, 9H) .
Figure imgf000230_0001
Step Bi
TERT-BUTYL 4- [3- (2-OXO-l-PYRROLIDINYL) PHENYL] -1-
PIPERIDINECARBOXYLATE : To a solution of tert-butyl 4- [3- (2 -oxo-1-pyrrolidinyl) phenyl] -1-piperidinecarboxylate (0.429 g, 16.9 mmol) in dioxane (100 mL) was bubbled HCl gas for 1 h at 25 °C. The resulting crude mixture was basified with 10% KOH solution (100 mL) , the aqueous layer was extracted with 3:1 CHC13 : iso-propyl alcohol (3 X 150 mL) . The combined organic layers were washed with brine (100 mL) , dried over Na2S04, filtered, and concentrated in vacuo . The residue was purified by preparative TLC using 20% NH3 (2.0 M in MeOH) in CH2C12 solution to give the desired product tert-butyl 4- [3- (2- oxo-1-pyrrolidinyl) phenyl] -1 -piperidinecarboxylate (245 mg, 78.7 %) : E NMR (400 MHz, CDCl3) δ 7.52 (t, IH, J = 1.8 Hz), 7.41 (ddd, IH, J = 8.1, 2.3, 0.9 Hz), 7.30 (t, IH, J = 7.9 Hz), 7.02 (d, IH, J = 7.9 Hz), 3.86 (t, 2H, J = 7.3 Hz), 3.21 (dt, 2H, J = 11.9, 2.9 Hz), 2.76 (dt, 2H, J = 12.1, 2.4 Hz), 2.65 (tt, IH, J = 11.9, 3.5 Hz), 2.61 (t, 2H, J = 8.3 Hz), 2.22 (br s, IH) , 2.16 (qt, 2H, J = 7.5 Hz), 1.85 (d, 2H, J = 12.4 Hz), 1.67 (dq, 2H, J = 12.5, 4.0 Hz) .
Figure imgf000231_0001
TERT-BUTYL 4- (4-AMINOPHENYL) -1-PIPERIDINECARBOXYLATE :
Available from Arch Chemical Company, NJ.
2-METHYL-N- [4- (4-PIPERIDINYL) PHENYL] PROPANAMIDE: To a solution of tert-butyl 4- (4-aminophenyl) -1- piperidinecarboxylate (8.20 g, 29.7 mmol) and triethylamine (8.4 mL, 60 mmol) in dry THF (100 mL) at 0 °C was slowly added a solution of 2-methylpropanoyl chloride (3.84 g, 36.0 mmol) in THF (50 mL) . The reaction mixture was then warmed up to room temperature and stirred for 2 h. After removing the solvent in vacuo, the crude product was purified by recrystallization (hexane/THF) , affording the desired amide, tert-butyl 4- [4- (isobutyrylamino) phenyl] -1- piperidinecarboxylate, as a white solid (8.60 g, 84%) . The tert-butyl 4- [4- (isobutyrylamino) phenyl] -1- piperidinecarboxylate was dissolved in CH2C1 (50 mL) at room temperature, TFA (13.68 g, 120 mmol, 5 equiv.) was added by syringe. The reaction mixture was stirred for 3 or 4 h and another 5 equivalents of TFA was added and the mixture was stirred for 2 or 3 more hours. The reaction solution was then basified to pH > 14 by KOH (aq, 2 M) . The solution was extracted with CH2C12 (8 x 200 mL) . The combined organic layer was dried over K2C03. Removal of solvent under reduced pressure gave the free amine, 2 -methyl -N- [4- (4- piperidinyl) phenyl] propanamide, as a brownish solid (5.99 g, 98%). XH ΝMR (400 MHz, CDC13) δ 7.55-7.35 (m, 2H) , 7.35-6.9 (m, 3H) , 3.26-2.98 (m, 2H) , 2.84-2.64 (m, 2H) , 2.64-2.53 (m, IH) , 2.53-2.32 (m, IH) , 1.90-1.68 (m, 2H) , 1.68-1.36 (m, 3H) , 1.22 (d, 6H, J = 6.0 Hz); ESMS m/e : 247.1 (M + H) X
N- [4- (4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by the procedure for 2 -methyl -N- [4- (4- piperidinyl) phenyl] propanamide using tert-butyl 4- (4- aminophenyl) -1-piperidinecarboxylate and propanoyl chloride: ESMS m/e : 233.1 (M + H)
N- [4- (4-PIPERIDINYL) PHENYL] BUTANAMIDE: Prepared by the procedure for 2 -methyl -N- [4- (4- piperidinyl) phenyl] propanamide using tert-butyl 4- (4- aminophenyl) -1-piperidinecarboxylate and butanoyl chloride: ESMS /e : 247.2 (M + H)+.
N- [3 - (4-PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE :
Prepared by the procedure for 2 -methyl -N- [4- (4- piperidinyl) phenyl] propanamide using tert-butyl 4- (3- aminophenyl) -1-piperidinecarboxylate • and cyclopropanecarbonyl chloride: Anal. Calcd for Cα5H2oΝ2O+0.15CH2Cl2: C, 70.8; H, 7.87; N, 10.9. found: C, 70.9; H, 7.68; N, 11.1; ESMS m/e : 245.0 (M + H) + . N- [3- (4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by the procedure for 2-methyl-N- [4- (4- piperidinyl) phenyl] propanamide using tert-butyl 4- (3- aminophenyl) -1-piperidinecarboxylate and propanoyl chloride: Anal. Calcd for Ci4H20Ν2O: C, 72.2; H, 8.63; N,
12.1. found: C, 72.4; H, 8.68; N, 12.1; ESMS m/e: 233.1.
Procedure N
Scheme AV
Figure imgf000233_0001
Figure imgf000233_0002
The library was constructed in polypropylene Robbins 46 well plates Reactor Blocks. In the initial incubation period, each well was charged with PS-TBD resin (from
Argonaut Technologies, 0.280 mmol, 2.50 eq, 200 mg) and piperidine (0.120 mmol, 1.10 eq) in acetonitrile (0.500 mL) and agitated for 1 h. A solution of benzyl iodide or bromide (0.110 mmol, 1.00 eq) in acetonitrile (0.500 mL) was added to each well followed by additional acetonitrile (1.00 mL) to make a total volume of 2.00 mL and the mixture was rotated in a Robbins rotating oven at room temperature for 16 h. Then AP-Isocyanate resin (Argonaut Technologies, 250 mg, 0.430 mmol, 4.00 eq) was added to each well and reacted further at room temperature for another 12 h. The mixture was filtered and the filtrate was concentrated in vacuo to obtain the desired product that was characterized via LC-MS.
Procedure O
Alkylation of Piperidines Using Alcohols and PS-TSC1 Resin in Robbins 48 well "Reactor Blocks"
Scheme W
Figure imgf000234_0001
The library was constructed in polypropylene Robbins "Reactor Blocks", 46 well plates. PS-TSC1 resin (100 mg, 1.00 eq, purchased from Argonaut Technologies) was placed in each well of the "Reactor Blocks" 46 well plates. To each well was added an alcohol (1.50 mmol) in 3.00 mL of CH2Cl2 and pyridine (1:1) . The mixture was stirred for 5 h and the resin was washed with CH2C12 (3 x 4mL) , DMF (5 X 4.0 mL) , DMF/H20 (3:1, 5 x 4.0 mL) , THF (3 x 4.0 mL) , CH2C12 (3 x 4.0 L) , acetonitrile (2 x 4.0 mL) and dried under reduced pressure. A solution of an amine (0.0750 mmol, 0.500 eq) and N,N-diisopropylethyl amine (19.0 mg, 0.150 mmol, 1.00 eq) in acetonitrile (3.00 mL) was added to the well containing the derivatized resin and the mixture was reacted at 70 °C for 16 h. Finally, AP-Isocyanate resin (120 mg, 0.150 mmol, 1.00 eq) and THF (2.00 mL) was added to the reaction vessel and reacted at room temperature for another 3 h. The solution was filtered into the Robbins receiving plates and concentrated in vacuo to give the desired tertiary amine, which was analyzed via LC-MS. Procedure P
. Scheme AB
Figure imgf000235_0001
Figure imgf000235_0002
N- {3 - [1- (3-{ [ (4-FLUOROAΝILIΝO) CARBONYL] AMINθ}PROPYL) -4- PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: A solution of N- { 3 - [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide (26.4 mg, 0.0870 mol), l-fluoro-4- isocyanatobenzene (11.9 mg, 0.0870 mmol), in THF (1.00 mL) was stirred for 12 h at 25 °C . The resulting crude mixture was diluted with water (10 mL) , the aqueous layer was extracted with CH2C12 (3 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using 2.5 % of ΝH3 (2.0 M in methanol) in CH2C12 to give the desired product N- { 3 - [1- (3-{ [ (4-fluoroanilino) carbonyl] amino} propyl) -4-piperidinyl] phenyl} -2-methylpropanamide (4.18 mg, 10.9 %) : E ΝMR (400 MHz, CDCl3) 7.45 (q, 2H, J = 4.7 Hz), 7.23-7.21 (m, 4H) , 7.05 (t, 4H, J = 7.8 Hz), 6.75 (m, IH) , 4.05 (m, IH) , 3.19 (s, IH) , 2.71 (m, IH) , 2.53 (m, IH) , 2.26-2.21 (m, 3H) , 1.80-1.60 (m,
9H) , 1.25 (d, 6H, J = 6.4 Hz) ; ESMS m/e: 439.4 (M + H)+.
Procedure Qi
Scheme AT
electrophile, base
Figure imgf000236_0002
Figure imgf000236_0001
If reacted individually, a solution of the amine (1.0 eq) , an electrophile (1.5 eq) , diisopropylethylamine
(2.0 eq) in CH2C12 was stirred for 1 day. The solvent was removed in vacuo and the crude product was chromatographed to give the final product.
Figure imgf000236_0003
2-METHYL-N-{3- [l-(3-{[(4-
METHYLPHEΝYL) SULFOΝYL] AMIΝθ}PROPYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE: A solution of 4- methylbenzenesulfonyl chloride (16.6 mg, 0.0870 mmol), N- {3- [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide (26.4 mg, 0.0870 mmol), TEA (10.0 mg, 0.174 mmol) in THF (1.00 mL) was stirred for 12 h at 25 °C. The resulting crude mixture was diluted with water (20 mL) , the aqueous layer was extracted with CH2C12 (2 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using 2.5 % of NH3 (2.0 M in methanol) in
CH2C12 to give the desired product 2 -methyl-N- {3- [1- (3-
{ [ (4-methylphenyl) sulfonyl] amino} propyl) -4- piperidinyl] phenyl }propanamide (17.3 mg, 43.6 %) : 1H ΝMR
(400 MHz, CDC13) δ 8.19 (s, IH) , 7.53 (s, IH) , 7.41 (s,
IH) , 7.32-7.21 (m, 4H) , 7.16 (s, IH) , 6.97 (d, IH, J =
7.9 Hz), 3.44 (t, 2H, J = 6.3 Hz), 3.15 (d, 2H, J = 9.8
Hz), 2.62-2.45 (m, 4H) , 2.15 (m,- 3H) , 2.05 (s, 3H) , 1.95-1.71 (m, 5H) , 1.26 (d, 6H, J = 6 . 6 Hz); ESMS m/e :
458.2 (M + H)+.
Procedure Q2
The Capture and Release Method for the Synthesis and Purification of the Piperidine Library
The commercially obtained Amberlyst 15 exchange resin (Aldrich) was activated using the following procedure: 1. The resin was shaken in methanol for 24 hr. 2. The resin was filtered and washed with methanol on a fritted funnel.
3. The resin was neutralized with 2Ν NH3 in MeOH (pH checked) - shaken for 1 hr.
4. The neutralized resin was acidified with 3M HCl in MeOH (pH checked) - shaken for 1 hr.
5. The resin was captured on a fritted funnel and washed with MeOH.
6. The resin was dried in vacuo and stored. ■
Synthesis (Acylation of the Amines) :
The library was constructed in polypropylene Robbins "Reactor Blocks", 46 well plates. In each plate an array of 5 amines (0.10 mmol) and 8 electrophiles (acid chlorides, sulfonyl chlorides, 1.5 eq.) in the presence of triethylamine (2.0 eq) in THF/DCM 3:1 (2.0 L) were reacted overnight to give 40 compounds/plate.
The reactions were rigorously monitored via TLC to the depletion of the starting amine due to the ensuing purification methodology via the acidic Amberlyst 15 resin. Following the disappearance of the starting amine, the desired products were captured and then released using the process outlined below.
Purification of the Piperidine Products: Activated Amberlyst 15 ion-exchange resin (0.90 g, Aldrich) was added to each well, and the plates were rotated for 2 hours in a Robbins rotating oven to capture the desired final product from the reaction mixture. The solvent was filtered and the resin was washed with CH30H and CH2C12 (x 3) alternately with each of the solvents (for 10 minutes each time) . After the last filtration, 2 N ammonia in methanol was added to the resin (2 mL to each well) and the reaction blocks were rotated for 2 hours to release the desired compounds from the resin. The final compounds were filtered into Robbins' "Receiving Blocks" , the solvent was removed and the compounds were analyzed via LC-MS.
Procedure R
Scheme Z
Figure imgf000239_0001
n = 1-4
X = F, Cl, Br, I
[ (3-CHLOROPROPYL) SULFANYL] BENZENE: A mixture of benzenethiol (0.550 g, 5.00 mmol), l-bromo-3- chloropropane (106 mg, 5.50 mmol), TEA (1.01 g, 10.0 mmol) and THF (10.0 mL) was stirred for 12 h at 25 °C. The resulting crude mixture was diluted with water (40 mL) , the aqueous layer was extracted with CH2C12 (3 X 30 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using hexane: EtOAc (10:1) to give the desired product
[ (3 -chloropropyl) sulfanyl] benzene (1.05 g, 100 %) .
Scheme AA
Figure imgf000239_0002
X = F, Cl, Br, I
Procedure S
3-CHLOROPROPYL 4-FLUOROPHENYL SULFOXIDE: A solution of 3-chloropropyl 4-fluorophenyl sulfide (77.5 mg, 0.380 mmol) in CH2C12 (2.00 mL) was cooled to 0 °C. To this solution m-CPBA (78.7 mg, 0.460 mmol) was added. The reaction mixture was stirred at 0 °C for 30 min, then at 23 °C for 4 h. The resulting crude mixture was diluted with 10% aqueous Na2S03 (10 mL) , the aqueous layer was extracted with CH2C12 (2 X 15 mL) . The combined organic layers were washed with brine (10 mL) , dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by preparative TLC using 2.5 % of NH3 (2.0 M in methanol) in CH2C12 to give the desired product 3-chloropropyl 4-fluorophenyl sulfoxide (47.8 mg, 57.0 %) .
Procedure T
Scheme AD
B Baassee,, TTHHFF,, CCHH3I
Figure imgf000240_0001
Figure imgf000240_0003
Figure imgf000240_0002
N- (3-{l- [4- (3,4-DIMETHYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) -N, 2-DIMETHYLPROPANAMIDE: A mixture of N- (3-{l- [4- (3,4-dimethylphenyl) -4-oxobutyl] -4- piperidinyl}phenyl) -2-methylpropanamide (15.0 mg, 0.0357 mmol), Mel (5.07 mg, 0.0357 mmol), ΝaOtBu (6.86 mg,
0.0714 mmol) and THF (1.00 mL) was stirred for 5 h at 25
°C . The resulting crude mixture was diluted with water
(10 mL) , the aqueous layer was extracted with CH2C12 (3 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using 4.0 % of ΝH3 (2.0 M in methanol) in CH2C12 to afford the desired product N- (3- {l- [4- (3 , 4- dimethylphenyl) -4- oxobuty1] -4- piperidinyl}phenyl) -N, 2-dimethylpropanamide (13.8 mg, 89.1 %) : E ΝMR (400 MHz, CDC13) 7.76 (s, IH) , 7.72 (dd, IH, J = 1.8, 7.7. Hz), 7.33(t, IH, J = 8.8 Hz), 7.22 (d, IH, J = 7.8 Hz), 7.18(d, IH, J = 8.8 Hz), 7.01 (m, 2H) , 3.24 (s, 3H) , 3.10 (d, IH, J = 10.6 Hz), 3.00 (t, IH, J = 7.6 Hz), 2.49-2.44 (m, 4H) , 2.33 (s, 6H) , 2.112.10 (m, 2H) , 1.99 (m, IH) , 1.79-1.77 (m, 4H) , 1.26 (t, 2H, J = 7.6 Hz), 1.02 (d, 6H, J = 7.6 Hz); ESMS m/e : 435.2 (M + H)+.
Procedure U
Scheme AK
Figure imgf000241_0001
n = 1-4
X = F, Cl, Br, I
Figure imgf000241_0002
1- [3- (3 -CHLOROPROPOXY) PHENYL] ETHAΝOΝE: To a suspension of NaH (50.5 mg, 2.00 mmol) in DMF (1.00 mL) was added 1- (3-hydroxyphenyl) ethanone (136 mg, 1.00 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. To this mixture was added a solution of l-bromo-3- chloropropane (188 mg, 1.20 mmol) in DMF (0.500 mL) . The reaction mixture was stirred at room temperature for 5 h. The resulting crude mixture was diluted with water (20 mL) , the aqueous layer was extracted with CH2C12 (3 x 20 mL) . The combined organic layers were washed with brine (20 mL) , dried over NaS04, filtered, and concentrated in vacuo. The residue was purified by preparative TLC using hexane :EtOAc (4:1) to afford the desired product 1- [3- (3-chloropropoxy) phenyl] ethanone
(235 mg, 55.2 %) : 1H NMR (400 MHz, CDC13) δ 7.7 (d, IH, J = 6 . 6 Hz), 7.52(s, IH) , 7.25 (t, IH, J = 6.6 Hz), 7.01
(m, IH) , 4.11 (t, 2H, J =• 7.9 Hz), 3.69 (t, 2H, J = 7.9 Hz), 2.61 (s, 3H) , 1.95-1.92 (m, 2H) .
Procedure V
Scheme AE
Figure imgf000242_0001
1- [ (2,2-DIMETHYLPROPANOYL)OXY] -4- (4, 4, 5, 5-TETRAMETHYL- 1,3, 2-DIOXABOROLAN-2-YL) -1,2,3, 6-TETRAHYDROPYRIDINE: To a 50-mL RB-flask, charged with bis (pinacolato) diboron (422 mg; "1'.66 mmol), KOAc (444 mg, 4.53 mmol) and PdCl2dppf (37.0 mg, 3.00 mol%) , dppf (25.0 mg, 3.00 mol%) , was added a solution of l-[(2,2- dimethylpropanoyl) oxy] -1,2,3, 6-tetrahydro-4-pyridinyl trifluoromethanesulfonate (500 mg, 1.51 mmol) in 1,4- dioxane (10.0 mL) at room temperature unde argon. The mixture ' was heated at 80 °C overnight. After cooled to room temperature, the mixture was filtered through celite and the celite was washed with EtOAc (3 x 20 mL) . The filtrates were concentrated in vacuo. The resulting residue was dissolved in EtOAc and washed with H20 and brine, dried over MgS04, filtered and concentrated in vacuo . The crude material was purified by flash chromatography (1:9 EtOAc:hexane) to give l-[(2,2- dimethylpropanoyl)oxy] -4- (4,4,5, 5-tetramethyl-l, 3,2- dioxaborolan-2-yl) -1,2,3, 6-tetrahydropyridine (355 mg, 76.0 %) .
Procedure W
Scheme AF
Figure imgf000243_0001
TERT-BUTYL 4- [5- (ISOBUTYRYLAMINO) -2-METHYLPHENYL] -3,6- DIHYDRO-K2H) -PYRIDINECARBOXYLATE: To a 50-mL RB flask containing 1- [ (2, 2-dimethylpropanoyl) oxy] -4- (4,4,5,5- tetramethyl-1, 3 , 2-dioxaborolan-2-yl) -1,2,3,6- tetrahydropyridine (500 .mg, 1.62 mmol), K2C03 (670 mg, 4.86 mmol) and PdCl2dppf (155 mg) was added -a solution of N- (3-bromo-4-methylphenyl) -2-methylpropanamide (415mg, 1.62 mmol) in DMF (10.0 mL) at room temperature under argon. The mixture was heated to 80 °C under argon overnight. After cooled to room temperature, the mixture was filtered through celite and the celite was washed with EtOAc (3 x 20 mL) . The filtrates were washed with H20 (20 mL) , brine (20 mL) , dried over MgS0, filtered and concentrated in vacuo. The crude material was purified flash chromatography (20% EtOAc/ hexane) to give tert-butyl 4- [5- (isobutyrylamino) -2-methylphenyl] -
3,6-dihydro-l (2H) -pyridinecarboxylate (360 mg, 62.0 %) .
Scheme AG
Figure imgf000244_0001
Procedure X
TERT-BUTYL 4- [5- (ISOBUTYRYLAMINO) -2-METHYLPHENYL] -1- PIPERIDINECARBOXYLATE : A solution of tert-butyl 4- [5- (isobutyrylamino) -2-methylphenyl] -3, 6-dihydro-l (2H) - pyridinecarboxylate (335 mg, 0.93 mmol) and 10% Pd/C (35.0 mg) in EtOH (20.0 mL) was hydrogenated at room temperature overnight using the hydrogen balloon method. The reaction mixture was filtered through celite and washed with ethanol (3 x 10 mL) . The combined extracts were concentrated in vacuo to afford tert-butyl 4- [5- (isobutyrylamino) -2-methylphenyl] -1- piperidinecarboxylate (335 mg, 100 %) .
Procedure Y Scheme AH
Figure imgf000245_0001
2-METHYL-N- [4-METHYL-3- (4-PIPERIDIΝYL) PHENYL] PROPANAMIDE: Into a solution of tert-butyl 4- [5-
(isobutyrylamino) -2-methylphenyl] -1- piperidinecarboxylate (335 mg, 0.930 mmol) in CH2C12
(10.0 mL) was added TFA (10.0 mL) at room temperature. The reaction mixture was stirred for 2 h and concentrated in vacuo. The residue was dissolved in 20 mL of CHCl3/i-PrOH (3:1) and was basified with 5% KOH solution (10 mL) . The aqueous layer was extracted with CHCl3/i-PrOH (3:1, 3 x 10 mL) . The combined organic extracts were washed with brine, dried over MgS0 , filtered and concentrated in vacuo to give 2-methyl -N-
[4-methyl-3- (4-piperidinyl) phenyl] propanamide (190 mg, 78.0 %) .
Procedure Z
Scheme Al
Figure imgf000245_0002
Figure imgf000246_0001
N- (3-{l- [4,4-BIS (4-FLUOROPHENYL) BUTYL] -4-PIPERIDINYL}-4- METHYLPHENYL) -2-METHYLPROPANAMIDE: A solution of 2- methyl-N- [4-methyl-3- (4-piperidinyl) phenyl] propanamide (49.0 mg, 0.190 mmol), 1- [4-chloro-l- (4- fluorophenyl) butyl] -4-fluorobenzene (58.0 mg, 0.210 mmol), Νal (42.0 mg, 0.280 mmol) and K2C03 (52.0 mg, 0.380 mmol) in DMF (10.0 mL) was heated at 95 °C overnight. The mixture was diluted with water (20 mL) and the aqueous layer was extracted with EtOAc (3 x 20 mL) . The combined organic layers were washed with brine, dried over MgS04 and concentrated in vacuo. The crude product was purified by flash chromatography [5% ΝH3 (2.0 M in MeOH) in CH2C12] to afford N- (3- {l- [4, 4- bis (4-fluorophenyl) butyl] -4-piperidinyl} -4- methylphenyl) -2-methylpropanamide (37.0 mg, 38.0 %).
Procedure AA
Scheme AJ
Figure imgf000247_0001
N- (3-{l- [4- (3,4-DIFLUOROPHEΝOXY)BEΝZYL] -4-PIPERIDINYL}- 4-METHYLPHENYL) -2-METHYLPROPANAMIDE: To a solution of 4- (3 , 4-Difluorophenoxy) benzaldehyde (41.0 mg, 0.170 mmol) and 2 -methyl-N- [4-methyl-3- (4- piperidinyl) phenyl] propanamide (45.0 mg, 0.170 mmol) in 1, 2-dichloroethane (5.00 mL) was added sodium triacetoxyborohydride (110 mg, 0.520 mmol) and AcOH (10.0 μL, 0.170 mmol) at room temperature. The mixture was stirred overnight. The reaction mixture was quenched by saturated ΝaHC03 solution (10 mL) and extracted with CH2C12 (3 x 10 mL) . The combined organic layers were washed with brine, dried over MgS04, concentrated in vacuo . The crude product was purified by preparative TLC using 5% NH3 {2.0 M in MeOH) in CH2C12 to give the desired product N- (3- {l- [4- (3 , 4- difluorophenoxy) benzyl] -4-piperidinyl} -4-methylphenyl) - 2-methylpropanamide (44.0 mg, 54.0 %) .
Procedure AC Scheme AT: Synthesis of Amides using PS -
Carbodiimide Resin
Figure imgf000248_0001
A mixture of a carboxylic acid (0.0800 mmol) and PS- Carbodiimide Resin (2.00 eq, 80.0 mg, 1.34 mmol/g) in DCM: DMF (10:1, 3.00 mL) was shaken for 30 min. To the reaction mixture was added amine (0.0540 mmol) and the resulting mixture was shaken for 12 h at room temperature. The reaction mixture was filtered and the resin was washed with CH2C12. The combined organic extracts were concentrated to a small volume, applied to a preparative TLC plate and eluted with 6 % NH3 (2.0 M in MeOH) in CH2C12 to give the desired product.
Procedure AD
Scheme X bromopropylamine.HBr + (B0C)20 + base
Figure imgf000249_0001
Figure imgf000249_0002
TERT-BUTYL N- (3-BROMOPROPYL) CARBAMATE: Prepared from 3- bromopropylamine hydrobromide and BOC20 in the presence of base in CH2C12 : ' XE ΝMR (300 MHz) δ 5.07 (br, 1 H) , 3.31 (t, 2 H, J = 6.6 Hz), 3.12 (apparent br q, 2 H, J = 6.0 Hz), 1.92 (p, 2 H, J = 6.6 Hz), 1.30 (s, 9H) .
Figure imgf000249_0003
Step 1. To a solution of piperidine (19.3 mmol) in dioxane (20.0 mL) was N- ( ert-butoxycarbonyl) -3- bromopropylamine (21.2 mmol) and potassium carbonate
(38.7 mmol) at room temperature and the mixture was heated at reflux temperature for 24 h. The reaction mixture was cooled to room temperature, concentrated in vacuo and partitioned between CHC13 (40 mL) and water (5 mL) . The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by column chromatography (ethyl acetate: methanol 9:1) to yield the required product tert-butyl 3- {4- [3- (acetylamino) phenyl] -1- piperidinyl }propylcarbamate as a colorless oil: ESMS m/e: 376.2 [M+H] + .
Step 2. HCl gas was bubbled into a solution of the boc- protected amine (12.1 mmol) in dioxane (5.00 mL) for 10- 20 minutes at 0-5 °C. The resulting solution was stirred at 0-5 °C for 1 h, concentrated, neutralized with 10 % KOH solution (10 mL) and extracted into CH2C12 (25 mL) . The organic extract was washed with brine, dried over sodium sulfate and concentrated in vacuo. The crude product was chromatographed to give the desired product N-{3- [1- (3-aminopropyl) -4-piperidinyl]phenyl}acetamide: ESMS m/e: 276.1 [M+H] + .
Procedure AE Scheme Y
Figure imgf000250_0001
Step 1: A mixture of piperidine (1.00 eq, 0.0226 mmol), N- (bromoalkyl) phthalimide (1.50 eq, 0.0338 mmol) , Bu4ΝI
(200 mg) and diisopropylethylamine (5.00 eq, 0.113 mmol) in dioxane (200 mL) was heated at 99 °C for 24 h.
The reaction was followed by TLC analysis (95:5
CH2C12 :methanol) . If necessary additional 0.0113 mmol of the appropriate bromoalkylphthalimides was added to each reaction mixture and the heating was continued for additional 48 h. The reaction mixture was cooled to room temperature, the ammonium salts were . filtered out and the solvent was removed under reduced pressure . The crude product was chromatographed to give the desired product .
Figure imgf000251_0001
ESMS m/e: 420.2 ESMS m/e: 434.4 [M+H] + [M+H] +
Figure imgf000251_0002
ESMS m/e: 448.4 ESMS m/e: 462.4 [M+H] + [M+H] +
Figure imgf000251_0003
ESMS m/e: 476.4 [M+H] + Step 2 : Deprotection of the resulting phthalimides was conducted by heating a solution of phthaliamide- protected amines with excess hydrazine hydrate (10 eq) in ethanol (0.5-1.0 M) at 90 °C for 4 h. The reaction mixture was monitored by TLC to completion. Upon- the reaction was completed, the mixture was cooled to room temperature, the insoluble by-products were filtered out through celite and the solvent was removed in vacuo.
The crude product was chromatographed (dichloromethane- methanol-isoprpylamine) to give the desired products.
Figure imgf000252_0001
ESMS m/e: 290.2 [M+H] ESMS m/e: 304.1 [M+H]
Figure imgf000252_0002
ESMS m/e: 318.2 [M+H] ESMS m/e: 332.2 [M+H]
Figure imgf000252_0003
ESMS m/e: 346.3 [M+H]
Figure imgf000253_0001
Figure imgf000253_0003
Figure imgf000253_0002
Scheme H
Figure imgf000253_0004
(ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -2-OXO- 1,3-OXAZOLIDINE-3-CARBOXAMIDE was synthesized according to Scheme H and Procedure AF: To a solution of (4R) -4-
(3 , 4-difluorophenyl) -1, 3-oxazolidin-2-one (this compound and analogs were prepared according to J. Med. Chem 2000, 43 , 2775) (0.300 mol, 60.0 mg) in THF (5.00 mL) was added LDA (2.0 M in THF, 0.390 mmol, 0.200 mL) at - 78 °C under argon. After 30 min at -78 °C, to the mixture was added a solution of 4-nitrophenyl chloroformate (0.330 mmol, 51.2 mg) in THF (0.500 L) at -78 °C. After stirring for 30 min at -78 °C the reaction mixture was diluted with a saturated Na2C03 solution
(5.0 mL) and the aqueous layer was extracted with CH2C12 (3 x 10 mL) . The combined organic layers were washed with brine (10 mL) , dried over Na2S04 and concentrated in vacuo. The residue was purified by preparative TLC plates (10:1 hexane : ethyl acetate) to afford 4- nitrophenyl (4R) -4- (3, 4-difluorophenyl) -2-oxo-l, 3- oxazolidine-3 -carboxylate (51.5 mg, 54.0 %) .
4-Nitrophenyl (4R) -4- (3,4-difluorophenyl) -2-oxo- 1, 3-oxazolidine-3-carboxylate (169 mg, 0.465 mmol), N- {3- [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide (14l mg, 0.465 mmol), K2C03 (0.193 g, 1.39 mmol), CH2C12 (10 mL) , and methanol (0.1 mL) were combined in a flask. The mixture was stirred overnight at room temperature, the solvent was removed in vacuo, and the residue was purified by chromatography [2.5% of ΝH3 (2.0 M in methanol) in CH2C12] to afford the desired product (26.1 mg, 10.6 %) : 1H NMR (400 MHz, CDC13) δ 8.08 (t, IH, J = 5.5 Hz), 7.45 (S, 2H) , 7.38 (d, IH, J = 8.6 Hz), 7.24-7.12 (m, 3H) , 7.06 (m, IH) , 6.97 (d, IH, J = 8.6 Hz), 5.40 (dd, IH, J = 3.9-8.8 Hz), 4.71 (t, IH, J = 8.8 Hz), 4.23 (dd, IH, J = 4.4, 9.1 Hz), 3.32 (qt, 2H, J = 6.1 Hz), 2.99 (d, 2H, J = 11.0 Hz), 2.49 (qt, 2H, J = 7.0 Hz), 2.41(t, 2H, J = 7.0 Hz), 1.99-1.97 (m, 2H) , 1.82-1.68 (m, 6H) , 1.23 (d, 6H, J = 7.3 Hz) ; Anal.
Calcd. for C28H34F2N404+HC1 + 0.185CHCl3 : C, 57.6; H, 6.04; N, 9.54. Found: C, 58.5; H, 6.08; N, 9.47; ESMS m/e: 529.1 (M + H)+.
Procedure AG
Figure imgf000255_0001
Step 1: A solution of ketoester (10 mmol), Meldrum' s acid (10 mmol) , aldehyde (10 mmol) and an ammonium acetate (11 mmol) in HOAc (10 mL) was heated at reflux temperature for 18 h.1 The cooled reaction mixture was poured over ice (100 g) . The precipitated oils were collected and dried under reduced pressure. The benzyl ester protected analogs solidified upon trituration with a mixture of ether/hexane.
Figure imgf000255_0002
1 MORALES, A.; OCHOA, E.; SUAREZ, M.; VERDECIA, Y.; GONZALEZ, L.; MARTIN, N.; QUINTEIRO, M.; SEOANE, C; SOTO, J. L.; J". Heterocycl . Chem. [JHTCAD] 1996, 33 (1) , 103-107. Step 2: A mixture of a benzyl ester and 10% Pd/C in methanol was hydrogenated using the balloon method at room temperature. The reaction mixture was monitored
(TLC) to completion, filtered through Celite 545 and the Celite filter cake was washed with methanol (3 x 10 mL) .
The combined methanol extracts were concentrated in vacuo to give the desired carboxylic acid that was used in the next step without any further purification.
Figure imgf000256_0001
4- (2, 4-DIFLUOROPHENYL) -2-METHYL-6-OXO-l,4, 5, 6- TETRAHYDRO-3-PYRIDINECARBOXYLIC ACID was synthesized according to Procedure AG and Scheme AR: 1H NMR (CDC13, 400 MHz) δ 7.82 (s, IH) , 7.00--6.72 (m, 3H) , 4.51 (d, IH, J = 8.4 Hz), 2.90 (dd, IH, J = 8.4, 16.3 Hz), 2.68 (d, IH, J = 16.3 Hz), 2.46 (s, 3H) .
Figure imgf000256_0002
4- (3,4-DIFLUOROPHENYL) -2-METHYL-6-OXO-1, 4, 5, 6- TETRAHYDRO-3-PYRIDINECARBOXYLIC ACID was synthesized according to Procedure AG and Scheme AR: E NMR (CDC13, 300 MHz) δ 7.40-6.80 (m, 4 H) , 4.23 (d, 1 H, J = 7.5 avg. Hz), 2.93 (dd, 1 H, J = 16.8, 7.5 avg. Hz), 2.68 (d, 1 H, J = 16.5 avg. Hz), 2.45 (s, 3 H) . Procedure AH
Figure imgf000257_0001
1- (6-CHLOROHEXYL) -Iff-INDO"tU: : To a mixture -of NaH (0.249 g, 10.0 mmol) in DMF (5.00 mL) was added a solution of 1-ff- indole (0.585 g, 5.00 mmol) in DMF (2.00 mL) at 0 °C.
The reaction mixture was stirred for 30 minutes at 0 °C and warmed up to room temperature. To the reaction mixture l-bromo-6-chlorohexane (0.998 g, 5.00 mmol) was added dropwise via syringe and the reaction mixture was stirred overnight. The reaction mixture was diluted with EtOAc (30 mL) , washed with water (3 X 10 mL) , brine (10 mL) , dried over MgS04, concentrated in vacuo and purified by chromatography using hexane:EtOAc (97.5:2.5) to give the desired prod»et (0.900 g, 76.0 %) : 1H NMR (400 MHz, CDC13) δ 7.76-7.54 (m, IH) , 7.47-6.96 (m, 4H) , 6.60-6.34 (m, IH) , 4.13 (t, 2H, J = 6.8 Hz), 3.50 (t, 2H, J" = 5.6 Hz), 1.98-1.79 (m, 2H) , 1.79-1.64 (m, 2H) , 1.54-1.17 (m, 4H) .
N- (3-{l- [6- (Iff-IΝDOL-1-YL) HEXYL] -4-PIPERIDIΝYL}PHEΝYL) -
2-METHYLPROPANAMIDE: A mixture of 1- (6-Chlorohexyl) -IH- indole (23.6 mg, 0.100 mmol), 2 -methyl -N- [3- (4 - piperidinyl) phenyl] propanamide (24.6 mg, 0.100 mmol), K2C03 (27.6 mg, 0.200 mmol), al (22.5 mg, 0.150 mmol) and DMF (1.00 mL) was hejfeted at 100 °C for 12 h. .The reaction mixture was cooled to room temperature and the crude material was purified by preparative TLC using 5 % of NH3 (2.0 M in methanol) in CH2C12 to give the desired product as a yellow solid (40 mg, 90 %) : λE NMR
(400 MHz, CDC13) δ 8.08-6.52 (m, 11H) , 4.17 (t, 2H, " =
7.2 Hz), 3.26 (d, 2H, J = 11.6 Hz), 2.74-2.52 (m, 4H) , 2.44-2.28 (m, 2H) , 2.20-2.02 (m, 2H) , 1.98-1.82 (m, 4H) ,
1.-78-1.62 (m, 2H) , 1.43-1.28 (m, 4H) , 1.28 (d, 6H, J =
6.8 Hz); ESMS m/e: 446.5 (M + H)+.
Procedure Al:
Scheme AU: Preparation of tert-Piperdines Usingd PS-S02C1 Resin
Figure imgf000258_0001
Figure imgf000258_0002
The library was constructed in polypropylene Robbins "Reactor Blocks", 48 well plates. PS-TSC1 resin (100 mg, 1.00 eq, purchased from Argonaut Technologies) was placed in each well of the "Reactor Blocks" 48 well plates. To each well was added 2-10 eq of an alcohol in dichloromethane :pyridine (1:1, 3.00 mL) . The mixture was stirred at room temperature for 5 h and the resin was washed with dichloromethane (3 x 4.00 mL) , DMF (5 x 4.00 mL) , DMF/H20 (3:1, 5 x 4.00 mL) , THF (3 x 4.00 mL) , dichloromethane (3 x 4.00 mL) , acetonitrile (2 x 4.00 mL) and dried under reduced pressure. A solution of an amine (0.0750 mmol, 0.500 eq) and N,N-diisopropylethyl amine (19.0 mg, 0.150 mmol, 1.00 eq) in acetonitrile (3.00 mL) was added to the well containing the derivatized resin and the mixture was reacted at 70 °C for 16 h in the Robbins rotating oven. After cooling,
AP-isocyanate- resin (120 mg, 0.150 mmol, 1.00 eq) and
THF (2.00 mL) was added to the each reaction vessel and reacted at room temperature for additional 3 h. The solution was filtered into the Robbins receiving plates and concentrated in vacuo to give the desired tertiary amines which were analyzed via LC-MS.
Procedure AJ:
Scheme AV: Preparation of tert-Piperidines Using Piperdines,
Figure imgf000259_0001
Figure imgf000259_0002
The library was constructed in polypropylene Robbins 48 well plates Reactor Blocks. In the initial incubation period, each well was charged with PS-TBD resin (from
Argonaut Technologies, 200 mg, 0.280 mmol, 2.50 eq) and piperidine (0.120 mmol, 1.10 eq) in acetonitrile (0.500 mL) and agitated for 1 h. A solution of .benzyl iodide or bromide (0.110 mmol, 1.00 eg) in acetonitrile (0.500 mL) was added to each well followed by additional acetonitrile (1.00 mL) to make a total volume of 2 mL and the mixture was rotated in a Robbins rotating oven at room temperature for 16 h. Then AP-Isocyanate resin (Argonaut Technologies, 250 mg (0.430 mmol, 4.00 eq) was added to each well and reacted further at room temperature for another 12 h. The mixture was filtered and the filtrate was concentrated in vacuo to obtain the desired product that, was characterized via LC-MS.
Scheme AX
Figure imgf000260_0001
Example 117
N-(3-{l- [3- (4-BROMOPHENYL) -3-OXOPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Procedure K (Kl) and Scheme E (K2C03) using 1- (4-bromophenyl) -3- chloro-1-propanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 457.1 (M + H) + .
Example 118
N-(3-{l-[3- ( -CHLOROPHENYL) -3-OXOPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Procedure K
(Kl) and Scheme E (K2C03) using 3-chloro-l- (4- chlorophenyl) -1-propanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 413.1 (M +
H)\
Example 119
N-(3-{l- [3- (4-METHOXYPHEΝYL) -3-OXOPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Procedure K
(Kl) and Scheme E (KC03) using 3-chloro-l- (4- methoxyphenyl) -1-propanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 409.2 (M +
H) + .
Example 120
N- (3- {l- [3- (2,3-DIHYDRO-lff-IΝDEΝ-5-YL) -3-OXOPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Procedure K (Kl) and Scheme E (K2C03) using 3-chloro-l- (2, 3-dihydro- lH-inden-5-yl) -1-propanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS /e : 419.2 (M + H) + .
Example 121
2-METHYL-N-{3- [1- (3-OXO-3-PHEΝYLPROPYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Procedure K (Kl) and Scheme E (K2C03) using 3-chloro-l-phenyl-l-propanone and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 379.2 (M + H)+.
Example 122
2-METHYL-N- (3-{1- [3- (4-METHYLPHENYL) -3-OXOPROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Procedure K (Kl) and Scheme E (K2C03) using 3-chloro-l- (4-methylphenyl) -1- propanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 393.2 (M + H)\
Example 123
N- (3 - { l- [3- (4-FLUOROPHENYL) -3-OXOPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Procedure K (Kl) and Scheme E (K2C03) using 3-chloro-l- (4- fluorophenyl) -1-propanone and 2-methyl -N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 397.2 (M + H) + .
Example 124
N- (3 - {l- [3- (4-CHLOROPHENYL) -3-HYDROXYPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- { l- [3- (4- chlorophenyl) -3-oxopropyl] -4-piperidinyl}phenyl) -2- methylpropanamide: ESMS m/e: 415.1 (M + H)+.
Example 125
N- (3 - {l- [3- (4-CHLOROPHENYL) -3- (3,4- DIFLUOROPHENOXY) PROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-chlorophenyl) -3-hydroxypropyl] -4- piperidinyl }phenyl) -2-methylpropanamide and 3,4- difluorophenol: ESMS m/e : 526.8 (M + H)+.
Example 126
N- (3 - {l- [3- (4-CHLOROPHENYL) -3- (2-METHYLPHENOXY) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and o-cresol: ESMS m/e : 505.4 (M + H) + .
Example 127
N- (3 - {l- [3 - (4-FLUOROPHENYL) -3-HYDROXYPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-oxopropyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 399.2 (M + H)+.
Example 128 N- (3- {l- [3-HYDROXY-3- (4- METHOXYPHEΝYL) PROPYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using N- (3- {l- [3- (4- methoxyphenyl) -3-oxopropyl] -4-piperidinyl }phenyl) -2- methylpropanamide: ESMS m/e : 411.2 (M + H)+.
Example 129
N- (3- {l- [3 - (4-BROMOPHEΝYL) -3-HYDROXYPROPYL] -4- PIPERIDINYL} HENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-oxopropyl] -4-piperidinyl}phenyl) -2- methylpropanamide: ESMS m/e : 459.1 (M + H) + .
Example 130 N- (3- { l- [3- (4-CHLOROPHENYL) -3- (4-METHOXYPHENOXY) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenol : ESMS m/e : 520.8 (M + H)+.
Example 131
N- (3 - {l- [3- (4-CHLOROPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- meth lpropanamide and 4-chlorophenol : ESMS m/e: 509.1 (M + H) + .
Example 132
N- (3 - {l- [3- (4-FLUOROPHENYL) -3- (2,3,4,5,6- PENTAFLUOROPHENOXY) PROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3- hydroxypropyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 2,3,4,5,6-pentafluorophenol: ESMS m/e : 564.7 (M +
H) + .
Example 133
N- (3 - {l- [3 - (4-BROMOPHEΝYL) -3- (2-METHYLPHENOXY) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2-methylphenol : ESMS m/e: 548.8
(M + H) + .
Example 134 Nr- (3 - {l- [3-(3,4-DIFLUOROPHEΝOXY)-3- (4-
FLUOROPHENYL) PROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-fluorophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 3,4- difluorophenol: ESMS m/e : 511.1 (M + H) + .
Example 135
N- (3 - {l- [3- (4-BROMOPHEΝOXY)-3- (4-FLUOROPHENYL) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-bromophenol : ESMS m/e: 553.0 (M + H) + .
Example 136
N- (3 - {l- [3- (3,4-DICHLOROPHEΝOXY) -3- (4- FLUOROPHEΝYL) PROPYL] -4-PIPERIDIΝYL}PHEΝYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4- fluorophenyl) -3- hydroxypropyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 3,4-dichlorophenol: ESMS m/e: 542.7 (M + H)+.
Example 137
N- [3- (l-{3- (4-FLUOROPHENYL) -3- [4-
(TRIFLUOROMETHYL) HENOXY] PROPYL}-4-PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-fluorophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- (trifluoromethyl) phenol: ESMS m/e: 543.1 (M + H)+.
Example 138
N- (3- {l- [3- (3-BROMOPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2-. methylpropanamide and 3-bromophenol : ESMS m/e : 552.7 (M
+ H) + .
Example 139
N- (3 - {l- [3 - (4-FLUOROPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using N- 3- { l- [3 - (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-fluorophenol : ESMS m/e: 493.2
(M + H) + .
Example 140 N- (3 - {l- [3 - (3-FLUOROPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl Jphenyl) -2- methylpropanamide and 3- fluorophenol : ESMS m/e :
492.9 (M + H)+.
Example 141 N- (3 - {l- [3-(2,6-DICHLOROPHEΝOXY) -3- (4-
FLUOROPHENYL) PROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-fluorophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 2,6- dichlorophenol : ESMS /e: 543.0 (M + H)
Example 142
N- (3 - {l- [3- (2,5-DIFLUOROPHEΝOXY) -3- (4- FLUOROPHEΝYL) PROPYL] -4-PIPERIDIΝYL}PHEΝYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-fluorophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 2,5- difluorophenol: ESMS m/e: 511.5 (M + H)
Example 143
N- (3 - {l- [3 - (3-CHLOROPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3-chlorophenol : ESMS m/e: 509.1 (M + H) + .
Example 144
N- (3 - {l- [3- (4-BROMOPHEΝYL) -3- (3-METHYLPHENOXY) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl Jphenyl) -2- methylpropanamide and 3- methylphenol : ESMS m/e :
549.1 (M + H)+.
Example 145 N- (3 - {l- [3- ( [1,1'-BIPHEΝYL] -4-YLOXY) -3- (4-
BROMOPHENYL) PROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-bromophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- phenylphenol : ESMS m/e : 611.2 (M + H)+.
Example 146
N- (3 - {l- [3- (2,4-DIFLUOROPHEΝOXY) -3- (4- FLUOROPHEΝYL) PROPYL] -4-PIPERIDIΝYL}PHEΝYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-fluorophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 2,4- difluorophenol: ESMS m/e: 511.1 (M + H)+.
Example 147
N- (3 - {l- [3- (4-BROMOPHEΝYL) -3- (3-METHOXYPHEΝOXY) PROPYL] - 4-PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 3-methoxyphenol : ESMS m/e: 564.6 (M + H) + .
Example 148
METHYL 4- (1- (4-BROMOPHEΝYL) -3-{4- [3- (ISOBUTYRYLAMINO) PHE YL] -l-PIPERIDINYL}PROPOXY) BENZOATE:
Prepared by Procedure A and Scheme AN using N- (3- {l- [3 - (4-bromophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) - 2-methylpropanamide ' and methyl 4-hydroxybenzoate :
ESMS m/e: 593.0 (M + H) + .
Example 149 N- (3 -{ l- [3- (4-BROMOPHENYL) -3- (4-PHENOXYPHENOXY) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-phenoxyphenol : ESMS m/e : 626.6 (M + H) + .
Example 150
N- (3 -{ l- [3- (4-BROMOPHENYL) -3- (2-CHLORO-4- METHYLPHENOXY) PROPYL] -4-PIPERIDINYL}PHENYL) -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-bromophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 2-chloro-4- methylphenol : ESMS m/e: 583.0 (M + H)+.
Example 151
N- (3 - {l- [3 - (4-BROMOPHENYL) -3-PHENOXYPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and phenol: ESMS m/e : 535.0 (M + H)+. Example 152
N- [3- (l-{3- (4-BROMOPHENYL) -3- [4-
(TRIFLUOROMETHYL) PHENOXY] PROPYL}-4-PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-bromophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- (trifluoromethyl) phenol : ESMS m/e: 603.1 (M + H) + . Example 153
N- (3- {l- [3- (2-ACETYLPHENOXY) -3- (4-BROMOPHENYL) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A -and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2-acetylphenol: ESMS m/e: 576.6
(M + H) + .
Example 154 N- (3- {l- [3- (3-ACETYLPHEΝOXY) -3- (4-BROMOPHENYL) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bro ophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3-acetylphenol : ESMS m/e: 576.9 (M + H) + .
Example 155
N- (3 -{l- [3- (3-ACETYLPHEΝOXY) -3- (2, 3-DIHYDRO-lff-IΝDEΝ-5-
YL) PROPYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- { l- [3 - (2, 3-dihydro-lH-inden-5-yl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 3- acetylphenol : ESMS m/e: 539.2 (M + H)+.
Example 156
N- (3 - {l- [3- (2,3-DIHYDRO-lff-IΝDEΝ-5-YL) -3-PHENOXYPROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (2, 3-dihydro- lH-inden-5-yl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and phenol: ESMS m/e: 497.2 (M + H) + .
Example 157 N- (3 - {l- [3- (2- ACETYLPHENOXY) -3- (2,3-
DIHYDRO-Iff-INDEN-5-YL) PROPYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE:
Prepared by Procedure A and Scheme AN using N- (3- { l- [3 - (2,3-dihydro-lff-inden-5-yl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide 2-acetylphenol: ESMS m/e : 539.1 (M + H)+.
Example 158 N- (3 - {l- [3- (4-BROMOPHEΝOXY) -3- (4-BROMOPHENYL) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-bromophenol : ESMS m/e : 612.7 (M + H)+.
Example 159
N- (3 - {l- [3- (4-BROMOPHENYL) -3- (4-CHLOROPHENOXY) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-chlorophenol : ESMS m/e: 568.7 (M + H) + .
Example 160
N- (3 - {l- [3 - (4-BROMOPHENYL) -3- (4-FLUOROPHENOXY) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N--(3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-fluorophenol : ESMS m/e : 552.8 (M + H) + .
Example 161 N- (3-{l- [3- (2, 3-DIHYDRO- lff-INDEN-5-YL) -3- (4-
METHOXYPHENOXY) PROPYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (2, 3-dihydro-lH-inden-5-yl) -3- hydroxypropyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 4-methoxyphenol: ESMS m/e: 527.3 (M + H) + .
Example 162
N- (3- {l- [3- (2,3-DIHYDRO-lff-IΝDEΝ-5-YL) -3- (4- FLUOROPHENOXY) PROPYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (2, 3-dihydro-lH-inden-5-yl) -3- hydroxypropyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 4-fluorophenol: ESMS m/e : 515.2 (M + H)
Example 163
N- (3 - {l- [3- (2, 3-DIHYDRO-Iff-IΝDEΝ-5-YL) -3-HYDROXYPROPYL] -
4-PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE
Prepared by Procedure L and Scheme AN using N- (3- { l- [3 - (2, 3-dihydro-lff-inden-5-yl) -3-oxopropyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 421.2 (M + H) + .
Example 164 N- [3- (l-{3- (2,3-DIHYDRO-lff-IΝDEΝ-5-YL) -3- [4-
( RIFLUOROMETHYL) PHENOXY] PROPYL}-4-PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (2, 3-dihydro-lH-inden-5-yl) -3- hydroxypropyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 4-trifluoromethylphenol : ESMS m/e: 565.0 (M + H)
Example 165 N- (3- {l- [3- (4- BROMOPHEΝOXY) -3- (2,3-
DIHYDRO-Iff-IΝDEΝ-5-YL) PROPYL] -4-PIPERIDIΝYL}PHEΝYL) -2-
METHYLPROPANAMIDE:
Prepared by Procedure A and Scheme AN using N- (3- { l- [3 - (2, 3-dihydro-lH-inden-5-yl) -3-hydroxypropyl] -4- piperidinyljphenyl) -2-methylpropanamide and 4- bromophenol :
ESMS m/e : 577.4 (M + H)+.
Example 166
N- (3 - {l- [3- (3-ACETYLPHEΝOXY) -3- (4-CHLOROPHENYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 3-acetylphenol : SMS m/e: 533.1 (M + H) + .
Example 167 " N- (3 - {l- [3- (4-METHOXYPHEΝOXY) -3- (4- METHOXYPHENYL) PROPYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3 -hydroxy-3- (4-methoxyphenyl) propyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- methoxyphenol : ESMS m/e : 517.4 (M + H)+.
Example 168
N- (3 - {l- [3- (4-CHLOROPHEΝOXY) -3- (2, 3-DIHYDRO-Iff-IΝDEΝ-5- YL) PROPYL] -4-PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- { l- [3 - (2,3-dihydro-lH-inden-5-yl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- chlorophenol : ESMS m/e: 531.1 (M + H)+. Example 169
N- (3 - {l- [3- (2-ACETYLPHEΝOXY) -3- (4-CHLOROPHENYL) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2-acetylphenol: ESMS m/e: 533.4
(M + H) + .
Example 170 N- (3 - {l- [3- (4-BROMOPHENYL) -3- (4-METHOXYPHENOXY) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- bromophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenol : ESMS m/e : 565.0 (M + H) + .
Example 171
N- (3 - {l- [3- (4-BROMOPHEΝOXY) -3- (4-CHLOROPHENYL) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-bromophenol : ESMS m/e: 568.8 (M + H) + .
Example 172
N- (3 - {l- [3- (4-CHLOROPHEΝOXY) -3- (4-CHLOROPHENYL) ROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N-. (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-chlorophenol : ESMS m/e: 525.0 (M + H) + .
Example 173 N- (3 - {l- [3- (4- METHOXYPHENYD-3-
PHENOXYPROPYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3 -hydroxy-3- (4-methoxyphenyl) propyl] -4- piperidinyl}phenyl) -2-methylpropanamide and phenol:
ESMS m/e: 487.4 (M + H)+.
Example 174
N- (3 - {l- [3- (4-FLUOROPHENYL) -3-PHENOXYPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- (l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenol: ESMS m/e : 475.6 (M + H)+.
Example 175
N- (3- {l- [3 - (2-ACETYLPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2-acetylphenol: ESMS m/e: 517.1 (M + H) + .
Example 176
N- (3 - {l- [3- (3-ACETYLPHEΝOXY) -3- (4-FLUOROPHENYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 3-acetylphenol : ESMS m/e: 516.9 (M + H) + .
Example 177
N- (3 - {l- [3- (4-FLUOROPHENYL) -3- (4-METHOXYPHENOXY) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- { l- [3- (4- fluorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenol : ESMS m/e: 505.2
(M + H) + .
Example 178
N- (3 - {l- [3 - (4-CHLOROPHEΝOXY) -3- (4-METHOXYPHEΝYL) PROPYL] -
4-PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using N- (3- {l- [3-hydroxy-3- (4- methoxyphenyl) propyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-cholorophenol : ESMS m/e 521.5
(M + H) + .
Example 179 N- (3- {l- [3 - (3-ACETYLPHEΝOXY) -3- (4-METHOXYPHEΝYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3-hydroxy-3- (4- methoxyphenyl)propyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3-acetylphenol : ESMS m/e: 529.0 (M + H) + .
Example 180
N- (3 - {l- [3- (4-CHLOROPHENYL) -3-PHENOXYPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenol. ESMS m/e: 490.9 (M + H) + .
Example 181 N- (3 - {l- [3- (4-BROMOPHEΝOXY) -3- (4-METHOXYPHENYL) PROPYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3-hydroxy-3- (4- methoxyphenyl) propyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4- bromophenol : ESMS m/e -.
564.9 (M + H)+.
Example 182 N- [3- (l-{3- (4-METHOXYPHEΝYL) -3- [4-
(TRIFLUOROMETHYL) PHENOXY] PROPYL}- -PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3-hydroxy-3- (4-methoxyphenyl) propyl] - 4-piperidinylJphenyl) -2-methylpropanamide and 4- trifluoromethyphenol: ESMS m/e: 555.1 (M + H) + .
Example 183
N- (3- {l- [3 - (4-CHLOROPHENYL) -3- (4-FLUOROPHENOXY) ROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3- (4- chlorophenyl) -3-hydroxypropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-fluorophenol : ESMS m/e: 509.1 (M + H) + .
Example 184
N- (3 - {l- [3- (4-FLUOROPHENOXY) -3- (4-METHOXYPHENYL) PROPYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- {l- [3-hydroxy-3- (4- ethoxyphenyl) propyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-fluorophenol : ESMS m/e : 505.5 (M + H) + .
Example 185
N- (3 - {l- [3- (2-ACETYLPHEΝOXY) -3- (4-METHOXYPHEΝYL) PROPYL] - 4-PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3- { l- [3-hydroxy-3- (4- methoxyphenyl) propyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2- acetylphenol : ESMS m/e :
529.2 (M + H)X
Example 186 N- [3- (l-{3- (4-CHLOROPHENYL) -3- [4-
(TRIFLUOROMETHYL) PHENOXY] PROPYL} -4 -PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using N- (3-{l- [3- (4-chlorophenyl) -3-hydroxypropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- trifluoromethylphenol: SMS m/e : 559.1 (M + H) + .
Example 187
Ν-(3-{l- [(3S) -3- (3-ACETYLPHEΝOXY) -3-PHEΝYLPROPYL] -4-
PIPERIDIΝYL} -4 -METHYLPHENYL) -2 -METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Al using l-(3-{[(lS)- 3-chloro-l-phenylpropyl] oxy}phenyl) ethanone and 2- methyl -N- [4-methyl-3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 513.0 (M + H)+.
2- (ISOPEΝTYLOXY) -1-NAPHTHALDEHYDE: 2-Hydroxy-l- naphthaldehyde (1.72 g, 10.0 mmol) and THF (50 .ml) were combined in a flask. NaH (312 mg, 13 mmol) was added, followed by l-bromo-3-methylbutane (1.20 mL, 10.0 mmol). The solution was stirred at room temperature overnight, the solvent was removed in vacuo, and the residue was purified by chromatography (5-10 % ethyl acetate / hexane): E NMR (400 MHz, CDC13) δ 10.9 (s, IH) , 9.28
(dd, IH, J = 0.7 Hz, 8.6 Hz), 8.02 (d, IH, J = 9.1 Hz),
7.75 (d, IH, J = 8.1 Hz), 7.63-7.59 (m, IH) , 7.43-7.39 (m, IH) , 7.27 (d, IH, J = 9.2 Hz), 4.25 (t, 2H, J" = 6.5 Hz), 1.98-1.84 (m, IH) , 1.80-1.75 (m, 2H) , 0.99 (d, 6H, J" = 6.6 Hz) ; ESMS m/e : 242.8 (M + H) "X Example 188
N- [3- (l-{ [2- (ISOPENTYLOXY) -1-NAPHTHYL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2- (isopentyloxy) -1- naphthaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 473.3 (M + H)+.
2-PROPOXY-1-NAPHTHALDEHYDE: Prepared according to the Procedure for 2- (isopentyloxy) -1-naphthaldehyde using 2- hydroxy-1-naphthaldehyde and 1-bromopropane.
Example 189
2-METHYL-N- (3-{1- [ (2-PROPOXY-l-ΝAPHTHYL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 2-propoxy-1-naphthaldehyde and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 445.2 (M + H)+.
4-{ ( (1-FORMYL-2-ΝAPHTHYL) OXY]METHYL}BEΝZOΝITRILE: Prepared according to the Procedure for 2- (isopentyloxy) -1-naphthaldehyde using 2-hydroxy-l- naphthaldehyde and 4- (bromomethyl) benzonitrile.
Example 190 N- {3 - [1- ({2- [ (4-CYAΝ0BEΝZYL)0XY] -1-NAPHTHYL}METHYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE : Prepared by Procedure F and Scheme R using 4- { [ (l-formyl-2- naphthyl) oxy] methyl}benzonitrile and 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide: ESMS m/e 518.2 (M + H) + .
[ (1-FORMYL-2-ΝAPHTHYL) OXY] ACETONITRILE: Prepared according to the Procedure for 2- (isopentyloxy) -1- naphthaldehyde using 2- hydroxy-1 -naphthaldehyde and bromoacetonitrile.
Example 191 N- [3- (l-{ [2- (CYAΝOMETHOXY) -1-ΝAPHTHYL] METHYL} -4-
PIPERIDINYL) HENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using [ (l-formyl-2- naphthyl) oxy] acetonitrile and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 442.2 (M + H)+.
2 - [ (3 -CHLOROBEΝZYL) OXY] -1-NAPHTHALDEHYDE : Prepared according to the Procedure for 2- (isopentyloxy) -1- naphthaldehyde using 2 -hydroxy-1-naphthaldehyde and 1- (bromomethyl) -3-chlorobenzene.
Example 192
N- {3 - [1- ({2- [ (3 -CHLOROBEΝZYL) OXY] -1-ΝAPHTHYL}METHYL) -4- PIPERIDIΝYL] PHENYL} -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2- [ (3-chlorobenzyl) oxy] - 1-naphthaldehyde and 2 -methyl-N- [3- (4-" piperidinyl) phenyl] propanamide: ESMS m/e : 527.2 (M + H)+.
Example 193
N- (3 - { l- [4 - (4-CHLOROPHEΝOXY) BENZYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (4- chlorophenoxy) benzaldehyde and 2-methyl-Iv'- [3- (4- piperidinyl) phenyl] propanamide: 1H NMR (400 MHz, CDC13) δ 7.50 (s, IH) , 7.34-7.19 (m, 7H) , .6.98-6.87 (m, 5H) , 3.50 (s, 2H) , 2.98 (d, 2H, J = 11.8 Hz), 2.58-2.44 (m, 2H) , 2.10-1.98 (m, 2H) , 1.83-1.76 (m, 4H) , 1.24 (d, 6H, J = 6.8 Hz); ESMS m/e : 463.2 (M + H) + . Example 194 N- (3 - {l- [4 - (3 , 4 - DIFLUOROPHEΝOXY) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure F and Scheme R using 4- (3,4- difluorophenoxy) benzaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 465.2 (M + H) + .
4- (ISOPENTYLOXY) -1-NAPHTHALDEHYDE: Prepared according to the Procedure for 2- (isopentyloxy) -1-naphthaldehyde using 4-hydroxy-1-naphthaldehyde and l-bromo-3- ethylbutane .
Example 195
N- [3- (l- { [4- (ISOPENTYLOXY) -1-NAPHTHYL]METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (isopentyloxy) -1- naphthaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 473.3 (M + H) + .
Example 196
N- (3 -{1- [4- (4-METHOXYPHEΝOXY) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (4- methoxyphenoxy) benzaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 459.2 (M + H) + .
4-PROPOXY-1-NAPHTHALDEHYDE: Prepared according to the Procedure for 2- (isopentyloxy) -1-naphthaldehyde using 4- hydroxy-1-naphthaldehyde and 1-bromopropane .
Example 197
2-METHYL-N- (3 - {l- [ (4-PROPOXY-1-NAPHTHYL) METHYL] -4-
PIPERIDINYL}PHENYL) ROPANAMIDE: Prepared by Procedure F and Scheme R using 4- propoxy-1-naphthaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide:
ESMS m/e : 445.2 (M + H) + .
Example 198
N- (3- {l- [4 - (3,4-DICHLOROPHEΝOXY)BEΝZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (3,4- dichlorophenoxy) benzaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 497.1 (M + H) + .
Example 199
N- (3 - {l- [4- (DIPHEΝYLAMIΝO) BENZYL] -4-PIPERIDINYL}PHENYL) - 2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (diphenylamino) benzaldehyde and 2-methyl-N- [3 - (4-piperidinyl) phenyl] propanamide: ESMS m/e : 504.2 (M + H) + .
Example 200 N- {3 - [1- ({2, 5-DIMETHYL-1- [3- (TRIFLUOROMETHYL) PHENYL] -lff- PYRROL-3 -YL} ETHYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2 , 5-dimethyl-1- [3- (trifluoromethyl) phenyl] -1H- pyrrole-3-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e 498.2 (M + H)+.
Example 201
2-METHYL-N- (3- {1- [1- (2-PHEΝYL-l, 3-THIAZOL-4-YL) ETHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 1- (2-phenyl-l, 3-thiazol-4-yl) ethanone and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 434.2 (M + H) "X Example 202
N- (3 - { l- [ (5-CHLORO-3 -METHYL- l-PHEΝYL- lff-PYRAZOL-4 -
YL) METHYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
Prepared by Procedure F and Scheme R using 5-chloro-3- methyl-1-phenyl-IH-pyrazole-4-carbaldehyde and 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 451.2 (M + H) + .
Example 203 2-METHYL-N- (3-{l- [ (2-PHEΝYL-lff-IMIDAZOL-4-YL) METHYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 2-phenyl-lH-imidazole-4-carbaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 403.2 (M + H) + .
Example 204
N- [3- (l-{ [4-BROMO-l- (4-CHLOROBEΝZYL) -lff-PYRAZOL-5-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure F and Scheme R using 4-bromo-l- (4- chlorobenzyl) -IH-pyrazole-5-carbaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e-. 529.1 (M + H) + .
Example 205 2-METHYL-N-{3- [1- (3-PHEΝOXYBEΝZYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure F and Scheme R using 3 -phenoxybenzaldehyde and 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 429.2 (M + H) + .
Example 206
N- (3 - {l- [3 - (3 , 4-DICHLOROPHEΝOXY) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (3,4- dichlorophenoxy) benzaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 497.15 (M + H) + .
Example 207
N- (3 - {l- [3 - (3,5-dichlorophenoxy)benzyl] -4- piperidinyl}phenyl) -2-methylpropanamide: Prepared by Procedure F and Scheme R using 3- (3,5- dichlorophenoxy) benzaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e: 497.2 (M + H) + .
Example 208
2-METHYL-Ν-(3-{l- [3- (4-METHYLPHENOXY) BENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (4-methylphenoxy) benzaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 443.2 (M + H) + .
Example 209
2-METHYL-Ν- [3- (l-{3- [3- (TRIFLUOROMETHYL) PHENOXY] BENZYL}- 4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure F and Scheme R using 3- [3- (trifluoromethyl) phenoxy] benzaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 497.2 (M + H) + .
Example 210
N- (3- { l- [3 - (4-CHLOROPHEΝOXY) BENZYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (4- chlorophenoxy) benzaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 463.2 (M + H)+. Example 211
N- 3 - {l- [3- (DIMETHYLAMIΝO) BENZYL] -4-PIPERIDINYL}PHENYL) - 2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (dimethylamino) benzaldehyde and 2 -methyl-N- [3 - (4-piperidinyl) phenyl] propanamide: ESMS /e : 380.2 (M + H) + .
Example 212 N- (3 - {l- [3 - (4-METHOXYPHEΝOXY) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (4- methoxyphenoxy) benzaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 459.2 (M + H)+.
Example 213
Ν-(3-{l- [3- (4-TERT-BUTYLPHΞΝOXY) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3-(4-tert- butylphenoxy) benzaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 485.3 (M + H) + .
Example 214
2-METHYL-N- (3-{l- [3-ΝITRO-4- (1-PIPERIDINYL) BENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 3-nitro-4- (1-piperidinyl).benzaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 465.2 (M + H) + .
Example 215 N- (3 - {l- [ (3,4- DIMETHYLTHIENO[2,3-
B] THIEN-2-YL) METHYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3 , 4-dimethylthieno [2, 3-b] thiophene-2-carbaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide :
ESMS m/e: 427.1 (M + H)+.
Example 216
2-METHYL-N-{3- [1- ({3- [4- (TRIFLUOROMETHYL) PHENYL] -lff- PYRAZOL-4-YL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure F and Scheme R using 3- [4- (trifluoromethyl) phenyl] -lH-pyrazole-4-carbaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 471.1 (M + H) + . Example 217
2-METHYL-N- (3-{1- [4- (lff-1, 2, 4-TRIAZOL-l-YL) BENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme R using 4- (1H-1, 2 , 4-triazol-l-yl) benzaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS /e : 404.1 (M + H) + .
Example 218
2 -METHYL-N- (3-{1- [ (5-METHYL-l-PHEΝYL-lff-PYRAZOL-4- YL) METHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 5-methyl-1-phenyl-1H- pyrazole-4-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 417.1 (M + H) + .
Example 219
2-METHYL-N- (3 - {l- [4- (4-MORPHOLIΝYL) -3-NITROBENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (4-morpholinyl) -3-nitrobenzaldehyde and 2 -methyl -N- [3 - ( 4 - piperidinyl) phenyl] propanamide: ESMS m/e : 467.1 (M + H)+.
Example 220 N- {3 - [1- ({5- [2-CHLORO-4- (TRIFLUOROMETHYL) PHENYL] -2-
FURYL}METHYL) -4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE :
Prepared by Procedure F and Scheme R using 5- [2-chloro- 4- (trifluoromethyl) phenyl] -2-furaldehyde and 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 505.0 (M + H)+.
Example 221
ETHYL 4- ({4- [3- (ISOBUTYRYLAMIΝO) PHENYL] -1-
PIPERIDINYL}METHYL) -2, 5-DIMETHYL-1-PHENYL-Iff-PYRROLE-3- CARBOXYLATE: Prepared by Procedure F and Scheme R using ethyl 4-formyl-2 , 5-dimethyl-1-phenyl-IH-pyrrole-3 - carboxylate and 2-methyl-N- [3- (4- piperidinyl)phenyl] propanamide : ESMS m/e : 502.2 (M + H)+.
Example 222
ETHYL 5- (4-CHLOROPHENYL) -2- ({4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}METHYL) -3- FUROATE: Prepared by Procedure F and Scheme R using ethyl 5- (4-chlorophenyl) -2-formyl-3-furoate and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 509.0 (M + H)+.
Example 223
N- {3 - [1- (2,3-DIHYDRO-l,4-BEΝZODIOXIΝ-6-YLMETHYL) -4- PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2, 3-dihydro-1, 4- benzodioxine-6-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 395.1 (M + H)+. Example 224
2-METHYL-N- (3-{1- [ (6-PHENOXY-3-PYRIDIΝYL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 6-phenoxynicotinaldehyde and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 430.1 (M + H)+.
Example 225 2-METHYL-N- [3- (l-{ [5- (2-PYRIDIΝYL) -2-THIENYL] METHYL} -4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure F and Scheme R using 5- (2-pyridinyl) -2- thiophenecarbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 420.1 (M + H) + .
Example 226
2-METHYL-N-{3- [1- ({5- [l-METHYL-3- (TRIFLUOROMETHYL) -lff-
PYRAZOL-5-YL] -2-THIENYL}METHYL) -4-
PIPERIDIΝYL] PHENYL}PROPANAMIDE: Prepared by Procedure F and Scheme R using 5- [l-methyl-3- (trifluoromethyl) -1H- pyrazol-5-yl] -2-thiophenecarbaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e 491.0 (M + H) + .
Example 227
2 -METHYL-N- [3- (l-{ [1- (PHEΝYLSULFOΝYL) -lff-IΝDOL-3- YL] METHYL}-4-PIPERIDINYL) HENYL] PROPANAMIDE: Prepared by Procedure F and Scheme R using 1- (phenylsulfonyl) -lff- indole-3 -carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 516.1 (M + H)+.
Example 228 N- (3 - {l- [(1,5-DIMETHYL-3- OXO-2-PHENYL-2, 3-DIHYDRO- lff-PYRAZOL-4-YL)METHYL] -4-PIPERIDINYL}PHENYL) -2-
METHYLPROPANAMIDE : Prepared by Procedure F and Scheme R using 1, 5-dimethyl-3-oxo-2-phenyl-2 , 3-dihydro-lH- pyrazole-4-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 447.2 (M + H) + .
Example 229
N- (3- {l- [4- (4-TSRT-BUTYL-l,3-THIAZOL-2-YL)BEΝZYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (4- tert-butyl-1, 3- thiazol-2-yl) benzaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide .
Example 230
N-{3 - [1- (2,3-DIHYDRO-l-BEΝZOFURAΝ-5-YLMETHYL) -4- PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2 , 3-dihydro-1-benzofuran- 5-carbaldehyde and 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 379.1 (M + H)+.
Example 231
2-METHYL-N- (3-{1- [ ( -METHYL-2-PHENYL-5-
PYRIMIDINYL) METHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 4-methyl-2- phenyl-5-pyrimidinecarbaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 429.2 (M + H)+.
Example 232 N- {3 - [1- (2,l,3-BEΝZOTHIADIAZOL-5-YLMETHYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2 , 1, 3-benzothiadiazole-5- carbaldehyde and 2 -methyl- N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e 395.1 (M + H)
Example 233
2 -METHYL-N- (3 - {l- [ (5-PHE YL-2 -THIENYL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 5-phenyl-2-thiophenecarbaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 419.1 (M + H)+.
Example 234 -{3- [1- (3,4-DIHYDRO-2ff-l,5-BEΝZODIOXEPIΝ-7-YLMETHYL) -4- PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3 , 4-dihydro-2H-l, 5- benzodioxepine-7-carbaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e: 409.2 (M + H) + .
Example 235 2 -METHYL-N- [3- (l-{ [3- (2-THIEΝYL) -lff-PYRAZOL-4-
YL] METHYL} -4 -PIPERIDINYL) PHENYL] PROPANAMIDE : Prepared by Procedure F and Scheme R using 3- (2 -thienyl) -1H- pyrazole-4-carbaldehyde and 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 409.1 (M + H)+.
Example 236
N- {3 - [1- ( [1,1'-BITHIEΝYL] -4-YLMETHYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure F and Scheme R using 2 , 2' -Bithiophene-5- carboxaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e 425.0 (M + H)
Example 237 N- (3 - {l- [ (2, 2-DIMETHYL- 3,4-DIHYDRO-2ff-CHROMEΝ-6-
YL) METHYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
Prepared by Procedure F and Scheme R using 2, 2-dimethyl-
6-chromanecarbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 421.2 (M + H)+.
Example 238
2-METHYL-N-{3- [1- ({5- [l-METHYL-5- (TRIFLUOROMETHYL) -lff-
PYRAZOL-3-YL] -2-THIENYL}METHYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure F and Scheme R using 5- [l-methyl-5- (trifluoromethyl) -1H- pyrazol-3-yl] -2-thiophenecarbaldehyde and 2 -methyl-N- [3-
(4-piperidinyl) phenyl] propanamide: ESMS m/e : 491.1 (M +
H) + .
Example 239
2-METHYL-N- (3-{l- [ (2-PHENYL-1, 3 -THIAZOL-4-YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 2-phenyl-l, 3-thiazole-4-carbaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 420.0 (M + H) + .
Example 240
2-METHYL-N- (3-{l- [ (3 -PHEΝOXY-2-THIENYL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 3 -phenoxy-2-thiophenecarbaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 435.0 (M + H)+.
Example 241
N- {3 - [1- ({2- [(4-CHLOROPHENYL) SULFAΝYL] -3- THIENYL}METHYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 2- [(4- chlorophenyl) sulfanyl] -3- thiophenecarbaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 485.0 (M + H)+.
Example 242
N- [3- (l-{ [1- (4-CHLOROPHENYL) -Iff-PYRROL-2-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 1- (4-chlorophenyl)-1H- pyrrole-2-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 436.0 (M + H)+.
Example 243
2 -METHYL-N-{3- [1- ({5- [2- (TRIFLUOROMETHOXY) HENYL] -2-
FURYL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure F and Scheme R using 5- [2- (trifluoromethoxy)phenyl] -2-furaldehyde and 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 487.1 (M + H) + .
Example 244
2 -METHYL-N- (3 - {l- [2- (4-MORPHOLIΝYL) BENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 2- (4-morpholinyl) benzaldehyde and 2- methyl-N- [3- (4-piperidinyl)phenyl] propanamide: ESMS m/e : 422.2 (M + H)
Example 245
N- [3- (l-{ [3- (4-METHOXYPHEΝYL) -lff-PYRAZOL-4-YL]METHYL}-4- PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (4-methoxyphenyl) -lff- pyrazole-4-carbaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 433.1 (M + H)\ Example 246
2-METHYL-N- (3 -{l- [4- (Iff-PYRAZOL-1-YL) BENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (IH-pyrazol-1-yl) benzaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 402.8 (M + H)+. Example 247
2-METHYL -N-{3 - [1- (4-QUIΝOLIΝYLMETHYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure F and Scheme R using 4-quinolinecarbaldehyde and 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 388.1 (M + H) + .
Example 248
2 -METHYL-N- (3-{1- [4- (4-MORPHOLIΝYL) BENZYL] -4- PIPERIDINYL}PHENYL) ROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (4-morpholinyl) benzaldehyde and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 422.5 (M + H)+.
Example 249
2-METHYL-N- (3-{l- [4- (2-THIENYL) BENZYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (2-thienyl) benzaldehyde and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 419.1 (M + H)+.
Example 250 2-METHYL-N- (3-{l- [ (2-METHYL-5-PHENYL-3 -FURYL)METHYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 2-methyl-5-phenyl-3-furaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 417.2 (M + H)+. Example 251
N- (3 - {l- [3- (CYCLOPEΝTYLOXY) -4-METHOXYBEΝZYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 3- (cyclopentyloxy) -4- methoxybenzaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS /e : 451.1 (M + H) + .
Example 252
2-METHYL-N- {3- [1- ({5- [4- (TRIFLUOROMETHOXY) PHENYL] -2- FURYL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure F and Scheme R using 5- [4- (trifluoromethoxy) phenyl] -2-furaldehyde and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 487.1 (M + H) + .
Example 253
N- {3 - [1- (l-BEΝZOTHIEΝ-2-YLMETHYL) -4-PIPERIDINYL] PHENYL} - 2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using l-benzothiophene-2-carbaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 393.2 (M + H) + .
Example 254
2-METHYL-N-{3- [1- ({5- [3- (TRIFLUOROMETHOXY) PHENYL] -2- FURYL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure F and Scheme R- using 5- [3- (trifluoromethoxy) phenyl] -2-furaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS /e : 487.2 (M + H) + .
Example 255 2-METHYL-N-{3- [1- (2- QUIΝOLIΝYLMETHYL) -4-
PIPERIDIΝYL]PHEΝYL}PROPAΝAMIDE: Prepared by Procedure F and Scheme R using 2-quinolinecarbaldehyde and 2-methyl-
N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 388.1 (M + H) + .
Example 256
Ν-(3-{l- [4- (Iff-IMIDAZOL-1-YL) BENZYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (IH-imidazol-1- yl) benzaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 403.2 (M + H) "X
Example 257 N- {3 - [1- (9ff-FLUOREΝ-2-YLMETHYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 9H-fluorene-2-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 425.1 (M + H) + . Example 258 METHYL 3- [5- ({4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}METHYL) -2-FURYL] -2-THIOPHENECARBOXYLATE: Prepared by Procedure F and Scheme R using methyl 3- (5- formyl-2-furyl) -2-thiophenecarboxylate and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 467.1 (M + H)+.
Example 259
2-METHYL -N-{3 - [l- (4 -PHEΝOXYBEΝZYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: .Prepared by Procedure F and Scheme R using 4-phenoxybenzaldehyde and 2-methyl -N-
[3- (4-piperidinyl)phenyl] propanamide: ESMS m/e: 429.2
(M + H)X Example 260
N- {3 - [1- ( [l,l'-BIPHEΝYL]-4-YLMETHYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure F and Scheme R using [1, 1 ' -biphenyl] -4- carbaldehyde and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 413.2 (M +
H) + .
Example 261 N- (3 - {l- [4- (DIBUTYLAMIΝO) BENZYL] -4-PIPERIDINYL}PHENYL) -
2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (dibutylamino) benzaldehyde and 2 -methyl-N- [3 - (4-piperidinyl) phenyl] propanamide: ESMS m/e : 464.6 (M + H) + . Example 262
2-METHYL-N- [3- (l-{4- [ (4-METHYLPHENYL) SULFANYL] -3- NITROBENZYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure F and Scheme R using 4-[(4- methylphenyl) sulfanyl] -3-nitrobenzaldehyde and 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/: e 504.2 (M + H) + .
Example 263
2-METHYL-N- (3-{1- [4- (1, 2, 3-THIADIAZOL-4-YL) BENZYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R using 4- (1, 2, 3-thiadiazol-4-yl) benzaldehyde and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 421.1 (M + H) + .
1- (3-{ [ (IS) -3-CHLORO-l-PHEΝYLPROPYL]OXY}PHEΝYL)ETHAΝOΝE:
(1R) -3 -Chloro-1-phenyl-1-propanol (1.000 g, 5.86 mmol), 1- (3-hydroxyphenyl) ethanone (0.797 g, 5.86 mmol), triphenylphosphine (1.54 g, 5.86 mmol) and diethylazodicarboxylate (1.53 g, 8.79 mmol) were combined in a flask, which was immediately flushed with argon. THF (20 mL) was added and the mixture was stirred overnight under argon. THF was removed in vacuo, the crude product was dissolved in 50 mL of
CH2C12/H20 (1:1) and the organic layer was separated and dried over MgS04. After removing the solvent in vacuo, the residue was purified by flash chromatography using
10 % ethyl acetate/hexane to yield the desired product (900 mg, 76.0 %) : E NMR (400 MHz, CDC13) δ 7.49-7.46 (m, 2H) , 7.40-7.26 (m, 6H) , 7.07-7.04 (m, IH) , 5.46-5.43 (dd, IH, 7 = 4.4 Hz, 8.8 Hz), 3.84-3.78 (m, IH) , 3.64- 3.59 (m, IH) , 2.52 (s, 3H) , 2.51-2.46 (m, IH) , 2.29-2.22 (m, IH) .
4- (3 , 4-DIFLUOROPHENOXY) BENZALDEHYDE : 4-
Fluorobenzaldehyde (5.32 mL, 49.6 mmol), 3,4- difluorophenol (7.10 g, 54.6 mmol) and K2C03 (8.31 g, 60.1 mmol) were combined in a flask, which was immediately flushed with argon. DMF (50.0 mL) was added and the mixture was heated at reflux under argon for 6 h. Upon cooling to room temperature, EtOAc (100 mL) and H20 (100 mL) were added; the ethyl acetate layer was separated and washed with H20 (2 X 100 mL) . The combined organic layers were washed with brine, dried over MgS04, and the solvent was removed in vacuo . The desired product was obtained (11.4 g, 98.0 %) : H NMR (400 MHz, CDCI3) δ 9.95 (s, IH) , 7.88 (dd, 2H, J = 0.8 Hz, 8.8 Hz), 7.24-7.17 (m, IH) , 7.07 (d, 2H, J = 8.8 Hz), 6.97-6.92 (m, IH) , 6.86-6.82 (m, IH) ; ESMS m/e : 235.0 (M + H)
TERT-BUTYL 4 - (4 , 4 , 5, 5- ETRAMETHYL-1, 3 , 2-DIOXABOROLAN-2 - YL) -3,6-DIHYDRO-l(2ff) -PYRIDINECARBOXYLATE: To a flask were added bis (pinacolato) diboron
(422 mg, 1.66 mmol), KOAc (444 mg, 4.53 mmol), PdCl2dppf
(37.0 mg, 3.00 mol%) , dppf (25.0 mg, 3.00 mol%) and the flask was flushed with argon. A solution of tert-butyl 4-{ [ (trifluoromethyl) sulfonyl] oxy} -1,2,3, 6-tetrahydro-l- pyridinecarboxylate (500 mg, 1.51 mmol) in 1,4-dioxane
(10.0 ml) was added and the mixture was stirred at 80 °C overnight. The mixture was filtered through Celite and the filtrate was evaporated in vacuo . The resulting residue was dissolved in EtOAc and washed with H20, followed by brine. The organic layer was dried over MgS04, filtered and concentrated in vacuo . The crude material was purified by flash chromatography (10% EtOAC/hexane) to give tert-butyl 4- (4, 4, 5, 5-tetramethyl- l,3,2-dioxaborolan-2-yl) -3 , 6-dihydro-l (2H) - pyridinecarboxylate (355 mg, 76.0%): XH NMR (400 MHz, CDC13) δ 6.44 (br s, IH) , 3.93 (br s, 2H) , 3.42 (br s, 2H) , 2.21 (br s, 2H) , 1.45 (s, 9H) , 1.25 (s, 12H) ; ESMS m/e : 310.4 (M + H) + .
N- ( 6 -BROMO-2 -PYRIDINYL) -2-METHYLPROPANAMIDE: Prepared by Procedure Ql using 2-methylpropanoyl chloride and 6- bromo-2-pyridinamine: ESMS /e : 242.8 (M + H)+.
TERT-BUTYL 4- [6- (ISOBUTYRYLAMINO) -2 -PYRIDINYL] -3 , 6- DIHYDRO-l(2ff) -PYRIDINECARBOXYLATE: Prepared by
Procedure and Scheme AF using N- (6-bromo-2-pyridinyl) - 2-methylpropanamide and tert-butyl . 4- (4,4,5,5- tetramethyl-1 , 3 , 2-dioxaborolan-2-yl) -3 , 6-dihydro-l (2H) - pyridinecarboxylate: ESMS m/e : 245.8 (M - 100) +.
2 -METHYL-N- [6- (4-PIPERIDINYL) -2-PYRIDINYL] PROPANAMIDE:
Prepared by Procedures X and Y, Schemes AG and AH, respectively using tert- butyl 4- [6-
(isobutyrylamino) -2-pyridinyl] -3, 6-dihydro-l (2H) - pyridinecarboxylate: ESMS m/e : 248.1 (M + H)+.
Example 264
N- (6- {l- [4- (3,4-DIMETHYLPHEΝYL) -4-OXOBUTYL] -4- PIPERIDIΝYL}-2-PYRIDIΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Al using 4-chloro-l- (3,4- dimethylphenyl) -1-butanone and 2 -methyl-N- [6- (4- piperidinyl) -2-pyridinyl] propanamide: ESMS m/e : 422.1 (M + H) + .
Example 265
N- (6-{1- [4 , 4-BIS (4-FLUOROPHENYL) BUTYL] -4-PIPERIDINYL}-2- PYRIDINYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Al using 1- [4-chloro-l- (4- fluorophenyl) butyl] -4-fluorobenzene and 2 -methyl-N- [6- (4-piperidinyl) -2-pyridinyl] propanamide: ESMS m/e : 492.2 (M + H) + .
Example 266
N- (6 - {l- [4- (3,4-DIFLUOROPHEΝOXY)BEΝZYL] -4-PIPERIDINYL}- 2-PYRIDINYL) -2-METHYLPROPANAMIDE: Prepared by Procedure AA and Scheme AJ using 4- (3,4- difluorophenoxy) benzaldehyde and. 2-methyl-N- [6- (4- piperidinyl) -2-pyridinyl] propanamide : ESMS m/e : 466.0 (M + H) + .
N- (3-BROMO-4-METHYLPHENYL) -2-METHYLPROPANAMIDE : Prepared by Procedure Ql using 2-methylpropanoyl chloride and 3-bromo-4-methylaniline : ESMS m/e 255.9 (M + H) + . TERT-BUTYL 4- [5- (ISOBUTYRYLAMINO) -2-
METHYLPHENYL] -3 , 6-DIHYDRO-l (2ff) -PYRIDINECARBOXYLATE:
Prepared by Procedure W and Scheme AF using N- (3-bromo- 4-methylphenyl-) -2-methylpropanamide and tert-butyl 4- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl) -3,6- dihydro-1 (2H) -pyridinecarboxylate: ESMS m/e: 259.1 (M - 100)+.
2-METHYL-N- [4-METHYL-3- (4- PIPERIDINYL) PHE YL] PROPANAMIDE: Prepared by Procedures X and Y, Schemes AG and AH, respectively using tert- butyl 4- [5- (isobutyrylamino) -2-methylphenyl] -3 , 6- dihydro-1 (2H) -pyridinecarboxylate: ESMS m/e: 261.0 (M + H) + .
Example 267
N- (3 - {l- [4- (3,4-DIFLUOROPHEΝOXY)BEΝZYL] -4-PIPERIDINYL}- 4-METHYLPHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure AA and Scheme AJ using 4- (3,4- difluorophenoxy) benzaldehyde and using 2-methyl-N- [4- methyl-3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 479.1 (M + H)X
N- (5-BROMO-2-METHYLPHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure Ql using 2-methylpropanoyl chloride and 5-bromo-2-methylaniline : ESMS m/e: 255.9 (M + H) + .
TERT-BUTYL 4- [3- (ISOBUTYRYLAMINO) -4-METHYLPHENYL] -3,6- DIHYDRO-1 (2ff) -PYRIDINECARBOXYLATE: Prepared by
Procedure W and Scheme AF using N- (5-bromo-2- methylphenyl) -2-methylpropanamide and tert-butyl 4-
(4,4,5, 5-tetramethyl-l, 3 , 2-dioxaborolan-2-yl) -3 , 6- dihydro-1 (2H) - pyridinecarboxylate: ESMS m/e: 259.1 (M - 100)+.
2-METHYL-N- [2-METHYL-.5- (4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedures X and Y, Schemes AG and AH, respectively using tert- butyl 4- [3- (isobutyrylamino) -4-methylphenyl] -3 , 6- dihydro-1 (2H) -pyridinecarboxylate: ESMS m/e : 261.0 (M + H) + .
Example 268
N- (5 -{l- [(9-ETHYL-9ff-CARBAZOL-3-YL) METHYL] -4- PIPERIDIΝYL}-2-METHYLPHENYL) -2-METHYLPROPANAMIDE:
Prepared by Procedure AA and Scheme AJ using 9-ethyl-9H- carbazole-3-carbaldehyde and 2-methyl-N- [2-methyl-5- (4- piperidinyl) phenyl] propanamide : ESMS m/e: 468.1 (M + H)+.
Example 269
N- (5 - {l- [4- (3,4-DIFLUOROPHEΝOXY)BEΝZYL] -4-PIPERIDINYL}- 2-METHYLPHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure AA and Scheme AJ using 4- (3,4- difluorophenoxy) benzaldehyde and 2 -methyl-N- [2-methyl-5- (4-piperidinyl) phenyl] propanamide : ESMS m/e: 479.2 (M + H) + .
Example 270
N- (3 - {l- [ (9-ETHYL-9H-CARBAZOL-3-YL) METHYL] -4- PIPERIDIΝYL}-4-METHYLPHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure AA and Scheme AJ using 9-ethyl-9H- carbazole-3 -carbaldehyde and 2-methyl-N- [4-methyl-3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 468.1 (M + H)+. Example 271
2 -METHYL-N- [2 -METHYL- 5 - (4 -
PIPERIDIΝYL) PHENYL] PROPANAMIDE: Prepared by Procedure G and Scheme Al using 1- [4-chloro-l- (4- fluorophenyl) butyl] -4-fluorobenzene and 2 -methyl-N- [2- methyl-5- (4-piperidinyl) phenyl] propanamide: ESMS m/e :
505.1 (M + H)+.
Example 272 N- (3- {l- [ (3S) -3 - (3-ACETYLPHEΝOXY) -3-PHEΝYLPROPYL] -4- PIPERIDIΝYL}-4-METHYLPHENYL) -2-METHYLPROPANAMIDE :
Prepared by Procedure G and Scheme Al using 1- (3-{ [ (IS) - 3-chloro-l-phenylpropyl] oxy}phenyl) ethanone and 2- methyl- - [4-methyl-3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 513.0 (M + H) + .
Example 273 N- (5- {l- I (3S) -3- (3-ACETYLPHEΝOXY) -3-PHEΝYLPROPYL] -4- PIPERIDIΝYL}-2-METHYLPHENYL) -2-METHYLPROPANAMIDE : Prepared by Procedure G and Scheme Al using l-(3-{[(lS)- 3-chloro-l-phenylpropyl] oxyjphenyl) ethanone and 2- methyl-N- [2-methyl-5- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 512.9 (M + H) + .
N- (2-IODOPHEΝYL) -2-METHYLPROPANAMIDE : Prepared by Procedure Ql using 2-methylpropanoyl chloride and 2- iodoaniline: ESMS m/e : 289.9 (M + H)+.
TERT-BUTYL 4- [2- (ISOBUTYRYLAMINO) PHENYL] -3, 6 -DIHYDRO- l(2ff) -PYRIDINECARBOXYLATE: Prepared by Procedure and
Scheme AF using N- (2-iodophenyl) -2-methylpropanamide and tert-butyl 4- (4, 4, 5, 5-tetramethyl-l, 3 , 2-dioxaborolan-2- yl) -3 , 6-dihydro-l (2H) - pyridinecarboxylate : ESMS m/e : 245.1 (M - 100)+.
2-METHYL-N- [2- (4-PIPERIDINYL) HENYL] PROPANAMIDE: Prepared by Procedures X and Y, Schemes AG and AH, respectively using tert-butyl 4- [2- (isobutyrylamino) phenyl] -3 , 6-dihydro-l (2H) - pyridinecarboxylate: ESMS m/e : 247.1 (M + H)+.
Example 274
N- (2 - {l- [ (9-ETHYL-9ff-CARBAZOL-3-YL) METHYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure AA and Scheme AJ using 9-ethyl-9H-carbazole-3 - carbaldehyde and 2 -methyl-N- [2- (4- piperidinyl) phenyl] propanamide: ESMS m/e 454.1 (M + H)+.
Example 275
N- (3-{1- [4, 4-BIS (4-FLUOROPHENYL) BUTYL] -4-PIPERIDINYL}-4- METHYLPHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Al using 1- [4-chloro-l- (4- fluorophenyl) butyl] -4-fluorobenzene and 2 -methyl -N- [4- methyl-3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 505.0 (M + H)+.
Example 276
N- (2- {l- [4, 4-BIS ( -FLUOROPHENYL) BUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Al using 1- [4-chloro-l- (4- fluorophenyl) butyl] -4-fluorobenzene and 2 -methyl -N- [2- (4-piperidinyl)phenyl] propanamide: ESMS m/e : 490.9 (M + H) + . N- [2-BROMO-4- (TRIFLUOROMETHOXY) PHENYL] -
2-METHYLPROPANAMIDE: Prepared by Procedure Ql using 2- methylpropanoyl chloride and 2-bromo-4-
(trifluoromethoxy) aniline: ESMS m/e: 325.9 (M + H)+.
TERT-BUTYL 4- [2- (ISOBUTYRYLAMINO) -5-
(TRIFLUOROMETHOXY) PHENYL] -3 , 6-DIHYDRO-l (2ff) - PYRIDINECARBOXYLATE: Prepared by Procedure W and Scheme AF using N- [2-bromo-4- (trifluoromethoxy) phenyl] -2- methylpropanamide and tert-butyl 4- (4, 4, 5, 5-tetramethyl- l,3,2-dioxaborolan-2-yl) -3 , 6-dihydro-l (2H) - pyridinecarboxylate: ESMS m/e: 329.0 (M - 100)+.
2-METHYL-N- [2- ( -PIPERIDINYL) -4- (TRIFLUOROMETHOXY) PHENYL] PROPANAMIDE: Prepared by Procedures X and Y, Schemes AG and AH, respectively using tert-butyl 4- [2- (isobutyrylamino) -5- (trifluoromethoxy) phenyl] -3, 6-dihydro-l (2H) - pyridinecarboxylate: ESMS m/e: 330.9 (M + H)+.
Example 277 N- [2-{l- [4, 4-B S (4-FLUOROPHENYL) BUTYL] -4-PIPERIDINYL}-4- (TRIFLUOROMETHOXY) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Al using 1- [4-chloro-l- (4- fluorophenyl) butyl] -4-fluorobenzene and 2 -methyl-N- [2- (4-piperidinyl) -4- (trifluoromethoxy) phenyl] propanamide: ESMS m/e : 574.8 (M + H)+.
N- {3 - [1- (4-HYDROXYBUTYL) - 4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE: Prepared by Procedure G and Scheme
Bl using 4-chloro-1-butanol and 2 -methyl-N- [3- (4- piperidinyl) henyl] propanamide: ESMS m/e : 319.3 (M + H) "X
Ν-{3- [1- (5-HYDROXYPEΝTYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE : Prepared by Procedure G and Scheme
Bl using 5-chloro-l-pentanol and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 333.3 (M + H) + .
Ν-{3- [1- (6-HYDROXYHEXYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE : Prepared by Procedure G and Scheme Bl using 6-chloro-1-hexanol and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 347.3 (M + H) + .
Ν-{3- [1- (3-HYDROXYPROPYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE : Prepared by Procedure G and Scheme Bl using 3-chloro-1-propanol and 2 -methyl-N- [3- (4- piperidinyl) henyl] propanamide: ESMS m/e : 305.3 (M + H)+.
Ν-(3-{l- [(2S) -2-HYDROXY-2-PHEΝYLETHYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using (IS) -2-chloro-l- phenylethanol and 2 -methyl-N- [3- (4- piperidinyl) henyl] propanamide: ESMS m/e: 367.2 (M + H)+.
N- (3 - {l- [(2R) -2-HYDROXY-2-PHEΝYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
Prepared by Procedure G and Scheme Bl using (IR) -2- chloro-1-phenylethanol and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e 367.2 (M + H)+. N- (3 - {l- t (2S) -3-HYDROXY-2-METHYLPROPYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using (2R) -3-chloro-2- methyl-1-propanol- and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 319.2 (M + H) + .
N- (3 - {l- [(2R) -3-HYDROXY-2-METHYLPROPYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using (2S) -3 -chloro-2-methyl- 1-propanol and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 319.2. (M + H) + .
Example 278
N- (3 -{l- [(3R) -3-HYDROXY-3-PHEΝYLPROPYL] -4- PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE:
Prepared by Procedure G and Scheme Bl using (lR)-3- chloro-1-phenyl-1-propanol and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 379.2 (M + H)+.
Example 279 N- {3 - [1- (4-HYDR0XY-4-PHEΝYLBUTYL) -4-PIPERIDINYL] PHENYL}- 2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN, Step 1 using 2-methyl-N- {3- [1- (4-oxo-4-phenylbutyl) - 4-piperidinyl] phenyl}propanamide: Anal. Calcd for C25H34Ν2O2+0.08CHCl3: C, 74.5; H, 8.50; N, 6.93. Found: C, 74.5; H, 8.63; N, 6.81; ESMS m/e: 395.2 (M + H)+.
Example 280
N- {3 - [1- (5-HYDR0XY-5-PHEΝYLPEΝTYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN, Step 1 using 2 -methyl-N- {3- [1- (5-oxo-5-phenylpentyl) -4- piperidinyl] phenyl}propanamide: Anal. Calcd for C26H36N2O2+0.25CHCl3: C, 71.9; H, 8.33; N, 6.39.
Found: C, 71.3; H, 8.96; N, 6.86; ESMS /e: 409.2 (M +
H) + .
Example 281
N-{3- [1- (6-HYDROXY-6-PHEΝYLHEXYL) -4-PIPERIDINYL] PHENYL}- 2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN, Step 1 using 2-methyl-N- {3- [1- (6-oxo-6-phenylhexyl) - 4-piperidinyl] phenyl}propanamide: Anal. Calcd for C27H38Ν2O2+0.1CHCl3: C, 75.5; H, 8.93; N, 6.50. Found: C, 75.3; H, 8.52; N, 6.00; ESMS m/e: 423.2 (M + H) + .
Example 282
N-{3- [1- (7-HYDROXY-7-PHEΝYLHEPTYL) -4- PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN, Step 1 using 2-methyl-N- {3- [1- (7-oxo-7-phenylheptyl) -4- piperidinyl] phenyl}propanamide: Anal. Calcd for
C28H40Ν2O2+0.1CHCl3: C, 75.8; H, 9.10; N, 6.29. Found: C, 75.1; H, 9.24; N, 6.51; ESMS m/e: 437.1 (M + H) + .
Example 283
N-(3-{l-[4- (4-FLUOROPHENYL) -4-HYDROXYBUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN, Step 1 using N- (3- {l- [4- (4- fluorophenyl) -4-oxobutyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 413.1 (M + H)+.
Example 284 4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1-
PHENYLBUTYL 3- (2, 6-DICHLOROPHENYL) - 5 -METHYL- 4-
ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and
Scheme C2 (TEA) using N- {3- [1- (4-hydroxy-4-phenylbutyl) - 4-piperidinyl] phenyl} -2- methylpropanamide and 3-
(2, 6-dichlorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: λE NMR (400 MHz, CDC13) δ 7.56 (m, IH) , 7.47
(m, 2H) , 7.44-7.39 (m, 3H) , 7.25 (m, 2H) , 7.09 (s, IH) , 7.03 (m, 2H) , 6.95 (m, IH) , 6.83 (m, IH) , 5.75 (t, IH, J
= 7.1 Hz), 3.03 (t, 2H, J = 7.2 Hz), 2.93 (m, 2H) , 2.78
(s, 3H) , 2.48 (m, 3H) , 2.25 (m, 2H) , 1.48 (m, 3H) , 1.77
(m, 2H) , 1.54 (m, 2H) , 1.25 (d, 6H, J = 7.3 Hz); ESMS m/e : 641 . 1 (M + H) + .
Example 285
4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLBUTYL (4-FLUOROPHENYL) ACETATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [l- (4 - hydroxy-4-phenylbutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and (4-fluorophenyl) acetyl chloride: 1H ΝMR (400 MHz, CDCl3) δ 7.45 (s, IH) , 7.34-7.19 (m, 8H) , 7.11 (m, IH) , 6.98 (m, 3H) , 5.75 (t, IH, J = 6.8 Hz), 3.61 (s, 2H) , 2.92 (d, 2H, J = 8.1 Hz), 2.48 (m, 2H) , 2.31 (m, 2H) , 1.99-1.84 (m, 4H) , 1.84-1.67 (m, 5H) , 1.55-1.35 (m, 2H) , 1.25 (d, 6H, J = 6.9 Hz); ESMS m/e : 531.1 (M + H)+.
Example 286 3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL
(4-FLUOROPHENYL) ACETATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [1- (3-hydroxypropyl) -4- piperidinyl] phenyl} -2-methylpropanamide • and (4- fluorophenyl) acetyl chloride: ESMS m/e : 441.3 (M + H)+.
Example 287
3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL 3- (2-CHLORO- 6-FLUOROPHENYL) -5-METHYL-4 - ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- {3- [1- (3-hydroxypropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 3-(2-chloro-
6-fluorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: ESMS m/e: 542.2 (M + H) + .
Example 288
3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL 3- (2, 6-DICHLOROPHENYL) -5-METHYL-4-ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3- [1- (3-hydroxypropyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2 , 6-dichlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 558.2 (M + H) X
Example 289
3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL 3- (2-CHLOROPHENYL) -5-METHYL-4-1SOXAZOLECARBOXYLATE:
Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [1- (3-hydroxypropyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2-chlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 524.2 (M + H)
Example 290
(IS) -3 -{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLPROPYL 3- (2, 6-DICHLOROPHENYL) -5-METHYL-4-
ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- (3- {l- [ (3S) -3-hydroxy-3- phenylpropyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 3- (2, 6-dichlorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: ESMS m/e: 633.6 (M + H)+. Example 291
4_{4_ [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}BUTYL 3- (2-CHLORO-6-FLUOROPHENYL) -5-METHYL-4-
ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- {3- [1- (4-hydroxybutyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 3-(2-chloro- 6-fluorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: Anal. Calcd for C30H35ClFΝ3O4+CH2Cl2 : C, 63.3; H, 6.23; N, 7.33. Found: C, 63.0; H, 6.39; N, 7.03; ESMS m/e : 556.2 (M + H)+.
Example 292
4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}BUTYL 3- (2-CHLOROPHENYL) -5-METHYL-4-ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [1- (4-hydroxybutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2-chlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 538.2 (M + H) "X
Example 293
3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}PROPYL 5- METHYL-3 -PHENYL-4-ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [l- (3 - hydroxypropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 5-methyl-3-phenyl-4-isoxazolecarbonyl chloride: ESMS m/e: 490.3 (M + H) + .
Example 294
4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}BUTYL 3- (2,6-DICHLOROPHENYL) -5-METHYL-4-ISOXAZOLECARBOXYLATE:
Prepared by Procedure Ql and Scheme C2 (TEA) using N- {3 - [1- (4-hydroxybutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3 - ( 2 , 6 -dichlorophenyl) -5 - methyl-4 - isoxazolecarbonyl chloride : ESMS m/e : 572 . 2 (M
+ H) + .
Example 295
4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLBUTYL 3- (2-CHLORO-6-FLUOROPHENYL) .-5-METHYL-4- ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [1- (4-hydroxy-4-phenylbutyl) - 4-piperidinyl] phenyl} -2-methylpropanamide and 3- (2- chloro-6-fluorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: Anal. Calcd for C36H39C1FΝ3O4+0.54CHC13 : C, 63.0; H, 5.72; N, 6.03. Found: C, 63.0; H, 5.54; N, 6.05; ESMS m/e : 632.2 (M + H) + .
Example 296
4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}BUTYL 5- METHYL-3 -PHENYL-4-ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [l- (4 - hydroxybutyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 5-methyl-3-phenyl-4-isoxazolecarbonyl chloride: ESMS m/e : 504.3 (M + H)+.
Example 297 6-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}HEXYL 3- (2, 6-DICHLOROPHENYL) -5-METHYL-4-ISOXAZOLECARBOXYLATE:
Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [1- (6-hydroxyhexyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2 , 6-dichlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 600.0 (M + H)+. Example 298
6-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}HEXYL 5-
METHYL-3 -PHENYL-4-ISOXAZOLECARBOXYLATE: Prepared by
Procedure Ql and Scheme C2 (TEA) using N- { 3 - [l- ( 6- hydroxyhexyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 5-methyl-3-phenyl-4-isoxazolecarbonyl chloride: ESMS m/e: 532.1 (M + H) + .
Example 299 4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDIΝYL}BUTYL (4- FLUOROPHENYL) ACETATE : Prepared by Procedure Ql and Scheme C2 (TEA) using N- {3- [1- (4-hydroxybutyl) -4- piperidinyl] phenyl} -2-methylpropanamide and (4- fluorophenyl) acetyl chloride: ESMS m/e: 455.3 (M + H)+.
Example 300 4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLBUTYL 3- (2-CHLOROPHENYL) -5-METHYL-4-
ISOXAZOLECARBOXYLATE: Prepared by Procedure Ql and Scheme C2 (TEA) using N- {3- [1- (4-hydroxy-4-phenylbutyl) - 4-piperidinyl] phenyl} -2-methylpropanamide and 3- (2- chlorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: ESMS m/e : 614.2 (M + H) + .
Example 301
4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLBUTYL 5-METHYL-3 -PHENYL-4-1SOXAZOLECARBOXYLATE:
Prepared by Procedure Ql and Scheme C2 (TEA) using N- { 3 - [1- (4-hydroxy-4-phenylbutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 5-methyl-3-phenyl-4- isoxazolecarbonyl chloride: ESMS m/e : 580.0 (M + H)+. Example 302
(IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1-
PHENYLPROPYL (4-FLUOROPHENYL) ACETATE: Prepared by
Procedure Ql and Scheme C2 (TEA) using N- (3- {l- [ (3S) -3- hydroxy-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and (4-fluorophenyl) acetyl chloride
Anal. Calcd for C32H37FΝ2O3+0.07CHC13 : C, 73.4; H, 7.12
N, 5.34. Found: C, 73.4; H, 6.96; N, 5.14; ESMS m/e
517.1 (M + H)+.
Example 303 N-( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYDBENZAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino-3-phenylpropyl] -4- piperidinyl }phenyl) -2-methylpropanamide and benzoyl chloride: Anal. Calcd for C31H37Ν3O2+0.55CHC13 : C, 69.0; H, 6.89; N, 7.65. Found: C, 69.7; H, 6.73; N, 6.03; ESMS m/e: 484.4 (M + H) + .
Example 304
N-[3-(l-{(3S)-3-t (DIPHENYLACETYL) AMINO] -3-PHENYLPROPYL}- 4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4 -piperidinyl}phenyl) -2- methylpropanamide and diphenylacetyl chloride: ESMS m/e: 574.3 (M + H)+.
Example 305
3-CHLORO-N-( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL} -1-PHENYLPROPYL) BENZAMIDE: Prepared by
Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3- chlorobenzoyl chloride:
ESMS m/e : 518.3 (M + H) + .
Example 306 3 , 5-DICHLORO-N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}-l-PHENYLPROPYL)BENZAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3 , 5-dichlorobenzoyl chloride: ESMS m/e: 552.3 (M + H) + .
Example 307
2- (ETHYLSULFANYL) -N- ( (IS) -3-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1- PHENYLPROPYDNICOTINAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 2- (ethylsulfanyl) nicotinoyl chloride: ESMS m/e : 545.3 (M + H) + .
Example 308 N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} - 1-PHENYLPROPYL) [1, 1 • -BIPHENYL] -4-CARBOXAMIDE : Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3- amino-3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and [1, 1 ' -biphenyl] -4-carbonyl chloride: ESMS m/e : 560.3 (M + H)+.
Example 309 N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -2-PYRIDINECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- { l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2- pyridinecarbonyl chloride:
ESMS m/e : 484.6 (M + H) + .
Example 310 N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHE YL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -2-METHOXYBENZAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2-methoxybenzoyl chloride: ESMS m/e: 514.1 (M + H)+.
Example 311
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -1-NAPHTHAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 1-naphthoyl chloride: ESMS m/e : 533.7 (M + H) + .
Example 312 2, 4 -DIFLUORO-N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}-1-PHENΥLPR0PYL)BENZAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2, 4-difluorobenzoyl chloride: ESMS m/e: 520.2 (M + H)
Example 313
3- (2-CHLORO-6-FLUOROPHENYL) -N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1-PHENYLPROPYL) - 5-METHYL-4-ISOXAZOLECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 3- (2-chloro-6- fluorophenyl) -5 -methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 617.2 (M + H)+.
Example 314 3 -CHLORO-N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}-1-PHENYLPROPYL) -2-THIOPHENECARBOXAMIDE:
Prepared by Procedure Ql and Scheme AC using N- (3 - { l - [ (3S) -3-amino-3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3-chloro-2-thiophenecarbonyl chloride: ESMS m/e : 524.2 (M + H)+.
Example 315
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] - 1-PIPERIDINYL} - 1-PHENYLPROPYL) -2-PHENOXYNICOTINAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 2-phenoxynicotinoyl chloride: ESMS m/e : 577.3 (M + H) + .
Example 316
1- (4 -CHLOROPHENYL) -N- ( (IS) -3 -{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1 -PIPERIDINYL} -1-PHENYLPROPYL) - 3 -PROPYL- Iff-PYRAZOLE-4 -CARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1- (4-chlorophenyl) -3 -propyl- 1H- pyrazole-4 -carbonyl chloride: ESMS m/e : 626.3 (M + H)+.
Example 317 4 -CHLORO-N- (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}- 1-PHENYLPROPYL) -1, 3 -DIMETHYL-lff- PYRAZOLO [3, 4 -B] PYRIDINE- 5-CARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3 - {l- [ (3S) -3-amino- 3-phenylpropyl] -4- piperidinyl}phenyl) -2- methylpropanamide and 4-chloro-1 , 3-dimethyl-lff- pyrazolo [3,4 -b] pyridine-5-carbonyl chloride: ESMS m/e:
587.3 (M + H)+.
Example 318
5- (3,5-DICHLOROPHENOXY) -N- ( (IS) -3-{4- _3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} -1-PHENYLPROPYL) -
Iff-PYRROLE-2-CARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 5- (3,5- dichlorophenoxy) -IH-pyrrole-2-carbonyl chloride: ESMS m/e : 634.2 (M + H)+.
Example 319
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYDNICOTINAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl }phenyl) -2-methylpropanamide and nicotinoyl chloride: ESMS m/e: 485.3 (M + H)+.
Example 320
3 , 4 -DIFLUORO-N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}-1-PHENYLPROPYL) BENZAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (35) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 3 , 4-difluorobenzoyl chloride: ESMS m/e 520.3 (M + H)+.
Example 321
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -l-PHENYL-3-PROPYL-lff-PYRAZOLE-4- CARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- { l- [ (3S) -3 - amino-3 -phenylpropy1] -4- piperidinyl }phenyl) -2-methylpropanamide and l-phenyl-3- propyl-lH-pyrazole-4-carbonyl chloride: ESMS /e: 592.2
(M + H) + .
Example 322
4- (DIMETHYLAMINO) -N- ( (IS) -3-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}-1-
PHENYLPROPYDBENZAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4-
(dimethylamino) benzoyl chloride: ESMS m/e: 527.3 (M +
H) + .
Example 323
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL} - 1-PHENYLPROPYL) -2-THIOPHENECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N~ (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 2-thiophenecarbonyl chloride: ESMS m/e : 490.2 (M + H) + .
Example 324
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -5-NITRO-2-FURAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 5-nitro-2-furoyl chloride: ESMS m/e : 519.2 (M + H) + .
Example 325 N- (3- {4- [3 - (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}PROPYL) -5-METHYL-3 -PHENYL-4- ISOXAZOLECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 5-methyl-3- phenyl-4-isoxazolecarbonyl chloride: ESMS m/e : 489.1 (M + H)+.
Example 326
N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -2-FURAMIDE: Prepared by Procedure Ql and Scheme AC using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 2-furoyl chloride: ESMS m/e: 474.2 (M + H) + .
Example 327 N- ( (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}- 1-PHENYLPROPYL) -l- (4-NITROPHENYL) -5- (TRIFLUOROMETHYL) -
Iff-PYRAZOLE-4-CARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- (3- {l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 1- (4- nitrophenyl) -5- (trifluoromethyl) -lH-pyrazole-4-carbonyl chloride: ESMS m/e : 663.2 (M + H) + .
Example 328
3- (2-CHLORO-6-FLUOROPHENYL) -N- (3 -{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -5-METHYL- 4-ISOXAZOLECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 3- (2-chloro- 6-fluorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: ESMS m/e : 541.2 (M + H) + .
Example 329
N- [3- (l-{3- [ (DIPHEΝYLACETYL) AMIΝO] ROPYL}-4- PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure Ql and Scheme AC using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and diphenylacetyl chloride: XE ΝMR (400 MHz, CDC13) δ
7.51 (s, IH) , 7-.33-7.21 (m, 13H) , 6.94 (m, 2H) , 4.88 (s, IH) , 3.39 (t, 2H, J = 5.6 Hz), 2.93 (d, 2H, J = 11.3
Hz), 2.52-2.36 (m, 4H) , 1.97 (t, 2H, J = 11.3 Hz), 1.83-
1.58 (m, 6H) , 1.24 (d, 6H, J = 7.6 Hz); Anal. Calcd for
C32H39Ν3O2+HCl+0.19CHCl3: C, 69.44; H, 7.27; N, 7.55.
Found: C, 69.44; H, 7.43; N, 7.43; ESMS m/e: 498.4 (M + H)+.
Example 330
N-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}PROPYL) -1-BENZOTHIOPHENE-3 -CARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and l-benzothiophene-3 -carbonyl chloride: ESMS m/e: 464.2 (M + H)+.
Example 331
3- (2 -CHLOROPHENYL) -N-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] - l-PIPERIDINYL}PROPYL) -5-METHYL-4 -ISOXAZOLECARBOXAMIDE:
Prepared by Procedure Ql and Scheme AC using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 3- (2 -chlorophenyl) -5-methyl-4-isoxazolecarbonyl chloride: ESMS m/e: 523.1 (M + H)+.
Example 332
3- (2,6-DICHLOROPHEΝYL) -Ν-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINY }PROPYL) -5-METHYL- 4-ISOXAZOLECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using N-{3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 3- (2,6- dichlorophenyl) -5-methyl- 4-isoxazolecarbonyl chloride: 1H NMR (400 MHz, CDC13) δ 7.50 (d, IH, J = 2.3
Hz), 7.48 (s, IH) , 7.4 (m, IH) , 7.39 (s, IH) , 7.37 (m,
2H) , 7.24 (t, IH, J = 7.2 Hz), 6.92 (d, IH, J = 7.9 Hz), 6.06 (s, IH) , 3.31 (q, 2H, J = 6.4 Hz), 2.94 (d, 2H, J =
10.8 Hz), 2.79 (s, 3H) , 2.53 (q, IH, J = 6.1), 2.47 (tt,
IH, J = 4.2, 11.4 Hz), 2.29 (t, 2H, J = 7.2 Hz), 1.99
(t, 2H, J = 11.4 Hz), 1.81 (m, 2H) , 1.69 (dt, 2H, J =
2.4, 11.6), 1.59 (q, 2H, J = 6.6 Hz), 1.24 (d, 6H, J = 6.5 Hz); ESMS m/e : 557.0 (M + H) + .
1- [3 - (3 -CHLOROPROPOXY) PHENYL] ETHANONE : Prepared by Procedure U and Scheme AK using 1- (3- hydroxyphenyl) ethanone and l-bromo-3 -chloropropane .
1- (3 -CHLOROPROPOXY) -2 -FLUOROBENZENE : Prepared by Procedure U and Scheme AK using 2 -fluorophenol and 1- bromo-3 -chloropropane.
l-CHLORO-3- (3 -CHLOROPROPOXY) BENZENE: Prepared by Procedure U and Scheme AK using 3-chlorophenol and 1- bromo-3 -chloropropane .
l-CHLORO-4- (3 -CHLOROPROPOXY) BENZENE: Prepared by Procedure U and Scheme AK using 4-chlorophenol and 1- bromo-3-chloropropane .
1- (3 -CHLOROPROPOXY) -3 -FLUOROBENZENE: Prepared by Procedure U and Scheme AK using 3 -fluorophenol and 1- bromo-3 -chloropropane . 1- (3-CHLOROPROPOXY) -4- FLUOROBENZENE: Prepared by Procedure U and Scheme AK using 4-fluorophenol and 1- bro o-3 -chloropropane .
1-CHLORO-2- (3-CHLOROPROPOXY) BENZENE: Prepared by Procedure U and Scheme AK using 2-chlorophenol and 1- bromo-3 -chloropropane .
4- (3-CHLOROPROPOXY) -1,2-DIMETHYLBENZENE: Prepared by Procedure U and Scheme AK using 3 , -dimethylphenol and 1-bromo-3-chloropropane.
l-BROMO-2- (3 -CHLOROPROPOXY) BENZENE: Prepared by Procedure U and Scheme AK using 2-bromophenol and 1- bromo-3 -chloropropane .
1-BROMO-3- (3 -CHLOROPROPOXY) BENZENE: Prepared by Procedure U and Scheme AK using 3-bromophenol and 1- bromo-3 -chloropropane .
l-BROMO-4- (3 -CHLOROPROPOXY) BENZENE: Prepared by Procedure U and Scheme AK using 4-bromophenol and 1- bromo-3 -chloropropane.
1- (3 -CHLOROPROPOXY) -4-METHYLBENZENE: Prepared by Procedure U and Scheme AK using p-cresol and l-bromo-3- chloropropane .
4-BROMOPHENYL (2R) -3-CHLORO-2-METHYLPROPYL ETHER:
Prepared by Procedure U and Scheme AK using 4- bromophenol and (2S) -l-bromo-3-chloro-2-methylpropane .
l-{ [(2R) -3-CHLORO-2-METHYLPROPYL]OXY}-2,4,5- TRIFLUOROBENZENE: Prepared by Procedure U and Scheme AK using 2,4,5- trifluorophenol and (2S) -
1-bromo-3-chloro-2-methylpropane .
l-CHLORO-3-{ [ (2R) -3-CHLORO-2-METHYLPROPYL] OXY}BENZENE: Prepared by Procedure U and Scheme AK using 3- chlorophenol and (2 S) -1-bromo-3-chloro-2-methylpropane .
l-{ [ (2R) -3-CHLORO-2-METHYLPROPYL] OXY}-4-FLUOROBENZENE:
Prepared by Procedure U and Scheme AK using 4- fluorophenol and (2S) -1-bromo-3-chloro-2-methylpropane .
l-{ [ (2R) -3-CHLORO-2-METHYLPROPYL] OXY}-3-FLUOROBENZENE:
Prepared by Procedure U and Scheme AK using 3- fluorophenol and (2 S) -1-bromo-3-chloro-2-methylpropane .
l-CHLORO-2-{ [ (2R) -3-CHLORO-2-METHYLPROPYL] OXY}BENZENE:
Prepared by Procedure U and Scheme AK using 2- chlorophenol and (2 S) -1-bromo-3-chloro-2-methylpropane.
l-{ [(2R) -3 -CHLORO-2-METHYLPROPYL] OXY}-2-FLUOROBENZENE:
Prepared by Procedure U and Scheme AK using 2- fluorophenol and (2S) -1-bromo-3-chloro-2-methylpropane . l-CHLORO-4-{ [ (2R) -3-CHLORO-2-METHYLPROPYL] OXY}BENZENE:
Prepared by Procedure U and Scheme AK using 4- chlorophenol and (2S)'-l-bromo-3-chloro-2-methylpropane .
3-BROMOPHENYL (2R) -3-CHLORO-2-METHYLPROPYL ETHER:
Prepared by Procedure U and Scheme AK using 3- bromophenol and (2S) -1-bromo-3-chloro-2-methylpropane .
2-BROMOPHENYL (2R) -3-CHLORO-2-METHYLPROPYL ETHER:
Prepared by Procedure U and Scheme AK using 2- bromophenol and (2S) -l-bromo-3-chloro-2-methylpropane . l-{ [ (2S) -3-CHLORO-2-METHYLPROPYL]OXY}-3-FLUOROBENZENE:
Prepared by Procedure U and Scheme AK using 3- fluorophenol and (2R) -l-bromo-3-chloro-2-methylpropane.-.
l-{ [ (2S) -3-CHLORO-2-METHYLPROPYL]OXY}-4-FLUOROBENZENE:
Prepared by Procedure U and Scheme AK using 4- fluorophenol and (2R) -l-bromo-3-chloro-2-methylpropane.
l-{ [ (2S) -3 -CHLORO-2-METHYLPROPYL] OXY}-2-FLUOROBENZENE:
Prepared by Procedure U and Scheme AK using 2- fluorophenol and (2R) -l-bromo-3-chloro-2 -methylpropane .
l-CHLORO-2-{ [(2S) -3-CHLORO-2-METHYLPROPYL] OXY}BENZENE: Prepared by Procedure U and Scheme AK using 2- chlorophenol and (2R) -l-bromo-3-chloro-2 -methylpropane.
l-CHL0R0-4-{ [ (2S) -3-CHLORO-2-METHYLPROPYL] OXY}BENZENE:
Prepared by Procedure U and Scheme AK using 4- chlorophenol and (2R) -l-br*mo-3>-chloro-2-methylpropane.
4-BROMOPHENYL (2S) -3-CHLORO-2-METHYLPROPYL ETHER:
Prepared by Procedure U and Scheme AK using 4- bro ophenol and (2R) -l-bromo-3-chloro-2-methylpropane .
3-BROMOPHENYL (2S) -3-CHLORO-2-METHYLPROPYL ETHER:
Prepared by Procedure U and Scheme AK using 3- bromophenol and (2R) -1-bromo-3-chloro-2-methylpropane.
2-BROMOPHENYL (2S) -3-CHLORO-2-METHYLPROPYL ETHER:
Prepared by Procedure fiS-- and Scheme ---AK using- 2- bromophenol and (2R) -l-bromo-3-chloro-2-methylpropane. l- CHLORO- 3 - { [ (2S) - 3 - CHLORO- 2 -
METHYLPROPYL]OXY}BENZENE: Prepared by Procedure U and
Scheme AK using 3-chlorophenol and (2R) -1-bromo-3- chloro-2-methylpropane .
1_ [3_ (4-CHLOROBUTOXY) PHENYL] ETHANONE: Prepared by
Procedure U and Scheme AK using 1- (3- hydroxyphenyl) ethanone and l-bromo-4-chlorobutane.
1- [3- (4-CHLOROBUTOXY) PHENYL] ETHANONE: Prepared by Procedure U and Scheme AK using 1- (3- hydroxyphenyl) ethanone and l-bromo-4-chlorobutane.
1- (4-CHLOROBUTOXY) -3 -METHOXYBENZENE: Prepared by Procedure U and Scheme AK using 3-methoxyphenol and 1- bromo-4-chlorobutane .
1- (4-CHLOROBUTOXY) -4 -METHOXYBENZENE: Prepared by Procedure U and Scheme AK using 4-methoxyphenol and 1- bromo-4-chlorobutane .
1- (4-CHLOROBUTOXY) -2 -METHOXYBENZENE: Prepared by Procedure U and Scheme AK using 2-methσxyphenol and 1- bromo-4-chlorobutane .
4- (4-CHLOROBUTOXY) -1, 2-DIMETHYLBENZENE: Prepared by Procedure U and Scheme AK using 3 , 4-dimethylphenol and l-bromo-4-chlorobutane .
1- {3-[ (5-CHLOROPENTYL) OXY] PHENYL}ETHANONE: Prepared by Procedure U and Scheme AK using 1- (3- hydroxyphenyl) ethanone and l-bromo-5-chloropentane . l- {3 - [ ( 5 -
CHLOROPENTYL)OXY]PHENYL}ETHANONE: Prepared by Procedure
U and Scheme AK using 1- (3 -hydroxyphenyl) ethanone and 1- bromo- 5 - chloropentane .
1- {3 - [(6 -CHLOROHEXYL) OXY] PHENYL}ETHANONE: Prepared by
Procedure U and Scheme AK using 1- (3- hydroxyphenyl) ethanone and l-bromo-6-chlorohexane .
1- {3- [(6 -CHLOROHEXYL) OXY] PHENYL}ETHANONE: Prepared by Procedure U and Scheme AK using 1- (3- hydroxyphenyl) ethanone and l-bromo-6-chlorohexane.
Example 333 N- (3 - { l- [ (2S) - 2 - (3-ACETYLPHEΝOXY) -2-PHEΝYLETHYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme Bl using 1- (3- hydroxyphenyl ) ethanone and N- (3 - {l- [ (2R) -2 -hydroxy-2- phenylethyl] -4 -piperidinyl }phenyl) -2-methylpropanamide: ESMS m/e : 485.0 (M + H) + .
Example 334
Ν-(3-{l-[(2S)-2- (2-ACETYLPHEΝOXY) -2-PHEΝYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme Bl using 1- (2- hydroxyphenyl ) ethanone and N- (3- {l- [ (2R) -2-hydroxy-2- phenylethyl] -4-piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 485.2 (M + H) "X
Example 335
N- (3 - { l- [ (2S) - 2 - (3-CHLOROPHEΝOXY)-2-PHEΝYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme Bl using 3-chlorophenol and N- (3- {l- [ (2R) -2-hydroxy-2- phenylethyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e: 477.1
(M + H) + .
Example 336
N-(3-{l- [ (2S) -2- (3,4-DIMETHOXYPHEΝOXY) -2-PHENYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme Bl using 3,4-dimethoxyphenol and N- (3-{l- [ (2R) -2-hydroxy-2-phenylethyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e: 503.2 (M + H) + .
Example 337 N-(3-{l- [ (2R) -2- (4-FLUOROPHENOXY) -2-PHENYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme Bl using 4-fluorophenol and N- (3- {l- [ (2S) -2-hydroxy-2 -phenylethyl] -4-piperidinyl }phenyl) - 2-methylpropanamide: ESMS m/e: 461.2 (M + H)+.
Example 338
N-(3-{l- [ (2R) -2- (3-METHOXYPHEΝOXY) -2 -PHENYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure B and Scheme Bl using 3-methoxyphenol and N- (3-{l- [ (2S) -2-hydroxy-2-phenylethyl] -4- piperidinyl }phenyl) -2-methylpropanamide : ESMS m/e: 472.9
(M + H) + .
Example 339
N-C3-{1- [(2R) -2- (3-CHLOROPHEΝOXY)-2-PHENYLETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme Bl using 3-chlorophenol and N- (3- {l- [ (2S) -2-hydroxy-2 -phenylethyl] -4-piperidinyl}phenyl) - 2-methylpropanamide: ESMS m/e: 478.5 (M + H) + . N- {3 - [1- (3,3-DIMETHOXYPROPYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 3-bromo-l, 1-dimethoxypropane and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 349.2 (M + H) +
Example 340
N- (3- {l- [ (3S) -3- (3-ACETYLPHEΝOXY) -3-PHEΝYLPROPYL] -4- PIPERIDIΝYL}PHEΝYL)CYCLOPROPAΝECARBOXAMIDE: Prepared by
Procedure B and Scheme Bl using 1- (3- hydroxyphenyl) ethanone and N- (3-{l- [ (3R) -3 -hydroxy-3 - phenylpropyl] -4- piperidinyl}phenyl) cyclopropanecarboxamide: ESMS m/e -. 497.1 (M + H)+.
Example 341
N- (3- {l- [3 - (3-ACETYLPHEΝOXY) PROPYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- [3- (3- chloropropoxy) phenyl] ethanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 423.2 (M + H)+.
Example 342 N- f3- {l- [3- (3-ACETYLPHEΝOXY) PROPYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- [3- (3- chloropropoxy) phenyl] ethanone and • N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 421.2 (M + H)+.
Example 343
N- (3- {l- [3 - (2-FLUOROPHENOXY) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- (3-chloropropoxy) -
2 -fluorobenzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 399.2 (M + H) + .
Example 344
N- (3 - { l- [3- (3 -CHLOROPHEΝOXY) PROPYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure G and Scheme Bl using l-chloro-3- (3- chloropropoxy) benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 415.2 (M + H)+.
Example 345
N- (3 - { l- [3 - (4 -CHLOROPHEΝOXY) PROPYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-4- (3- chloropropoxy) benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: E ΝMR (400 MHz, CDC13) δ 7.71 (dd, IH, J = 3.2, 5.7 Hz), 7.53 (dd, IH, J = 3.2, 5.7 Hz), 7.50 (m, IH) , 7.31 (m, IH) , 7.24-7.20 (m, 2H) , 6.94 (d, IH, J = 7.9 Hz), 6.85-6.82 (m, 2H) , 4.00 (t, 2H, J = 6.1 Hz), 3.07 (d, 2H, J = 10.9 Hz), 2.55 (m, 3H) , 2.50 (sept, IH, J = 6.2 Hz), 2.08 (dt, 2H, J = 3.1, 10.9 Hz), 2.00 (m, 2H) , 1.83 (m, 3H) , 1.69 (qt, IH, J = 6.2 Hz), 1.24 (d, 6H, J = 6.8 Hz); Anal. Calcd for C24H31C1Ν202+HC1: C, 63.8; H, 7.09; N, 6.21. Found: C, 63.3; H, 7.04; N, 6.27; ESMS m/e : 415.2 (M + H)
Example 346
N- (3 - { l- [3 - (3 -FLUOROPHENOXY) PROPYL] -4 - PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- (3-chloropropoxy) -3- fluorobenzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 399.2 (M + H)"X Example 347
N-(3-{l-[3- (4-FLUOROPHENOXY) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- (3-chloropropoxy) -4- fluorobenzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 399.2 (M + H)+.
Example 348 N-(3-{l-[3- (2-CHLOROPHEΝOXY) PROPYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-2- (3- chloropropoxy) benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 415.2 (M + H)+.
Example 349 N-(3-{l-[3- (3,4-DIMETHYLPHEΝOXY)PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure G and Scheme Bl using 4- (3-chloropropoxy) -1, 2- dimethylbenzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 409.2 (M + H)+.
Example 350
N- 3-{l-[3- (2-BROMOPHEΝOXY) PROPYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-bromo-2- (3- chloropropoxy) benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: 1H ΝMR (400 MHz, CDC13) δ 7.53 (dd, IH, J = 1.6, 7.9 Hz), 7.48 (s, IH) , 7.32 (m, IH) , 7.28-7.22 (m, 3H) , 7.17 (s, IH) , 6.98 (d, IH, J = 7.7 Hz), 6.93 (dd, IH, J = 1.4, 8.4 Hz), 6.82 (dt, IH, J = 7.6, 1.4 Hz), 4.11 (t, 2H, J = 6.3 Hz), 3.07 (d, 2H, J = 11.3 Hz), 2.61 (t, 2H, J = 6.9 Hz), 2.50 (m, 3H) , 2.07 (m, IH) , 1 . 8 - 1 . 75 (m, 5H) , 1 . 25 ( d, 6H , J = 6 . 7 Hz ) ;
Anal. Calcd for C24H31BrN202.HCl+0.2 CHC13 : C, 55.9; H, 6.24; N, 5.39. Found: C, 55.8; H, 6.23; N, 5.47; ESMS m/e : 459.1 (M + H) + .
Example 351 N- (3 - { l- [3 - (3 -BROMOPHENOXY) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure G and Scheme Bl using l-bromo-3- (3- chloropropoxy) benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e: 459.1 (M + H) + .
Example 352
Ν-(3-{l-[3- (4-BROMOPHENOXY) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1-bromo-4- (3- chloropropoxy) benzene and 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide : 1H ΝMR (400 MHz, CDC13) δ 7.51 (s, IH) , 7.37 (d, 2H, J = 7.6 Hz), 7.26 (m, 3H) , 6.97 (d, IH, J = 7.7 Hz), 6.79 (d, 2H, J = 7.7 Hz), 4.01 (t, 2H, J = 5.6 Hz), 3.08 (d, 2H, J = 9.4 Hz), 2.53 (m, 4H) , 2.05 ( , 4H) , 1.84 (m, 4H) , 1.24 (d, 6H, J = 5.9 Hz); Anal. Calcd for C24H31BrΝ202.HCl+0.34CHC13 : C, 54.5; H, 6.08; N, 5.22. Found: C, 54.5; H, 6.22; N, 5.22; ESMS m/e : 459.1 (M + H) + .
Example 353 N-(3-{l-[(3R)-3- (3,4-DIMETHOXYPHENOXY) -3-PHENYLPROPYL] - 4-PIPERIDINYL}PHENYL) -N, 2-DIMETHYLPROPANAMIDE: Prepared by Procedure T and Scheme AD using N- (3- {l- [ (3R) -3- (3 , 4- dimethoxyphenoxy) -3-phenylpropyl] -4-piperidinyl}phenyl) - 2-methylpropanamide and methyl iodide: ESMS m/e : 531.2 (M + H) + . Example 354
N- (3 - {l- [ (3R) -3- (3-ACETYLPHEΝOXY) -3-PHEΝYLPROPYL] -4- PIPERIDIΝYL}PHEΝYL) -N, 2-DIMETHYLPROPANAMIDE: Prepared by Procedure T and Scheme AD using N- (3- {l- [ (3R) -3- (3- acetylphenoxy) -3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and methyl iodide: ESMS m/e: 513.2 (M + H) + .
Example 355
N- (3 - { l- [ (3S) -3- (3-ACETYLPHEΝOXY) -3-PHEΝYLPROPYL] -4- PIPERIDIΝYL}PHEΝYL) -N, 2-DIMETHYLPROPANAMIDE : Prepared by Procedure T and Scheme AD using N- (3- {l- [ (3S) -3- (3- acetylphenoxy) -3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide and methyl iodide: ESMS m/e : 513.2 (M + H) + .
Example 356 iV-(3-{l-[(2S)-3- (4-BROMOPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 4-bromophenyl (2R)-3- chloro-2-methylpropyl ether and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e: 473.0 (M + H) + .
Example 357
2-METHYL-N- (3 -{1- [ (2S) -2-METHYL-3- (2,4,5-
TRIFLUOROPHENOXY) PROPYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- { [ (2R) -3-chloro-2- methylpropyl] oxy} -2, 4, 5-trifluorobenzene and 2 -methyl-N-
[3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 449.2 (M
+ H) + . Example 358
N-(3-{l-[(2S)-3- (3-CHLOROPHEΝOXY) -2-METHYLPROPYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure G and Scheme Bl using l-chloro-3-{ [ (2R) -3- chloro-2-methylpropyl] oxy}benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 429.2 (M + H) + .
Example 359
N-(3-{l-[(2S)-3- (4-FLUOROPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- { [ (2R) -3-chloro-2- methylpropyl] oxy} -4-fluorobenzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 413.2 (M + H)+.
Example 360 N-(3-{l-[(2S)-3- (3-FLUOROPHENOXY) -2-METHYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- { [ (2R) -3-chloro-2- methylpropyl] oxy} -3 -fluorobenzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 413.2 (M + H) + .
Example 361 N-(3-{l- [ (2S) -3- (2-CHLOROPHEΝOXY) -2-METHYLPROPYL] -4- PIPERIDIΝYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-2- { [ (2R) -3- chloro-2-methylpropyl] oxy}benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 429.1 (M + H) + .
Example 362
N-(3-{l- [ (2S) -3- (2-FLUOROPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- { [ (2R) -3-chloro-2- methylpropyl] oxy} -2 -fluorobenzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 413.2 (M + H)+. Example 363
N- (3 - {l- [ (2S) -3- (4-CHLOROPHEΝOXY) -2-METHYLPROPYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-4- { [ (2R) -3- chloro-2-methylpropyl] oxy}benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e 429.2 (M + H) + .
Example 364 N- (3 - {l- [ (2S) -3- (3-BROMOPHENOXY) -2-METHYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 3-bromophenyl (2R)-3- chloro-2 -methylpropyl ether and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 474.0 (M + H) + .
Example 365 N- (3 - {l- [ (2S) -3- (2-BROMOPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 2-bromophenyl (2R) -3- chloro-2-methylpropyl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS /e : 473.0 (M + H)+.
Example 366
N- (3 - {l- [ (2R) -3 - (3 -FLUOROPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- { [ (2S) -3-chloro-2- methylpropyl] oxy} -3 -fluorobenzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 413.2 (M + H)+. Example367 N- (3 - {l- [ (2R) -3- (4-FLUOROPHENOXY) -2-METHYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- { [ (2S) -3-chloro-2- methylpropyl] oxy} -4- fluorobenzene and 2- methyl-N- [3- (4-piperidinyl)phenyl] propanamide: ESMS m/e:
413.8 (M + H)+.
Example 368
N- (3 - {l- [ (2R) -3- (2-CHLOROPHEΝOXY) -2-METHYLPROPYL] -4- PIPERIDIΝYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-2- { [ (2S) -3- chloro-2 -methylpropyl] oxy}benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 429.1 (M + H)+.
Example 369
N- (3 -{l- [ (2R) -3- (4-CHLOROPHEΝOXY) -2-METHYLPROPYL] -4- PIPERIDIΝYL} HENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-4- { [ (2£) -3- chloro-2-methylpropyl] oxy}benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 429.1 (M + H)+.
Example 370 N- (3-{l- [ (2R) -3- (4-BROMOPHENOXY) -2-METHYLPROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 4-bromophenyl (2S)-3- chloro-2-methylpropyl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 473.0 (M + H) + .
Example 371 N- (3 - {l- [ (2R) -3- (3-BROMOPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 3-bromophenyl (2S)-3- chloro-2 -methylpropyl ether and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 473.0 (M + H) + . Example 372 N- (3 - {l- [ (2R) -3- (2-BROMOPHENOXY) -2-METHYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 2-bromophenyl (2S)-3- chloro-2 -methylpropyl ether and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 473.0 (M + H) + .
Example 373 N- (3 -{l- [ (2R) -3- (3 -CHLOROPHEΝOXY) -2-METHYLPROPYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-chloro-3- { [ (2S) -3- chloro-2-methylpropyl] oxy}benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 429.1 (M + H)+.
Example 374 N- (3 - {l- [3- (5,5-DIMETHYL-l,3-DIOXAΝ-2-YL) PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 2- (3-bromopropyl) -5, 5- dimethyl-1, 3-dioxane and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 403.2 (M + H) +
Example 375 N- (3 -{l- [4- (3 -ACETYLPHEΝOXY) BUTYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- [3- (4- chlorobutoxy) phenyl] ethanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 437.2 (M + H)+.
Example 376
N- (3- {l- [4- (3-METHOXYPHEΝOXY)BUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- (4-chlorobutoxy) -3- methoxybeήzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 425.2 (M + H) + . Example 377 N- (3- {l- [4- (4-METHOXYPHEΝOXY)BUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- (4-chlorobutoxy) -4- methoxybenzene and 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide: ESMS m/e : 425.2 (M + H) + .
Example 378 N- (3 - {l- [4- (2-METHOXYPHEΝOXY)BUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 1- (4-chlorobutoxy) -2- methoxybenzene and 2 -methyl-N- [3- (4-' piperidinyl) phenyl] propanamide: ESMS m/e : 425.2 (M + H)+.
Example 379 Ν-(3-{l- [4- (3,4-DIMETHYLPHEΝOXY)BUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 4- (4-chlorobutoxy) -1, 2- dimethylbenzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 423.2 (M + H)+.
Example 380
N- (3- {l- [4- (l,3-DIOXOLAΝ-2-YL)BUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 2- (4-chlorobutyl) -1, 3- dioxolane and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 375.2 (M + H) +
Example 381
N- (3 - {l- [5- (3-ACETYLPHEΝOXY) PENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-{3-[(5- chloropentyl) oxy] phenyl} ethanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 451.3 (M + H)+.
Example 382 N- (3 - {l- [5- (3-ACETYLPHEΝOXY) PENTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure G and Scheme Bl using l-{3-[(5- chloropentyl) oxy] phenyl}ethanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 449.2 (M + H)+.
Example 383
N- (3 - {l- [6 - (3-ACETYLPHEΝOXY) HEXYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-{3-[(6- chlorohexyl) oxy] phenyl}ethanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 465."3 (M + H) + .
Example 384 N- (3 - {l- [6- (3-ACETYLPHEΝOXY) HEXYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure G and Scheme Bl using l-{3-[(6- chlorohexyl) oxy] phenyl}ethanone and N- [3 - (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 463.3 (M + H) + .
Example 385
N- (3 - {l- [4- (4-CHLOROPHEΝOXY) -4- (4-CHLOROPHENYL) BUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure B and Scheme AN using 4-chlorophenol and N- (3- {l- [4- (4-chlorophenyl) -4-hydroxybutyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 562.9 (M + 23)+. Example 386
2-METHYL-N- (3-{l- [2- (1-METHYL-2-PHENYL-1H-INDOL-3- YL) ETHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (4-oxo- 4-phenylbutyl) -4-piperidinyl] phenyl}propanamide and 1- methyl-1-phenylhydrazine: ESMS m/e : 480.3 (M + H)+.
Example 387 2 -METHYL-N- (3-{1- [2- (2-PHENYL-Iff-BEΝZO [G] INDOL-3-
YL) ETHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (4-oxo- 4-phenylbutyl) -4-piperidinyl] phenyl}propanamide and 1- (1-naphthyl) hydrazine hydrochloride: ESMS m/e : 516.4 (M + H) + .
Example 388
2 -METHYL-N- (3 - {l- [3- (2-PHENYL-Iff-BEΝZO [G] INDOL-3- YL) PROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (5- oxo-5-phenylpentyl) -4-piperidinyl] phenyl}propanamide and 1- (1-naphthyl) hydrazine hydrochloride: ESMS m/e: 530.2 (M + H)+.
Example 389
2 -METHYL-N- [3- (l-{3- [2-PHEΝYL-5- (TRIFLUOROMETHOXY) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- {3- [1- (5-oxo-5-phenylpentyl) -4- . piperidinyl] phenyl}propanamide and 1- [4- (tri luoromethoxy)phenyl] hydrazine hydrochloride: ESMS m/e : 564.2 (M + H)+. Example 390
2-METHYL-N- [3- (l-{4- [2-PHENYL-5- (TRIFLUOROMETHOXY) -1H-
INPOL-3-YL] BUTYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2 -methyl -N- {3- [1- (6-oxo-6-phenylhexyl) -4- piperidinyl] phenyl}propanamide and 1- [4- (trifluoromethoxy) phenyl] hydrazine hydrochloride: ESMS m/e: 578.2 (M + H)+.
Example 391
2-METHYL-Ν- (3-{l- [3- (1-METHYL-2-PHE YL-1H-IΝDOL-3- YL) PROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (5-oxo- 5-phenylpentyl) -4-piperidinyl] phenyl}propanamide and 1- methyl-1-phenylhydrazine: ESMS m/e: 495.3 (M + H)+.
Example 392
Ν- (3-{l- [4- (l,2-DIPHEΝYL-lH-IΝDOL-3-YL) BUTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE : Prepared by Procedure E and Scheme M using 2-methyl-N-{3- [1- (6-oxo-
6-phenylhexyl) -4-piperidinyl] phenyl}propanamide and
1,1-diphenylhydrazine hydrochloride: ESMS m/e : (M + H)+.
570.3
Example 393 2-METHYL-Ν- [3- (l-{5- [2-PHENYL-5- (TRIFLUOROMETHOXY) -1H-
INDOL-3-YL] PENTYL} -4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N-
{3- [1- (7-oxo-7-phenylheptyl) -4- piperidinyl] phenyl}propanamide and 1- [4- (trifluoromethoxy) phenyl] hydrazine hydrochloride: ESMS m/e : 592.3 (M + H) "X
Example 394 N- ( 3 - { l - [5 - ( 1 , 2 -DIPHENYL- 1H- INDOL- 3 -YL) PENTYL] -4 -
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure E and Scheme M using 2-methyl-N- {3- [1- (7-oxo-
7-phenylheptyl) -4-piperidinyl]phenyl}propanamide and 1,1-diphenylhydrazine hydrochloride: ESMS m/e: 584.3 (M
+ H) +.
Example 395
2-METHYL-Ν- (3-{l- [5- (1-METHYL-2-PHENYL-1H-IΝDOL-3- YL) PENTYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (7-oxo- 7-phenylheptyl) -4-piperidinyl]phenyl}propanamide and 1- methyl-1-phenylhydrazine: ESMS m/e: 522.3 (M + H)+.
Example 396
2-METHYL-Ν- (3-{l- [4- (2-PHENYL-IH-BEΝZO [G] INDOL-3- YL) BUTYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (6-oxo- 6-phenylhexyl) -4-piperidinyl] phenyl}propanamide and 1- (1-naphthy1) hydrazine hydrochloride: ESMS m/e: 544.3 (M
+ H) + .
Example 397
2-METHYL-Ν- (3-{l- [4- (1-METHYL-2-PHENYL-1H-IΝDOL-3- YL) BUTYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (6-oxo- 6-phenylhexyl) -4-piperidinyl] phenyl}propanamide and 1- methyl-1-phenylhydrazine: ESMS m/e : 508.3 (M. + H)+.
Example 398
2-METHYL-Ν- (3-{l- [5- (2-PHE YL-1H-BEΝZO [G] INDOL-3-
YL) PENTYL] -4-PIPERIDINYL} PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N-{3- [1- (7- oxo-7-phenylheptyl) -4- piperidinyl]phenyl}propanamide and 1- (1- naphthy1) hydrazine hydrochloride: ESMS m/e: 558.2 (M +
H) + .
Example 399
2-METHYL-N- (3-{l- [2- (5-METHYL-2-PHENYL-IH- INDOL-3- YL) ETHYL] -4-PIPERIDINYL} PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (4-oxo- 4-phenylbutyl) -4-piperidinyl]phenyl}propanamide and 1- (4-methylphenyl) hydrazine hydrochloride: ESMS m/e: 480.2 (M + H)+. Example 400
Ν- (3-{l- [2- (7-METHOXY-2-PHEΝYL-1H-IΝDOL-3-YL) ETHYL] -4- PIPERIDINYL} PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (4-oxo- 4 -phenylbutyl) -4 -piperidinyl] henyl}propanamide and 1- (2 -methoxyphenyl) hydrazine hydrochloride: ESMS m/e: 496.2 (M + H)+.
Example 401
2-METHYL-Ν- (3-{l- [2- (7-METHYL-2-PHENYL- IH- INDOL-3 - • YL) ETHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (4-oxo- 4-phenylbutyl) -4-piperidinyl] phenyl}propanamide and 1- (2 -methylphenyl) hydrazine hydrochloride: ESMS m/e: 480.2 (M + H) + .
Example 402 N- (3-{l- [3- (7-METHOXY-2-PHENYL- IH- INDOL- 3 -YL) PROPYL] -4-
PIPERIDINYL} PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (5-oxo- 5-phenylpentyl) -4 -piperidinyl] phenyl}propanamide and 1- 5-phenylpentyl) -4- piperidinyl] phenyl}propanamide and 1- (2- methoxyphenyl) hydrazine hydrochloride: ESMS m/e: 510.2
(M + H)X
Example 403
2-METHYL-N- (3-{l- [4- (7-METHYL-2-PHENYL-1H-INDOL-3-
YL) BUTYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (6- oxo-6-phenylhexyl) -4-piperidinyl] phenyl}propanamide and
1- (2-methylphenyl) hydrazine hydrochloride: ESMS /e
508.3 (M + H) + .
Example 404 Ν- (3-{l- [2- (5-METHOXY-2-PHEΝYL-lH-IΝDOL-3-YL)ETHYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- {3- [1- (4-oxo- 4-phenylbutyl) -4-piperidinyl] phenyl}propanamide and 1- (4-methoxyphenyl) hydrazine hydrochloride: ESMS m/e : 496.2 (M + H)+.
Example 405
2-METHYL-Ν- (3-{l- [3- (5-METHYL-2-PHEΝYL-1H-IΝDOL-3- YL) PROPYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl -N- {3- [1- (5- oxo-5-phenylpentyl) -4-piperidinyl] phenyl}propanamide and 1- (4-methylphenyl) hydrazine hydrochloride: ESMS m/e : 494.3 (M + H)+.
Example 406
Ν- (3-{l- [4- (7-METHOXY-2-PHEΝYL-1H-IΝDOL-3-YL) BUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE Prepared by Procedure E and Scheme M using 2- methyl-N- { 3 - [1- (6-oxo-6-phenylhexyl) -4- piperidinyl]phenyl}propanamide and 1- (2- methoxyphenyl) ydrazine hydrochloride: ESMS m/e : 524.3 (M + H) + .
Example 407
2-METHYL-Ν- (3-{l- [3- (1-PHEΝYL-1H-IΝDOL-3-YL) PROPYL] -4- PIPERIDINYL}PHENYL) ROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [4- (1, 3-dioxolan-2-yl) butyl] - 4-piperidinyl}phenyl) -2-methylpropanamide and 1,1- diphenylhydrazine hydrochloride: ESMS m/e : 480.2 (M + H) + .
Example 408
2-METHYL-Ν- (3-{l- [2- (1-PHEΝYL-1H-IΝDOL-3-YL) ETHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [3- (1, 3-dioxolan-2- yl) propyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 466.2 (M + H) + .
Example 409
2-METHYL-Ν- (3-{l- [2- (7-METHYL-1H-IΝDOL-3 -YL) ETHYL] -4- PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [3- (1, 3-dioxolan-2- yl) propyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride:. ESMS m/e: 404.2 (M + H)+.
Example 410
2-METHYL-Ν- (3-{l- [2- (1-METHYL-1H-IΝDOL-3-YL) ETHYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [3- (1, 3-dioxolan-2- yl) propyl] -4-piperidinyl}phenyl) -2-methylpropanamide and
1-methyl-1-phenylhydrazine : ESMS m/e : 404.2 (M + H) + .
Example 411
2-METHYL-Ν- (3-{l- [2- (5-METHYL-1H-IΝDOL-3-YL) ETHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure H and Scheme S using N-(3-{l- [3- (1, 3-dioxolan-2- yl) ropyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 1- (4-methylphenyl) hydrazine hydrochloride: ESMS m/e: 404.2 (M + H)+.
Example 412
2-METHYL-N- [3- (l-{2- [5- (TRIFLUOROMETHOXY) -1H-INDOL-3- YL] ETHYL}- -PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [3- (1, 3-dioxolan- 2-yl) propyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 1- [4- (trifluoromethoxy) phenyl] hydrazine hydrochloride: ESMS m/e: 474.2 (M + H)+.
Example 413
Ν- (3-{l- [3- (lH-BEΝZO[G]IΝDOL-3-YL) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [4- (1, 3-dioxolan- 2~yl) butyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 1- (1-naphthyl) hydrazine hydrochloride: ESMS 454.2 m/e: (M + H)+.
Example 414 2 -METHYL-N- (3-{1- [3- (l-METHYL-lff-IΝDOL-3-YL) PROPYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure H and Scheme S. A mixture of N- (3- {l- [4- (1, 3-dioxolan-2- yl) butyl] -4-piperidinyl}phenyl) -2-methylpropanamide (100 mg, 0.270 mmol), 1-methyl- 1-phenylhydrazine (106 mg,
0.870 mmol), ZnCl2 (119 mg, 0.870 mmol) and HOAc (1.00 mL) was heated for 12 h at 80 °C. The resulting crude mixture was diluted with water (20 mL) , the aqueous layer was neutralized with a saturated K2C03 solution (10 mL) and extracted with CH2C12 (3 X 20 mL) . The combined organic layers were concentrated in vacuo and the residue was purified by preparative TLC using 3 % of NH3
(2.0 M in methanol) in CH2C12 to give the desired product 2 -methyl -N- (3-{l- [3- ( 1-methyl-Iff-indol-3 -yl) propyl] -4- piperidinyl}phenyl) propanamide (20.7 mg, 18.7 %) : ^Η ΝMR (400 MHz, CDC13) δ 7.60 (d, IH, J = 8.1 Hz), 7.45 (s, IH) , 7.35 (d, IH, J = 7.4 Hz), 7.25 (m, 4H) , 7.09 (t, IH, J = 7.3 Hz), 6.97 (d, IH, J = 7.3 Hz), 6.86 (s, IH) , 3.75 (s, 3H) , 3.11 (d, 2H, J = 11.6 Hz), 2.79 (t, 2H, J = 7.3 Hz), 2.51 (m, 4H) , 2.12-1.81 (m, 8H) , 1.25 (d, 6H, J = 7.1 Hz); Anal. Calcd for C27H35Ν3O+0.225 CHC13 : C, 73.57; H, 7.99; N, 9.45. Found: C, 73.93; H, 7.90; N, 9.23; ESMS m/e : 418.2 (M + H) + .
Example 415
2-METHYL-N- (3-{l- [3- (5-METHYL- IH-INDOL-3 -YL) PROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [4- (1, 3-dioxolan-2- yl) butyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 1- (4-methylphenyl) hydrazine hydrochloride: ESMS m/e : 418.2 (M + H)+.
Example 416 2-METHYL-Ν- [3- (l-{3- [5- (TRIFLUOROMETHOXY) -1H-IΝDOL-3-
YL] PROPYL}-4 -PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [4- (1, 3-dioxolan- 2-yl)butyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 1 - [4 -
(trifluoromethoxy) phenyl] hydrazine hydrochloride: ESMS m/e : 488.2 (M + H) + .
Example 417
2-METHYL-N- (3-{l- [3- (7-METHYL-IH- NDOL-3 -YL) ROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [4- (1, 3-dioxolan-2-yl)butyl] - 4-piperidinyl}phenyl) -2-methylpropanamide and 1- (2- methylphenyl) hydrazine hydrochloride: ESMS m/e: 418.2 (M + H) + .
Example 418
Ν- (3-{l- [3- (7-METHOXY-1H-IΝDOL-3-YL) PROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [4- (1, 3-dioxolan- 2-yl) butyl] -4-piperidinyl}phenyl) -2-methylpropanamide and 1- (2-methoxyphenyl) hydrazine hydrochloride: ESMS m/e : 434.0 (M + H) + .
Example 419
Ν- (3-{l- [2- (7-METHOXY-lH-IΝDOL-3-YL)ETHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [3- (1, 3-dioxolan- 2-yl) propyl] -4-piperidinyl }phenyl) -2-methylpropanamide and 1- (2-methoxyphenyl) hydrazine hydrochloride: ESMS m/e: 420.2 (M + H) + .
Example 420 Ν- (3-{l- [2- (5-METHOXY-lH-IΝDOL-3-YL)ETHYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure H and Scheme S using N- (3- {l- [3- (1, 3-dioxolan- 2-yl) propyl] -4-piperidinyl}phenyl) -2-methylpropanamide and l-(4- methoxyphenyl) hydrazine hydrochloride: ESMS /e : 420.2 (M + H)
Example 421 2-METHYL-N- (3-{l- [4- (5-METHYL-2-PHENYL-IH-INDOL-3-
YL) BUTYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- {3- [1- (6-oxo- 6-phenylhexyl) -4-piperidinyl] phenyl}propanamide and 1- (4-methylphenyl) hydrazine hydrochloride: ESMS /e: 508.3 (M + H) + .
Example 422
2-METHYL-Ν- [4- (l-{ [1- (4-METHYLPHENYL) -1H-INDOL-3- YL]METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [4- (4- piperidinyl) phenyl] propanamide and 1- (4-methylphenyl) - IH-indole: ESMS m/e : 466.2 (M + H)+.
Example 423 Ν- [4- (l-{ [1- (4-METHYLPHENYL) -1H-INDOL-3-YL] METHYL}-4-
PIPERIDINYL) PHENYL] BUTANAMIDE : Prepared by Procedure D and Scheme N using N- [4- (4-piperidinyl) phenyl] butanamide and 1- (4-methylphenyl) -IH-indole: ESMS m/e : 466.2 (M + H) + .
Example 424
Ν- [3- (l-{ [2- (2-AMIΝOPHEΝYL) -1H-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 2- (lH-indol-2- yl) aniline: ESMS m/e : 467.2 (M + H)+.
Example 425 ETHYL 3 - ({4- [3- (ISOBUTYRYLAMINO) PHENYL] -
1-PIPERIDINYL}METHYL) -IH-INDOLE-2-CARBOXYLATE: Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and ethyl lH-indole-2- carboxylate: ESMS m/e: 448.2 (M + H)+.
Example 426
2-METHYL-Ν- (3-{l- [ (1-METHYL-1H-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 1-methyl-IH-indole: ESMS m/e : 390.2 (M + H)+.
Example 427 Ν- (3-{l- [ (5-METHOXY-2-METHYL-1H-IΝDOL-3-YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 5-methoxy-2-methyl- 1H-indole: ESMS m/e: 420.2 (M + H) + .
Example 428
2-METHYL-Ν- (3-{l- [ (1-METHYL-2-PHENYL-1H-IΝDOL-3-
YL) METHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by
Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 1-methyl-2-phenyl-IH- indole: ESMS m/e : 466.2 (M + H) + .
Example 429
2-METHYL-Ν- (3-{l- [ (5-ΝITRO-1H-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 5-nitro-lH-indole: ESMS m/e : 421.1 (M + H) Example 430
2-METHYL-N- (3-{l- [ (2-METHYL-IH-INDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide and 2-methyl-IH-indole: ESMS m/e: 390.2 (M + H) +.
Example 431 Ν- (3-{l- [ (4-BROMO-1H-IΝDOL-3-YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 4-bromo-IH-indole: ESMS m/e : 455.0 (M + H) + .
Example 432
Ν- [3- (l-{ [2- (4-FLUOROPHENYL) -1H-INDOL-3-YL] METHYL} -4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) henyl] propanamide and 2- (4-fluorophenyl) - lff-indole: ESMS m/e: 470.0 (M + H)+.
Example 433
Ν- (3-{l- [ (l,2-DIPHEΝYL-lH-IΝDOL-3-YL)METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] ropanamide and 1, 2-diphenyl-lff- indole: ESMS m/e: 528.2 (M + H)+.
Example 434
N- [3 - ( l- { [2 - (4 - CHLOROPHENYL) - 1 -ETHYL- 1H- INDOL- 3 -
YL] METHYL} - 4 - PIPERIDINYL) PHENYL] - 2 -METHYLPROPANAMIDE :
Prepared by Procedure D and Scheme N using 2-methyl -N- [3 - ( 4- piperidinyl)phenyl] propanamide and 2- (4-chlorophenyl) -1- ethyl-IH-indole: ESMS m/e: 514.1 (M + H)+.
Example 435
N- (3-{l- [(5-CHLORO-2-METHYL-1H-IND0L-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl)phenyl] propanamide and 5-chloro-2 -methyl-lff- indole: ESMS m/e 424.1 (M + H) + .
Example 436
Ν- (3-{l- [ (5-CYAΝO-1H-IΝDOL-3-YL) METHYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide and lH-indole-5- carbonitrile: ESMS m/e: 401.1 (M + H)X
Example 437 2-METHYL-Ν- (3-{l- [ (5-METHYL-2-PHEΝYL-1H-IΝDOL-3-
YL) METHYL] -4-PIPERIDINYL} PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using
2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide and 5- methyl-2-phenyl-IH-indole: ESMS m/e: 466 . 2 (M + H)+.
Example 438
2-METHYL-Ν- [3- (l-{ [1- (4-ΝITROPHEΝYL) -1H-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:. Prepared by
Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 1- (4-nitrophenyl) -IH- indole: ESMS m/e : 497.2 (M + H) + .
Example 439 N- [3- (l-{ [1- (2- FLUOROPHENYL) -1H-INDOL-3-
YL]METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure D and Scheme N using 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide and 1- (2- fluorophenyl) -IH-indole: ESMS m/e: 470.1 (M + H)+.
Example 440
Ν-(3-{l-[(5,6-DIMETHOXY-IH-INDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 5, 6-dimethoxy-IH- indole: ESMS m/e : 436.2 (M + H) + .
Example 441 2-METHYL-Ν- [3- (l-{ [1- (3 -METHYLPHENYL) -1H-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 1- (3 -methylphenyl) - IH-indole: ESMS m/e : 466.2 (M + H)+.
Example 442
2-METHYL-Ν-{3- [1- ({l- [3- (TRIFLUOROMETHYL) PHENYL] -1H- INDOL-3-YL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure D and Scheme N using 2 -methyl -N- [3- (4-piperidinyl) phenyl] propanamide and 1- [3- (trifluoromethyl) phenyl] -IH-indole: ESMS m/e 520.2 (M + H) + .
Example 443 Ν- [3- (l-{ [1- (4-METHOXYPHEΝYL) -1H-IΝDOL-3-YL] METHYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 5-methoxy-2-phenyl- lff-indole: ESMS m/e: 482.2 (M + H)+.
Example 445
2-METHYL-N- (3-{l- [ (5-METHYL-IH-INDOL-3 -YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 2-methyl-N- [3- (4- piperidinyl) phenyl] ropanamide and 5-methyl-Iff-indole: ESMS m/e: 390.2 (M + H)+.
Example 446
N- [3 - (l- { [l- (2-ΝITROPHEΝYL) -Iff-INDOL-3 -YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (2-nitrophenyl) -1H- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 497.2 (M + H)+.
Example 447
N- [3- (l-{ [1- (2-METHOXYPHEΝYL) -lff-IΝDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (2-methoxyphenyl) -IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 482.2 (M + H)+.
Example 448
2-METHYL-N-{3- [1- ({l- [2- (TRIFLUOROMETHYL) PHENYL] -lff- INDOL-3 -YL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure D and Scheme N using 1- [2- (trifluoromethyl) phenyl] -IH-indole, and 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 520.2 (M + H) + .
Example 449 N- (3 -{l- [(5-METHOXY-lff- IΝDOL-3-YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure D and Scheme N using lH-indol-5-yl methyl ether and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 406.2 (M + H)+.
Example 450
N- [3- (l-{ [1- (4-FLUOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (4-fluorophenyl) -IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 470.2 (M + H)+.
Example 451 N- [3- (l-{ [1- (3-METHOXYPHEΝYL) -Iff-IΝDOL-3-YL] METHYL}-4-
PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (3-methoxyphenyl) -IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 482.2 (M + H)+.
Example 452
2-METHYL-N- [3- (l-{ [1- (2-METHYLPHENYL) -lff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by
Procedure D and Scheme N using 1- (2-methylphenyl) -lff- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 466.2 (M + H) + . Example 453
ETHYL 3- ({4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}METHYL) -5-METHOXY-Iff-INDOLE-2-CARBOXYLATE: Prepared by Procedure D and Scheme N using ethyl 5- methoxy-lH-indole-2-carboxylate and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 478.2 (M + H)+. Example 454
N- (3 - { l- [ (5-FLUORO-Iff-IΝDOL-3 -YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure D and Scheme N using 5-fluoro-IH-indole and 2- methyl -N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e :
394.2 (M + H)+.
1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and iodobenzene: ESMS /e : 193.9 (M + H)+.
1- (4-CHLOROPHENYL) -Iff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and l-chloro-4-iodobenzene :
ESMS m/e : 227.9 (M + H)+.
1- (3 -CHLOROPHENYL) -Iff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and l-chloro-3 -iodobenzene :
ESMS m/e : 227.9 (M + H)+.
1- (2 -CHLOROPHENYL) -Iff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and 1-chloro-2-iodobenzene:
ESMS m/e : 227.9 (M + H)+.
1- [2- (TRIFLUOROMETHYL) PHENYL] -lff-INDOLE: Prepared by Procedure C and Scheme 0 using IH-indole and l-iodo-2- (trifluoromethyl) benzene: ESMS m/e : 262.0 (M + H) + .
4- (Iff- INDOL-1-YDBENZONITRILE: Prepared by Procedure C and Scheme 0 using IH-indole and 4-iodobenzonitrile: ESMS m/e : 219.0 (M + H)
1- (4-NITROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and 1-iodo-4-nitrobenzene: ESMS m/e : 238.2 (M + H)+. 1- (2-NITROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using IH-indole and 1-iodo-2-nitrobenzene: ESMS m/e : 238.2 (M + H) + .
Example455 N- [3- (l-{ [1- (4-CHLOROPHENYL) -Iff-INDOL-3 -YL] METHYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (4-chlorophenyl) -IH-indole and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 472.1 (M + H) + .
Example 456
N- [3 - (l- { [l- (3-CHLOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (3 -chlorophenyl) -IH-indole and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS /e : 472.1 (M + H) + .
Example 457
N- [3- (l-{ [1- (2-CHLOROPHENYL) -Iff-INDOL-3 -YL] METHYL}-4- PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 1- (2-chlorophenyl) -IH- indole and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 484.1 (M + H)+.
Example 458
N- [3- (l-{ [1- (3-CHLOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (3-chlorophenyl) -IH- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 486.1 (M + H)+. Example 459
N- [3- (l-{ [1- (4-CHLOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (4-chlorophenyl) -IH- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 486.2 (M + H)
Example 460 N- [3- (l-{ [1- (2-CHLOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (2-chlorophenyl) -lff- i'ndole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 486.2 (M + H)+.
Example 461
N- [3- (l-{ [1- (2-CHLOROPHENYL) -Iff-INDOL-3 -YL] METHYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (2-chlorophenyl) -IH-indole and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 472.1 (M + H) + .
Example 462
N- [3- (l-{ [1- (4-CHLOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 1- (4-chlorophenyl) -IH- indole and N- [3- (4- piperidinyl)phenyl] cyclopropanecarboxamide: . ESMS m/e : 484.1 (M + H)+.
Example 463
N- [3- (l-{ [1- (3-CHLOROPHENYL) -Iff-INDOL-3 -YL] METHYL}-4-
PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 1- (3-chlorophenyl) -
IH-indole and N- [3 - (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e :
484.1 (M + H) + .-
Example 464
N- (3- {l- [ (1-PHEΝYL-lff-IΝDOL-3-YL) METHYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 1-phenyl-IH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 438.2 (M + H)+.
Example 465
N- (3-{l- [(l-PHEΝYL-lff-IΝDOL-3-YL)METHYL] -4- PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 1-phenyl-IH-indole and N- [3- (4-piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e: 450.2 (M + H) + .
6-CHLORO-1- (4-ΝITROPHEΝYL) -Iff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-lff-indole and 1- iodo-4-nitrobenzene: ESMS m/e: 272.6 (M + H) + .
6-CHLORO-l- (2, 3-DICHLOROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-IH-indole and l,2-dichloro-3-iodobenzene: ESMS m/e : 296.5 (M + H)+.
6-CHLORO-l- (3 -METHYLPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-lH-indole and 1- iodo-3-methylbenzene: ESMS m/e: 241.9 (M + H)+.
6-CHLORO-l- ( -METHYLPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-lH-indole and 1- iodo-2-methylbenzene: ESMS m/e : 241.9 (M + H)+. 2- (6-CHLORO-lff-INDOL-1-YL) PHENYL METHYL ETHER: Prepared by Procedure C and Scheme 0 using 6-chloro-IH-indole and l-iodo-2-methoxybenzene: ESMS m/e: 257.9 (M + H)+.
6-CHLORO-l- [3- (TRIFLUOROMETHYL) HENYL] -lff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-lff- indole and l-iodo-3- (trifluoromethyl) benzene : ESMS m/e: 295.6 (M + H)+.
6-CHLORO-l- (2-FLUOROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-IH-indole and 1- fluoro-2-iodobenzene: ESMS m/e: 245.9 (M + H)+.
6-CHLORO-l- (3-CHLOROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-chloro-lH-indole and 1- chloro-3 -iodobenzene: ESMS m/e 261.9 (M + H) "X
6-CHLORO-l- (4-CHLOROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-chloro- IH-indole and 1- chloro-4-iodobenzene: ESMS m/e : 262.9 (M + H)+.
6-CHLORO-l- (2-CHLOROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-chloro-lH-indole and 1- chloro-2-iodobenzene: ESMS m/e : 262.9 (M + H)
3- (6-CHLORO-lff-INDOL-l-YL) PHENYL METHYL ETHER: Prepared by Procedure C and Scheme O using 6-chloro-lH-indole and l-iodo-3 -methoxybenzene : ESMS m/e: 257.9 (M + H) + .
6-CHLORO-l- [4- (TRIFLUOROMETHYL) PHENYL] -lff-INDOLE:
Prepared by Procedure C and Scheme 0 using 6-chloro-IH- indole and l-iodo-4- (trifluoromethyl) benzene
ESMS m/e : 295.6 (M + H) + .
6-CHLORO-l- (4-METHYLPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-chloro-IH-indole and 1- iodo-4-methylbenzene: ESMS m/e : 241.9 (M + H) + .
6-CHLORO-l- (4-FLUOROPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 6-chloro-IH-indole and 1- fluoro-4-iodobenzene: ESMS m/e : 245.9 (M + H) "X
Example 466
N- [3- (l-{ [6-CHLORO-l- (4-FLUOROPHENYL) -lff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 6-chloro-1- (4-fluorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 502.1 (M + H)X
Example 467
N- [3- (l-{ [6-CHLORO-l- (4-FLUOROPHENYL) -lff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-chloro-1- (4- fluorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 490 . 1 (M + H)
Example 468
N- (3 - {l- [ (6-FLUORO-lff-IΝDOL-3-YL)METHYL] -4- • PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-fluoro-lH-indole and N- [3 - (4- piperidinyl) phenyl] propanamide: ESMS m/e : 380.1 (M + H)+. Example 469
N- (3 - {l- [(6-FLUORO-1H-IΝDOL-3-YL) METHYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure D and Scheme N using 6-fluoro-IH-indole and N- [3- (4-piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e: 392.1 (M + H)+.
Example 470
N- (3 - {l- [ (6-FLUORO-lff-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6-fluoro-IH-indole and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 394.1 (M + H) + .
Example 471
N- [3- (l-{ [6-CHLORO-l- (4-FLUOROPHENYL) -Iff-INDOL-3-
YL] METHYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure D and Scheme N using 6-chloro-l-
(4-fluorophenyl) -IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e 504.1 (M + H) + .
Example 472
N- [3- (l-{ [6-CHLORO-l- (2-FLUOROPHENYL) -lff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-chloro-l- (2- fluorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 490.1 (M + H)+.
Example 473 N- [3- (l-{ [6-CHLORO-l- (2-FLUOROPHENYL) -Iff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE :
Prepared by Procedure D and Scheme N using 6-chloro-l- (2-fluorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e: 502.1 (M + H)+.
Example 474 N- [3- (l-{ [6-CHLORO-l- (2-FLUOROPHENYL) -Iff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE :
Prepared by Procedure D and Scheme N using 6-chloro-1- (2-fluorophenyl) -IH-indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide ESMS m/e: 504.1 (M + H)+.
Example 475
N- [3- (l-{ [6-CHLORO-l- (4-CHLOROPHENYL) -Iff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-chloro-l- (4- chlorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] propanamide ESMS m/e: 506.1 (M + H)+.
Example 476
N- [3- (l-{ [6-CHLORO-l- (4-CHLOROPHENYL) -Iff-INDOL-3- YL] METHYL}-4 -PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE:
Prepared by Procedure D and Scheme N using 6-chloro-1- (4-chlorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide ESMS m/e : 518.1 (M + H)+.
Example 477
N- [3- (l-{ [6-CHLORO-l- (4-CHLOROPHENYL) -Iff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE :
Prepared by Procedure D and Scheme N using 6-chloro-l- (4-chlorophenyl) -IH-indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide ESMS m/e: 520.1 (M + H)+. Example 478
N- [3- (l-{ [6-CHLORO-l- (3 -CHLOROPHENYL) -Iff-INDOL-3-
YL] METHYL}-4 -PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure -D and Scheme N using 6-chloro-l- (3- chlorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 506.1 (M + H) + .
Example 479
Ν- [3- (l-{ [6-CHLORO-l- (3 -CHLOROPHENYL) -lff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE:
Prepared by Procedure D and Scheme N using 6-chloro-l- (3 -chlorophenyl) -IH-indole and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : 1H ΝMR (400 MHz, CDC13) δ 7.72 (d, IH, J = 8.4 Hz), 7.68 (s, IH) , 7.49 (m, 2H) , 7.44 (d, 2H, J = 7.9 Hz), 7.49-7.25 (m, 4H) , 7.21 (d, IH, J = 7.9 Hz), 7.17 (d, IH, J = 7.9 Hz), 6.93 (d, IH, J = 7.9 Hz), 3.79 (s, 2H) , 3.13 (d, 2H, J = 9.4 Hz), 2.48 (sept, IH, J = 7.5 Hz), 2.16 (m, 2H) , 1.80 (m, 4H) , 1.51 (s, IH) , 1.06 (m, 2H) , 0.806 (m, 2H) ; Anal. Calcd for C30H29Cl2Ν3θ+HCl+l .4H20: C, 62.11; H, 5.70; N, 7.24. Found: C, 62.19; H, 6.21; N, 7.06; ESMS m/e : 519.2 (M + H) + .
Example 480 N- [3- (l-{ [6-CHLORO-l- (3 -CHLOROPHENYL) -lff-INDOL-3-
YL] METHYL} -4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure D and Scheme N using 6-chloro-l-
(3 -chlorophenyl) -IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 520.1 (M + H)+.
Example 481
N- (3 - {l- [ (5-FLUORO-Iff-IΝDOL-3 -YL) METHYL] -4-
PIPERIDIΝYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 5-fluoro-Iff-indole and N- [3- (4-piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 392.1 (M + H)+.
Example 482
N- [3- (l-{ [6-CHLORO-l- (2-CHLOROPHENYL) -lff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE :
Prepared by Procedure D and Scheme N using 6-chloro-l-
(2-chlorophenyl) -IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 520.2 (M + H) + .
Example 483
N- [3- (l-{ [6-CHLORO-l- (3-METHOXYPHEΝYL) -lff-IΝDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure D and Scheme N using 3- (6-chloro- IH-indol-1-yl) phenyl methyl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 516.2 (M + H)+.
Example 484 N- [3- (l-{ [6-CHLORO-l- (2-METHOXYPHEΝYL) -lff-IΝDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE :
Prepared by Procedure D and Scheme N using 2- (6-chloro- lH-indol-1-yl) phenyl methyl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 516.2 (M + H)+.
Example 485
N- [3- (l-{ [6-CHLORO-l- (2, 3-DICHLOROPHENYL) -Iff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure D and Scheme N using 6-chloro-1- (2, 3 -dichlorophenyl) -IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 555.1 (M + H)+. Example 486
N- [3- (l-{ [6-CHLORO-l- (4-METHYLPHENYL) -lff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE :
Prepared by Procedure D and Scheme N using 6-chloro-1- (4-methylphenyl) -IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 500.2 (M + H) + . Example 487
N- {3- [1- ({6-CHLORO-l- [3- (TRIFLUOROMETHYL) PHENYL] -lff- INDOL-3-YL}METHYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6-chloro-l- [3- (trifluoromethyl) phenyl] -IH-indole and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 554.2 (M + H) + .
Example 488
N- {3 - [1- ({6-CHLORO-l- [4- (TRIFLUOROMETHYL) PHENYL] -Iff- INDOL-3-YL}METHYL) -4-PIPERIDINYL] PHENYL} -2- METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6-chloro-l- [4- (trifluoromethyl) phenyl] -IH-indole and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 554.2 (M + H) + .
Example 489
N- [3- (l-{ [6-CHLORO-l- (2-METHYLPHENYL) -lff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure D and Scheme N using 6-chloro-l-
(2-methylphenyl) -IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 500.2 (M + H)+.
Example 490
N- [3- (l-{ [6-CHLORO-l- (3-METHYLPHENYL) -lff-INDOL-3- YL] METHYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure D and Scheme N using 6-chloro-l- (3-methylphenyl) -IH-indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 500.2 (M + H) X
Example 491
N- (3 - {l- [ (7-CHLORO-Iff-IΝDOL-3-YL)METHYL] -4- PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 7-chloro-IH-indole and N- [3- (4-piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 408.1 (M + H)+.
Example 492
N- (3 - {l- [(7-CHLORO-lff-IΝDOL-3-YL)METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 7-chloro-lH-indole and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS /e : 410.1 (M + H)+.
Example 493
N- (3 - {l- [(4-FLUORO-lff-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 4-fluoro-lH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 380.2 (M + H)+.
Example 494 N- (3 - {l- [ (7-CHLORO-Iff-IΝDOL-3 -YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 7-chloro-lH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 39-6.1 (M + H) + .
Example 495
2 -METHYL-N- (3-{1- [ (6-METHYL-lff-IΝDOL-3 -YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-methyl-IH-indole and 2 -methyl-N- [3- ( 4 - piperidinyl) phenyl] propanamide: ESMS m/e : 390.2 (M + H)+.
Example 496 N- [3- (l-{ [6- (BENZYLOXY) -Iff-INDOL-3 -YL] METHYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6- (benzyloxy) -IH-indole and 2-methyl -N- [3- (4-piperidinyl)phenyl] propanamide : ESMS m/e : 482.2 (M + H) "X
Example 497
N- (3 - {l- [ (6-METHOXY-lff-IΝDOL-3-YL)METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using lff-indol-6-yl methyl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 406.2 (M + H)+.
Example 498
METHYL 3- ({4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}METHYL) -Iff-INDOLE-6-CARBOXYLATE: Prepared by Procedure D and Scheme N using methyl lff-indole-6- carboxylate and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 434.2 (M + H) + .
Example 499
2 -METHYL-N- [3- (l-{ [6- (TRIFLUOROMETHYL) -lff-IΝDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE : Prepared by Procedure D and Scheme N using 6- (trifluoromethyl) - IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: λE ΝMR (400 MHz, CDC13) δ 8.11 (s, IH) , 7.66 (s, IH) , 7.63 (s, 2H) , 7.44 (d, IH, J = 8.4 Hz), 7.39 (s, 2H) , 7.32 (d, IH, J = 8.4 Hz), 7.16 (t, IH, J = 8.4 Hz), 6.84 (d, IH, J = 8.4 Hz), 4.06 (s, 2H) , 3.27 (d, 2H, J = 11.6 Hz) , 2.56 (sept, IH, J =
6.8 Hz) , 2.37 (m, 3H) , 1.93 (m, 2H) , 1.75 (m, 2H) , 1.22
(d, 6H, J = 6.8 Hz) ; Anal. Calcd for
C25H28F3N3O+2HCl+0.5EtOAc : C, 57.8; H, 6.11; N, 7.50. Found: C, 56.5; H, 6.46; N, 7.77; ESMS m/e: 444.2 (M +
H) + .
1- (2-PYRIDINYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using 2-iodopyridine and IH-indole: ESMS m/e: 195.0 (M + H)+.
1- (3-PYRIDINYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 3-iodopyridine and IH-indole: ESMS m/e: 195.0 (M + H)+.
Example 500
2-METHYL-N- [3- (l-{ [1- (3-PYRIDIΝYL) -lff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE : Prepared by Procedure D and Scheme N using 1- (3-pyridinyl) -lff- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 453.2 (M + H)+.
Example 501
2-METHYL-N- [3- (l-{ [1- (2-PYRIDIΝYL) -Iff-IΝDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 1- (2-pyridinyl) -IH- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 453.2 (M + H)+.
Example 502
N-(3-{l- [(6-FLUORO-l-PHEΝYL-lff-IΝDOL-3-YL)METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6-fluoro-1-phenyl-IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e -. 470.2 (M + H) + .
Example 503
Ν-(3-{l- [(6-CHLORO-l-PHEΝYL-lff-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D. and Scheme N using 6-chloro-l -phenyl -IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 486.2 (M + H) + .
7-METHYL-l-PHEΝYL-lff-IΝDOLE: Prepared by Procedure C and Scheme O using 7-methyl- IH-indole and iodobenzene: ESMS m/e : 208.1 (M + H)+.
METHYL 1-PHENYL-Iff-INDOLE-6 -CARBOXYLATE: Prepared by Procedure C and Scheme 0 using methyl lH-indole-6- carboxylate and iodobenzene: ESMS m/e : 252.0 (M + H)+. 6-METHYL-1- HENYL-Iff-INDOLE: Prepared by Procedure C and Scheme O using 6-methyl-IH-indole and iodobenzene: ESMS m/e -. 208.0 (M + H) + .
7-CHLORO-1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme O using 7-chloro-lH-indole and iodobenzene: ESMS m/e : 228.0 (M + H)+.
6-NITRO- 1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-nitro- IH-indole and iodobenzene: ESMS m/e: 238.2 (M + H)+.
6-METHOXY-1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme 0 using lH-indol-6-yl methyl ether and iodobenzene: ESMS m/e : 224.0 (M + H)+. BENZYL 1-PHENYL-Iff-INDOL- 6-YL ETHER: Prepared by
Procedure C and Scheme 0 using 6- (benzyloxy) -IH-indole and iodobenzene: ESMS m/e: 300.0 (M + H)+.
1-PHENYL-Iff-INDOL-6-YL TRIFLUOROMETHYL ETHER: Prepared by Procedure C and Scheme 0 using 6- (trifluoromethoxy) - IH-indole and iodobenzene: ESMS m/e: 278.0 (M + H)+.
7-METHOXY-1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme O using lff-indol-7-yl methyl ether and iodobenzene: ESMS m/e: 224.0 (M + H)+.
l-PHENYL-6- (TRIFLUOROMETHYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using 6- (trifluoromethyl) -1H- indole and iodobenzene: ESMS m/e 262.0 (M + H)+.
1- (4-PYRIDINYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and 4-iodopyridine: ESMS m/e: 195 (M + H)+.
Example 504
N- [3- (l-{ [6- (BENZYLOXY) -l-PHENYL-lff-INDOL-3-YL] METHYL}- 4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using benzyl 1-phenyl-lH-indol- 6-yl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 558.0 (M + H)+.
Example 505
2-METHYL-N- (3- {l- [ (6-METHYL-1-PHENYL-Iff-IΝDOL-3- YL) METHYL] - -PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-methyl-1-phenyl-IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ^Η ΝMR (400 MHz, CDC13) δ 7.66 (s, IH) , 7.64 (d, IH, J = 7.8 Hz) , 7.51 (d, IH,
J = 3.9 Hz) , 7.50 (m, 3H) , 7.4 (m, 2H) , 7.36-7.32 (m,
2H) , 7.31 (s, IH) , 7.19 (t, IH, J= 7.8 Hz) , 7.04 (d, IH,
J = 7.8 Hz) , 6.91 (d, IH, J = 7.8 Hz) , 3.94 (s, 2H) , 3.25 (d, 2H, J = 9.2 Hz) , 2.52 (sept, IH, J = 6.4 Hz) ,
2.46 (s, 3H) , 2.28 (dt, 2H, J = 11.8, 2.6 Hz) , 1.89 (dq,
2H, J = 2.9 Hz) , 1.80 (m, 3H) , 1.22 (d, 6H, J = 6.9 Hz) ;
Anal. Calcd for C31H35N3O+HCI+0.6EtOAc: C, 72.2; H, 7.41;
N, 7.57. Found: C, 71.0; H, 7.40; N, 7.66; ESMS m/e: 466 (M + H)+.
Example 506
METHYL 3- ({4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}METHYL) -1-PHENYL-Iff-INDOLE-6-CARBOXYLATE: Prepared by Procedure D and Scheme N using methyl 1- phenyl-IH-indole-6-carboxylate and 2-methyl-N- [3- (4- piperidinyl) henyl] propanamide: ESMS m/e: 510.0 (M + H) + .
Example 507 2-METHYL-N- (3-{l- [ (6-ΝITRO-lff-IΝDOL-3-YL) METHYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 6-nitro-lH-indole and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 421.0 (M + H)X
Example 508
2-METHYL-N- [3- (l-{ [l-PHEΝYL-6- (TRIFLUOROMETHYL) -lff- INDOL-3-YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using l-phenyl-6- (trifluoromethyl) -IH-indole and 2-methyl-N- [3- (4- piperidinyl)phenyl] propanamide: ESMS m/e: 520.0 (M + H) + . Example 509
2 -METHYL-N- (3 - { l- [ (7 -METHYL- l-PHENYL-lff- INDOL-3 -
YL) METHYL] -4-PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 7-methyl-1-phenyl-lff- indole and 2 -methyl-N- [3- ( - piperidinyl) phenyl] propanamide: ESMS m/e : 466.0 (M + H)+.
Example 510
N- (3- {l- [(7-METHOXY-lff-Il jOL-3-YL)METHYLr-4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using lH-indol-7-yl methyl ether and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 406.0 (M + H)+.
Example 511
N- (3 - {l- [ (7-METHOXY-1-PHENYL-Iff-IΝDOL-3-YL) METHYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 7-methoxy-1-phenyl-IH- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propaaamide: -ESMS m/e : 482.0 (M + H)+.
Example 512
N- (3 - {l- [ (7-CHLORO-1-PHEΝYL-Iff-IΝDOL-3 -YL) METHYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 7-chloro-1-phenyl-IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 488.6 (M + H)+.
Example 513 2 -METHYL-N- ( -{1- [ (7-ΝITRO-Iff-IΝDOL-3-YL) METHYL] -4-
PIPERIDIΝYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 7-nitro-lH-indole and 2 -methyl-N- [3- ( 4 - piperidinyl) phenyl] propanamide: ESMS m/e 421.1 (M + H) + .
Example 514 N- (3 - {l- [ (7-ΝITRO-Iff-IΝDOL-3 -YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure D and Scheme N using 7-nitro-lff-indole and N- [3- (4-piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 419.5 (M + H) + .
Example 515
N- (3 - {l- [(7-ΝITRO-Iff-IΝDOL-3 -YL) METHYL] -4-
PIPERIDIΝYL}PHENYL) PROPANAMIDE: Prepared by Procedure D and Scheme N using 7-nitro-IH-indole and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e 407.3 (M + H)+.
7- (2 -FLUOROPHENYL) -Iff-I DOLE: Prepared by Procedure I and Scheme T using 7-bromo-IH-indole and 2- fluorophenylboronic acid: ESMS m/e : 211.9 (M + H)+.
Example 516
N- [3- (l-{ [7- (2-FLUOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N. A solution of 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide (23.3 mg, 0.0948 mmol) and 37 wt % aqueous formaldehyde (11.4 mg, 0.142 mmol) in 1.00 mL of HOAc : dioxane (1:4) was added to 7- (2- fluorophenyl) -IH-indole (20.0 mg, 0.0948 mmol) and the reaction mixture was stirred for 12 h at room temperature. The resulting mixture was diluted with H20
(10 mL) . The aqueous layer was extracted with CH2C12 (3
X 10 mL) . The combined organic extracts were washed with brine (10 mL) , dried over MgS04, and concentrated in vacuo. The residue was purified by preparative
TLC on silica using 4 % of NH3 (2.0 M in methanol) in
CH2C1 to give the desired product (56.1 mg, 100%): XH
NMR (400 MHz, CDC13) δ 8.58 (s, IH) , 7.73 (dd, IH, J = 2.8, 6.3 Hz), 7.69 (s, IH) , 7.53 (dt, IH, J = 1.8, 7.6
Hz), 7.44 (d, IH, J = 8.1 Hz), 7.38 (m, 2H) , 7.32 (s,
IH) , 7.27-7.21 (m, 4H) , 7.17 (t, IH, J = 7.6 Hz), 6.88
(d, IH, J = 7.6 Hz), 3.92 (s, 2H) ; 3.20 (d, IH, J = 11.6
Hz), 2.51 (qt, IH, J = 6.7 Hz), 2.42 (m, IH) , 2.25 (dt, 2H, J = 2.2, 11.6 Hz), 1.89-1.72 (m, 5H) , 1.22 (d, 6H, J
= 7.3 Hz); ESMS m/e : 470.1 (M + H) + .
7- (4 -ETHYLPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 7-bromo-IH-indole and 4- ethylphenylboronic acid: ESMS m/e : 222.0 (M + H)+.
7- (2-NAPHTHYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 7-bromo-IH-indole and 2-naphthylboronic acid: ESMS m/e : 244.0 (M + H)+.
7- (3 -CHLOROPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 7 -bromo- IH-indole and 3- chlorophenylboronic acid: ESMS m/e : 227.9 (M + H)+.
6- (2 -FLUOROPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 6-bromo-IH-indole and 2- fluorophenylboronic acid: ESMS m/e : 211.9 (M + H) + .
7- (3 -NITROPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 7 -bromo-IH-indole and 3- nitrophenylboronic acid: ESMS m/e : 238.9 (M + H)+. 1- [4- (lff-INDOL-7- YL) PHENYL] ETHANONE:
Prepared by Procedure I and Scheme T using 7-bromo-IH- indole and 4-acetylphenylboronic acid: ESMS m/e : 235.2 (M + H) + .
6- (2-METHYLPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 6-bromo-IH-indole and 2- methylphenylboronic acid: ESMS m/e: 207.9 (M + H) + .
6- (3-CHLOROPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 6-bromo-IH-indole and 3- chlorophenylboronic acid: ESMS m/e: 227.9 (M + H)+.
1- [4- (Iff-INDOL-6-YL) PHENYL] ETHANONE: Prepared by Procedure I and Scheme T using 6-bromo-IH-indole and 4- acetylphenylboronic acid: ESMS m/e : 235.8 (M + H)+.
7- (2 -METHYLPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 7-bromo-IH-indole and 2- methylphenylboronic acid: ESMS m/e : 208 (M + H)+.
6- (4-ETHYLPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 6-bromo-IH-indole and 4- ethylphenylboronic acid: ESMS m/e: 221.9 (M + H)+.
Example 517
2 -METHYL-N- [3- (l-{ [7- (2-ΝAPHTHYL) -Iff-INDOL-3 -YL] METHYL}- 4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared, by Procedure D and Scheme N using 7- (2-naphthyl) -IH-indole and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 502.2 (M + H)+.
Example 518 N- [3- (l-{ [7- (4- ETHYLPHENYL) -lff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure D and Scheme N using 7- (4- ethylphenyl) -IH-indole and 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 480.2 (M + H)+.
Example 519
2 -METHYL-N- [3- (l-{ [6- (2-METHYLPHENYL) -lff-INDOL-3-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 6- (2 -methylphenyl) -IH- indole and 2 -methyl -N- [3- (4- piperidinyl) phenyl] propanamide: XE ΝMR (400 MHz, CDC13) δ 8.2 (s, IH) , 7.53 (m, 4H) , 7.41 (d, IH, J = 8.4 Hz), 7.34 (m, 2H) , 7.27-7.12 (m, 5H) , 6.81 (d, IH, J = 8.4 Hz), 4.09 (s, 2H) , 3.32 (d, 2H, J = 11.4 Hz), 2.57 (q, 2H, J = 7.6 Hz), 2.43 (m, 3H) , 2.08 (s, 3H) , 1.98 (m, IH) , 1.75 (m, 2H) , 1.22 (d, 6H, J = 6.3 Hz); Anal. Calcd for C31H3sΝ30+CHCl3+DMF: C, 57.0; H, 6.09; N, 8.06. Found: C, 56.5; H, 5.94; N, 7.76; ESMS m/e : 466.2 (M + H)+.
Example 520
N- [3- (l-{ [7- (3 -CHLOROPHENYL) -Iff-INDOL-3 -YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 7- (3 -chlorophenyl) -IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 486.1 (M + H)+.
Example 521 2 -METHYL-N- [3- (l-{ [7- (3 -NITROPHENYL) -lff-INDOL-3-
YL] METHYL} -4 -PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 7- (3-nitrophenyl) -IH- indole and 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide: ESMS m/e: 497.0 (M + H)+.
Example 522 N- [3- (l-{ [7- (4-ACETYLPHEΝYL) -Iff-IΝDOL-3-YL] METHYL}-4-
PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure D and Scheme N using 1- [4- (lH-indol-7- yl) phenyl] ethanone and 2-methyl -N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 493.6 (M + H)+.
Example 523
N- [3- (l-{ [6- ( -ETHYLPHENYL) -Iff-INDOL-3 -YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6- (4-ethylphenyl) -1H- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 480.1 (M + H)+.
Example 524
2-METHYL-N- [3- (l-{ [7- (2-METHYLPHENYL) -Iff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 7- (2 -methylphenyl) -IH- indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e: 466.1 (M + H)+.
Example 525
N- [3- (l-{ [6- (2-FLUOROPHENYL) -Iff-INDOL-3-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 6- (2-fluorophenyl) -IH- indole and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 470.2 (M + H)+. 5- (4-METHYLPHEΝOXY) -lff-INDOLE: Prepared by Procedure J and Scheme U using 5-bromo-IH-indole and p-cresol: ESMS m/e : 224.0 (M + H) + . Example 526
N- (3 -{l- [(5-BROMO-Iff-IΝDOL-3-YL)METHYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure D and Scheme N using 5-bromo-IH-indole and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 454.0 (M + H)+.
1- (4-PYRIDINYL) -6- (TRIFLUOROMETHYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using 6- (trifluoromethyl) - IH-indole and 4-iodopyridine: ESMS m/e : 262.9 (M + H)+.
Example 527
2-METHYL-N- [3- (l-{ [5- (4-METHYLPHEΝOXY) -Iff-INDOL-3- YL] METHYL}-4-PIPERIDINYL) HENYL] PROPANAMIDE: Prepared by Procedure D and Scheme N using 5- (4-methylphenoxy) - IH-indole and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 481.9 (M + H)+.
1- (4-METHYLPHENYL) -Iff-INDOLE: Prepared by Procedure C and Scheme 0 using IH-indole and l-iodo-4-methylbenzene: ESMS m/e : 208.0 (M + H) + .
1- (3-METHYLPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and l-iodo-3-methylbenzene : ESMS m/e: 208.0 (M + H) "X
1- [3- (TRIFLUOROMETHYL) PHENYL] -lff-INDOLE: • Prepared by Procedure C and Scheme 0 using IH-indole and l-iodo-3- (trifluoromethyl) benzene: ESMS m/e: 262.0 (M + H)+. 1- (4-METHOXYPHENYL) -Iff- INDOLE: Prepared by
Procedure C and Scheme 0 using IH-indole and l-iodo-4- methoxybenzene: ESMS m/e : 224.0 (M + H) "X
1- (2-METHOXYPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and l-iodo-2- methoxybenzene : ESMS /e: 224.0 (M + H)+.
1- (3-METHOXYPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme 0 using IH-indole and l-iodo-3 - methoxybenzene: ESMS m/e: 224.0 (M + H) + .
1- (2-METHYLPHENYL) -lff-INDOLE: Prepared by Procedure C and Scheme O using IH-indole and l-iodo-2-methylbenzene*. ESMS m/e : 208.0 (M + H)+.
6-FLUORO-1-PHENYL-lff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-fluoro-lH-indole and iodobenzene: ESMS m/e: 212.0 (M + H)+.
6-CHLORO-1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme 0 using 6-chloro-lH-indole and iodobenzene: ESMS m/e : 228.0 (M + H)+.
7-CHLORO-1-PHENYL-Iff-INDOLE: Prepared by Procedure C and Scheme 0 using 7-chloro-IH-indole and iodobenzene: ESMS m/e: 228.0 (M + H) "X
6- (2-FLUOROPHENYL) -lff-INDOLE: Prepared by Procedure I and Scheme T using 6-bromo-IH-indole and 2- fluorophenylboronic acid: ESMS m/e-. 211.9 (M + H) + . Example 528
2- ETHY -N-{3- [1- (7-OXO-7-PHENYLHEPTYL) -4-
PIPERIDINYL] PHENYL} ROPANAMIDE: Prepared by Procedure K and Scheme Bl using 7-chloro-1-phenyl-1-heptanone and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e :
435.1 (M + H)+.
Example 529
2 -METHYL-N-{3- [1- (6-OXO-6-PHENYLHEXYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 6-chloro-1-phenyl-1-hexanone and 2- methyl -N- [3- (4-piperidinyl) phenyl] propanamide: Anal.
Calcd for C27H36Ν2O2+0.1CHC13 : C, 75.3; H, 8.39; N, 6.46.
Found: C, 75.4; H, 7.89; N, 6.18; ESMS m/e: 421.1 (M + H)+.
Example 530
2 -METHYL-N-{3- [1- (5-OXO-5-PHEΝYLPEΝTYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-1-phenyl-1-pentanone and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e : 407.1 (M + H)+.
Example 531 N- (3 -{l- [4- (4-METHOXYPHEΝYL) -4-OXOBUTYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using .4-chloro-l- (4-methoxyphenyl) -1- butanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS ιτ?/e: 409.2 (M + H) + . Example 532
N- (3-{l- [4- (4-CHLOROPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4-chlorophenyl) -1- butanone and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 413.1 (M + H)+.
Example 533 N- (3- {l- [4- ( -BROMOPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 1- (4-bromophenyl) -4-chloro-1- butanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 457.1 (M + H)+.
Example 534 N- (3 - {l- [4- (4-TERT-BUTYLPHEΝYL) -4-OXOBUTYL] -4- PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 1- (4- ert-butylphenyl) -4-chloro-1- butanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 435.2 (M + H) + .
Example 535 N- (3 - {l- [4- (4-FLUOROPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4-fluorophenyl) -1- butanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 397.2 (M + H) + .
Example 536
N- (3 - {l- [4-0X0-4- (4-PHEΝOXYPHEΝYDBUTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4-phenoxyphenyl) -1- butanone and N- [3- (4-piperidinyl)phenyl] propanamide: ESMS m/e: 471.2 (M + H) "X Example 537
N- (3- {l- [4- (4-ISOPROPYLPHEΝYL) -4-OXOBUTYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure K- and Scheme Bl using 4-chloro-l- (4- isopropylphenyl) -1-butanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e :
433.2 (M + H)+.
Example 538 N- (3 - {l- [4- (4-METHOXYPHEΝYL) -4-OXOBUTYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4- methoxyphenyl) -1-butanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 421.2 (M + H)+.
Example 539
N- (3 - {l- [4-0X0-4- (4-PHEΝOXYPHEΝYDBUTYL] -4- PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4- phenoxyphenyl) -1-butanone and N- [3- (4- piperidinyl)phenyl] cyclopropanecarboxamide: ESMS m/e : 483.2 (M + H)+.
Example 540
N- (3 - {l- [4- (4-ISOPROPYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4-isopropylphenyl) -1- butanone and N- [3- (4-piperidinyl)phenyl] propanamide: ESMS m/e : 421.3 (M + H) + . Example 541
N- (3 - {l- [4- (4-TERT-BUTYLPHEΝYL) -4-OXOBUTYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure K and Scheme Bl using 1- (4- tert-butylphenyl) - 4-chloro-1-butanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e :
447.2 (M + H)+.
Example 542 N- (3-{l- [4- (4-METHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4-methylphenyl) -1- butanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 393.2 (M + H) + .
Example 543 N- (3 - {l- [4- (3,4-DIMETHYLPHEΝYL) -4-OXOBUTYL] -4- PIPERIDIΝYLjPHEΝYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (3 , 4-dimethylphenyl) -1- butanone and N- [3- (4-piperidinyl)phenyl] propanamide: ESMS m/e : 407.2 (M + H)+.
Example 544
N- (3 -{l- [4- (4-BROMOPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 1- (4-bromophenyl) -4- chloro-1-butanone and N- [3 - (4- piperidinyl) phenyl] cyclopropanecarboxamide: • ESMS m/e : 469.1 (M + H)+. Example 545
N- (3- {l- [5- (4-FLUOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (4-fluorophenyl) -1- pentanone and N- [3 - (4- piperidinyl) phenyl] propanamide: ESMS m/e: 411.2 (M + H) + .
Example 546 N- (3 - {l- [4- (3,4-DIMETHYLPHEΝYL) -4-OXOBUTYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (3 , 4- dimethylphenyl) -1-butanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 419.2 (M + H)X
Example 547
N- (3 - {l- [4- (4-METHYLPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4- methylphenyl) -1-butanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e: 405.2 (M + H)+.
Example 548
N- (3 - {l- [4- (4-FLUOROPHENYL) -4-OXOBUTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 4-chloro-l- (4- fluorophenyl) -1-butanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 409.2 (M + H)+.
Example 549
N- (3 - {l- [5- (3-FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-1- (3- fluorophenyl) -1-pentanone and N- [3 - (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 423 .2 (M + H) + .
Example 550 N- [3- (l-{5-OXO-5- [4- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4-
PIPERIDINYL) HENYL] PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-1- [4-
(trifluoromethyl) phenyl] -1-pentanone and N- [3 - (4- piperidinyl) phenyl] propanamide: ESMS m/e: 461.2 (M + H)+.
Example 551 N- (3 - {l- [5- (4-FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (4- fluorophenyl) -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e: 423.2 (M + H) + .
Example 552 N- (3 - {l- [5- (3 -NITROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (3-nitrophenyl) -1- pentanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 438.2 (M + H)+.
Example 553
N- (3 - {l- [5- (3-NITROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (3- nitrophenyl) -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 450.2 (M + H)+. Example 554
N-(3-{l-[5- (2-FLUOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (2-fluorophenyl) -1- pentanone and N- [3- (4-piperidinyl) phenyl] propanamide:
ESMS m/e: 411.2 (M + H)
Example 555 N-(3-{l- [5- (3 -FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (3 -fluorophenyl) -1- pentanone and N- [3- (4 -piperidinyl) phenyl] propanamide: ESMS m/e 411.2 (M + H)+.
Example 556
N-(3-{l- [5-(4-ΝITROPHEΝYL)-5-OXOPEΝTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (4-nitrophenyl) -1- pentanone and N- [3 - (4-piperidinyl) phenyl] propanamide : ESMS m/e: 438.1 (M + H)+.
Example 557
N-(3-{l- [5- (4 -NITROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (4- nitrophenyl) -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e: 450.1 (M + H)+.
Example 558
N-(3-{l-[5- (4-CHLOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure K and Scheme Bl using 5-chloro-l- (4- chlorophenyl) -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e :
439.1 (M + H)+.
Example 559
N- [3- (l-{5-OXO-5- [2- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- [2- (trifluoromethyl) phenyl] -1-pentanone and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 461.2 (M + H) + .
Example 560
N- [3- (l-{5-OXO-5- [2- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4- PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- [2- (trifluoromethyl) phenyl] -1-pentanone and N- [3 - (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 473.2 (M + H)X
Example 561
N- (3 - {l- [5- (4-CHLOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (4-chlorophenyl) -1- pentanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 427.1 (M + H)
Example 562
N- (3- {l- [5- (3-CHLOROPHENYL) -5-OXOPENTYL] -4- ■ PIPERIDINYL}PHENYL) PROPANAMIDE: . Prepared by Procedure K and Scheme Bl using 5-chloro-l- (3-chlorophenyl) -1- pentanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 427.1 (M + H) + . Example 563
N- (3 - {l- [5-(2-FLUOROPHENYL) -5-OXOPEΝTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure K and .Scheme Bl using 5-chloro-l- (2- fluorophenyl) -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e :
423.1 (M + H)+.
Example 564 N- (3 - {l- [5- (3-CHLOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINΗι}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (3- chlorophenyl) -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 439.1 (M + H)+.
Example 565
N- [3- (l-{5-OXO-5- [4- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4- PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- [4- (trifluoromethyl) phenyl] -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e :
473.2 (M + H)X
Example 566
N- (3- {l- [5- (2-CHLOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- (2-chlorophenyl) -1- pentanone and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 427.1 (M + H) + . Example 567
N- (3 - {l- [5- (2-CHLOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure K and Scheme Bl using 5-chloro-l- (2- chlorophenyl) -1-pentanone and N- [3- (4- piperidinyl ) phenyl] cyclopropanecarboxamide : ESMS m/e :
439.1 (M + H)+.
Example 568 N- [3- (l-{5-OXO-5- [3- (TRIFLUOROMETHYL) PHENYL] PENTYL} -4-
PIPERIDINYL) PHENYL] CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure K and Scheme Bl using 5-chloro-l- [3-
(trifluoromethyl) phenyl] -1-pentanone and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 473.2 (M + H) + .
Example 569
N- (3 - {l- [4- (3, 4-DIMETHYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) -N, 2 -DIMETHYLPROPANAMIDE : Prepared by Procedure T and Scheme AD using N- (3- {l- [4- (3 , 4- dimethylphenyl) -4-oxobutyl] -4-piperidinyl }phenyl) -2- methylpropanamide and methyl iodide: 1H ΝMR (400 MHz, CDC13) δ 7.76 (s, IH) , 7.72 (dd, IH, J = 1.8, 7.7 Hz), 7.33 (t, IH, J = 8.8 Hz), 7.22 (d, IH, J = 7.8 Hz), 7.18 (d, IH, J = 8.8 Hz), 7.01 (m, 2H) , 3.24 (s, 3H) , 3.10 (d, IH, J = 10.6 Hz), 3.00 (t, IH, J = 7.6 Hz), 2.49 (m, 4H) , 2.33 (s, 6H) , 2.11 (m, 3H) , 1.99 (m, IH) , 1.79 (m, 4H) , 1.26 (t, 2H, J = 7.6 Hz), 1.02 (d, 6H,- J = 7.6 Hz); ESMS m/e : 435.2 (M + H) + .
Example 570
2 -METHYL-N- {3- [1- (1-METHYL-4-OXO-4-PHEΝYLBUTYL) -4- PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 4- chloro-1-phenyl-1- pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 407.2 (M + H)+.
Example571
N- [3- (1-{5-0X0-5- [3- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K and Scheme Bl using 5-chloro-l- [3- (trifluoromethyl) phenyl] -1-pentanone and N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 461 .2 (M + H) + .
3- (5-CHLOROPEΝTAΝOYL) -4- (3, 4-DIFLUOROPHENYL) -1,3- OXAZOLIDIN-2-ONE: Prepared by Procedure AF and Scheme H using 4- (3 , 4-difluorophenyl) -1, 3-oxazolidin-2-one and 5-chloropentanoyl chloride.
3- (5-CHLOROPENTYL) -4- (3,4-DIFLUOROPHENYL) -1,3- OXAZOLIDIN-2-ONE: Prepared by Procedure G and Scheme Cl using 4- (3 , 4-difluorophenyl) -1, 3-oxazolidin-2-one and 1- bromo-5-chloropentane .
Example 572
N- [3-(l-{5- [(4R) -4- (3,4-DIFLUOROPHENYL) -2-0X0-1,3- 0XAZ0LIDIN-3-YL] -5-OXOPENTYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE: ' Prepared by Procedure G and Scheme Bl using (4R) -3- (5-chloropentanoyl) -4- (3 , 4- difluorophenyl) -1, 3-oxazolidin-2-one and 2 -methyl-N- [3 - (4-piperidinyl) phenyl] propanamide: ESMS m/e: 528.2 (M + H) + .
Example 573 (4R) -4- (3, 4-DIFLUOROPHENYL) -N- (3- {4- [3- (ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -2-0X0- 1,3-OXAZOLIDINE-3- CARBOXAMIDE: Prepared by
Procedure AF and Scheme H using 4-nitrophenyl (4R)-4-
(3, 4-difluorophenyl) -2-oxo-1, 3 -oxazolidine-3 -carboxylate and N-{3- [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide: 1H ΝMR (400 MHz, CDC13) δ 8.08 (t, IH,
J = 5.5 Hz), 7.45 (S, 2H) , 7.38 (d, IH, J = 8.6 Hz),
7.24-7.12 (m, 3H) , 7.06 (m, IH) , 6.97 (d, IH, J = 8.6
Hz), 5.40 (dd, IH, J = 3.9,8.8 Hz), 4.71 (t, IH, J = 8.8
Hz), 4.23 (dd, IH, J = 4.4, 9.1 Hz), 3.32 (qt, 2H, J = 6.1 Hz), 2.99 (d, 2H, J = 11.0 Hz), 2.49 (qt, 2H, J =
7.0 Hz), 2.41 (t, 2H, J = 7.0 Hz), 1.99 (m, 2H) , 1.82-
1.68 (m, 6H) , 1.23 (d, 6H, J = 7.3 Hz); ESMS m/e: 529.1
(M + H) + .
(4S) -3- (5-CHLOROPEΝTYL)-4- (3,4-DIFLUOROPHENYL) -1,3-
0XAZOLIDIN-2-ONE: Prepared by Procedure G and Scheme Cl using (4S) -4- (3 , 4-difluorophenyl) -1, 3-oxazolidin-2-one and l-bromo-5-chloropentane.
Example 574
N- [3- (l-{5- [(4S) -4- (3,4-DIFLUOROPHENYL) -2-0X0-1,3- OXAZOLIDIN- 3 - YL] PENTYL} - 4 - PIPERIDINYL) PHENYL] - 2 - METHYLPROPANAMIDE: . Prepared by Procedure G and Scheme Bl using (4S) -3- (5-chloropentyl) -4- (3 , 4-dif luorophenyl) - 1, 3-oxazolidin-2-one and 2-methyl-N- [3- (4 - piperidinyl) phenyl] propanamide : "Η ΝMR (400 MHz, CDC13) δ 7.48 (s, IH) , 7.32 (d, IH, J = 8.6 Hz) , 7.26-7.21 (m, 2H) , 7.20-7.12 (m, 2H) , 7.06 (m, IH) , 6.97 (d, IH, J = 6.96 Hz) , 4.76 (dd, IH, J = 6.3, 8.3 Hz) , 4.62 (t, IH, J = 9.0 Hz) , 4.06 (dd, IH, J = 6.4, 8.7 Hz) , 3.46 (m, IH) ,
3.0 (d, 2H, J = 9.0 Hz) , 2.77 (q, IH, J = 6.8 Hz) , 2.50 (q, 2H, J = 6.8 Hz) , 2.31 (t, 2H, J = 6.8 Hz), 2.01 (m, 4H) , 1.81 (m, 4H) , 1.48 (m, 4H) , 1.26 (d, 6H, J = 7.3 Hz); Anal. Calcd for C28H37F2N3O3+HCl+0.25CHC13 :
C, 60.6; H, 6.65; N, 7.25. Found: C, 60.7; H, 6.91; N,
7.05; ESMS m/e: 514.2 (M + H) + .
Example 575
N- [3- (l-{5- [ (4S) -4- (3,4-DIFLUOROPHENYL) -2-0X0-1, 3- OXAZOLIDIN-3-YL] -5-0X0PENTYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE : Prepared by Procedure G and Scheme Bl using (4S) -3- (5-chloropentanoyl) -4- (3 , 4- dif luorophenyl) -1, 3- oxazolidin- 2 -one and 2-methyl-N- [3 -
(4-piperidinyl) phenyl] propanamide: ESMS m/e: 528.1 (M + H) + .
Example 576 (4S) -4- (3, 4-DIFLUOROPHENYL) -N-(3-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -2-0X0- 1,3 -OXAZOLIDINE-3-CARBOXAMIDE: Prepared by Procedure AF and Scheme H using 4-nitrophenyl (4S) -4- (3,4- difluorophenyl) -2-oxo-l, 3-oxazolidine-3-carboxylate and N-{3-[l- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e: 529.1 (M + H)+.
Example 577 (4S) -N-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}PROPYL) -2-0X0-4- (3, 4, 5-TRIFLUOROPHENYL) -1,3- OXAZOLIDINE-3-CARBOXAMIDE: Prepared by Procedure AF and Scheme H using 4-nitrophenyl (4S)-4- (3,4- difluorophenyl) -2-oxo-l, 3-oxazolidine-3-carboxylate and N-{3- [1- (3-aminopropyl) -4-piperidinyl] phenyl-} -2- methylpropanamide: ESMS m/e: 547.1 (M + H) + .
Example 578
(4S) -4- (3, 5-DIFLUOROPHENYL) -N-(3-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -2-0X0- 1,3 -OXAZOLIDINE-3- CARBOXAMIDE: Prepared by
Procedure AF and Scheme H using 4-nitrophenyl (45) -4-
(3 , 4-difluorophenyl) -2-oxo-l , 3 -oxazolidine-3 -carboxylate and N- { 3 - [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e : 529.2 (M + H) + .
Example 579
N- (3 - {l- [3- (PHEΝYLSULFAΝYL) PROPYL] -4-
PIPERIDIΝYL}PHENYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [ (3 -chloropropyl) sulfanyl] benzene and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 382.9 (M + H)X
Example 580
N- (3 - {l- [3- (PHEΝYLSULFAΝYL) PROPYL] -4- PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure G and Scheme Bl using [(3- chloropropyl) sulfanyl] benzene and N- [3 - (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e : 395.1 (M + H)X
Example 581 2 -METHYL-N- (3 -{1- [3- (PHEΝYLSULFAΝYL) PROPYL] -4- PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [ (3 -chloropropyl) sulfanyl] benzene and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: 1H
ΝMR (400 MHz, CDC13) δ 7.63 (s, IH) , 7.48 (s, IH) , 7.33
(m, 3H) , 7.27 (t, 2H, J = 7.5 Hz), 7.20 (t, IH, J = 7.9
Hz), 7.15 (tt, IH, J = 7.2, 1.4 Hz), 6.95- (d, IH, J =
7.6 Hz), 2.97 (t, 4H, J = 7.3 Hz), 2.46 (m, 4H) , 1.99 (dt, 2H, J = 11.4, 3.0 Hz), 1.84 (qt, 2H, J = 7.3 Hz), 1.77 (m, 4H) , 1.21 (d, 6H, J = 6.8 Hz); ESMS m/e : 396.8 (M + H) + . Example 582
N- (3-{1- [6- (PHEΝYLSULFAΝYL) HEXYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by
Procedure G and Scheme Bl using [(6- chlorohexyl) sulfanyl] benzene and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e:
437.4 (M + H)+.
Example 583 N- (3 - {l- [4- (PHEΝYLSULFAΝYL) BUTYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [ (4-chlorobutyl) sulfanyl] benzene and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 396.8 (M + H)X
Example 584 N- (3 - { l- [4- (PHEΝYLSULFAΝYL) BUTYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure G and Scheme Bl using [(4- chlorobutyl) sulfanyl] benzene and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide : ESMS m/e :
409.5 (M + H)+.
Example 585 2 -METHYL-N- (3-{1- [4- (PHEΝYLSULFAΝYL) BUTYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [ (4-chlorobutyl) sulfanyl] benzene and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 410.6 (M + H) + .
Example 586
2 -METHYL-N- (3-{1- [5- (PHEΝYLSULFAΝYL) PENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [(5- chloropentyl) sulfanyl] benzene and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 425.1 (M + H)+.
Example 587
N- (3 -{l- [5- (PHEΝYLSULFAΝYL) PENTYL] -4-
PIPERIDINYL}PHENYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure G and Scheme Bl using [(5- chloropentyl) sulfanyl] benzene and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 423.1 (M + H)+.
[(6-CHLOROHEXYL) SULFANYL] BENZENE: Prepared by Procedure R and Scheme Z using benzenethiol and 1-bromo-6- chlorohexane .
[ (4-CHLOROBUTYL) SULFANYL] BENZENE: Prepared by Procedure
R and Scheme Z using benzenethiol and l-bromo-4- chlorobutane .
Example 588
N- (3 -{l- [6- (PHEΝYLSULFAΝYL) HEXYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [ (6-chlorohexyl) sulfanyl] benzene and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 425.4
(M + H)+.
[ (5-CHLOROPENTYL) SULFANYL] BENZENE: Prepared by
Procedure R and Scheme Z using benzenethiol and 1-bromo- 5-chloropentane .
[ (3-CHLOROPROPYL) SULFANYL] BENZENE: Prepared by
Procedure R and Scheme Z using benzenethiol and 1-bromo- 3 -chloropropane: XH NMR (400 MHz, CDC13) δ 7.37-
7.34 (m, 2H) , 7.32-7.26 (m, 2H) , 7.19 (tt, IH, J = 1.4,
7.3 Hz) , 3.67 (t, 2H, J = 6.6 Hz) , 3.08 (t, 2H, J = 6.6
Hz) , 2.06 (qt, 2H, J = 6.6 Hz) .
Example 589
N-(3-{l-[5- (PHEΝYLSULFAΝYL) PENTYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure G and Scheme Bl using [ (5-chloropentyl) sulfanyl] benzene and N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e:
411.1 (M + H)+.
3-CHLOROPROPYL 4-FLUOROPHENYL SULFIDE: Prepared by
Procedure R and Scheme Z using 4-fluorobenzenethiol and
1-bromo-3 -chloropropane .
l-BROMO-2- [ (3-CHLOROPROPYL) SULFANYL] BENZENE: Prepared by
Procedure R and Scheme Z using 2-bromobenzenethiol and
1-bromo-3 -chloropropane .
3-CHLOROPROPYL 4-FLUOROPHENYL SULFOXIDE: Prepared by Procedure S and Scheme AA using 3 -chloropropyl 4- fluorophenyl sulfide and 1 eq m-CPBA: ^Η NMR (400 MHz, CDC13) δ 7.65-7.62 (m, 2H) , 7.28-7.21 (m, 2H) , 3.65 (m, 2H) , 2.94 (m, 2H) , 2.28 (m, IH) , 2.06 (m, IH) ; ESMS m/e: 220.9 (M + H)+.
3-CHLOROPROPYL 3-FLUOROPHENYL SULFIDE: Prepared by Procedure R and Scheme Z using 3 -fluorobenzenethiol and 1-bromo-3-chloropropane .
3-CHLOROPROPYL 2-FLUOROPHENYL SULFIDE: Prepared by Procedure R and Scheme Z using 2-fluorobenzenethiol and l-bromo-3 -chloropropane . l-BROMO-2- [ (3-CHLOROPROPYL) SULFINYL] BENZENE: Prepared by Procedure S and Scheme AA using l-bromo-2- [ (3- chloropropyl) sulfanyl] benzene and 1 eq m-CPBA: ESMS m/e : 282.8 (M + H)+.
1-CHLORO-2 - [ (3 -CHLOROPROPYL) SULFANYL] BENZENE : Prepared by Procedure R and Scheme Z using 2-chlorobenzenethiol and 1-bromo- 3 -chloropropane.
l-CHLORO-3- [ (3-CHLOROPROPYL) SULFANYL] BENZENE: Prepared by Procedure R and Scheme Z using 3-chlorobenzenethiol and 1 -bromo- 3-chloropropane .
l-CHLORO-4- [ (3-CHLOROPROPYL) SULFANYL] BENZENE: Prepared by Procedure R and Scheme Z using 4-chlorobenzenethiol and 1 -bromo- 3-chloropropane .
l-BROMO-3- [(3-CHLOROPROPYL) SULFANYL] BENZENE: Prepared by Procedure R and Scheme Z using 3-bromobenzenethiol and l-bromo-3-chloropropane.
l-BROMO-4- [ (3-CHLOROPROPYL) SULFANYL] BENZENE: Prepared by Procedure R and Scheme Z using 4-bromobenzenethiol and l-bromo-3-chloropropane .
3-CHLOROPROPYL 3,4-DIMETHYLPHENYL SULFIDE: Prepared by Procedure R and Scheme Z using 3 , 4-dimethylbenzenethiol and 1 -bromo- 3-chloropropane .
Example 590
N- [ 3 - ( l- { 3 - [ (4 -FLUOROPHENYL) SULFINYL] PROPYL} -4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using 3 -chloropropyl 4- fluorophenyl sulfoxide and 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide: E ΝMR (400 MHz, CDC13) δ
7.64 (m, 2H) , 7.53 (s, IH) , 7.24 (m, 5H) , 6.94 (d, IH, J
= 7.7 Hz), 2.89 (m, 4H) , 2.45 (m, 4H ), 1.99 (m, 3H) , 1.77 (m, 5H) , 1.24 (d, 6H, J = 6.8 Hz); Anal. Calcd for
C24H31FΝ2O2S + 0 . 6EtOAc : C , 65 . 5 ; H, 7 . 45 ; N, 5 . 79 .
Found: C, 65.4; H, 7.30; N, 5.73; ESMS m/e: 431.1 (M +
H) + .
Example 591
N- [3- (l-{3- [ (2-BROMOPHENYL) SULFINYL] PROPYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure G and Scheme Bl using l-bromo-2- [ (3- chloropropyl) sulfinyl] benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: Anal. Calcd for C24H31BrΝ2O2S+0.3CHCl3: ESMS m/e: 491.0 (M + H) + .
Example 592
N- {3 - [1- ( (3S) -3-{ [ (3, -DIFLUOROPHENYL) SULFONYL]AMINθ}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:
Prepared by Procedure Ql and Scheme AC using 3,4- difluorobenzenesulfonyl chloride and N- (3- {l- [ (3S) -3- amino-3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 556.2 (M + H)+.
Example 593 3-CHLORO-N- C (IS) -3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}-1-PHENYLPROPYL) -2-THIOPHENECARBOXAMIDE: Prepared by Procedure Ql and Scheme AC using 3-chloro-2- thiophenecarbonyl chloride and N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 524.2 (M + H) + . Example 594
N- (3- {l- [(3S)-3-({[5-(DIMETHYLAMIΝO) -1- NAPHTHYL] SULFONYL}AMINO) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure Ql and Scheme AC using 5- (dimethylamino) -1- naphthalenesulfonyl chloride and N- (3- {l- [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 613.3 (M + H)+. Example 595 2 -METHYL-N-{3- [1- ( (35) -3-{ [ (4-
METHYLPHEΝYL) SULFOΝYL] AMIΝθ}-3 -PHEΝYLPROPYL) -4- PIPERIDINYL]PHENYL}PR0PANAMIDE: Prepared by Procedure Ql and Scheme AC using 4-methylbenzenesulfonyl chloride and N- (3-{l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e 534.2 (M + H) + .
Example 596
N- {3 - [1- ( (3S) -3-{ [(3,5-DICHLORO-2- HYDROXYPHENYL) SULFONYL] AMINO}-3-PHENYLPROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared
Procedure Ql and Scheme AC using 3 , 5-dichloro-2- hydroxybenzenesulfonyl chloride and N- (3- {l- [ (3S) -3- amino-3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide: ESMS m/e: 605.4 (M + H)
Example 597
2-METHYL-N- [3- (l-{ (3S) -3- [ (METHYLSULFOΝYL) MIΝO] -3- PHEΝYLPROPYL} -4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure Ql and Scheme AC using methanesulfonyl chloride and N- (3- (l- [ (35) -3-amino-3- phenylpropyl] -4-piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 458.6 (M + H) + . Example 598
N- {3 - [1- ( (3S) -3-{ [(4-FLUOROPHENYL) SULFONYL]AMINO}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE:
Prepared by Procedure Ql and Scheme AC using 4- fluorobenzenesulfonyl chloride and N- (3- {l- [ (3S) -3- amino-3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 538.1 (M + H)+.
Example 599 N- {3 - [1- ( (3S) -3-{ [ (4-TERT-BUTYLPHENYL) SULFONYL] AMINO}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE:
Prepared by Procedure Ql and Scheme AC using 4-tert- butylbenzenesulfonyl chloride and N- (3- { l - [ (3S) -3-amino- 3-phenylpropyl] -4-piperidinyl}phenyl) -2- methylpropanamide: ESMS m/e: 576.2 (M + H) + .
Example 600
N- {3 - [1- ( (3S) -3-{ [ (2, 5-DICHLOROPHEΝYL) SULFONYL] AMIΝO}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE: Prepared by Procedure Ql and Scheme AC using 2,5- dichlorobenzenesulfonyl chloride and N- (3- {l- [ (3S) -3- amino-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e : 588.0 (M + H)+.
Example 601
2-METHYL-N- [3- (l-{ (3S) -3-PHEΝYL-3-
[ (PROPYLSULFONYL)AMINO] PROPYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure
Ql and Scheme AC using 1-propanesulfonyl chloride and N- (3-{l- [ (3S) -3-amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 486.2
(M + H) + . Example 602
N- {3 - [1- ( (3S) -3 - { [ (3 , 5 -DIMETHYL-4 -
ISOXAZOLYL) SULFONYL]AMIΝO}-3 -PHEΝYLPROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Ql and Scheme AC using 3 , 5-dimethyl-4- isoxazolesulfonyl chloride and N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl}phenyl) -2-methylpropanamide:
XE ΝMR (400 MHz, CDC13) δ 7.53 (s, 2H) , 7.3-7.1 (m, 5H) ,
7.05 (t, 2H, J = 6.5 Hz), 6.81 (d, IH, J = 7.1 Hz), 4.65 (dd, IH, J = 6.3, 2.2 Hz), 3.11 (t, 2H, J = 7.2 Hz), 2.4
(m, 4H) , 2.2 (s, 3H) , 2.05 (m, 2H) , 2.01 (s, 3H) , 2.0- 1.8 (m, 7H) , 1.21 (d, 6H, J = 7.1 Hz); ESMS m/e : 539.5
(M + H) + .
Example 603
METHYL 3-{[(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}PROPYL) AMINO] SULFONYL}-2-
THIOPHENECARBOXYLATE: Prepared Procedure Ql and Scheme AC using methyl 3- (chlorosulfonyl) -2- thiophenecarboxylate and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide : Anal. Calcd for C24H33Ν305S.HC1: C, 6.00; H, 5.30; N, 7.72. Found: C, 52.9; H, 6.04; N, 7.59; ESMS m/e : 508.2 (M + H) + .
Example 604
2 -METHYL-N-{3- [1- ( (3S) -3-{ [(4-
PHEΝOXYAΝILIΝO) CARBONYL] AMINO}-3-PHENYLPROPYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isocyanato-4-phenoxybenzene and N- (3- { l- [ (3S) -3 -amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 591.3 (M + H) + . PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE:
Prepared by Procedure Ql and Scheme AC using 3,5- dimethyl-4-isoxazolesulfonyl chloride and N- (3- {l- [ (3S) -
3-amino-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide: XE ΝMR (400 MHz, CDC13) δ 7.53 (s,
2H) , 7.3-7.1 (m, 5H) , 7.05 (t, 2H, J = 6.5 Hz), 6.81 (d,
IH, J = 7.1 Hz), 4.65 (dd, IH, J = 6.3, 2.2 Hz), 3.11
(t, 2H, J = 7.2 Hz), 2.4- (m, 4H) , 2.2 (s, 3H) , 2.05 (m,
2H) , 2.01 (s, 3H) , 2.0-1.8 (m, 7H) , 1.21 (d, 6H, J = 7.1 Hz); ESMS m/e : 539.5 (M + H) + .
Example 603 METHYL 3-{[(3-{4-[3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}PROPYL) MINO] SULFONYL} -2 - THIOPHENECARBOXYLATE: Prepared Procedure Ql and Scheme AC using methyl 3- (chlorosulfonyl) -2- thiophenecarboxylate and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide: Anal. Calcd for C24H33Ν3O5S.HCI: C, 6.00; H, 5.30; N, 7.72. Found: C, 52.9; H, 6.04; N, 7.59; ESMS m/e : 508.2 (M + H)
Example 604
2 -METHYL-N- {3- [1- ((3S)-3-{ [(4-
PHEΝOXYAΝILIΝO) CARBONYL] AMIΝO} -3 -PHEΝYLPROPYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isocyanato-4-phenoxybenzene and N-
(3-{l- [ (3S) -3-amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 591.3
(M + H) + .
Example 605
N- [3- (l-{ (3S) -3- [ (AΝILIΝOCARBOΝYL) AMIΝO] -3-
PHEΝYLPROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using isocyanatobenzene and N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e: 499.2 (M + H)+-
Example 606
N- {3 - [1- ( (3S) -3-{ [(TERT-BUTYLAMIΝO)CARBOTHIOYL]AMIΝθ}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P arid Scheme AB using 2- isothiocyanato-2-methylpropane and N- (3- {l- [ (3S) -3- amino-3-phenylpropyl] -4-piperidinyl }phenyl) -2 - methylpropanamide : ESMS m/e : 495.1 (M + H)+.
Example 607 N- {3 - [1- ( (3S) -3-{ [ (2-FLUOROAΝILIΝO) CARBONYL] AMIΝO} -3-
PHENYLPROPYL) -4-PIPERIDINYL] HENYL}-2-METHYLPROPANAMIDE:
Prepared by Procedure P and Scheme AB using l-fluoro-2- isocyanatobenzene and N- (3- {l- [ (3S) -3-amino-3- phenylpropyl] -4-piperidinyl }phenyl) -2-methylpropanamide: ESMS m/e : 517.0 (M + H) *-
Example 608
2-METHYL-N- [3- (l-{ (3S) -3-PHEΝYL-3- [ (2- TOLUIDINOCARBOTHIOYL) AMINO] PROPYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isothiocyanato-2-methylbenzene and N- (3-{l- [ (3S) -3-amino-3-phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e : 529.1 (M + H)+.
Example 609 $" ~
N- {3 - [1- ((3S) -3-{ [ (BEΝZYLAMIΝO) CARBONYL]AMIΝO}-3- PHENYLPROPYL) -4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: phenylpropyl] -4- piperidinyl }phenyl) -2- methylpropanamide : XH NMR (400 MHz, CDC13) δ 8.44 (s,
IH) , 7.67 (d, IH, J = 7.9 Hz), 7.31-7.13 (m, 13H) , 6.38
(s, IH) , 6.80 (d, IH, J = 7.9 Hz), 5.54 (m, IH) , 4.81 (m, IH) , 4.41 (dd, IH, J = 14.8, 6.2 Hz), 4.29 (dd, IH,
J = 14.9, 5.4 Hz), 2.99 (d, IH, J = 11.2 Hz), 2.87 (d,
IH, J = 11.2 Hz), 2.67 (q, IH, J = 6.2 Hz), 2.3 (m, 3H) ,
2.0-1.5 (m, 7H) , 1.23 (d, 6H, J = 6.7 Hz); ESMS m/e :
513.2 (M + H)+.
Example 610
2 -METHYL-N- {3- [1- ( (3S) -3-{ [(2-
ΝITROAΝILIΝO) CARBONYL] AMINO} -3 -PHENYLPROPYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isocyanato-2-nitrobenzene and N- (3-{l- [ (3S) -3 -amino-3 -phenylpropyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 543.6 (M + H) + .
Example 611
N- {3 - [1- ( (3S) -3-{ [ (3,4-DICHLOROAΝILIΝO) CARBONYL] AMINO}- 3 -PHENYLPROPYL) -4 -PIPERIDINYL] PHENYL} -2 -
METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using 1, 2-dichloro-4-isocyanatobenzene and N- (3- { l - [ (3S) -3-amino-3-phenylpropyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e : 567.1 (M + H) + .
Example 612
2 -METHYL-N- (3 - {l- [ (3S) -3- ({ [2- (METHYLSULFAΝYL) AΝILIΝO] CARBONYL} MIΝO) -3 -PHENYLPROPYL] -
4 -PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isocyanato-2- (methylsulfanyl) benzene and N- (3- {l- [ (3S) -3 -amino-3- phenylpropyl] -4- piperidinyl }phenyl) -2- methylpropanamide: ESMS m/e: 545.0 (M + H)+.
Example 613 N-{3- [1- (3-{ [ (4-FLUOROAΝILIΝO) CARBONYL] AMIΝθ}PROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using . l-fluoro-4- isocyanatobenzene and N-{3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13) δ 7.45 (q, 2H, J = 4.7 Hz), 7.23 (m, 4H) , 7.05 (t, 4H, J = 7.8 Hz), 6.75 (m, IH) , 4.05 (m, IH) , 3.19 (s, IH) , 2.71 (m, IH) , 2.53 (m, IH) , 2.25 (m, 3H) , 1.8 (m, 9H) , 1.25 (d, 6H, J = 6.4 Hz); ESMS m/e: 441.1 (M + H) + .
Example 614
N-{3-[l-(3-{[(3,4-
DICHLOROAΝILIΝO) CARBONYL] AMINO}PROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using 1, 2-dichloro-4- isocyanatobenzene and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e: 493.2 (M + H) + .
Example 615
2-METHYL-Ν- [3- (l-{3- [ (2- TOLUIDIΝOCARBOTHIOYL) AMIΝO] PROPYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isothiocyanato-2-methylbenzene and N-{3-[l- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e: 453.2 (M + H)+. Example 616
N- {3- [1- (3-{ [ (BEΝZYLAMIΝO) CARBONYL]AMIΝθ}PROPYL) -4- PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using (isocyanatomethyl) benzene and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide: ESMS /e: 437.2 (M + H) + .
Example 617 N- {3 - [1- (3-{ [ (4-ETHOXYAΝILIΝO) CARBONYL] AMIΝθ}PROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using l-ethoxy-4- isocyanatobenzene and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 467.2 (M + H) + .
Example 618
N- [3 - (l- {3 - [ (AΝILIΝOCARBOΝYL)AMIΝO] PROPYL}-4- PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using isocyanatobenzene and N- {3- [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e : 422.9 (M + H) + .
Example 619 2 -METHYL-N- (3-{1- [3- ({ [2-
(METHYLSULFAΝYL) AΝILIΝO] CARBONYL}AMIΝO) PROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isocyanato-2- (methylsulfanyl) benzene and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 469.1 (M + H) + . Example 620
N- {3 - [1- (3-{ [ (TERT-BUTYLAM ΝO) CARBOTHIOYL] AMIΝθ}PROPYL) - 4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure P and Scheme AB using 2-isothiocyanato-2- methylpropane and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 419 . 0 (M + H) + .
Example 621 2 -METHYL-N-{3- [1- (3-{ [(4-
PHEΝOXYAΝILIΝO) CARBONYL] AMIΝθ}PROPYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure P and Scheme AB using l-isocyanato-4-phenoxybenzene ' and N- {3- [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e: 515.5 (M + H) + .
Example 622
N- f3 - {4 - [3- (ACETYLAMIΝO) PHENYL] -l-PIPERIDINYL}PROPYL) -4- (2, 4-DIFLUOROPHENYL) -2 -METHYL-6-OXO-1, 4 , 5 , 6-TETRAHYDRO- 3-PYRIDINECARBOXAMIDE: Prepared by Procedure AC and Scheme AM using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl }acetamide and 4- (2, 4-difluorophenyl) - 2-methyl-6-oxo-1, 4,5, 6-tetrahydro-3-pyridinecarboxylic acid: ESMS m/e: 525.2 (M + H)+.
Example 623
N- (3 - {4 - [3- (ACETYLAMIΝO) PHENYL] -l-PIPERIDINYL}PROPYL) -4- (3, 4-DIFLUOROPHENYL) -2-METHYL-6-OXO-1, 4, 5, 6-TETRAHYDRO- 3-PYRIDINECARBOXAMIDE: Prepared by Procedure AC and Scheme AM using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl}acetamide and 4- (3,4 difluorophenyl) -2-methyl-6-oxo-1,4, 5, 6-tetrahydro-3- pyridinecarboxylic acid: ESMS m/e : 525.2 (M + H)+. Example 624
N-(6-{4-[3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}HEXYL) -1- (4-NITROPHENYL) -5- (TRIFLUOROMETHYL) -lff-PYRAZOLE-4-CARBOXAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N-{3-[l-(6- aminohexyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 1- (4-nitrophenyl) -5- (trifluoromethyl) -lH-pyrazole-4- carbonyl chloride: ESMS m/e: 629.2 (M + H) + .
Example 625
N-[3-(l-{6- [ (DIPHEΝYLACETYL) AMIΝO] HEXYL} -4-
PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by
Procedure Ql (THF) and Scheme AT using N-{3-[l-(6- aminohexyl) -4-piperidinyl]phenyl}-2-methylpropanamide and diphenylacetyl chloride: ESMS m/e: 540.3 (M + H)+.
Example 626
5- (3,5-DICHLOROPHEΝOXY) -N- 6-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}HEXYL) -2- FURAMIDE:
Prepared by Procedure Ql (THF) and Scheme AT using N-{3- [1- (6-aminohexyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 5- (3 , 5-dichlorophenoxy) -2-furoyl chloride: ESMS m/e: 600.2 (M + H) + .
Example 627
N-(6-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}HEXYL) -2-PHENOXYNICOTINAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N-{3-[l-(6- aminohexyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 2-phenoxynicotinoyl chloride: ESMS m/e: 543.3 (M + H) + . Example 628
N-(6-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}HEXYL) -2-NAPHTHAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (6-aminohexyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 2-naphthoyl chloride: ESMS m/e : 500.3 (M + H) + .
Example 629 l-BEΝZYL-3 -TERT-BUTYL-N- ( 6 - {4 - [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}HEXYL) -lff- PYRAZOLE-5-CARBOXAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (6-aminohexyl) -4- piperidinyl] phenyl} -2-methylpropanamide and l-benzyl-3- tert-butyl-Iff-pyrazole-5-carbonyl chloride: ESMS m/e : 586.3 (M + H)+.
Example 630
3 -CHLORO-N- ( 6 - {4 - [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}HEXYL) -4- (ISOPROPYLSULFONYL) -2-
THIOPHENECARBOXAMIDE: Prepared by Procedure Ql (THF) and
Scheme AT using N- {3- [1- (6-aminohexyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 3-chloro-4-
(isopropylsulfonyl) -2-thiophenecarbonyl chloride: ESMS m/e: 596.2 (M + H)
Example 631
N- [3- (l-{6- [ (AΝILIΝOCARBOΝYL)AMIΝO] HEXYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- { 3 - [l- (6- aminohexyl) -4-piperidinyl] phenyl} -2-methylpropanamide and phenyl isocyanate : ESMS m/e : 465.2 (M + H)+. Example 632
N- {3 - [1- (6-{ [ (2, 4-DICHLOROAΝILIΝO) CARBONYL] AMIΝ0}HEXYL) -
4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure Ql (THF) and Scheme AT using N- {3 - [l - (6- aminohexyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 2, 4-dichlorophenyl isocyanate: ESMS m/e: 533.2 (M +
H) + .
Example 633 N- ( 6 - {4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}HEXYL) -1-PHENYL-5-PROPYL-lff-PYRAZOLE-4- CARBOXAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (6-aminohexyl) -4-piperidinyl] phenyl} -2- methylpropanamide and l-phenyl-5-propyl-lH-pyrazole-4- carbonyl chloride: ESMS m/e: 558.3 (M + H)+.
Example 634
2-METHYL-N-{3- [l-(6-{[(l- ΝAPHTHYLAMIΝO) CARBONYL] AMINθ}HEXYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (6-aminohexyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 1-naphthyl isocyanate: ESMS m/e : 515.3 (M + H)+.
Example 635
Ν-{3- [l-(6-{[( [l,l'-BIPHEΝYL]-4-
YLAMINO) CARBONYL]AMINθ}HEXYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (6-aminohexyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 4-biphenyl isocyanate: ESMS m/e : 541.3 (M + H)+.
Example 636 2 -METHYL-N- {3- [1- (6-{ [(2-
NAPHTHYLAMINO) CARBONYL] AMINO}HEXYL) -4-
PIPERIDINYL]PHENYL}PR0PANAMIDE: Prepared by Procedure Ql
(THF) and Scheme AT using N- {3- [1- (6-aminohexyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 2-naphthyl isocyanate: ESMS m/e: 515.3 (M + H)+.
Example 637 Ν-{3-[l-(3-{[(3,4- DIMETHOXYPHEΝYL) SULFONYL] AMINθ}PROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 3 , 4-dimethoxybenzenesulfonyl chloride: ESMS m/e: 504.2 (M + H)+.
Example 638
N-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}PROPYL)-5-METHYL-3-PHENYL-4- ISOXAZOLECARBOXAMIDE: Prepared by Procedure Ql (THF) and
Scheme AT using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 5-methyl-3- phenyl-4-isoxazolecarbonyl chloride: ESMS m/e: 489.3 (M
+ H) + .
Example 639
N-{3- [1- (3-{ [(4-FLUOROPHENYL) ACETYL] AMINθ}PROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure Ql (THF) and Scheme AT using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and (4-fluorophenyl) acetyl chloride: ESMS m/e: 440.3 (M
+ H) + . Example 640
N-{3-[l- (3-{ [(4-CHLORO-3-
ΝITROPHEΝYL) SULFONYL] AMIΝθ}PROPYL) -4-
PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 4-chloro-3-nitrobenzenesulfonyl chloride: ESMS m/e:
523.1 (M + H)X
Example 641
2- (4-CHLOROPHEΝOXY) -N- 3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] - l-PIPERIDINYL}PROPYL)NICOTINAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 2- (4- chlorophenoxy) nicotinoyl chloride: ESMS m/e: 535.2 (M + H) + .
Example 642
5- (3,5-DICHLOROPHEΝOXY) -N-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -l-PIPERIDINYL}PROPYL) -2-
FURAMIDE :
Prepared by Procedure Ql (THF) and Scheme AT using N-{3- [1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 5- (3 , 5-dichlorophenoxy) -2-furoyl chloride: ESMS m/e: 558.2 (M + H) "X
Example 643
N-{3- [1- (3-{ [ (2-FLUOROPHENYL) SULFONYL] AMINθ}PROPYL) -4- PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N-{3-[l-(3- aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 2-fluorobenzenesulfonyl chloride: ESMS m/e: 462.2 (M + H) + . Example 644
N- {3 - [l-(3-{ [(3,5-DIMETHYL-4-
ISOXAZOLYL) SULFONYL] AMIΝO}PROPYL) -4-PIPERIDINYL] PHENYL}- 2-METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and
Scheme AT using N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 3,5- dimethyl-4-isoxazolesulfonyl chloride: ESMS m/e: 463.2
(M + H)+.
Example 644
N- {3 - [1- (3-{ [ (4 -TERT-BUTYLPHEΝYL) SULFONYL] AMINO}PROPYL) -
4-PIPERIDINYL] PHENYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure Ql (THF) and Scheme AT using N- { 3 - [l- (3 - aminopropyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 4- tert-butylbenzenesulfonyl chloride: ESMS m/e :
500.3 (M + H)+.
Example 646 N- {3 - [1- (6-AMINOHEXYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE : Prepared by Procedure AE and Scheme Y using N- (3- {l- [6- (1, 3-dioxo-l , 3-dihydro-2H-isoindol-2- yl) hexyl] -4-piperidinyl}phenyl) -2-methylpropanamide and hydrazine hydrate: ESMS m/e: 346.2 (M + H)+.
Example 647
N- {3 - [1- (2-{ [([1,1'-BIPHEΝYL] -4-
YLAMINO) CARBONYL] AMINO}ETHYL) -4-PIPERIDINYL]PHENYL}-2-
METHYLPROPANAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (2-aminoethyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 4-biphenyl isocyanate: ESMS m/e : 485.2 (M + H)+. Example 648
5- (3,5-DICHLOROPHENOXY)-N-(2-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}ETHYL) -3-
FURAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- { 3 - [1- (2-aminoethyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 5- (3 , 5-dichlorophenoxy) -3 -furoyl chloride: ESMS m/e : 544.1 (M + H)+.
Example 649
Ν-[3-(l-{2- [ (DIPHENYLACETYL)AMINO] ETHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure Ql (THF) and Scheme AT using N- { 3 - [l- (2 - aminoethyl) -4-piperidinyl] phenyl} -2-methylpropanamide and diphenylacetyl chloride: ESMS m/e.- 484.2 (M + H) + .
Example 650
N- (2 - {4 - [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}ETHYL) -2-NAPHTHAMIDE: Prepared by Procedure Ql (THF) and Scheme AT using N- {3- [1- (2-aminoethyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 2-naphthoyl chloride: ESMS m/e : 444. 2 (M + H)+.
Example 651 3- (2,6-DICHLOROPHEΝYL) -N- 4 - {4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}BUTYL) -5-METHYL- 4 -ISOXAZOLECARBOXAMIDE:
Prepared by Procedure Ql (THF) and Scheme AT using N- { 3 - [1- (4-aminobutyl) -4-piperidinyl].phenyl} -2- methylpropanamide and 3- (2, 6-dichlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 571.2 (M + H)
Example 652 3- (2,6-DICHLOROPHENYL)-N- (5-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}PENTYL) -5-METHYL-
4-ISOXAZOLECARBOXAMIDE:
Prepared by Procedure Ql (THF) and Scheme AT using N-{3- [1- (5-aminopentyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2, 6-dichlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride. ESMS m/e: 585.2. (M + H)
Example 653 N-[3-(l-{4-[ (DIPHENYLACETYL) AMIΝO] BUTYL} -4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by
Procedure Q2 (THF/DCM, 1:3)) and Scheme AT using N-{3- [1- (4-aminobutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and diphenylacetyl chloride: ESMS m/e: 512.0 (M + H)+.
Example 654
N- [3- (l-{5- [ (DIPHENYLACETYL) AMIΝO] PENTYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3)) and Scheme AT using N-{3- [1- (5-aminopentyl) -4-piperidinyl] phenyl} -2- methylpropanamide and diphenylacetyl chloride: ESMS m/e: 526.0 (M + H) + .
Example 655
3,5-DICHLORO-N-(4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}BUTYL)BENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using • N-{3-[l-(4- aminobutyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 3, 5-dichlorobenzoyl chloride: ESMS m/e: 490.0 (M + H) + .
Example 656 5- (3,5-DICHLOROPHENOXY)-N- (4-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}BUTYL) -2-
FURAMIDE:
Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N- {3- [1- (4-aminobutyl) -4-piperidinyl]phenyl} -2- methylpropanamide and 5- (3 , 5-dichlorophenoxy) -2-furoyl chloride: ESMS m/e: 572.0 (M + H) + .
Example 657 3-CHLORO -N-(4-{4-[3-(ISOBUTYRYLAMIΝO) PHENYL] -1-
PIPERIDINYL}BUTYL)BENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-[l-(4- aminobutyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 3-chlorobenzoyl chloride: ESMS m/e: 456.0 (M + H) + .
Example 658
3,4-DIFLUORO-N-(4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1- PIPERIDINYL}BUTYL)BENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N-{3-[l-(4- aminobutyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 3 , 4-difluorobenzoyl chloride: ESMS m/e: 458.0 (M + H) + .
Example 659 N-{3- [1- (4-{ [(3, 5-DICHLOROAΝILIΝO) CARBONYL] AMIΝθ}BUTYL) - 4-PIPERIDINYL] PHENYL} -2-METHYLPROPANAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N- (3- {l- [4- (formylamino) butyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 3 , 5-dichlorophenyl isocyanate: ESMS m/e: 505.0 (M + H) + .
Example 660 N- {3 - [1- (4-{[([l,l'- BIPHEΝYL]-4-
YLAMINO) CARBONYL] AMINO}BUTYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE: Prepared by Procedure Q2 (THF/DCM,
1:3) and Scheme AT using N- (3- [1- (4-aminobutyl) -4- piperidinyl] phenyl} -2-methylpropanamide and 4-biphenyl isocyanate: ESMS m/e : 513.0 (M + H)+.
Example 661
2-METHYL-N- (3 -{1- [5- (4-NITROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 5-chloro-l- (4-nitrophenyl) - 1-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 452.2 (M + H) + .
Example 662
N- (3 - {l- [5- (4-FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 5-chloro-l- (4- fluorophenyl) -1-pentanone and 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide: ESMS m/e: 425.2 (M + H)+.
Example 663
2 -METHYL-N- [3- (l-{5-OXO-5- [2- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4- PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 5-chloro-l- [2- (trifluoromethyl) phenyl] -1-pentanone and 2 -methyl-N- [3 - (4-piperidinyl) phenyl] propanamide: ESMS m/e : 475.2 (M +
H) + .
Example 664
N- (3 - {l- [5- (3 -BROMOPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (3- bromophenyl) -5-chloro-1-pentanone and 2 -methyl-N- [3- (4- piperidinyl)phenyl] propanamide: ESMS m/e : 485.1 (M + H) "X
Example 665
2 -METHYL-N- (3 -{1- [5- (3-NITROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 5-chloro-l- (3-nitrophenyl) - 1-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 452.2 (M + H) + .
Example 666
N- (3 - {l- [5- (3 -CHLOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using l-(3- chlorophenyl) -5-chloro-1-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 441.1 (M + H) + .
Example 667 N- (3 - {l- [5- (4-BROMOPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (4- bromophenyl) -5-chloro-1-pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 485.1 (M + H)+.
Example 668
N- (3 - {l- [5- (2-IODOPHEΝYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (2- iodophenyl) -5-chloro-1-pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 533.0 (M + H) "X
Example 669 N- (3- {l- [5- (3- FLUOROPHENYL) -5-
OXOPENTYL] -4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE:
Prepared by Procedure K and Scheme Bl (K2C03) using 1- (3-fluorophenyl) -5-chloro-l-pentanone and 2 -methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 425.2 (M + H) + .
Example 670
2 -METHYL-N- [3- (l-{5-OXO-5- [3- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- [3-
(trifluoromethyl) phenyl] -5-chloro-l-pentanone and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 475.2 (M + H)+.
Example 671
Ν-(3-{l- [5- (2-FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (2- fluorophenyl) -5-chloro-l-pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 425.2 (M + H)+.
Example 672 N- (3 - {l- [5- (3-IODOPHEΝYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (3- iodophenyl) -5-chloro-l-pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 533.0 (M + H)+.
Example 673
Ν-(3-{l-[5- (2-CHLOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (2- chlorophenyl) -5-chloro-l-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 441.1 (M + H)+.
Example 674
2-METHYL-N- [3- (l-{5-OXO-5- [4- (TRIFLUOROMETHYL) HENYL] PENTYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- [4- (trifluoromethyl) phenyl] -5-chloro-l-pentanone and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e 475.2 (M + H)+.
Example 675 N- (3 - {l- [5- (4-CHLOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (4- chlorophenyl) -5-chloro-l-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 441.1 (M + H)+.
Example 676
N- (3 - {l- [5- (4-IODOPHEΝYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (4- iodophenyl) -5-chloro-l-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 533 (M + H) + .
Example 677
N- (3 - {l- [5- (2-BROMOPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme Bl (K2C03) using 1- (2- bromophenyl) -5-chloro-l-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 485.1 (M + H)+. Example 678
2- (4-CHLOROPHENOXY) -N- (4 - {4- [3- (ISOBUTYRYLAMINO) PHENYL] - l-PIPERIDINYL}BUTYL)NICOTINAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N- { 3 - [l- (4- aminobutyl) -4-piperidinyl] phenyl} -2-methylpropanamide and 2- (4-chlorophenoxy) nicotinoyl chloride: ESMS m/e : 549.0 (M + H)+.
Example 679
Ν-(4-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}BUTYL) -3,4-DIMETHOXYBENZAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N- { 3 - [1- (4-aminobutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3 , 4-dimethoxybenzoyl chloride: ESMS m/e : 482.0 (M + H)
Example 680
3- (2-CHLOROPHENYL) -N- (4- {4- [3- (ISOBUTYRYLAMINO) PHENYL] - 1-PIPERIDINYL}BUTYL) -5-METHYL-4-ISOXAZOLECARBOXAMIDE:
Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N- {3 - [1- (4-aminobutyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2-chlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e 537.0 (M + H)+.
Example 681
3- (2-CHLOROPHENYL) -N-(5-{4- [3- (ISOBUTYRYLAMINO) PHENYL] - 1-PIPERIDINYL}PENTYL) -5-METHYL-4-ISOXAZOLECARBOXAMIDE: Prepared by Procedure Q2 (THF/DCM, 1:3) and Scheme AT using N- {3- [1- (5-aminopentyl) -4-piperidinyl] phenyl} -2- methylpropanamide and 3- (2-chlorophenyl) -5-methyl-4- isoxazolecarbonyl chloride: ESMS m/e : 551.0 (M + H)+. Example 682
2 -METHYL-N-{3- [1- (3-{l-METHYL-2- [4- (TRIFLUOROMETHYL) PHENYL] -Iff-INDOL-3-YL}PROPYL) -4-
PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- [3- (1- {5-oxo-5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide and 1-methyl-l- phenylhydrazine : ESMS m/e: 562.2 (M + H)+.
Example 683
2 -METHYL-N- {3- [1- (3-{l-METHYL-2- [4-
(TRIFLUOROMETHYL) PHENYL] -Iff-INDOL-3-YL}PROPYL) -4- PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- [3- (1- {5-oxo-5- [4- (trifluoromethyl) phenyl] pentyl} - - piperidinyl) phenyl] propanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 632 . 2 (M + H) + .
Example 684
2 -METHYL-N-{3- [1- (3-{2- [4- (TRIFLUOROMETHYL) PHENYL] -Iff- INDOL-3-YL}PROPYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- [3- (l-{5-oxo-5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide and phenylhydrazine: ESMS m/e: 548.2 (M + H) + .
Example 685
2 -METHYL-N-{3- [1- (3-{l-PHEΝYL-2- [4- (TRIFLUOROMETHYL) PHENYL] -Iff-INDOL-3-YL}PROPYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- [3- (1- {5-oxo-5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] ropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 624.2 (M + H) + .
Example 686 2 -METHYL-N-{3- [1- (3-{2- [4- (TRIFLUOROMETHYL) PHENYL] -lff- BENZO[G]INDOL-3-YL}pROPYL) -4-
PIPERIDINYL]PHENYL}PR0PANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N-.[3- (1- {5-oxo-5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e: 598.2 (M + H) + .
Example 687
2 -METHYL-N-{3- [1- (3-{7-METHYL-2- [4- (TRIFLUOROMETHYL) PHEΝYL] -Iff-IΝDOL-3-YL}PROPYL) -4-
PIPERIDIΝYL] PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl-N- [3- (l-|5-oxo-5- [4-
(trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide and 1- (2- methylphenyl) hydrazine hydrochloride: ESMS m/e : 562.2 (M
+ H) + .
Example 688
2 -METHYL-N-{3- [1- (3-{5-METHYL-2- [4- (TRIFLUOROMETHYL) PHEΝYL] -Iff-IΝDOL-3-YL}PROPYL) -4-
PIPERIDIΝYL] PHEΝYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- [3- (1- {5-oxo-5- [4-
(trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide and 4- methylphenylhydrazine hydrochloride: ESMS m/e : 562.2 (M +
H) + .
Example 689 N- {3 - [1- ( 3 - { 5 -METHOXY- 2 - [4 -
(TRIFLUOROMETHYL) PHEΝYL] -Iff-IΝDOL-3 -YL}PROPYL) -4-
PIPERIDIΝYL] PHEΝYL}-2-METHYLPROPANAMIDE: Prepared by
Procedure E and Scheme M using 2 -methyl-N- [3- (1- {5-oxo- 5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide and 4- methoxyphenylhydrazine hydrochloride: ESMS m/e : 578.2 (M
+ H) + .
Example 690
N- [3- (l-{3- [2- (3-FLUOROPHENYL) -7-METHYL-Iff-INDOL-3- YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (3 -fluorophenyl) -5-oxopentyl] -4-piperidinylJphenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e : 512.2 (M + H)+.
Example 691
N- [3- (l-{3- [2- (4-CHLOROPHENYL) -1-METHYL-Iff-INDOL-3- YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-methyl-l-phenylhydrazine: ESMS m/e : 528.2 (M + H)+.
Example 692
N- [3- (l-{3- [2- (4-FLUOROPHENYL) -5-METHOXY-lff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e: 528.2 (M + H)+. Example 693
N- [3- (l-{3- [2- (2-FLUOROPHENYL) -Iff-INDOL-3-YL] PROPYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by
Procedure E and . Scheme M using N- (3- {l- [5- (2- fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 498.2
(M + H) + .
Example 694 N- [3- (l-{3- [2- (3-FLUOROPHENYL) -5- (TRIFLUOROMETHOXY) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- {l- [5- (3 -fluorophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4- (trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 582.2 (M + H)+.
Example 695
N- [3- (l-{3- [2- (2-FLUOROPHENYL) -5- (TRIFLUOROMETHOXY) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-
METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3-{l- [5- (2-fluorophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) -2-methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 582.2 (M + H) + .
Example 696
N- [3- (l-{3- [2- (4-FLUOROPHENYL) -1-PHENYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 548.2 (M + H)+. Example 697
N- [3-(l-{3- [2- (2-FLUOROPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure Ξ and Scheme M using N- (3- { l- [5- (2-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 547.7 (M + H)+.
Example 698 N- [3- (l-{3- [2- (2-FLUOROPHENYL) -5-METHYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 512.2 ( M + H) +.
Example 699
N- [3- (l-{3- [2- (3 -FLUOROPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 548.2 (M + H)X
Example 700
N- [3- (l-{3- [2- (4-FLUOROPHENYL) -l-METHYL-lff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e: 512.2 (M + H) + .
Example 701 N- [3- (l-{3- [2- (3- FLUOROPHENYL) -5-METHOXY- lff-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-
METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3 -fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e: 528.2 (M + H)+.
Example 702 N- [3- (l-{3- [2- (3-FLUOROPHENYL) -1-PHENYL-lff-INDOL-3-
YL] PR0PYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3 -fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 574.2 (M + H)+.
Example 703
N- [3 - (l- {3 - [2 - (4-CHLOROPHENYL) -5- (TRIFLUOROMETHOXY) -lff-
INDOL-3-YL] PROPYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3-{l- [5- (4- chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 598.2 (M + H) X'
Example 704
N- [3- (l-{3- [2- (3-FLUOROPHENYL) -Iff-INDOL-3 -YL] PROPYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- {l- [5- (3- fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 498.2 (M + H) + . Example 705 N- [3- (l-{3- [2- (3 -FLUOROPHENYL) -1-METHYL- Iff-INDOL-3- YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- 3- { l - [5 - (3 -fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 512.2 (M + H)+.
Example 706
N- [3- (l-{3- [2- (3 -FLUOROPHENYL) -5-METHYL-Iff-INDOL-3- YL] PROPYL} -4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (3 -fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e : 512.2 (M + H)+.
Example 707
N- [3- (l-{3- [2- (4-CHLOROPHENYL) -lff-BENZO [G] INDOL-3- YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- 3- { l- [5 - (4 -chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 564.2 (M + H) + .
Example 708
N- [3-(l-{3- [2- (4 -CHLOROPHENYL) -Iff-INDOL-3 -YL] PROPYL} -4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure E and Scheme M using N- (3- {l- [5- (4- chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-phenylhydrazine hydrochloride: ESMS m/e : 514.2 (M + H) + . Example 709
N- [3- (l-{3- [2- (2-FLUOROPHENYL) -1-METHYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e: 512.2 (M + H)+.
Example 710 N- [3- (l-{3- [2- (2-FLUOROPHENYL) -7-METHYL-Iff-INDOL-3-
YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e : 512.2 (M + H)+.
Example 711
N- [3- (l-{3- [2- (2-FLUOROPHENYL) -1-PHENYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2 -fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 574.2 (M + H)+.
Example 712
N- [3- (l-{3- [2- (2-FLUOROPHENYL) -5-METHOXY-lff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-fluorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e -. 528.2 (M + H) + .
Example 713 N- [3- (l-{3- [2- (4- CHLOROPHENYL) -5-METHOXY- lff-INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-
METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxypheny1hydrazine hydrochloride: ESMS m/e: 544.2 (M + H)+.
Example 714 N- [3- (l-{3- [2- (4-FLUOROPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 548.2 (M + H) + .
Example 715
N- [3- (l-{3- [2- (4-FLUOROPHENYL) -5- (TRIFLUOROMETHOXY) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE :
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 582.9 (M + H) + .
Example 716
Ν- [3- (l-{3- [2- (4-FLUOROPHENYL) -7-METHYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- (2 -methylphenyl) hydrazine hydrochloride: ESMS m/e: 512.2 (M + H) "X Example 717
N- [3-(l-{3- [2- (4-FLUOROPHENYL) -Iff-INDOL-3-YL] PROPYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- {l- [5- (4- fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 498.2 (M + H) + .
Example 718
N- [3- (l-{3- [2- (4-FLUOROPHENYL) -5-METHYL-Iff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 512.2 (M + H) "X
Example 719
N- [3- (l-{3- [2- (4-CHLOROPHENYL) -7 -METHYL-Iff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e: 528.2 (M + H)+.
Example 720
N- [3- (l-{3- [2- (4-CHLOROPHENYL) -5-METHYL-1H-INDOL-3-
YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e 528.2 (M + H) "X Example 721
N- [3- (l-{3- [2- (4-CHLOROPHENYL) -1-PHENYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- {l- [5- ( -chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 590.2 (M + H)+.
Example 722 N- [3- (l-{3- [2- (3-CHLOROPHENYL) -7-METHYL-Iff-INDOL-3-
YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e: 528.1 (M + H) + .
Example 723
N- [3- (l-{3- [2- (3-CHLOROPHENYL) -5- (TRIFLUOROMETHOXY) -lff- INDOL-3-YL] PROPYL}- -PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (3 -chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 598.2 (M + H)+.
Example 724
N- [3- (l-{3- [2- (3 -CHLOROPHENYL) -l-METHYL-lff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine : ESMS m/e: 528.2 (M + H) "X Example 725
N- [3- (l-{3- [2- (3-CHLOROPHENYL) -1-PHENYL-Iff-INDOL-3-
YLJ PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- 3- { l- [5- (3 -chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 590.3 (M + H)+.
Example 726
N- [3- (l-{3- [2- (3-CHLOROPHENYL) -5-METHOXY-lff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e: 544.3 (M + H)+.
Example 727
N- [3- (l-{3- [2- (3-CHLOROPHENYL) -5-METHYL-lff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3 -chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2 - methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e -. 528.2 (M + H) "X
Example 728
N- [3- (l-{3- [2- (3-CHLOROPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e: 564.2 (M + H) + . Example 729
N- [3- (l-{3- [2- (3 -CHLOROPHENYL) -Iff-INDOL-3 -YL] PROPYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l - [5 - (3 -chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 514.2 (M + H) + .
Example 730 N- [3- (l-{3- [2- (2-CHLOROPHENYL) -Iff-INDOL-3 -YL] PROPYL} -4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (2- chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 514.2 (M + H) + .
Example 731
N- [3- (l-{3- [2- (2-CHLOROPHENYL) -5- (TRIFLUOROMETHOXY) -lff-
INDOL-3 -YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using ' N- (3- {l- [5- (2 -chlorophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) -2- methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 598.2 (M + H)+.
Example 732
N- [3- (l-{3- [2- (2 -CHLOROPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: ..
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (2 -chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride:
ESMS /e : 564.2 (M + H) + . Example 733
N- [3- (l-{3- [2- (2-CHLOROPHENYL) -7-METHYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2 -chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e: 528.2 (M + H)
Example 734 N- [3- (l-{3- [2- (2-CHLOROPHENYL) -l-PHENYL-lff-INDOL-3-
YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (2-chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 590.2 (M + H)+.
Example 735
N- [3- (l-{3- [2- (2-CHLOROPHENYL) -1-METHYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-chlorophenyl) -5-oxopentyl] -4-piperidinyl Jphenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine: ESMS m/e : 528.2 (M + H)+.
Example 736
N- [3- (l-{3- [2- (2-CHLOROPHENYL) -5-METHYL-Iff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 528.2 (M + H)+.
Example 737 N- [3- (l-{3- [2- (3- IODOPHEΝYL) -lff-IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 606.2 (M + H) + .
Example 738
N- [3- (l-{3- [2- (3-IODOPHEΝYL) -l-METHYL-lff-IΝDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine : ESMS m/e: 620.2 (M + H)+.
Example 739
N- [3- (l-{3- [2- (3-IODOPHEΝYL) -l-PHEΝYL-lff-IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS /e : 682.2 (M + H) + .
Example 740 N- [3- (l-{3- [2- (3-IODOPHEΝYL) -Iff-BEΝZO [G] IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (3-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e: 656.2 (M + H)+.
Example 741 N- [3- (l-{3- [2- (3- IODOPHEΝYL) -5-
(TRIFLUOROMETHOXY) -Iff-IΝDOL-3-YL] PROPYL}-4-
PIPERIDIΝYL) PHEΝYL] -2-METHYLPROPANAMIDE :
Prepared by Procedure E and Scheme M using N- 3- { l- [5- (3-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 690.2 (M + H) + .
Example 742
N- [3- (l-{3- [2- (3-IODOPHEΝYL) -5-METHYL-lff-IΝDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e : 620.2 (M + H)+.
Example 743
Ν- [3- (l-{3- [2- (3-IODOPHEΝYL) -7-METHYL-Iff-IΝDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e: 620.2 (M + H) + .
Example 744
N- [3- (l-{3- [2- (4-IODOPHEΝYL) -5- (TRIFLUOROMETHOXY) -lff- IΝDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2- . METHYLPROPANAMIDE : Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4- (trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 690.1 (M + H) "X
Example 745 N- [3- (l-{3- [2- (4-IODOPHEΝYL) -5-METHYL-Iff-IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l - [5- (4-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 620.1 (M + H) + .
Example 746
N- [3- (l-{3- [2- (4-IODOPHEΝYL) -7-METHYL-Iff-IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHEΝYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-iodophenyl) -5-oxopentyl] - -piperidinyl}phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e: 620.1 (M + H) + .
Example 747
N- [3- (l-{3- [2- (4-IODOPHEΝYL) -1-PHEΝYL-Iff-IΝDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 682.1 (M + H)+.
Example 748
N- [3- (l-{3- [2- (4-IODOPHEΝYL) -1-METHYL-Iff-IΝDOL-3- YL] PROPYL}-4-PIPERIDIΝYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- methyl-1-phenylhydrazine :
ESMS m/e : 620.1 (M + H) + .
Example 749 N- [3- (l-{3- [2- (4-IODOPHEΝYL) -Iff-BEΝZO [G] IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e: 656.1 (M + H)+.
Example 750
N- [3- (l-{3- [2- (4-IODOPHEΝYL) -Iff-IΝDOL-3-YL] PROPYL}-4-
PIPERIDIΝYL) PHEΝYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 606.1 (M + H) + .
Example 751
N- [3- (l-{3- [2- (3-BROMOPHENYL) -5- (TRIFLUOROMETHOXY) -lff- INDOL-3-YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3-{l- [5- (3-bromophenyl) -5-oxopentyl] -4- piperidinyl }phenyl) -2-methylpropanamide and 4- (trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e: 642.0 (M + H)+.
Example 752 N- [3- (l-{3- [2- (4-BROMOPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- naphthylhydrazine hydrochloride: ESMS m/e: 608.0 (M + H)+.
Example 753 N- [3- (l-{3- [2- (4-BROMOPHENYL) -7-METHYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure Ξ and Scheme M using N- (3- { l- [5- (4-bromophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e: 572 (M + H)+.
Example 754
N- [3 - (l- {3 - [2 - (4-BROMOPHENYL) -5- (TRIFLUOROMETHOXY) -lff-
INDOL-3-YL]PROPYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3 - { 1- [5- (4-bromophenyl) -5-oxopenty1] -4- piperidinyl}phenyl) -2-methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 642 (M + H)+.
Example 755
N- [3- (l-{3- [2- (3 -BROMOPHENYL) -lff-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 608.0 (M + H) + .
Example 756 N- [3- (l-{3- [2- (4-BROMOPHENYL) -Iff-INDOL-3-YL] PROPYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- (l- [5- (4- bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e:
558.1 (M + H)+.
Example 757 N- [3- (l-{3- [2- (3-BROMOPHENYL) -1-PHENYL-Iff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- {.l- [5- (3 -bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 634.0 (M + H) + .
Example 758
N- [3- (l-{3- [2- (3-BROMOPHENYL) -1-METHYL-Iff-INDOL-3-
YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- 3- { l- [5- (3 -bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine : ESMS m/e : 572.0 (M + H)+.
Example 759
N- [3- (l-{3- [2- (4-BROMOPHENYL) -1-METHYL-Iff-INDOL-3- YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine : ESMS m/e : 572.0 (M + H) + .
Example 760
Ν- [3- (l-{3- [2- (4-BROMOPHENYL) -1-PHENYL-IH-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1,1- diphenylhydrazine hydrochloride: ESMS m/e: 634.0 (M + H)+.
Example 761 N- [3- (l-{3- [2- (4-BROMOPHENYL) -5-METHOXY-1H-INDOL-3 -
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- 3- { l- [5- (4-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e: 588.1 (M + H)+.
Example 762
Ν- [3- (l-{3- [2- (3-BROMOPHENYL) -7-METHYL-IH-INDOL-3-
YL] PROPYL} -4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3 -bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e : 572 (M + H)+.
Example 763
Ν- [3- (l-{3- [2- (3-BROMOPHENYL) -5-METHYL-IH-INDOL-3- YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3 -bromophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2 - methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 572 (M + H) + .
Example 764
Ν- [3- (l-{3- [2- (4-BROMOPHENYL) -5-METHYL-IH-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (4-bromophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4- methylphenylhydrazine hydrochloride: ESMS m/e: 572.0 (M + H) + .
Example 765 N- [3- (l-{3- [2- (3-BROMOPHENYL) -5-METHOXY-1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (3-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methoxyphenylhydrazine hydrochloride: ESMS m/e: 588.0 (M + H) + .
Example 766
2 -METHYL-N- [3- (l-{3- [2- (3-NITROPHENYL) -lff-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure E and Scheme M using 2-methyl -N- 3-{l- [5- (3-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and phenylhydrazine: ESMS m/e : 525.2 (M + H)+.
Example 767
2 -METHYL-N- [3- (l-{3- [2- (3 -NITROPHENYL) -lff-BENZO [G] INDOL- 3-YL] PROPYL}-4 -PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- (3- { 1- [5- (3-nitrophenyl) -5-oxopentyl] -4- piperidinyl }phenyl) propanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 575.1 (M + H)+.
Example 768
2-METHYL-N- [3- (l-{3- [2- (3-NITROPHENYL) -5- (TRIFLUOROMETHOXY) -Iff-INDOL-3-YL] PROPYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- (3- {l- [5- (3-ni rophenyl) - 5-oxopentyl] -4-piperidinyl }phenyl) propanamide and 4- (trifluoromethoxy)phenylhydrazine hydrochloride: ESMS m/e: 609.1 (M + H) + .
Example 769 2-METHYL-N- [3- (l-{3- [5-METHYL-2- (3-NITROPHENYL) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- (3-{l- [5- (3-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide ' and 4- methylphenylhydrazine hydrochloride: ESMS m/e : 539.2 (M + H) + .
Example 770
Ν- [3- (l-{3- [5-METHOXY-2- (3-NITROPHENYL) -Iff-INDOL-3- YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- (3- {l- [5- (3-nitrophenyl) -5-oxopentyl] -4- ~ piperidinyl}phenyl) propanamide and 4- methoxyphenylhydrazine hydrochloride: ESMS m/e: 555.2 (M + H)+.
Example 771
2-METHYL-N- [3- (l-{3- [2- (3 -NITROPHENYL) -1-PHENYL-Iff-
INDOL-3 -YL] PROPYL}-4 -PIPERIDINYL) PHENYL] PROPANAMIDE : Prepared by Procedure E and Scheme M using 2-methyl -N- (3- { 1- [5- (3-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 601.1 (M + H) + .
Example 772
2 -METHYL-N- [3- (l-{3- [l-METHYL-2- (3 -NITROPHENYL) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE :
Prepared by Procedure E and Scheme M using 2-methyl-N- (3- { l- [5- (3 -nitrophenyl ) - 5-oxopentyl] -4 - piperidinyl } phenyl) propanamide and l-methyl - 1 - phenylhydrazine : ESMS m/e : 539 . 2 (M + H) "X
Example 773
2-METHYL-N- [3- (l-{3- [7-METHYL-2- (3 -NITROPHENYL) -lff- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- (3- {l- [5- (3-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 1- (2- methylphenyl) hydrazine hydrochloride: ESMS m/e: 539.2 (M + H) + .
Example 774 Ν- [3- (l-{3- [5-METHOXY-2- (4-NITROPHENYL) -1H-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- (3- {l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 4- methoxyphenylhydrazine hydrochloride: ESMS m/e: 555.6 (M + H) + .
Example 775
Ν- [3- (l-{3- [2- (2-BROMOPHENYL) -1H-INDOL-3-YL] PROPYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- {l- [5- (2- bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 557.9 (M + H) + .
Example 776
2-METHYL-Ν- [3- (l-{3- [5-METHYL-2- (4-NITROPHENYL) -1H-
INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure E and Scheme M using 2- methyl-N- (3-{l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl)propanamide and 4- methylphenylhydrazine hydrochloride: ESMS m/e.- 539.1 (M + H) + .
Example 777
2-METHYL-Ν- [3- (l-{3- [2- (4-NITROPHENYL) -1H-BENZ0 [G] INDOL- 3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- (3- {l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e: 574.7 (M + H) "X
Example 778
2-METHYL-Ν-. (3-{l- [ (5E) -5- (4-NITROPHENYL) -5- (PHENYLHYDRAZONO) PENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE:
Prepared by Procedure E and Scheme AX using 2 -methyl -N- (3- {l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and phenylhydrazine: ESMS m/e: 542.4 (M + H)
Example 779 2-METHYL-Ν- [3- (l-{3- [7-METHYL-2- (4-NITROPHENYL) -1H- INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- ' (3- [l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 1- (2- methylphenyl) hydrazine hydrochloride: ESMS m/e : 538.8 (M + H) + .
Example 780 2-METHYL-N-{3- [1- ( (5E) -5- (4-NITROPHENYL) -5-{ [4-
(TRIFLUOROMETHOXY) HENYL] HYDRAZONO}PENTYL) -4- PIPERIDINYL]PHENYL}PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl-N- (3- {l- [5- (4-nitrophenyl) - 5-oxopentyl] -4-piperidinyl}phenyl) propanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 626 . 2 (M + H) "X
Example 781 Ν- [3- (l-{3- [2- (2-BROMOPHENYL) -1H-BENZO [G] INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- 3- { l- [5- (2-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e : 608.0 (M + H) + .
Example 782
Ν- [3- (l-{3- [2- (2-BROMOPHENYL) -5- (TRIFLUOROMETHOXY) -1H-
INDOL-3-YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE : Prepared by Procedure E and Scheme M using N- (3-{l- [5- (2-bromophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) -2-methylpropanamide and . 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e : 641.9 (M + H)+.
Example 783
Ν- [3- (l-{3- [2- (2-BROMOPHENYL) -7-METHYL-IH-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5 - (2-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e 572.0 (M + H)+. Example 784
N- [3- (l-{3- [2- (2-BROMOPHENYL) -1-PHENYL-IH-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme ■ M using N- (3- { l- [5- (2-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 634 (M + H)+.
Example 785 Ν- [3- (l-{3- [2- (2-BROMOPHENYL) -5-METHYL-IH-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2 -bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 572.0 (M + H)+.
Example 786
Ν- [3- (l-{3- [2- (2-IODOPHEΝYL) -5- (TRIFLUOROMETHOXY) -1H- IΝDOL-3 -YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-
(trifluoromethoxy) phenylhydrazine hydrochloride: ESMS m/e: 690.0 (M + H) "X
Example 787
Ν- [3- (l-{3- [2- (2-IODOPHEΝYL) -5-METHYL-IH-IΝDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 4-methylphenylhydrazine hydrochloride: ESMS m/e: 620.2 (M + H)+. Example 788
2-METHYL-N- [3- (l-{3- [l-METHYL-2- (4-NITROPHENYL) -1H-
INDOL-3-YL] PROPYL} -4 -PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure E and Scheme M using 2 -methyl -N- (3-{l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 1-methyl-l- phenylhydrazine: ESMS m/e : 539.6 (M + H)+.
Example 789
2-METHYL-Ν- [3- (l-{3- [2- (4-NITROPHENYL) -1-PHENYL-lH- INDOL-3-YL] PROPYL} -4 -PIPERIDINYL) PHENYL] PROPANAMIDE:
Prepared by Procedure E and Scheme M using 2-methyl -N- (3- (l- [5- (4-nitrophenyl) -5-oxopentyl] -4- piperidinyl}phenyl) propanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e : 601.6 (M + H)+.
Example 790
Ν- [3- (l-{3- [2- (2-IODOPHEΝYL) -1H-IΝDOL-3-YL] PROPYL}-4- PIPERIDINYL) PHENYL] -2 -METHYLPROPANAMIDE :
Prepared by Procedure E and Scheme M using N- 3- { l - [5 - (2-iodophenyl) -5-oxopentyl] -4 -piperidinyl }phenyl) -2- methylpropanamide and phenylhydrazine: ESMS m/e : 606 . 1 (M + H) + .
Example 791
Ν- [3- (l-{3- [2- (2-IODOPHEΝYL) -IH-BEΝZO [G] IΝDOL-3-
YL] PROPYL} -4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l - [5- (2-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-naphthylhydrazine hydrochloride: ESMS m/e -. 656.1 (M + H) + . Example 792
N- [3- (l-{3- [2- (2-IODOPHENYL) -1-PHENYL-IH-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- {l- [5- (2-iodophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide and 1, 1-diphenylhydrazine hydrochloride: ESMS m/e: 682.1 (M + H)+.
Example 793 Ν- [3- (l-{3- [2- (2-IODOPHEΝYL) -7-METHYL-IH-IΝDOL-3-
YL] PROPYL}-4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure E and Scheme M using N- (3- { l- [5- (2-iodophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1- (2-methylphenyl) hydrazine hydrochloride: ESMS m/e : 619.6 (M + H) + .
Example 794
Ν- [3- (l-{3- [2- (2-BROMOPHENYL) -1-METHYL-IH-INDOL-3-
YL] PROPYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure E and Scheme M using N- 3- { l - [5- (2-bromophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide and 1-methyl-1-phenylhydrazine : ESMS m/e : 572 (M + H) + .
Example 795
4- (3, 4-DIFLUOROPHENYL) -N-(3-{4- [3-
(ISOBUTYRYLAMINO) PHENYL] -1-PIPERIDINYL}PR0PYL) -2-METHYL- 6-OXO-1,4,5,6-TETRAHYDRO-3-PYRIDINECARBOXAMIDE :
Prepared by Procedure AC and Scheme AM using 4- (3,4- difluorophenyl) -2-methyl-6-oxo-l, 4,5, 6-tetrahydro-3- pyridinecarboxylic acid and N- {3- [1- (3-aminopropyl) -4- piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 553.0 (M + H)+. Example 796
4- (2,4-DIFL
UOROPHENYL) -N-(3-{4- [3- (ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}PROPYL) -2-METHYL-6-OXO-1, 4,5,6-TETRAHYDRO-3- PYRIDINECARBOXAMIDE: Prepared by Procedure AC and
Scheme AM using 4- (2, 4-difluorophenyl) -2-methyl-6-oxo~
1, 4 , 5, 6-tetrahydro-3-pyridinecarboxylic acid and N- { 3 ~
[1- (3-aminopropyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e : 553.0 (M + H)+.
Example 797 N- (3 - {l- [4- ( -METHOXYPHEΝYL) BUTYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure O and Scheme using 4- (4-methoxyphenyl) -1- butanol and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 409 (M + H) + .
Example 798
N- (4 -{l- [3- (l,2-DIPHEΝYL-lff-IΝDOL-3-YL) PROPYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure 0 and Scheme W using 3- (1, 2-diphenyl-lH-indol-3-yl) -1- propanol and N- [4- (4-piperidinyl) phenyl] propanamide : ESMS m/e: 542.0 (M + H) + .
Example 799
N- {4 - [1- (3,3-DIPHEΝYLPROPYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure O and Scheme using 3 , 3-diphenyl-1-propanol and
N- [4- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 427.0 (M + H)+.
Example 800 2 -METHYL-N- (3-{1- [4- (4- NITROPHENYL) BUTYL] -4-
PIPERIDINYL}PHENYL) : Prepared by Procedure 0 and Scheme
W using 4- (4-nitrophenyl) -1-butanol and 2-methyl-N- [3-
(4-piperidinyl)-phenyl] propanamide: ESMS m/e: 424.2 (M + H) + .
Example 801
2-METHYL-N- (3- {1- [2- (1-ΝAPHTHYL) ETHYL] -4-
PIPERIDIΝYL}PHEΝYL) PROPANAMIDE Prepared by Procedure 0 and Scheme using 2- (1-naphthyl) ethanol and 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 401.2 (M + H) + .
Example 802 N- {3 - [1- (3, 3 -DIPHEΝYLPROPYL) -4-PIPERIDINYL] PHEΝYL} -2-
METHYLPROPANAMIDE: Prepared by Procedure 0 and Scheme W using 3 , 3-diphenyl-l-propanol and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 441.2 (M + H)+.
Example 803
N- (3 - {l- [3- (3,4-DIMETHOXYPHEΝYL)PROPYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure 0 and Scheme using 3- (3 , 4-dimethoxyphenyl) - 1-propanol and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 425.2 (M + H)+.
Example 804
2 -METHYL-N-{3- [1- (3 -PHENYLPROPYL) -4-
PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure 0 and Scheme using 3-phenyl-1-propanol and
2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 365.2 (M + H) + . Example 805
2-METHYL-N- (3-{l- [3- (4-PYRIDINYL) PROPYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure O and Scheme W using 3- (4-pyridinyl) -1-propanol and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e:
366.2 (M + H)+.
Example 806
N- {3 - [1- (4-TERT-BUTYLBEΝZYL) -4-PIPERIDINYL] PHEΝYL}-2- METHYLPROPANAMIDE: Prepared by Procedure AJ and Scheme AV using 1-bromomethyl) -4-tert-butylbenzene and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide : ESMS m/e: 393.0 (M + H)+.
Example 807
N- {3 - [1- (4-BEΝZOYLBEΝZYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE: Prepared by Procedure AJ and Scheme AV using [4- (bromomethyl) phenyl] (phenyl)methanone and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 441.0 (M + H)+.
l,2-DICHLORO-4-{ [(IS) -3-CHLORO-l-
PHEΝYLPROPYL]OXY}BEΝZEΝE: Prepared by Procedure A using 3 , 4-dichlorophenol and (IR) -3-chloro-l-phenyl-l- propanol .
Example 808
N- (3-{1- [(3S) -3- (3, 4-DICHLOROPHENOXY) -3-PHENYLPROPYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A using 1, 2-dichloro-4- { [ (IS) -3-chloro-l- phenylpropyl] oxy}benzene and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 525.3 (M + H)+. Example 809
N- (3-{l- [6- (2-FLUOROPHENYL) -6-HYDROXYHEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [6- (2- fluorophenyl) -6-oxohexyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e: 441.3 (M + H)+.
Example 810 N- [3- (l-{5-HYDROXY-5- [4- (TRIFLUOROMETHYL) PHEΝYL] PEΝTYL}- 4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using 2 -methyl-N- [3- (1- {5-oxo- 5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl) phenyl] propanamide : ESMS m/e: 477.2 (M + H) + .
Example 811
Ν-(3-{l- [5- (4-FLUOROPHENYL) -5-HYDROXYPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [5- (4- fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 427.2 (M + H) + .
Example 812
N- (3 - { l- [7- (2-FLUOROPHENYL) -7-HYDROXYHEPTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [7- (2- fluorophenyl) -7-oxoheptyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e : 455.2 (M + H)"X-
Example 813
N- (3 - { l- [6- (3-FLUOROPHENYL) -6-HYDROXYHEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [6- (3- fluorophenyl) -6-oxohexyl] - 4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 441.2 (M + H) + .
Example 814 N- (3 - {l- [5- (2-FLUOROPHENYL) -5-HYDROXYPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [5- (2- fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 427.2 (M + H) + .
Example 815
N- (3 - {l- [5- (3 -FLUOROPHENYL) -5-HYDROXYPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [5- (3- fluorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e : 427.2 (M + H)+.
Example 816
N- (3 - {l- [5- (3 -CHLOROPHENYL) -5-HYDROXYPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [5- (3- chlorophenyl) -5-oxopentyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e : 443.1 (M + H) + .
Example 817
N- (3 - {l- [6- (4-FLUOROPHENYL) -6-HYDROXYHEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [6- (4- fluorophenyl) -6-oxohexyl] -4-piperidinyl }phenyl) -2- methylpropanamide: ESMS m/e: 441.2 (M + H) + . Example 818
N- (3 - {l- [6- (4-CHLOROPHENYL) -6-HYDROXYHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure L and Scheme AN using N- (3- {l- [6- (4- chlorophenyl) -6-oxohexyl] -4-piperidinyl }phenyl) -2- methylpropanamide: ESMS m/e : 456.9 (M + H)+.
Example 819
N- (3 - {l- [5- (4-CHLOROPHENYL) -5-HYDROXYPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure L and Scheme AN using N- (3- {l- [5- (4- chlorophenyl) -5-oxopentyl] -4-piperidinyl}phenyl) -2- methylpropanamide: ESMS /e: 443.0 (M + H)+.
Example 820
N- (4 - {l- [ (9-ETHYL-9H-CARBAZOL-3-YL) METHYL] -4- PIPERIDIΝYL}PHEΝYL) BUTANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 9-ethyl-9H-carbazole- 3-carbaldehyde and N- [4- (4- piperidinyl) phenyl] butanamide: ESMS m/e : 454.2 (M + H)+.
Example 821
N- (3 - {l- [ (9-ETHYL-9ff-CARBAZOL-3-YL) METHYL] -4- PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 9-ethyl-9ff-carbazole- 3 -carbaldehyde and N- [3- (4- piperidinyl) phenyl] propanamide : ESMS m/e : 440.5 (M + H)+.
Example 822 N- (3 - {l- [ (1,9-DIMETHYL-9H-CARBAZOL-3-YL) METHYL] -4-
PIPERIDIΝYL} HEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 1,9- dimethyl-9H-carbazole-3-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: 1H NMR (400 MHz, CDC13) δ
8.05-6.77 (m, 10H) , 5.20-5.12 (m, IH) , 4.04 (s, 3H) ,
3.93 (s, 2H) , 3.34-3.24 (m, 2H) , 2.79 (s, 3H) , 2.56-2.38 (m, 2H) , 2.38-2.26 (m, 2H) , 2.08-1.88 (m, 2H) , 1.82-1.70
(m, 2H) , 1.16 (d, 6H, J = 6.8 Hz); ESMS m/e 454.2 (M +
H) + .
Example 823 N- (3 - {l- [(9-ETHYL-9ff-CARBAZOL-3-YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) CYCLOPROPANECARBOXAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 9-ethyl- 9H-carbazole-3 -carbaldehyde and N- [3- (4- piperidinyl) phenyl] cyclopropanecarboxamide: ESMS m/e : 452.6 (M + H)+.
Example 824
1- (3-{l- [(9-ETHYL-9ff-CARBAZOL-3-YL) METHYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-PYRROLIDIΝOΝE: Prepared by Scheme R and Procedure F. A solution of 1- (9-ethyl-9H- carbazol-3-yl) ethanone (22.3 mg, 0.100 mmol) and 1- [3-
(4-piperidinyl) phenyl] -2-pyrrolidinone (27.2 mg, 0.100 mmol) in 1, 2-dichloroethane (1.00 mL) was treated with sodium triacetoxyborohydride (63.6 mg, 0.300 mmol) and HOAc (5.70 uL, 0.100 mmol). The mixture was stirred overnight at room temperature. The reaction mixture was treated with a saturated aqueous NaHC03 solution (10 mL) . The aqueous layer was extracted with CH2C12 (3 X 10 mL) and the combined organic layers- were washed with brine (10 mL) , dried over MgS04 and concentrated in vacuo. The residue was purified by preparative TLC using 5% of NH3 (2.0 M in methanol) in CH2C12 to give the desired product 1- (3-{l- [ (9-ethyl-9H-carbazol-3-yl) methyl] -4- piperidinyl }phenyl) -2- pyrrolidinone (4.60 mg,
9.43 %) : λE NMR (400 MHz, CDC13) δ 8.04 (d, IH, J = 7.4
Hz), 7.99 (s, IH) , 7.43-7.28 (m, 5H) , 6.96 (d, IH, J =
7.4 Hz), 4.31 (q, 2H,. J = 6.8 Hz), 3.77 (t, 2H, J = 7.3 Hz), 3.70 (s, 2H) , 3.06 (d, 2H, J = 10.6 Hz), 2.56-2.42
(m, 3H) , 2.07 (m, 4H) , 1.77 (m, 4H) , 1.36 (m, 3H) ;
ESMS m/e : 452.5 (M + H)+.
N- {3 - [1- (lff-IΝDOL-5-YLMETHYL) -4-PIPERIDINYL] PHENYL} -2- METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using lH-indole-5-carbaldehyde and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e:
376.2 (M + H)+.
1- (4-CHLOROBUTYL) -Iff-INDOLE: Prepared by Procedure AH, and Scheme P using IH-indole and 1-bromo-4-chlorobutane: XNMR (400 MHz, CDC13) δ 7.72-7.02 (m, 5H) , 6.49 (d, IH, J = 2.8 Hz), 4.13 (t, 2H, J = 6.8 Hz), 3.48 (t, 2H, J = 6.8 Hz), 2.06-1.92 (m, 2H) , 1.80-1.70 (m, 2H) .
1- (3-CHLOROPROPYL) -lff-INDOLE: Prepared by Procedure AH, and Scheme P using IH-indole and l-bromo-3- chloropropane : 1H NMR (400 MHz, CDC13) δ 7.70-7.04 (m, 5H) , 6.50 (d, IH, J = 2.8 Hz), 4.31 (t, 2H, J = 6.8 Hz), 3.42 (t, 2H, J = 6.4 Hz), 2.28-2.20 (m, 2H) .
Example 825
N- (4 - {l- [5- (Iff-IΝDOL-1-YL) PE TYL] -4-PIPERIDINYL}PHENYL) - 2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1- (5-chloropentyl) -IH-indole and 2- methyl-N- [4- (4-piperidinyl) phenyl] propanamide: ESMS m/e :
432.3 (M + H)+. Example 826
N- (4 - {l- [5- (Iff -IΝDOL- 1-YL) PENTYL] -4 -
PIPERIDINYL}PHENYL) BUTANAMIDE : Prepared by Procedure AH and Scheme P using 1- (5 -chloropentyl ) - IH- indole and N- [4 - ( 4-piperidinyl ) phenyl] butanamide : ESMS m/e: 432 . 3 (M
+ H) + .
Example 827
N- (4 - {l- [5- (Iff-IΝDOL-1-YL) PENTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure AH and Scheme P using 1- (5-chloropentyl) -IH-indole and N- [4- (4-piperidinyl)phenyl] propanamide: ESMS m/e: 418.2 (M + H) + .
Example 828
N- (4 - {l- [6-(lff-IΝDOL-l-YL)HEXYL] -4-
PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure
AH and Scheme P using 1- (6-chlorohexyl) -IH-indole and N-
[4- (4-piperidinyl) phenyl] propanamide: ESMS m/e: 432.3 (M + H)+.
Example 829
2-METHYL-N- (3-{l- [ (1-METHYL-Iff-IΝDOL-2-YL) METHYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure F and Scheme R, without HOAc, using 1-methyl-Iff-indole-2- carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 390.3 (M + H)+.
Example 830 N- {3 - [1- (lff-IΝDOL-4-YLMETHYL) -4-PIPERIDINYL] PHENYL}-2-
METHYLPROPANAMIDE : Prepared by Procedure F and Scheme R, without HOAc, using IH-indole-4-carbaldehyde and 2- methyl -N- [3 - ( 4 - piperidinyl) phenyl] propanamide: ESMS m/e : 376.2 (M + H)+.
Example 831 N- (4 - {l- [6- (lff-IΝDOL-1-YL) HEXYL] -4-PIPERIDIΝYL}PHEΝYL) -
2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1- (6-chlorohexyl) -IH-indole and 2-methyl- N- [4- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 446.3 (M + H)X
Example 832 Ν-{3- [1- (lff-INDOL-7-YLMETHYL) -4-PIPERIDINYL] PHENYL}-2- METHYLPROPANAMIDE : Prepared by Procedure F and Scheme R, without HOAc, using lff-indole-7-carbaldehyde and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 376.2 (M + H)+.
Example 833
N- [3 - (l- { [l- (4-METHOXYPHEΝYL) -Iff-IΝDOL-5-YL] METHYL}-4- PIPERIDINYL) PHEΝYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-4-methoxybenzene and N- {3- [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 482.0 (M + H)
Example 834 METHYL 4- [4- ({4- [3- (ISOBUTYRYLAMINO) PHEΝYL] -1-
PIPERIDINYL}METHYL) -Iff-INDOL-1-YL] BENZOATE: • Prepared by Procedure C and Scheme Ql , with CuBr in place of Cu, using methyl 4-iodobenzoate and N- {3- [1- (lH-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e :- 510.3 (M + H) + . Example 835
2-METHYL-N- [3- (l-{ [1- (3-METHYLPHENYL) -lff-INDOL-5-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3-methylbenzene and N- {3- [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide:
ESMS m/e : 466.3 (M + H)+.
Example 836 N- [3- (l-{ [1- (4-FLUOROPHENYL) -Iff-INDOL-4-YL] METHYL} -4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1-fluoro-4-iodobenzene and N- {3- [1- (lff-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide: XH ΝMR (400 MHz, CDC13) δ 7.66-6.92 (m, 12H) , 6.65 (d, IH, J = 3.2 Hz), 3.69 (s, 2H) , 3.15-3.02 (m, 2H) , 2.58-2.40 (m, 2H) , 2.20-2.04 ( , 2H) , 1.94-1.76 (m, 4H) , 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 470.6 (M + H) + .
Example 837
N- (3 - {l- [4- (Iff-IΝDOL-1-YL) BUTYL] -4-PIPERIDIΝYL}PHEΝYL) - 2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1- (4-chlorobutyl) -IH-indole and 2-methyl- N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 418.3 (M + H)+.
Example 838
N- [3- (l-{ [1- (4-CHLOROPHENYL) -Iff-INDOL-5-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1-chloro-4-iodobenzene and N- {3- [1- (lH-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 486.2 (M + H) + . Example 839
N- [3- (l-{ [1- (3-METHOXYPHEΝYL) -Iff-IΝDOL-5-YL] METHYL}-4- PIPERIDIΝYL) PHEΝYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3-methoxybenzene and N- { 3 - [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 482.2 (M + H)+.
Example 840
N- (4 - {l- [4- (lff-IΝDOL-1-YL) BUTYL] -4-
PIPERIDINYL}PHENYL) BUTANAMIDE: Prepared by Procedure AH and Scheme P using 1- (4-chlorobutyl) -IH-indole and N- [4- (4-piperidinyl) phenyl] butanamide: ESMS m/e: 418.2 (M + H)+.
Example 841
Ν- [3- (l-{ [1- (2-METHOXYPHEΝYL) -Iff-IΝDOL-5-YL] METHYL} -4- PIPERIDIΝYL) PHEΝYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-2-methoxybenzene and N- {3- [1- (lH-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 482.2 (M + H)+.
Example 842
Ν- [3- (l-{ [1- (3-CHLOROPHENYL) -Iff-INDOL-5-YL] METHYL} -4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1-chloro-3 -iodobenzene and N- {3- [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 486 .2 (M + H) Example 843
METHYL 2-[5-({4-[3-(ISOBUTYRYLAMINO) PHENYL] -1-
PIPERIDINYL}METHYL) -Iff-INDOL-1-YL] BENZOATE: Prepared by
Procedure C and Scheme Ql, with CuBr in place of Cu, using methyl 2-iodobenzoate and N- {3- [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide :
ESMS m/e: 510.2 (M + H) + .
Example 844 N- (3 - {l- [3- (Iff-IΝDOL-1-YL) PROPYL] -4-PIPERIDINYL}PHENYL) - 2-METHYLPROPANAMIDE: Prepared by Procedure AH and Scheme P using 1- (3 -chloropropyl) -IH-indole and 2- methyl-N- [3- (4-piperidinyl) phenyl] propanamide: ESMS m/e : 404.2 (M + H)+.
Example 845 2 -METHYL-N-{3- [1- ({l- [4- (TRIFLUOROMETHYL) PHEΝYL] -lff- IΝDOL-5-YL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-4- (trifluoromethyl) benzene and N- {3- [1- (lH-indol-5-ylmethyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e 520.2 (M + H) "X
Example 846 N- (3 - {l- [ (1- [1,1' -BIPHEΝYL] -2-YL-lff-IΝDOL-5-YL) METHYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 2-iodo-l, 1 ' -biphenyl and N- {3- [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e: 528.3 (M + H) + . Example 847
2-METHYL-N- [3- (l-{ [1- (2-METHYLPHENYL) -lff-INDOL-5-
YL] METHYL} -4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-2-methylbenzene and N- {3- [1- (lff-indol-5- ylmethyl) - -piperidinyl] phenyl} -2-methylpropanamide :
ESMS m/e: 466.2 (M + H)
Example 848 2-METHYL-N- [3- (l-{ [1- (4-METHYLPHENYL) -lff-INDOL-5-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-4-methylbenzene and N- {3- [1- (lH-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e: 466.3 (M + H)
Example 849
Ν- [3- (l-{ [1- (2-CHLOROPHENYL) -Iff-INDOL-5-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-chloro-2-iodobenzene and N- {3- [1- (lH-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 486.2 (M + H)+.
Example 850
2 -METHYL-N-{3- [1- ({l- [3- (TRIFLUOROMETHYL) PHEΝYL] -lff- IΝDOL-5-YL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3- (trifluoromethyl) benzene and N- { 3 - [1- (lH-indol-5-ylmethyl) -4-piperidinyl] phenyl} -2- methylpropanamide : XH ΝMR (400 MHz, CDC13) δ 7.80-6.94 (m, 12H) , 6.69 (d, IH, J = 3.6 Hz), 3.36 (s, 2H) , 3.10- 3.00 (m, 2H) , 2.58-2.42 (m, 2H) , 2.16-2.02 (m, 2H) , 1.85-1.75 (m, 4H) , 1.25 (d, 6H, J = 7.2 Hz); ESMS m/e : 520.2 (M + H) + .
Example 851 2-METHYL-N- [3- (l-{ [1- (2-NITROPHENYL) -lff-INDOL-5-
YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-2-nitrobenzene and N- { 3 - [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 497.2 (M + H) + .
Example 852
N- [3- (l-{ [1- (2-FLUOROPHENYL) -Iff-INDOL-5-YL] METHYL} -4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1-fluoro-2 -iodobenzene and N- { 3 - [1- (lff-indol-5- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 470.2 (M + H) + .
Example 853
2-METHYL-N- [3- (l-{ [1- (1-ΝAPHTHYL) -Iff-IΝDOL-5-YL] METHYL}- 4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1- iodonaphthalene and N- {3- [1- (lH-indol-5-ylmethyl) -4- piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 502.2 (M + H) + .
Example 854
N- [3- (l-{ [1- (2,3-DICHLOROPHENYL) -Iff-INDOL-5-YL] METHYL}- 4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1, 2-dichloro-3 -iodobenzene and N- {3- [1- (IH-indol- 5-ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : 1H NMR (400 MHz, CDC13) δ 7.68-6.94 (m, 12H) , 6.68
(d, IH, J = 2.8 Hz), 3.69 (s, 2H) , 3.15-3.02 (ra, 2H) ,
2.54-2.42 (m, 2H) , 2.18-2.02 (m, 2H) , 1.88-1.76 (m, 4H) ,
1.25 (d, 6H, J = 6.8 Hz); ESMS m/e 520.1 (M + H)+.
Example 855
N- [3 - (l- { [l- (2,3-DICHLOROPHEΝYL) -Iff-IΝDOL-7-YL] METHYL}-
4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by
Procedure C and Scheme Ql, with CuBr in place of Cu, using 1, 2-dichloro-3-iodobenzene and N- {3- [1- (lH-indol-
7-ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide :
ESMS m/e: 520.2 (M + H)+.
Example 856 N- [3- (l-{ [1- (3-METHOXYPHEΝYL) -lff-IΝDOL-4-YL] METHYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3-methoxybenzene and N- {3- [1- (lH-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 482.3 (M + H)+.
Example 857 N- [3- (l-{ [1- (2,3-DICHLOROPHEΝYL) -Iff-IΝDOL-4-YL] METHYL}- 4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1, 2-dichloro-3-iodobenzene and N- {3- [1- (lH-indol- 4-ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 520.2 (M + H)
Example 858
N- [3- (l-{ [1- (3-CHLOROPHENYL) -Iff-INDOL-4-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-chloro-3- iodobenzene and N- {3 - [l-
(IH-indol-4-ylmethyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e : 486.2 (M + H) + .
Example 859
2 -METHYL-N- [3- (l-{ [1- (3-METHYLPHENYL) -lff-INDOL-4- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3-methylbenzene and N- (3- [1- (lff-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS /e : 466.3 (M + H) "X
Example 860
N- [3- (l-{ [1- (3-METHOXYPHEΝYL) -Iff-IΝDOL-7-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3 -methoxybenzene and N- {3- [1- (lff-indol-7- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 482.3 (M + H) + .
Example 861 2 -METHYL-N- {3- [1- ({l- [3- (TRIFLUOROMETHYL) PHEΝYL] -lff- IΝDOL-4-YL}METHYL) -4-PIPERIDINYL] PHENYL} ROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-3- (trifluoromethyl) benzene and N- {3- [1- (IH- indol-4-ylmethyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e: 520.2 (M + H)+.
Example 862 N- [3 - ( l- { [1- (3 , 4 -DIMETHYLPHEΝYL) - Iff- IΝDOL- 4 -YL] METHYL} -
4 - PIPERIDINYL) PHENYL] - 2 -METHYLPROPANAMIDE : Prepared by Procedure C and Scheme Ql , with CuBr in place of Cu, using N- { 3 - [1- (Iff- indol -4 -ylmethyl) -4 - piperidinyl] phenyl} -2- methylpropanamide and 4 iodo-l,2-dimethylbenzene: ESMS m/e : 480.0 (M + H)+.
Example 863 N- [3- (l-{ [1- (3, 4 -DIFLUOROPHENYL) -Iff- INDOL-4 -YL] METHYL} -
4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1, 3 -dichloro-5 -iodobenzene and N- {3- [1- (lH-indol- 4 -ylmethyl) -4-piperidinyl] phenyl } -2 -methylpropanamide : ESMS m/e : 520.0 (M + H)+.
Example 864
N- [3- (l-{ [l-(3,4-DICHLOROPHEΝYL) -Iff- NDOL-4 -YL] METHYL} - 4-PIPERIDINYL) PHENYL] -2 -METHYLPROPANAMIDE : Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1, 2 -dichloro-4- iodobenzene and N- {3- [1- (lH-indol- 4-ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 520.0 (M + H) + .
Example 865
N- [3- (l-{ [1- (2-CHLORO-4-FLUOROPHEΝYL) -lff-INDOL-4- YL]METHYL}-4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE:
Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 2-chloro-4-fluoro- 1- iodobenzene and N- { 3 - [1- (IH- indol -4 -ylmethyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e : 504.0 (M + H) + .
Example 866
N- [3- (l-{ [1- (2, 4 -DIFLUOROPHENYL) -Iff-INDOL-4-YL] METHYL} - 4-PIPERIDINYL) HENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 2, 4-difluoro-1-iodobenzene and N- {3- [1- (lH-indol- 4-ylmethyl) -4- piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e: 488.0 (M + H)+.
Example 867 2-METHYL-N- [3- (l-{ [1- (3-PYRIDIΝYL) -Iff-INDOL-7-
YL] METHYL}-4-PIPERIDINYL) HENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 3-iodopyridine and N- {3- [1- .(IH-indol-7-ylmethyl) - 4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 453.1 (M + H)+.
Example 868
N- {3 - [1- (Iff-IΝDOL-6-YLMETHYL) -4-PIPERIDINYL] PHEΝYL}-2- METHYLPROPANAMIDE: Prepared by Procedure F and Scheme R using IH-indole-6-carbaldehyde and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 376.2 (M + H)..+ .
Example 869
2-METHYL-Ν- [3- (l-{ [1- (4-PYRIDIΝYL) -lff-INDOL-4- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 4-iodopyridine and N- {3- [1- (IH-indol-4-ylmethyl) - 4-piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e: 453.2 (M + H)+.
Example 870
2-METHYL-N- [3- (l-{ [1- (2-PYRIDIΝYL) -lff-IΝDOL-4- YL] METHYL} -4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 2-iodopyridine and N- {3 - [1- (IH-indol-4-ylmethyl) - 4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 453.2 (M '+ H) + . Example 871
N- [3- (l-{ [1- (2-FLUOROPHENYL) -Iff-INDOL-4-YL] METHYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by
Procedure C and Scheme Ql, with CuBr in place of Cu, using 1-fluoro-2-iodobenzene and N- {3- [1- (lH-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide :
ESMS m/e: 470.1 (M + H) + .
Example 872 N- [3- (l-{ [1- (4-CHLOROPHENYL) -Iff-INDOL-4-YL] METHYL}-4-
PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 1-chloro-4-iodobenzene and N- { 3 - [1- (lH-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 486.1 (M + H)+.
Example 873
2-METHYL-N- [3- (l-{ [1- (3-PYRIDIΝYL) -lff-INDOL-4- YL] METHYL}-4-PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using 3-iodopyridine and N- { 3 - [1- (IH-indol-4-ylmethyl) - 4-piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 453.2 (M + H)+.
Example 874
N- [3- (l-{ [1- (2,3-DIMETHYLPHEΝYL) -Iff-INDOL-4-YL] METHYL} - 4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in -place of Cu, using l-iodo-2 , 3-dimethylbenzene and N- {3- [1- (lH-indol- 4-ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 480.1 (M + H) + . Example 875
N- [3- (l-{ [1- (3 -FLUOROPHENYL) -Iff-INDOL-4-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-fluoro-3 -iodobenzene and N- { 3 - [1- (lff-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide: ESMS m/e : 470.1 (M + H) + .
Example 876 2 -METHYL-N-{3- [1- ({l- [2- (TRIFLUOROMETHYL) PHEΝYL] -lff- IΝDOL-4-YL}METHYL) -4-PIPERIDINYL] PHENYL}PROPANAMIDE:
Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-2- (trifluoromethyl) benzene and N- {3- [1- (IH-indol-4-ylmethyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ESMS m/e : 520.1 (M + H)+.
Example 877
N- [3- (l-{ [1- (2-CHLOROPHENYL) -Iff-INDOL-4-YL] METHYL}-4- PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql , with CuBr in place of Cu, using 1-chloro-2-iodobenzene and N- {3- [1- (lH-indol-4- ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 486.1 (M + H)+.
Example 878
N- [3- (l-{ [1- (2,3-DIMETHYLPHEΝYL) -Iff-INDOL-7-YL] METHYL} - 4-PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE: Prepared by Procedure C and Scheme Ql, with CuBr in place of Cu, using l-iodo-2 , 3 -dimethylbenzene and N- {3- [1- (lH-indol- 7-ylmethyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 480.0 (M + H) + . 2 -METHYL-N- [3 - (l- { 5 -OXO- 5 - [4 -
(TRIFLUOROMETHYL) PHEΝYL] PEΝTYL}-4-
PIPERIDINYL) PHENYL] PROPANAMIDE: Prepared by Procedure K and Scheme E using 5-chloro-l- [4- (trifluoromethyl) phenyl] -1-pentanone and 2 -methyl-N- [3 -
(4-piperidinyl) phenyl] propanamide: ESMS m/e: 475.1 (M +
H) + .
N- (3 - {l- [5- (4-FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using 5-chloro-l- (4- fluorophenyl) -1-pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 425.2 (M + H)+.
N- (3 - {l- [5- (3 -FLUOROPHENYL) -5-OXOPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using 5-chloro-l- (3- fluorophenyl) -1-pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 425.2 (M + H)+.
N- (3 - {l- [5- (3-CHLOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using 5-chloro-l- (3- chlorophenyl) -1-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 441.1 (M + H)+.
N- (3 - {l- [5- (4-CHLOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E . using 5-chloro-l- (4- chlorophenyl) -1-pentanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 441.1 (M + H)+. Example 879
2 -METHYL-N- {3- [1- (3 -OXO- 3 -PHENYLPROPYL) -4-
PIPERIDINYL] PHENYL} PROPANAMIDE: Prepared by Procedure K and Scheme E using K2C03 instead of Na2C03 and Nal instead of Kl and 3-chloro-l-phenyl-l-propanone and 2 -methyl -N-
[3- (4-piperidinyl)phenyl]propanamide: ESMS m/e 379.3 (M
+ H) + .
Example 880 N-(3-{l- [7- (2-FLUOROPHENYL) -7-OXOHEPTYL] -4-
PIPERIDINYL}PHENYL) -2 -METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using KC03 instead of Na2C03 and Nal instead of Kl and 7-chloro- 1- (2 -fluorophenyl) -1- heptanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: 1H ΝMR (400 MHz, CDC13) , δ 8.17 (s, br, IH) , 8.06-6.88 (m, 8H) , 3.08-2.94 (m, 4H) , 2.62-2.48 (m, IH) , 2.48-2.38 ' (m, IH) , 2^38-2.15 (rti, 2H) , 2.02-1.92 (m, 2H) , 1.84-1.77 (m, 4H) , 1.77-1.66 (m, 2H) , 1.62-1.46 (m, 2H) , 1.46-1.29 (M, 4H) , 1.21 (d, 6H, J = 6.8 Hz); ESMS m/e: 453.2 (M + H) + .
Example 881
N-(3-{l- [5- (2 -FLUOROPHENYL) -5-OXOPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K2C03 instead of NaC03 and Nal instead of Kl and 5-chloro-l- (2-fluorophenyl) -1- pentanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 425.2 (M + H)+.
Example 882
N-(3-{l-[6-(3- FLUOROPHENYL) - 6 - OXOHEXYL] - 4 -
PIPERIDINYL} PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure K and Scheme E using K2C03 instead of Na2C03 and Nal instead of Kl and 6- chloro-1- (3-fluorophenyl) -
1-hexanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 439.2 (M + H)+.
Example 883
Ν-(3-{l-[6- (2-FLUOROPHENYL) -6-OXOHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K2C03 instead of Na2C03 and Nal instead of Kl and 6-chloro-l- (2-fluorophenyl) -1- hexanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 439.2 (M + H)+.
Example 884
Ν-(3-{l-[7-(4-FLUOROPHENYL) -7-OXOHEPTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K2C03 instead of NaC03 and Nal instead of Kl and 7-chloro-l- (4-fluorophenyl) -1- heptanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 453.2 (M + H)+.
Example 885 N- (3 - {l- [6 - (4-CHLOROPHENYL) -6-OXOHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K2C03 instead of Na2C03 and Nal instead of Kl and 6-chloro-l- (4-chlorophenyl) -1- hexanone and 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 455.1 (M + H)+.
Example 886 Ν-(3-{l- [7- (4 -CHLOROPHENYL) -7-OXOHEPTYL] -4-
PIPERIDINYL} HENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure' K and Scheme E using K2C03 instead of Na2C03 and Nal instead of Kl and 7-chloro-l- (4-chlorophenyl) -1- heptanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e: 469.1 (M + H)+.
Example 887 N- (3- {l- [6- (4-FLUOROPHENYL) -6-OXOHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K and Scheme E using K2C03 instead of Na2C03 and Nal instead of Kl and 6-chloro-l- (4-fluorophenyl) -1- hexanone and 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide: ESMS m/e : 439.1 (M + H) + .
Example 888
N- (3 - {l- [6 - (3 -ACETYLPHEΝOXY) -6- (2-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1- (3- hydroxyphenyl) ethanone and N- (3-{l- [6- (2-fluorophenyl) - 6-hydroxyhexyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e : 559.5 (M + H)+.
Example 889
Ν-(3-{l-[6- (2-FLUOROPHENOXY) -6- (2-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluorophenol and N- (3- {l- [6- (2-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -'2-methylpropanamide : ESMS m/e : 535.1 (M + H) + .
Example 890
N- (3 - {l- [6- (4-FLUOROPHENOXY) -6- (2-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and N- (3- {l- [6- (2-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide: 1H ΝMR (400 MHz, CDCI3) , HCl salt δ 7.72- 6.72 (m, 12H) , 5.42-5.34
(m, IH) , 3.68-3.58 (m, br, 2H) , 3.02-2.92 (m, 2H) , 2.80-
2.46 (m, 6H) , 2.05-1.78 (m, 6H) , 1.68-1.56 (m, IH) ,
1.56-1.38 (m, 3H) , 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e : 535.1 (M + H)+.
Example 891
N- (3 - {l- [6- (2-FLUOROPHENYL) -6- (2-METHOXYPHENOXY) HEXYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-methoxyphenol and N-
(3-{l- [6- (2-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl }phenyl) -2-methylpropanamide : ESMS m/e : 547.0
(M + H) + .
Example 892
N- (3 - {l- [6- (2-FLUOROPHENYL) -6- (4-METHOXYPHENOXY) HEXYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: _Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N- (3-{l- [6- (2-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 547.1 (M + H) + .
Example 893
N- (3 - {l- [6 - (4-ACETYLPHEΝOXY) -6- (2-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1- (4- hydroxyphenyl) ethanone and N- (3-{l- [6- (2-fluorophenyl) - 6-hydroxyhexyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e: 559.2 (M + H) + .
Example 894
N- (3 - {l- [6- (3,4-DIMETHOXYPHEΝOXY) -6- (2- FLUOROPHEΝYL) HEXYL] -4-PIPERIDIΝYL}PHEΝYL) -2 - METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 3,4-dimethoxyphenol and N- (3- { l- [6-
(2-fluorophenyl) -6-hydroxyhexyl] -4-piperidinyl }phenyl) -
2-methylpropanamide: ESMS m/e: 577.6 (M + H)+.
Example 895
N- (3 - {l- l6- (2-ETHOXYPHEΝOXY) -6- (2-FLUOROPHENYL) HEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 2-ethoxyphenol and N- (3- {l- [6- (2-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e: 561.1
(M + H) + .
Example 896 N- (3 - { l- [6- (4-BROMOPHENOXY) -6-PHENYLHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and N- { 3 - [1- (6-hydroxy-6-phenylhexyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e : 577.0 (M + H) + .
Example 897 N- (3 - {l- [6 - (4-FLUOROPHENOXY) -6- (4-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and N- (3- {l- [6- (4-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz,
CDC13) , HCl salt δ 8.22 (s, br, IH) , 7.74-6.70 (m, 12H) ,
5.05-4.94 (m, IH) , 3.66-3.52 (m, br, 2H) , -3.02-2.83 (m, br, 2H) , 2.81-2.58 (m, br, 4H)-, 2.58-2.36 (m, br, 2H) , 2.02-1.66 (m, br, 6H) , 1.66-1.46 (m, br, IH) , 1.46-1.35
(m, br, 3H) , 1.26 (d, 6H, J = 6.0 Hz); ESMS m/e: 535.1
(M + H)+. Example 898
N- (3- {l- [6- (4-METHOXYPHEΝOXY) -6-PHENYLHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-methoxyphenol and N- {3- [1- (6-hydroxy-6-phenylhexyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e: 529.6 (M + H) + .
Example 899
N- (3 - {l- [6 - (4-CHLOROPHEΝOXY) -6- (4-CHLOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and N- (3- - {l- [6- (4-chloropheny1) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 566.9 (M + H)+.
Example 900 N- (3 - {l- [6 - (4-BROMOPHENOXY) -6- (4-FLUOROPHENYL) HEXYL] -4r PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and N- (3- {l-[6-(4-fluorophenyl) -6-hydroxyhex l] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 595.0 (M + H) + .
Example 901 N- (3 - {l- [6- (4-CHLOROPHEΝOXY) -6- (4-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and N- (3- {l- [6- (4-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13) , HCl salt δ 7.93 (s, IH) , 7.72-6.68 (m, 12H) , 5.06-4.98 (m, IH) , 3.66-3.50 (m, br, 2H) , 3.02-2.82 (m, br, 2H) , 2.80-2.57 (m, br, 4H) , 2.57-2.38 (m, br, 2H) , 2.02-1.76 (m, br, 6H) , 1.64-1.48 (m, br, IH) , 1.48-1.36 (m, br, 3H) , 1.25 (d, 6H, J = 6.8 Hz) ; Anal. Calc. for C33H41Cl2FN2O2-0.5EtOAc: C, 66.55; H, 7.18; N, 4.43;
Found: C, 66.35; H, 6.86; N, 4.46. ESMS m/e: 550.8 (M +
H) + .
Example 902
N-(3-{l-[6- (4-CHLOROPHENYL) -6- (4 -FLUOROPHENOXY) HEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-fluorophenol and N- (3- { 1- [6 - (4-chloropheny1) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide: 1H ΝMR (400 MHz,
CDC13) , HCl salt δ 8.22 (s, br, IH) , 7.74-6.68 (m, 12H) , 5.04-4.92 (m, IH) , 3.66-3.50 (m, br, 2H) , 3.00-2.82 (br, 2H) , 2.80-2.58 (m, br, 4H) , 2.58-2.40 (m, br, 2H) , 2.00- 1.68 (m, br, 6H) , 1.66-1.46 (m, br, IH) , 1.46-1.36 ( br, 3H) , 1.25 (d, 6H, J = 7.2 Hz); ESMS m/e: 551.1 (M + H) + .
Example 903
N-(3-{l-[6-(3-ACETYLPHEΝOXY) -6 -PHENYLHEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1- (3- hydroxyphenyl) ethanone and N- {3- [1- (6-hydroxy-6- phenylhexyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e: 541.2 (M + H) + .
Example 904
N-(3-{l-[6- (4-CHLOROPHEΝOXY) -6 -PHENYLHEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol -and N-{3- [1- (6-hydroxy- 6-phenylhexyl) -4-piperidinyl] phenyl} -2- methylpropanamide: ^Η ΝMR (400 MHz, CDC13) , HCl salt δ 8.28 (s, IH) , 7.78-6.70 (m, 13H) , 5.08-4.98 (m, IH) , 3.64-3.46 (m, br, 2H) , 3.02-2.82 (br, 2H) , 2.82-2.56 (m, br, 4H) , 2.56-2.34 (m, br, 2H) , 2.05-1.75 (m, br,
6H) , 1.64-1.48 (m, br, IH) , 1.48-1.34 ( br, 3H) , 1.25
(d, 6H, J = 6.8 Hz); ESMS m/e : 533.1 (M + H) + .
Example 905
N- (3 - {l- [6- (4-BROMOPHENOXY) -6- (4-CHLOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and N- (3- {l- [6- (4-chlorophenyl) -6-hydroxyhexyl] -4- piperidinyl }phenyl) -2-methylpropanamide: ESMS m/e : 611.0 (M + H) + .
Example 906
N- (3 - {l- [6 - (4-CHLOROPHENYL) -6- (4-METHOXYPHENOXY) HEXYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N- (3-{l- [6- (4-chlorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 563.1 (M + H) + .
Example 907 N- (3 - { l- [6 - (4 -FLUOROPHENYL) -6- (4-METHOXYPHENOXY) HEXYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N- (3-{l- [6- (4-fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13) , HCl salt δ 8.11 (s, IH) , 7.65-6.84 (m, 12H) , 5.21-5.10 (m, IH) , 3.66-3.56 (m, br, 2H) , 3.02-2.82 (br, 2H) , 2.82-2.56 (m, br, 4H) , 2.54 (s, 3H) , 2.53-2.32 (m, br, 2H) , 2.02-1.70 (m, br, 6H) , 1.64-1.48 (m, br, IH) , 1.48-1.34 (br, 3H) , 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e -. 547.1 (M + H)+. Example 908
N-(3-{l-[6- (3 -ACETYLPHEΝOXY) -6- (4-FLUOROPHENYL) HEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 1- (3- hydroxyphenyl) ethanone and N-(3-{l-[6-(4-fluorophenyl) -
6-hydroxyhexyl] -4-piperidinyl}phenyl) -2- methylpropanamide : ESMS m/e: 559.1 (M + H) + .
Example 909 N-(3-{l-[6-(4-FLUOROPHENOXY) -6-PHENYLHEXYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and- Scheme AN using 4-fluorophenol and N-{3- [1- (6 -hydroxy-6-phenylhexyl) -4-piperidinyl] phenyl} -2 - methylpropanamide: '^ ΝMR (400 MHz, CDC13) , HCl salt δ 8.05 (s, br, IH) , 7.72-6.70 (m, 13H) , 5.06-4.96 (m, IH) , 3.66-3.51 (m, 2H) , '3.01-2.82 (m, br, 2H) , 2.82-2.57 (m, br, 4H) , 2.57-2.34 (m, br, 2H) , 2.05-1.78 (m, br, 6H) , 1.64-1.52 (m, br, IH) , 1.52-1.16 (m, br, 3H) , 1.25 (d, 6H, J = 7.2 Hz); ESMS m/e: 517.0 (M + H) + .
Example 910 N-(3-{l- [6- (2-ACETYLPHEΝOXY) -6- (2-FLUOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme - AN using - 1- (2- hydroxyphenyl) ethanone and N- (3- {l- [6- (2-fluorophenyl) - 6-hydroxyhexyl] -4-piperidinyl }phenyl) -2- methylpropanamide : ESMS m/e: 559.0 (M + H)+.
Example 911 N- [3- (l-{6- (4-FLUOROPHENYL) -6- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] HEXYL} -4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N-(3-{l- [6- (4 -fluorophenyl) -6- hydroxyhexyl] -4 - piperidinyl }phenyl) -2-methylpropanamide: ^Η NMR (400 MHz,
CDCI3) , HCl salt δ 8.23 (s, br, IH) , 7.74-6.88 (m, 11H) ,
5.20-5.12 (m, -IH), 3.68-3.52 (m, br, 2H) , 3.02-2.82 (m, br, 2H) , 2.82-2.60 (m, 4H) , 2.58-2.38 (m, br, 2H) , 2.12-
2.02 (m, br, IH) , 2.02-1.80 (m, br, 5H) , 1.68-1.52 (m, br, IH) , 1.52-1.36 (br, 3H) , 1.25 (d, 6H, J = 7.2 Hz) ,-
ESMS m/e : 603.3 (M + H)+.
Example 912
N- (3 - {l- [6- (3-ACETYLPHEΝOXY) -6- (4-CHLOROPHENYL) HEXYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using l-(3- hydroxyphenyl) ethanone and N- (3- {l- [6- (4-chlorophenyl) - 6-hydroxyhexyl] -4-piperidinyl}phenyl) -2- methylpropanamide : λE ΝMR (400 MHz, CDC13) , HCl salt δ 8.41 (s, IH) , 7.72-6.84 (m, 12H) , 5.18-5.10 (m, IH) , 3.62-3.50 (m, br, 2H) , 3.00-2.92 (m, 2H) , 2.90-2.58 (m, 4H) , 2.54 (s, 3H) , 2.50-2.12 (m, 2H) , 2.02-1.70 (m, br, 6H) , 1.64-1.50 (m, br, IH) , 1.50-1.14 (m, br, 3H) , 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e : 575.3 (M + H)
Example 913
N- [3- (l-{6- (2 -FLUOROPHENYL) -6- [2-FLUORO-5- (TRIFLUOROMETHYL) PHENOXY] HEXYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N- (3- { l - [6- (2-fluorophenyl) -6 -hydroxyhexyl] -4- piperidinyl }phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13) , HCl salt δ 8.35 (s, IH) , 7.68-6.82 (m, 11H) , 5.58-5.48 (m, IH) , 3.64-3.50 (m, 2H) , 3.01-2.94 (m, br, 2H) , 2.92-2.54 (m, 4H) , 2.48-2.32 (m, br, 2H) , 2.20-2.04 (m, IH) , 2.01-1.80 (m, 5H) , 1.70-1.54 (m, IH) , 1.54-1.36 (m, 3H) , 1.25 (d, 6H, J = 7.2 Hz) . Anal. Calc. for
C34H4oClF5N202-0.6MeOH: C, 63.12; H, 6.49; N, 4.25; Found:
C, 63.38; H, 6.61; N, 3.95. ESMS m/e: 603.3 (M + H) + .
Example 914
N- [3- (l-{6- (4 -CHLOROPHENYL) -6- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] HEXYL} -4 -PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N-(3-{l- [6- (4-chlorophenyl) -6-hydroxyhexyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e: 619.2 (M + H) + .
Example 915 N- [3- (l-{6- (3 -FLUOROPHENYL) -6- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] HEXYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N-(3-{l- [6- (3 -fluorophenyl) -6-hydroxyhexyl] -4- piperidinyl }phenyl) -2-methylpropanamide : ESMS m/e: 603.3 (M + H) + .
Example 916 N- [3- (l-{6- [2-FLUORO-5- (TRIFLUOROMETHYL) PHENOXY] -6- PHENYLHEXYL} -4 -PIPERIDINYL) PHENYL] -2-METHYLPROPANAMIDE : Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N- {3- [1- (6-hydroxy-6- phenylhexyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e: 585.3 (M + H) + .
Example 917
N- [3- (l-{7- (2 -FLUOROPHENYL) -7- [2-FLUORO-5- (TRIFLUOROMETHYL) PHENOXY] HEPTYL}-4-PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N- (3-{l- [7- (2-fluorophenyl) -7-hydroxyheptyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e 617.3
(M + H) + .
Example 918
Ν-(3-{l-[5- (4-FLUOROPHENYL) -5- (4-METHOXYPHENOXY) PENTYL] - 4 -PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N- (3-{l- [5- (4-fluorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 533.1 (M + H) + .
Example 919
N- (3 - { l- [5- (4-BROMOPHENOXY) -5- (4-FLUOROPHENYL) PENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and N- (3- {l- [5- (4-fluorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13) , HCl salt δ 7.94 (s, br, IH) , 7.68-6.64 (m, 12H) , 5.12-5.04 (m, IH) , 3.68-3.52 (m, br, 2H) , 3.01-2.82 (br, 2H) , 2.78-2.58 (m, br, 4H) , 2.57-2.38 (m, br, 2H) , 2.05- 1.80 (m, br, 6H) , 1.64-1.38 (m, br, 2H) , 1.25 (d, 6H, J = 7.2 Hz); ESMS m/e : 581.0 (M + H) + .
Example 920
N- (3 - { l- [5 - (4 -CHLOROPHEΝOXY) -5- (4-CHLOROPHENYL) PENTYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and' Scheme AN using 4-chlorophehol and N- (3- {l- [5- (4 -chlorophenyl) -5-hydroxypentyl] -4- piperidinyl }phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13) , HCl salt δ 7.86 (s, br, IH) , 7.62-6.72 (m, 12H) , 5.12-5.02 (m, IH) , 3.68-3.52 (m, br, 2H) , 3.02-2.82 (br, 2H) , 2.82-2.56 (m, br, 4H) , 2.56-2.40 (m, br, 2H) , 2.06- 1.80 (m, br, 6H) , 1.64- 1.40 (m, br, 2H) , 1.25 (d,
6H, J = 6.8 Hz). Anal. Calc. for C32H39Cl3N2θ2-l .3MeOH: C,
63.25; H, 7.07; N, 4.42; Found: C, 63.41; H, 6.99; N,
4.17. ESMS m/e: 553.0 (M + H) + . Example 921
N-(3-{l-[5- (4-CHLOROPHEΝOXY) -5-PHEΝYLPEΝTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and N-{3- [1- (5-hydroxy-5-phenylpentyl) -4-piperidinyl] phenyl} -2- methylpropanamide: 1H ΝMR (400 MHz, CDC13) , HCl salt δ 7.72-6.72 (m, 13H) , 5.12-5.04 (m, IH) , 3.66-3.52 (m, br, 2H) , 3.01-2.83 (br, 2H) , 2.68-2.62 (m, br, 2H) , 2.62- 2.48 (m, br, 4H) , 2.04-1.82 (m, br, 6H) , 1.62-1.40 (m, br, 2H) , 1.25 (d, 6H, J = 7.2 Hz); ESMS m/e: 519.1 (M + H)+.
Example 922
N-(3-{l-[5- (3 -ACETYLPHEΝOXY) -5- (4 -FLUOROPHENYL) PENTYL] - 4 -PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using l-(3- hydroxyphenyl) ethanone and N- (3-{l- [5- (4-fluorophenyl) - 5-hydroxypentyl] -4 -piperidinyl }phenyl) -2- methylpropanamide: ESMS m/e: 545.1 (M + H)+.
Example 923
N-(3-{l-[5- (4-CHLOROPHENYL) -5- (4 -FLUOROPHENOXY) PENTYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and N- (3- {l- [5- (4-chlorophenyl) -5-hydroxypentyl] -4- piperidinyl }phenyl) -2-methylpropanamide: 1H ΝMR (400 MHz,
CDC13) , HCl salt δ 8.05 (s, br, IH) , 7.74-6.68 (m, 12H) , 5.08-4.99 (m, IH) , 3.67-3.56 (m, br, 2H) , 3.02-2.82 (br, 2H) , 2.80-2.57 (m, br, 4H) , 2.57-2.38 (m, br, 2H) , 2.05- 1.80 (m, br, 6H) , 1.64- 1.40 (m, br, 2H) , 1.25 (d,
6H, J = 7.2 Hz). Anal. Calc. for C32H39C12FN202-1.3EtOAc :
C, 64.93; H, 7.24; N, 4.07. Found: C, 65.01; H, 6.97;
N, 3.85. ESMS m/e: 537.1 (M + H) + .
Example 924
N- 3-{l- [5- (4 -BROMOPHENOXY) -5-PHENYLPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 4-bromophenol and N-{3- [1- (5-hydroxy-5-phenylpentyl) -4-piperidinyl] phenyl} -2 - methylpropanamide: 1H ΝMR (400 MHz, CDC13) , HCl salt δ 7.74-6.66 (m, 13H) , 5.13-5.02 (m, IH) , 3.73-3.51 (m, br, 2H) , 3.05-2.83 (br, 2H) , 2.83-2.62 (br, 4H) , 2.62-2.42 (m, br, 2H) , 2.10-1.80 (m, br, 6H) , 1.65-1.37 (m, br, 2H) , 1.25 (d, 6H, J = 6.8 Hz); ESMS m/e: 562.9 (M + H) + .
Example 925
N-(3-{l- [5- (4 -CHLOROPHENYL) -5- (4-METHOXYPHENOXY) PENTYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N-
(3-{l- [5- (4-chlorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz,
CDC13) , HCl salt δ 8.13 (s, br, IH) , 7.72-6.70 (m, 12H) ,
5.08-4.97 (m, IH) , 3.72 (s, 3H) , 3.66-3.50 (m, br, 2H) , 3.03-2.82 (br, 2H) , 2.80-2.54 (m, br, 4H) , 2.53-2.17 (m, br, 2H) , 2.08-1.78 (m, br, 6H) , 1.65-1.38 (m, br, 2H) , 1.25 (d, 6H, J = 6.8 Hz) . Anal. Calc. for C33H42Cl2Ν203O.54CH2Cl2: C, 63.80; H, 6.88; N, 4.44. Found: C, 63.84; H, 7.18; N, 4.00. ESMS m/e: 549.1 (M + H)+. Example 926
N- (3-{l- [5- (4-FLUOROPHENOXY) -5- (4-FLUOROPHENYL) PENTYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and N- (3- {l- [5- (4-fluorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz,
CDC13) , HCl salt δ 7.62-6.70 (m, 12H) , 5.10-5.00 (m, IH) , 3.71-3.56 (m, br, 2H) , 3.04-2.82 (br, 2H) , 2.78-2.64 (m, br, 3H) , 2.64-2.48 (m, br, 3H) , 2.05-1.82 (m, br, 6H) , 1.62-1.42 (m, br, 2H) , 1.25 (d, 6H, J = 6.0 Hz); ESMS m/e : 521.2 (M + H)+.
Example 927 Ν-(3-{l-[5- (3-ACETYLPHENOXY) -5-PHENYLPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1- (3- hydroxyphenyl) ethanone and N- { 3 - [1- (5 -hydroxy-5 - phenylpentyl) -4-piperidinyl] phenyl} -2-methylpropanamide : ESMS m/e : 526.9 (M + H) + .
Example 928
Ν-(3-{l- [5- (4-METHOXYPHENOXY) -5-PHENYLPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-methoxyphenol and N- {3- [1- (5-hydroxy-5-phenylpentyl) -4-piperidinyl] phenyl} - 2-methylpropanamide: ESMS m/e : 515.6 (M + H)+.
Example 929
N- [3- (l-{5- [2-FLUORO-5- (TRIFLUOROMETHYL) PHENOXY] -5- [4- (TRIFLUOROMETHYL) PHENYL] PENTYL}-4-PIPERIDINYL) PHENYL] -2- METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N- [3- (1- {5-hydroxy-5- [4- (trifluoromethyl) phenyl] pentyl} -4- piperidinyl ) phenyl] -2 - methylpropanamide : ESMS m/e : 639 . 2 (M + H) + .
Example 930 N- [3- (l-{5- (3 -CHLOROPHENYL) -5- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] PENTYL} -4 -PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure. A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N- (3- { l - [5- (3 -chlorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz, CDC13), HCl salt δ 8.17 (s, br, IH) , 7.75-6.88 (m, 11H) , 5.26-5.14 (m, IH) , 3.68-3.56 (m, br, 2H) , 3.05-2.90 (br, 2H) , 2.90-2.60 (m, br, 4H) , 2.56-2.36 (m, br, 2H) , 2.18- 1.84 (m, br, 6H) , 1.70-1.44 (m, br, 2H) , 1.25 (d, 6H, J = 7.2 Hz). Anal. Calc. for C33H3aCl2F4Ν2O2-0.9EtOAc: C, 60.98; H, 6.32; N, 3.89; Found: C, 60.99; H, 6.17; N, 3.81. ESMS m/e : 605.2 (M + H) + .
Example 931 N- [3- (l-{5- (2 -FLUOROPHENYL) -5- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] PENTYL}-4-PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N- (3- { l- [5- (2-fluorophenyl) -5-hydroxypentyl] -4- piperidinyl }phenyl) -2-methylpropanamide: ^Η ΝMR (400 MHz, CDCI3) , HCl salt δ 7.89 (s, br, IH) , 7.72-6.88 (m, 11H) , 5.59-5.48 (m, IH) , 3.70-3.48 (br, 2H) , 3.05-2.84 (br, 2H) , 2.82-2.58 (m, br, 4H) , 2.58-2.40 (m, br, 2H) , 2.22- 1.82 (m, br, 6H) , 1.71-1.42 (m, br, 2H) , 1.25 (d, 6H, J = 6.4 Hz); ESMS m/e : 589.3 (M + H) + . Example 932
N- [3- (l-{5- (3 -FLUOROPHENYL) -5- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] PENTYL} -4-PIPERIDINYL) PHENYL] -
2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N-(3-{l-
[5- (3 -fluorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : 1H ΝMR (400 MHz,
CDC13) , HCl salt δ 7.79 (s, br, IH) , 7.63-6.82 (m, 11H) , 5.24-5.15 (m, IH) , 3.70-3.56 (br, 2H) , 3.04-2.84 (br, 2H) , 2.82-2.60 (m, br, 4H) , 2.60-2.42 (m, br, 2H) , 2.20- 1.83 (m, br, 6H) , 1.70-1.44 (m, br, 2H) , 1.25 (d, 6H, J = 6.4 Hz); ESMS m/e: 589.3 (M + H)+.
Example 933 N-(3-{l- [5- (3 -ACETYLPHEΝOXY) -5- (4 -CHLOROPHENYL) PENTYL] -
4 -PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 1- (3- hydroxyphenyl) ethanone and N- (3-{l- [5- (4-chlorophenyl) - 5-hydroxypentyl] -4-piperidinyl }phenyl) -2- methylpropanamide: XH ΝMR (400 MHz, CDC13) , HCl salt δ
8.05 (s, br, IH) , 7.74-6.88 (m, 12H) , 5.27-5.16 (m, IH) ,
3.69-3.52 (m, br, 2H) , 3.10-2.81 (br, 2H) , 2.81-2.57 (m, br, 4H) , 2.54 (s, 3H) , 2.52-2.40 (m, br, 2H) , 2.05-1.80
(m, br, 6H) , 1.66-1.42 (m, br, 2H) , 1.25 (d, 6H, J = 6.8 Hz) ; Anal. Calc. for C34H42Cl2Ν2θ3-0. 5CH2Cl2'l .0H2O : C,
63.46; H, 6.91; N, 4.30. Found: C, 63.46; H, 7.09; N, 4.00. ESMS m/e: 561.1 (M + H) + .
Example 934 N- [3- (l-{5- (4 -CHLOROPHENYL) -5- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] PENTYL} -4 -PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol and N-(3-{l- [5- (4-chlorophenyl) -5- hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide: XE NMR (400 MHz,
CDC13) , HCl salt δ 7.61-6.92 (m, 11H) , 5.24-5.16 (m, IH) ,
3.70-3.58 (m, 2H) , 3.02-2.91 (br, 2H) , 2.80-2.64 (m, br, 3H) , 2.64-2.50 (m, 3H) , 2.18-1.94 (m, br, 6H) , 1.62-1.44
(m, br, 2H) , 1.25 (d, 6H, J = 7.2 Hz); ESMS m/e : 605.3
(M + H) + .
Example 935 N- [3- (l-{5- (4-FLUOROPHENYL) -5- [2-FLUORO-5-
(TRIFLUOROMETHYL) PHENOXY] PENTYL}-4-PIPERIDINYL) PHENYL] - 2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-fluoro-5- (trifluoromethyl) phenol N- (3- { l- [5- (4-fluorophenyl) -5-hydroxypentyl] -4-piperidinyl }phenyl) - 2-methylpropanamide: ESMS m/e 589.3 (M + H)+.
Example 936
N- (3 - {l- [5- (4-BROMOPHENOXY) -5- (4-CHLOROPHENYL) PENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-bromophenol and N- (3- {l- [5- (4-chlorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide : ESMS m/e : 597.2 (M + H) + .
Example 937
N- (3 - {l- [5- (4-CHLOROPHEΝOXY) -5- (4-FLUOROPHENYL) PENTYL] - 4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-chlorophenol and N- (3- {l- [5- (4-fluorophenyl) -5-hydroxypentyl] -4- piperidinyl}phenyl) -2-methylpropanamide: ESMS m/e: 537.3 (M + H) + . Example 938
N-(3-{l-[5- (2-ACETYLPHENOXY) -5-PHENYLPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure A and Scheme AN using 1- (2- hydroxyphenyl) ethanone and N- {3- [1- (5-hydroxy-5- phenylpentyl) -4-piperidinyl] phenyl} -2-methylpropanamide:
ESMS m/e : 527.0 (M + H)+.
Example 939 N- 3- {l- [5- (2-ETHOXYPHEΝOXY) -5-PHENYLPENTYL] -4-
PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 2-ethoxyphenol and N- { 3 - [1- (5-hydroxy-5-phenylpentyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e: 529.2 (M + H)+.
Example 940
N- (3 - {l- [5- (4-FLUOROPHENOXY) -5-PHENYLPENTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure A and Scheme AN using 4-fluorophenol and N- { 3 - [1- (5-hydroxy-5-phenylpentyl) -4-piperidinyl] phenyl} -2- methylpropanamide : ESMS m/e: 503.2 (M + H) + .
Example 941
N- (3 - { l- [4- ( -FLUOROPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide and 4-chloro-l- (4- fluorophenyl) -1-butanone: ESMS m/e : 411.2 (M + H) + .
Example 942
2 -METHYL-N- (3-{1- [3- (Iff-PYRROL-3 -YL) PROPYL] -4- PIPERIDIΝYL}PHEΝYL) PROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2-methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 3- (3-bromopropyl) -1H- pyrrole: ESMS m/e : 354.2 (M + H)+.
Example 943 N- (3-{l- [4- (4-ISOPROPYLPHEΝYL) -4-OXOBUTYL] -4-
PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide and 4-chloro-l- (4- isopropylphenyl) -1-butanone: ESMS m/e : 435.2 (M + H) + .
Example 944
N- (3- {l- [4- (4-METHOXYPHEΝYL) -4-OXOBUTYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2-methyl -N- [3- (4-piperidinyl) phenyl] propanamide and 4-chloro-l- (4- methoxyphenyl) -1-butanone: ESMS m/e : 423.2 (M + H)+.
Example 945
2-METHYL-Ν-(3-{l- [4- (4-METHYLPHENYL) -4-OXOBUTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 4-chloro-l- (4- methylphenyl) -1-butanone: ESMS m/e : 407.2 (M + H)+.
Example 946
N- (3 - {l- [4- (4-TERT-BUTYLPHEΝYL) -4-OXOBUTYL] -4- PIPERIDIΝYL}PHEΝYL) -2-METHYLPROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2-methyl-N- [3- (4-piperidinyl) phenyl] propanamide and l-(4-tert- butylphenyl) -4-chloro-1-butanone: ESMS m/e 449.2 (M + H) + .
Example 947 N- (3 -{l- [4- (4- BROMOPHENYL) -4-OXOBUTYL] -
4-PIPERIDINYL}PHENYL) -2-METHYLPROPANAMIDE: Prepared by
Procedure K (Kl) and Scheme E (K2C03) using 2-methyl-N-
[3- (4-piperidinyl) phenyl] propanamide and 1- (4- bromophenyl) -4-chloro-1-butanone: ESMS m/e : 471.3 (M +
H) + .
Example 948
2-METHYL-N- (3- {l- [4-0X0-4- (2-THIENYL) BUTYL] -4- PIPERIDINYL}PHENYL) PROPANAMIDE: Prepared by Procedure K (Kl) and Scheme E (K2C03) using 2 -methyl-N- [3- (4- piperidinyl) phenyl] propanamide and 4-chloro-l- (2- thienyl) -1-butanone: ESMS m/e: 399.1 (M + H)
II. Synthetic Methods for General Structures
The examples described in Section I are merely illustrative of the methods used to synthesize MCHl antagonists. Further derivatives may be obtained utilizing generalized methods based on the synthetic methods used to synthesize the examples.
It may be necessary to incorporate protection and deprotection strategies for substituents such as amino, amido, carboxylic acid, and hydroxyl groups in the generalized synthetic methods to form further derivatives. Methods for protection and deprotection of such groups are well-known in the art, and may be found, for example in Green, T.W. and Wuts, P.G.M. (1991) Protection Groups in Organic Synthesis, 2n Edition John Wiley & Sons, New York.
III. Oral Compositions
As a specific embodiment of an oral composition of a compound of this invention, 100 mg of one of the compounds described herein is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
IV. Pharmacological Evaluation of Compounds at Cloned rat MCHl Receptor
The pharmacological properties of the compounds of the present invention were evaluated at the cloned rat MCHl receptor using protocols described below.
Host Cells A broad variety of host cells can be used to study heterologously expressed proteins. These cells include but are not restricted to assorted mammalian lines such as: Cos-7, CHO, LM(tk-), HEK293, Peak rapid 293, etc.; insect cell lines such as: Sf9, Sf21, etc.; amphibian cells such as xenopus oocytes; and others.
COS 7 cells are grown on 150 mm plates in DMEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% C02. Stock plates of COS-7 cells are trypsinized and split 1:6 every 3-4 days.
Human embryonic kidney 293 cells are grown on 150 mm plates in DMEM with supplements (10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% C02. Stock plates of 293 cells are trypsinized and split 1:6 every 3-4 days.
Human embryonic kidney Peak rapid 293 (Peakr293) cells are grown on 150 mm plates in DMEM with supplements (10% fetal bovine serum, 10% L-glutamine, 50 Fg/ml gentamycin) at 37°C, 5% C02. Stock plates of Peak rapid 293 cells are trypsinized and split 1:12 every 3-4 days.
Mouse fibroblast LM(tk-) cells are grown on 150 mm plates in DMEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% C02. Stock plates of LM(tk-) cells are trypsinized and split 1:10 every 3-4 days. Chinese hamster ovary (CHO) cells were grown on
150 mm plates in HAM=s F-12 medium with supplements (10% bovine calf serum, 4 mM L-glutamine and 100 units/ml penicillin/ 100 Fg/ml streptomycin) at 37°C, 5% C02. Stock plates of CHO cells are trypsinized and split 1:8 every 3-4 days.
Mouse embryonic fibroblast NIH-3T3 cells are grown on 150 mm plates in Dulbecco=s Modified Eagle Medium (DMEM) with supplements (10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 Fg/ml streptomycin) at 37°C, 5% C02. Stock plates of NIH-3T3 cells are trypsinized and split 1:15 every 3-4 days.
Sf9 and Sf21 cells are grown in monolayers on 150 mm tissue culture dishes in TMN-FH media supplemented with 10% fetal calf serum, at 27°C, no C02. High Five insect cells are grown on 150 mm tissue culture dishes in Ex- Cell 400™ medium supplemented with L-Glutamine, also at 27°C, no C02.
In some cases, cell lines that grow as adherent monolayers can be converted to suspension culture to increase cell yield and provide large batches of uniform assay material for routine receptor screening projects.
Transient expression
DNA encoding proteins to be studied can be transiently expressed in a variety of mammalian, insect, amphibian and other cell lines by several methods including but not restricted to; calcium phosphate-mediated, DEAE- dextran mediated, Liposomal-mediated, viral-mediated, electroporation-mediated and microinjection delivery. Each of these methods may require optimization of assorted experimental parameters depending on the DNA, cell line, and the type of assay to be subsequently employed.
A • typical protocol for the calcium phosphate method as applied to Peak rapid 293 cells is described as follows:
Adherent cells are harvested approximately twenty-four hours before transfection and replated at a density of 3.5 x 106 cells/dish in a 150 mm tissue culture dish and allowed to incubate over night at 37°C at 5% C02. 250 FI of a mixture of CaCl2 and DNA (15 Fg DNA in 250 mM CaCl2) is added to a 5 ml plastic tube and 500 FI of 2X HBS (280 mM NaCl, 10 mM KC1, 1.5 mM Na2HP04, 12 mM dextrose, 50 mM HEPES) is slowly added with gentle mixing. The mixture is allowed to incubate for 20 minutes at room temperature to allow a DNA precipitate to form. The DNA precipitate mixture is then added to the culture medium ' in each plate and incubated for 5 hours at 37°C, 5% C02. After the incubation, 5ml of culture medium (DMEM, 10% FBS, 10% L-glut and 50 μg/ml gentamycin) is added to each plate. The cells are then incubated for 24 to 48 hours at 37°C, 5% C02.
A typical protocol for the DEAE-dextran method as applied to Cos-7 cells is described as follows; Cells to be used for transfection are split 24 hours prior to the transfection to provide flasks which are 70-80% confluent at the time of transfection. Briefly, 8 Fg of receptor DNA plus 8 Fg of any additional DNA needed (e.g. Ga protein expression vector, reporter construct, antibiotic resistance marker, mock vector, etc.) are added to 9 ml of complete DMEM plus DEAE-dextran mixture (10 mg/ml in PBS) . Cos-7 cells plated into a
T225 flask (sub-confluent) are washed once with PBS and the DNA mixture is added to each flask. The cells are allowed to incubate for 30 minutes at 37°C, 5% C02.
Following the incubation, 36 ml of complete DMEM with 80
FM chloroquine is added to each flask and allowed to incubate ■ an additional 3 hours. The medium is then aspirated and 24 ml of complete medium containing 10% DMSO for exactly 2 minutes and then aspirated. The cells are then washed 2 times with PBS and 30 ml of complete DMEM added to each flask. The cells are then allowed to incubate over night. The next day the cells are harvested' by trypsinization and reseeded as needed depending upon the type of assay to be performed.
A typical protocol for liposomal-mediated transfection as applied to CHO cells is described as follows; Cells to be used for transfection are split 24 hours prior to the transfection to provide flasks which are 70-80% confluent at the time of transfection. A total of lOFg of DNA which may include varying ratios of receptor DNA plus any additional DNA needed (e.g. Gα protein expression vector, reporter construct, antibiotic resistance marker, mock vector, etc.) is used to transfect each 75 cm2 flask of cells. Liposomal mediated transfection is carried out according to the manufacturer=s recommendations (LipofectAMI-NE, GibcoBRL, Bethesda, MD) . Transfected cells are harvested 24 hours post transfection and used or reseeded according the requirements of the assay to be employed. A typical protocol for the electroporation method as applied to Cos-7 cells is described as follows; Cells to be used for transfection are split 24 hours prior to the transfection to provide flasks which are subconfluent at the time of transfection. The cells are harvested by trypsinization resuspended in their growth media and counted. 4 x 106 cells are suspended in 30.0 FI of DMEM and placed into an electroporation cuvette. 8 Fg of receptor DNA plus 8 Fg of any additional DNA needed (e.g. Ga protein expression vector, reporter construct, antibiotic resistance marker, mock vector, etc.) is added to the cell suspension, the cuvette is placed into a BioRad Gene Pulser and subjected to an electrical pulse (Gene Pulser settings: 0.25 kV voltage, 950 FF capacitance) . Following the pulse, 800 Fl of complete DMEM is added to each cuvette and the suspension transferred to a sterile tube. Complete medium is added to each tube to bring the final cell concentration to 1 x 105 cells/100 Fl . The cells are then plated as needed depending upon the type of assay to be performed.
A typical protocol for viral mediated expression of heterologous ' proteins is described as follows for baculovirus infection of insect Sf9 cells. The coding region of DNA encoding the receptor disclosed herein may be subcloned into pBlueBacIII into existing restriction sites or sites engineered into sequences 5' and 3' to the coding region of the polypeptides . • To generate baculovirus, 0.5 Fg of viral DNA (BaculoGold) and 3 Fg of DNA construct encoding a polypeptide may be co- transfected into 2 x 105 Spodoptera frugiperda insect Sf9 cells by the calcium phosphate co-precipitation method, as outlined in by Pharmingen (in "Baculovirus Expression Vector System: Procedures and Methods Manual") . The cells then are incubated for 5 days at 27°C. The supernatant of the co-transfection plate may be collected by centrifugation and the recombinant virus plaque purified. The procedure to infect cells with virus, to prepare stocks of virus and to titer the virus stocks are as described in Pharmingen=s manual. Similar principals would in general apply to mammalian cell expression via retro-viruses, Simliki forest virus and double stranded DNA viruses such as adeno-, herpes-, and vacinia-viruses, and the like.
Stable expression
Heterologous DNA can be stably incorporated into host cells, causing the cell to perpetually express a foreign protein. Methods for the delivery of the DNA into the cell are similar to those described above for transient expression but require the co-transfection of an ancillary gene to confer drug resistance on the targeted host cell. The ensuing drug resistance can be exploited to select and maintain cells that have taken up the heterologous DNA. An assortment of resistance genes are available including but not restricted to Neomycin, Kanamycin, and Hygromycin. For the purposes of receptor studies, stable expression of a heterologous receptor protein is carried out in, but not necessarily restricted to, mammalian cells including, CHO, HEK293, LM(tk-), etc.
Cell membrane preparation
For binding assays, pellets of transfected cells are suspended in ice-cold buffer (20 mM Tris.HCl, 5 mM EDTA, pH 7.4) and homogenized by sonication for 7 sec. The cell lysates are centrifuged at 200 x g for
5 min at 4°C. The supernatants are then centrifuged at
40,000 x g for 20 min at 4°C. The resulting pellets are washed once in the homogenization buffer and suspended in binding buffer (see methods for radioligand binding) .
Protein concentrations are determined by the method of Bradford (1976) using bovine serum albumin as the standard. Binding assays are usually performed immediately, however it is possible to prepare membranes in batch and store frozen in liquid nitrogen for future use .
Radioligand binding assays
Radioligand binding assays for the rat MCHl receptor were carried out using plasmid pcDNA3.1-rMCHl-f (ATCC Patent Deposit Designation No. PTA-3505) . Plasmid pcDNA3.1-rMCHl-f- comprises the regulatory elements necessary for expression of DNA in a mammalian cell operatively linked to DNA encoding the rat MCHl receptor so as to permit expression thereof. Plasmid pcDNA3.1- rMCHl-f was deposited on July 05, 2001, with the American Type Culture Collection (ATCC) , 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the' Deposit of Microorganisms for the Purposes of Patent Procedure and was accorded ATCC -Patent Deposit Designation No. PTA-3505.
Binding assays can also be performed as described hereinafter using plasmid pEXJ.HR-TL231 (ATCC Accession No. 203197) Plasmid pEXJ.HR-TL231 encodes the human MCHl receptor and was deposited on September 17, 1998, with the American Type Culture Collection (ATCC) , 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the
International Recognition of the Deposit of
Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Accession No. 203197.
Human embryonic kidney Peak rapid 293 cells (Peakr293 cells) were transiently transfected with DNA encoding the MCHl receptor utilizing the calcium phosphate method and cell membranes were prepared as described above. Binding experiments with membranes from Peakr293 cells transfected with the rat MCHl receptor were performed with 0.08 nM [3H] Compound A (the synthesis of Compound A is described in detail below) using an incubation buffer consisting of 50 mM Tris pH 7.4, 10 mM MgCl2, 0.16 mM PMSF, 1 mM 1,10 phenantroline and 0.2% BSA. Binding was performed at 25°C for 90 minutes. Incubations were terminated by rapid vacuum filtration over GF/C glass fiber filters, presoaked in 5% PEI using 50 nM Tris pH 7.4 as wash buffer. In all experiments, nonspecific binding is defined using 10 pM Compound A.
Functional assays Cells may be screened for the presence of endogenous mammalian receptor using functional assays. Cells with no or a low level of endogenous receptor present may be transfected with the exogenous receptor ■ for use in functional assays .
A wide spectrum of assays can be employed to screen for receptor activation. These range from traditional measurements of phosphatidyl inositol, cAMP, Ca++, and K+, ' for example; to systems measuring these same second messengers but which have been modified or adapted to be higher throughput, more generic, and more sensitive; to cell based platforms reporting more general cellular events resulting from receptor activation such as metabolic changes, differentiation, and cell division/proliferation, for example; to high level organism assays which monitor complex physiological or behavioral changes thought to be involved with receptor activation including cardiovascular, analgesic, orexigenic, anxiolytic, and sedation effects, for example.
Radioligand Binding Assay Results The compounds described above were assayed using cloned rat MCHl. The binding affinities of the compounds are shown in Table I .
Ki (nM)
EXAMPLE No. STRUCTURE rMCH1
Figure imgf000503_0001
Figure imgf000503_0002
Figure imgf000504_0001
Figure imgf000505_0001
Figure imgf000506_0001
Figure imgf000507_0001
Figure imgf000508_0001
Figure imgf000509_0001
Figure imgf000510_0001
Figure imgf000511_0001
Figure imgf000512_0001
Figure imgf000512_0002
EXAMPLE STRUCTURE Ki (nM) rMCHl
Figure imgf000513_0001
Figure imgf000514_0001
Figure imgf000515_0001
Figure imgf000516_0001
Figure imgf000517_0001
Figure imgf000518_0001
Figure imgf000518_0002
Figure imgf000519_0001
Figure imgf000519_0002
Figure imgf000519_0003
Figure imgf000519_0004
Figure imgf000520_0001
Figure imgf000520_0002
Figure imgf000520_0003
Figure imgf000520_0004
Figure imgf000521_0001
Figure imgf000521_0002
Figure imgf000521_0003
Figure imgf000522_0001
Figure imgf000523_0001
Figure imgf000524_0001
Figure imgf000525_0001
Figure imgf000526_0001
Figure imgf000527_0001
Figure imgf000528_0001
Figure imgf000529_0001
Figure imgf000530_0001
Figure imgf000530_0002
Figure imgf000531_0001
Figure imgf000532_0001
Figure imgf000533_0001
Figure imgf000534_0001
Figure imgf000535_0001
Figure imgf000536_0001
Example Structure rMCH1 Ki (nM)
Figure imgf000536_0002
Figure imgf000537_0001
Figure imgf000538_0001
Figure imgf000539_0001
Figure imgf000540_0001
Figure imgf000540_0002
Figure imgf000541_0001
Figure imgf000542_0001
Figure imgf000542_0002
Figure imgf000543_0001
Figure imgf000544_0001
Figure imgf000544_0002
Figure imgf000545_0001
Figure imgf000546_0001
Figure imgf000547_0001
Figure imgf000548_0001
Figure imgf000549_0001
Figure imgf000549_0002
Figure imgf000550_0001
Figure imgf000551_0001
Figure imgf000552_0001
Figure imgf000552_0002
Figure imgf000552_0003
Figure imgf000553_0001
Figure imgf000553_0002
Figure imgf000554_0001
Figure imgf000554_0002
Figure imgf000554_0003
Figure imgf000555_0001
Figure imgf000555_0002
Example Structure rMCH-1 Ki (nM)
Figure imgf000555_0003
Figure imgf000555_0004
Figure imgf000556_0001
Figure imgf000557_0001
Figure imgf000558_0001
Example Structure rMCH-1 Ki (nM) 278 Chiral 85.8
Figure imgf000559_0001
Figure imgf000559_0002
Figure imgf000559_0003
Figure imgf000560_0001
Figure imgf000560_0002
Figure imgf000561_0001
Figure imgf000561_0002
Figure imgf000561_0003
Figure imgf000562_0001
Figure imgf000563_0001
Figure imgf000564_0001
Figure imgf000564_0002
Figure imgf000565_0001
Example Structure rMCH-1 Ki (nM)
Figure imgf000565_0002
305 hiral 177.2
Figure imgf000565_0003
306 ral 167.9
Figure imgf000566_0001
Figure imgf000566_0002
309 hiral 310.1
Figure imgf000566_0003
310 hiral 152.2
Figure imgf000567_0001
Figure imgf000567_0002
Figure imgf000568_0001
Figure imgf000569_0001
320 hiral 10.6
Figure imgf000569_0002
Figure imgf000569_0003
Figure imgf000570_0001
Figure imgf000571_0001
Figure imgf000572_0001
Figure imgf000572_0002
Example Structure rMCH-1 Ki (nM)
Figure imgf000572_0003
Figure imgf000573_0001
336 hiral 693.0
Figure imgf000573_0002
Figure imgf000573_0003
Figure imgf000574_0001
340 Chiral 15.6
Figure imgf000574_0002
Figure imgf000574_0003
Figure imgf000575_0001
Figure imgf000575_0002
Figure imgf000575_0003
Figure imgf000576_0001
Figure imgf000576_0002
Figure imgf000577_0001
Figure imgf000577_0002
353 hiral 41.8
Figure imgf000577_0003
Figure imgf000578_0001
Figure imgf000578_0002
Figure imgf000579_0001
Figure imgf000580_0001
Figure imgf000580_0002
Figure imgf000580_0003
Figure imgf000581_0001
Figure imgf000582_0001
Figure imgf000582_0002
Figure imgf000582_0003
Figure imgf000583_0001
Figure imgf000584_0001
Figure imgf000584_0002
Figure imgf000584_0003
Figure imgf000585_0001
Figure imgf000585_0002
Figure imgf000585_0003
Example Structure rMCH1 Ki (nM)
Figure imgf000586_0001
Figure imgf000587_0001
Figure imgf000588_0001
Figure imgf000589_0001
400 43.9
Figure imgf000589_0002
401 44.6
Figure imgf000589_0003
Figure imgf000590_0001
Figure imgf000591_0001
408 21.6
Figure imgf000591_0002
Figure imgf000591_0003
Figure imgf000592_0001
Figure imgf000593_0001
Figure imgf000593_0002
Figure imgf000594_0001
419 83.9
Figure imgf000594_0002
Figure imgf000594_0003
Figure imgf000595_0001
Figure imgf000596_0001
Figure imgf000597_0001
Figure imgf000598_0001
Figure imgf000598_0002
Figure imgf000599_0001
Figure imgf000599_0002
Figure imgf000600_0001
Figure imgf000601_0001
Figure imgf000602_0001
Figure imgf000603_0001
Figure imgf000604_0001
Figure imgf000605_0001
Figure imgf000606_0001
Figure imgf000607_0001
Figure imgf000608_0001
Figure imgf000609_0001
Figure imgf000610_0001
Figure imgf000611_0001
Figure imgf000612_0001
Figure imgf000613_0001
Figure imgf000613_0002
Figure imgf000614_0001
Figure imgf000616_0001
Figure imgf000617_0001
Figure imgf000618_0001
Figure imgf000619_0001
Figure imgf000620_0001
Figure imgf000620_0002
Figure imgf000621_0001
Figure imgf000621_0002
Figure imgf000622_0001
Figure imgf000623_0002
Figure imgf000623_0003
Figure imgf000624_0001
Figure imgf000624_0002
Figure imgf000625_0001
Figure imgf000625_0002
Figure imgf000626_0001
Figure imgf000626_0002
Figure imgf000626_0003
Figure imgf000627_0001
0
Figure imgf000627_0002
Figure imgf000628_0001
Figure imgf000628_0002
Figure imgf000628_0003
Figure imgf000629_0001
Figure imgf000629_0002
Figure imgf000630_0001
Figure imgf000630_0002
Figure imgf000630_0003
Figure imgf000631_0001
Figure imgf000632_0001
Figure imgf000632_0002
le Structure rMCH1 Ki (nM-)
Figure imgf000632_0003
Figure imgf000633_0001
Figure imgf000633_0002
Figure imgf000633_0003
Figure imgf000634_0001
Example Structure rMCH1 Ki (nM)
Figure imgf000634_0002
Figure imgf000635_0001
Figure imgf000635_0002
Figure imgf000635_0003
Figure imgf000635_0004
Figure imgf000636_0001
Figure imgf000636_0002
Figure imgf000636_0003
Figure imgf000636_0004
Figure imgf000637_0001
Figure imgf000637_0002
Example Structure rMCH1 Ki (nM) 592 hiral 185.6
Figure imgf000637_0003
Figure imgf000637_0004
Figure imgf000638_0001
595 Chiral 36.3
596 Chiral 596.7
597 Chiral 222.7
Figure imgf000638_0002
Figure imgf000639_0001
599 Chiral 50.0
600 Chiral 41.3
Figure imgf000639_0002
601 Chiral 144.2
Figure imgf000639_0003
Figure imgf000640_0001
Example MOLSTRUCTURE rMCH1 Ki (nM) 604 iral 36.8_
605 Chiral 94.5
Figure imgf000640_0002
606 Chiral 40.4
Figure imgf000641_0001
Figure imgf000641_0002
Figure imgf000642_0001
611 iral 65.1
612 Chiral 121.0
Figure imgf000642_0002
Figure imgf000642_0003
Figure imgf000643_0001
Figure imgf000644_0001
Example Structure rMCH1 Ki (nM)
Figure imgf000645_0001
Figure imgf000645_0002
Figure imgf000646_0001
Figure imgf000646_0002
Figure imgf000646_0003
Figure imgf000647_0001
Figure imgf000647_0002
Figure imgf000647_0003
Figure imgf000648_0001
Figure imgf000648_0002
Figure imgf000648_0003
Figure imgf000648_0004
Figure imgf000649_0001
Figure imgf000649_0002
Figure imgf000649_0003
Figure imgf000650_0001
Figure imgf000650_0002
Figure imgf000650_0003
Figure imgf000650_0004
Figure imgf000651_0001
Figure imgf000651_0002
Figure imgf000651_0003
Figure imgf000651_0004
Figure imgf000652_0001
Figure imgf000652_0002
Figure imgf000652_0003
654 43.6
Figure imgf000653_0001
Figure imgf000653_0002
Figure imgf000654_0001
659 40.2
Figure imgf000654_0002
660 128.9
Figure imgf000654_0003
Figure imgf000655_0001
Figure imgf000655_0002
Figure imgf000655_0003
Figure imgf000656_0001
Figure imgf000656_0002
Figure imgf000656_0003
Figure imgf000656_0004
Figure imgf000657_0001
Figure imgf000657_0002
Figure imgf000657_0003
Figure imgf000657_0004
Figure imgf000658_0001
Figure imgf000658_0002
Figure imgf000658_0003
Figure imgf000658_0004
Figure imgf000659_0001
679 97.9
Figure imgf000659_0002
Figure imgf000659_0003
Figure imgf000660_0001
Figure imgf000661_0001
Figure imgf000662_0001
Figure imgf000662_0002
Figure imgf000663_0001
Figure imgf000663_0002
Figure imgf000664_0001
Figure imgf000664_0002
Figure imgf000665_0001
Figure imgf000666_0001
Figure imgf000666_0002
Figure imgf000667_0001
Figure imgf000667_0002
Figure imgf000667_0003
Figure imgf000668_0001
Figure imgf000668_0002
Figure imgf000668_0003
Figure imgf000669_0001
Figure imgf000669_0002
Figure imgf000670_0001
Figure imgf000670_0002
Figure imgf000671_0001
Figure imgf000671_0002
Figure imgf000672_0001
Figure imgf000672_0002
Figure imgf000672_0003
Figure imgf000673_0001
Figure imgf000673_0002
Figure imgf000673_0003
Figure imgf000674_0001
Figure imgf000674_0002
Figure imgf000674_0003
Figure imgf000675_0001
Figure imgf000675_0002
Figure imgf000676_0001
Figure imgf000676_0002
Figure imgf000676_0003
Figure imgf000677_0001
Figure imgf000677_0002
Figure imgf000678_0001
Figure imgf000678_0002
Figure imgf000679_0001
Figure imgf000679_0002
Figure imgf000680_0001
Figure imgf000680_0002
Figure imgf000681_0001
Figure imgf000682_0001
Figure imgf000683_0001
Figure imgf000683_0002
Figure imgf000683_0003
Figure imgf000684_0001
Figure imgf000684_0002
782 18.1
Figure imgf000685_0001
Figure imgf000685_0003
Figure imgf000685_0004
Figure imgf000686_0001
Figure imgf000686_0002
Figure imgf000687_0001
Figure imgf000687_0002
Figure imgf000687_0003
Figure imgf000687_0004
Figure imgf000688_0001
Figure imgf000688_0002
Example Structure rMCH1 Ki (nM)
Figure imgf000688_0003
Figure imgf000689_0001
Figure imgf000689_0002
Figure imgf000689_0003
802 36.7
Figure imgf000690_0001
803 298.6
Figure imgf000690_0002
804 89.2
Figure imgf000690_0003
805 903.9
Figure imgf000690_0004
Figure imgf000691_0001
808 10.8
Chiral
Figure imgf000691_0002
Example Structure rMCH1 Ki (nM)
Figure imgf000691_0003
Figure imgf000692_0001
Figure imgf000692_0002
Figure imgf000692_0003
Figure imgf000692_0004
Figure imgf000693_0001
Figure imgf000693_0002
Figure imgf000693_0003
Figure imgf000693_0004
Figure imgf000694_0001
Figure imgf000694_0002
Example Structure rMCH1 Ki (nM)
Figure imgf000694_0003
Figure imgf000695_0001
Example Structure rMCH1 Ki (nM)
Figure imgf000695_0002
Figure imgf000695_0003
Figure imgf000696_0001
Figure imgf000696_0002
Figure imgf000696_0003
Figure imgf000697_0001
Figure imgf000697_0002
Figure imgf000698_0001
Figure imgf000698_0002
Figure imgf000699_0001
Figure imgf000699_0002
Figure imgf000700_0001
Figure imgf000700_0002
Figure imgf000700_0003
Figure imgf000700_0004
Figure imgf000701_0001
Figure imgf000701_0002
Figure imgf000701_0003
Figure imgf000702_0001
Figure imgf000702_0002
Figure imgf000702_0003
Figure imgf000703_0001
Figure imgf000703_0002
Figure imgf000704_0001
Figure imgf000705_0001
#NAME?
Figure imgf000705_0002
Figure imgf000706_0001
Figure imgf000706_0002
Figure imgf000707_0001
Figure imgf000708_0001
Figure imgf000709_0001
Example Structure rMCH1 Ki (nM)
Figure imgf000709_0002
Figure imgf000709_0003
Figure imgf000710_0001
Figure imgf000710_0002
Figure imgf000710_0003
Figure imgf000711_0001
Figure imgf000711_0002
Figure imgf000711_0003
Figure imgf000711_0004
Figure imgf000712_0001
Figure imgf000712_0002
Figure imgf000712_0003
Figure imgf000712_0004
Figure imgf000713_0001
Figure imgf000713_0002
Figure imgf000713_0003
Figure imgf000714_0001
Figure imgf000714_0002
Figure imgf000714_0003
Figure imgf000714_0004
Figure imgf000715_0001
Figure imgf000715_0002
Figure imgf000716_0001
Figure imgf000716_0002
Figure imgf000717_0001
Figure imgf000718_0001
Figure imgf000719_0001
Figure imgf000720_0001
Figure imgf000721_0001
Figure imgf000722_0001
Figure imgf000722_0003
Figure imgf000723_0001
Figure imgf000723_0002
Figure imgf000723_0003
Figure imgf000723_0004
Figure imgf000724_0001
Figure imgf000724_0002
Table 2: Binding affinities (Ki) at the rat MCH1 , human Dopamine D2, human Histamine H1 and human Alpha-1a Adrenergic receptors.
C5 o o
H U α.
o o o o
Figure imgf000725_0001
O
σ ro
S?
3 CL 3*
<a
Figure imgf000726_0001
TJ
3"
>
'
- . o S -) σ ro ro α>
3"
Q. co
Figure imgf000727_0001
Figure imgf000727_0002
3 3-
α >. ω
3 o"
TJ H σ ro ro
3' g. 3"
ft)
Figure imgf000728_0001
> T3
3- ft)
>
^ Q.
g o'
■σ V. Synthesis of Compound A
Described below is the synthesis of Compound A. Compound A is the radiolabeled compound that was used in the radioligand binding assays described above.
N- [3- (1, 2, 3 , 6-TETRAHYDRO-4-PYRIDINYL) PHENYL] ACETAMIDE :
The reaction of saturated of aqueous Na2C03 solution (25 mL) , tert-butyl 4- {[ (trifluoromethyl) sulfonyl] oxy} - 1, 2 , 3 , 6-tetrahydro-l-pyridine-carboxylate (20 mmol), 3- acetamidophenylboronic acid (30 mmol) and tetrakis- triphenylphosphine palladium (0) (1.15 g) in dimethoxyethane (40 mL) at reflux temperature overnight gave tert-butyl 4- [3- (acetylamino) phenyl] -3 , 6-dihydro- 1 (2H) -pyridinecarboxylate. Deprotection of the BOC group using HCl in dioxane followed by basification (pH 11-12) gave the desired product.
TERT-BUTYL N- (3 -BROMOPROPYL) CARBAMATE : was prepared from 3-bromopropylamine hydrobromide and BOC20 in the presence of base in dichloromethane.
N- {3 - [1- (3 -AMINOPROPYL) -1, 2, 3 , 6-TETRAHYDRO-4- PYRIDINYL] PHEΝYL}ACETAMIDE : The reaction of tert-butyl
N- (3 -bromopropyl) carbamate and N- [3- (1, 2, 3 , 6-tetrahydro-
4-pyridinyl) phenyl] acetamide in refluxing dioxane with catalytic Bu4ΝI and base as described in Scheme A gave tert-butyl 3- (4- [3- (acetylamino) phenyl] -3 , 6-dihydro- 1 (2H) -pyridinyl)propylcarbamate. Deprotection of the
BOC group using HCl in dioxane followed by basification
(pH 11-12) gave the desired product. METHYL (4S) -3- ({ [3- (4- [3- (ACETYLAMINO) PHENYL] -3 , 6-
DIHYDRO-1 (2H) -PYRIDINYL) PROPYL] AMINO}CARBONYL) -4- (3,4- DIFLUOROPHENYL) -6- (METHOXYMETHYL) -2-0X0-1,2,3,4- TETRAHYDRO-5-PYRIMIDINECARBOXYLATE: Prepared from the reaction of 5-methyl 1- (4-nitrophenyl) (6S) -6- (3,4- difluorophenyl) -4- (methoxymethyl) -2-oxo-3 , 6-dihydro- 1,5 (2H) -pyrimidinedicarboxylate (describe in PCT Publication No. WO 00/37026, published June 29, 2000) and N- { 3 - [1- (3-aminopropyl) -1,2,3, 6-tetrahydro-4- pyridinyl] phenyl} acetamide: 1H ΝMR δ 8.90 (t, 1 H, J=3.6 Hz), 7.75 (s, 1 H) , 7.50-7.00 (m, 8 H) , 6.68 (s, 1 H) , 6.03 (br s, 1 H) , 4.67 (s, 2 H) , 3.71 (s, 3 H) , 3.47 (s, 3 H) , 3.38 (ABm, 2 H) , 3.16 (m, 2 H) , 2.71 (t, 2 H, J =5.4 Hz), 2.56 (m, 4 H) , 2.35-1.90 (br, 2 H) , 2.17 (s, 3 H) , 1.82 (p, 2 H, J=7.2 Hz); ESMS, 612.25 (M+H) + .
TRITIATED METHYL (4S) -3 -{[ (3-{4- [3 - (ACETYLAMIΝO) PHEΝYL] - 1-PIPERIDIΝYL>PROPYL) AMINO] CARBONYL}-4 - (3,4- DIFLUOROPHENYL) -6- (METHOXYMETHYL) -2-0X0-1,2,3,4- TETRAHYDRO-5-PYRIMIDINECARBOXYLATE ( [3H] COMPOUND A):
This radiochemical synthesis was carried out by Amersham Pharmacia Biotech, Cardiff, Wales. A methanolic solution of methyl (4S) -3- ( { [3- (4- [3- (acetylamino) phenyl] -3 , 6-dihydro-l (2H) - pyridinyl) propyl] amino} carbonyl) -4- (3,4-difluorophenyl) - 6- (methoxymethyl) -2-oxo-l , 2,3, 4-tetrahydro-5- pyrimidinecarboxylate was exposed to tritium gas at 1 atmosphere pressure in the presence of 5% palladium on carbon with stirring overnight to give the tritiated methyl (AS) -3- { [ (3- {4- [3- (acetylamino) phenyl] -1- piperidinyl}propyl) amino] carbonyl} -4- (3,4- difluorophenyl) -6- (methoxymethyl) -2-oxo-l , 2,3,4- tetrahydro-5-pyrimidinecarboxylate ( (+) -isomer) After purification by reverse phase HPLC (Hypersil ODS,
4.6 x 100 mm, methanol :H20:Et3N 10:90:1 to 100:0:1 in 15 min at 1.0 mL/min, with radiochemical and UV detection), this product was used as a radioligand in the MCHl binding assays . The same procedure was carried out with
H2 gas in place of 3H2 to afford the non-radioactive version of Compound A.
VI. In-Vivo Methods
The following in vivo methods were performed to predict the efficacy of MCHl antagonists for the treatment of obesity (3-day body weight and sweetened condensed milk) , depression (forced swim test) , anxiety ' (social interaction test) , and urinary disorders (DIRC and CSTI) .
Effects of MCHl Antagonists on Body Weight (3 Day)
Male Long Evans rats (Charles River) weighing 180-200 grams were housed in groups of four on a 12-hour light/dark cycle with free access to food and water.
Test compounds were administered twice daily via i.p. injection, 1 hour before the dark cycle and 2 hours after lights on, for three days. All rats were weighed daily after each morning injection. Overall results were expressed as body weight (grams) gained per day
(mean ± SEM) and were analyzed by two-way ANOVA. Data for each time point were analyzed by one-way ANOVA followed by post hoc Newman-Keuls test. The data were analyzed using the GraphPad Prism (v2.01) (GraphPad
Software, Inc., San Diego, CA) . All data were presented as means + S.E.M. Effects of MCHl Antagonists on Consumption of Sweetened Condensed Milk
Male C57BL/6 mice (Charles River) weighing 17-19 grams at the start of experiments were housed in groups of four or five on a 12 hour light/dark cycle with free access to food and water. For 7 days, mice were weighed, placed in individual cages and allowed to drink sweetened condensed milk (Nestle, diluted 1:3 with water) for 1 hour, 2-4 hours into the light cycle. The amount of milk consumed was determined by weighing the milk bottle before and after each drinking bout . On the test day, mice received i.p. injections of Test Compound
(3, 10 or 30 mg/kg in 0.01 % lactic acid), vehicle (0.01 % lactic acid) of d-fenfluramine (10 mg/kg in 0.01 % lactic acid) 30 min. prior to exposure to milk. The amount of milk consumed on the test day (in mis milk/ kg body weight) was compared to the baseline consumption for each mouse determined on the previous 2 days . Data for each time point were analyzed by one-way ANOVA.
Forced Swim Test (FST) in the Rat
Animals Male Sprague-Dawley rats (Taconic Farms, NY) were used in all experiments. Rats were housed 5 per cage and maintained on a 12:12-h light-dark cycle. Rats were handled for 1 minutes each day for 4 days prior to behavioral testing. Drug Administration
Animals were randomly assigned to receive a single i.p. administration of vehicle (2.5% EtOH / 2.5% Tween-80) , imipramine (positive control; 60 mg/kg), or Test Compound 60 minutes before the start of the 5 minute test period. All injections were given using 1 cc tuberculin syringe with 26 3/8 gauge needles (Becton-
Dickinson, VWR Scientific, Bridgeport, NJ) . The volume of injection was 1 ml/kg.
Experimental Design
The procedure used in this study was similar to that previously described (Porsolt, et al . , 1978), except the water depth was 31 cm in this procedure. The greater depth in this test prevents the rats from supporting themselves by touching the bottom of the cylinder with their feet. Swim sessions were conducted by placing rats in individual plexiglass cylinders (46 cm tall x 20 cm in diameter) containing 23-25°C water 31 cm deep. Swim tests were conducted always between 900 and 1700 hours and consisted of an initial 15-min conditioning test followed 24h later by a 5-minute test. Drug treatments were administered 60 minutes before the 5-minute test period. Following all swim sessions, rats were removed from the cylinders, dried with paper towels and placed in a heated cage for 15 minutes and returned to their home cages. All test s.essions were videotaped using a color video camera and recorded for scoring later. Behavioral Scoring
The rat's behavior was rated at 5-second intervals during the 5-minute test by a single individual, who was blind to the treatment condition. Scored behaviors were :
1. Immobility- rat remains floating in the water without struggling and was only making those movements necessary to keep its head above water; 2. Climbing - rat was making active movements with its forepaws in and out of the water, usually directed against the walls;
3. Swimming - rat was making active swimming motions, more than necessary to merely maintain its head above water, e.g. moving around in the cy1inder; and
4. Diving - entire body of the rat was submerged.
Data Analysis The forced swim test data (immobility, swimming, climbing, diving) were subjected to a randomized, oneway ANOVA and post hoc tests conducted using the Newman- Keuls test. The data were analyzed using the GraphPad Prism (v2.01) (GraphPad Software, Inc., San Diego, CA) . All data were presented as means + S.E.M. All data were presented as means ■+ S.E.M.
Forced Swim Test (FST) in the Mouse Animals DBA/2 mice (Taconic Farms, NY) were used in all experiments . Animals were housed 5 per cage in a controlled environment under a 12:12 hour light: dark cycle . Animals were handled 1 min each day for 4 days prior to the experiment. This procedure included a mock gavage with a 1.5 inch feeding tube.
Drug Administration Animals were randomly assigned to receive a single administration of vehicle (5% EtOH/5% Tween-80) , Test Compound, or imipramine (60 mg/kg) by oral gavage 1 hour before the swim test.
Experimental Design
The procedure for the forced swim test in the mouse was similar to that described above for the rat, with some modifications. The cylinder used for the test was a 1- liter beaker (10.5cm diameter X 15 cm height) fill to 800ml (10cm depth) of 23-25°C water. Only one 5-minute swim test was conducted for each mouse, between 1300 and 1700 hours. Drug treatments were administered 30-60 minutes before the 5-minute test period. Following all swim sessions, mice were removed from the cylinders, dried with paper towels and placed in a heated cage for 15 minutes. All test sessions were videotaped using a Sony color video camera and recorder for scoring later.
Behavioral Scoring The behavior during minutes 2-5 of the test was played back on a TV monitor and scored by the investigator. The total' time spent immobile (animal floating with only minimal movements to remain afloat) and mobile (swimming and movements beyond those required to remain afloat) were recorded. Data Analysis
The forced swim test data (time exhibiting immobility, mobility; seconds) were subjected to a randomized, oneway ANOVA and post hoc tests conducted using the Newma - Keuls test. The data were analyzed using the GraphPad Prism (v2.01) (GraphPad Software, Inc., San Diego, CA) . All data were presented as means + S.E.M.
Social Interaction Test (SIT) Rats are allowed to acclimate - to the animal care facility for 5 days and are housed singly for 5 days prior to testing. Animals are handled for 5 minutes per day. The design and procedure for the Social Interaction Test is carried out as previously described by Kennett, et al . (1997) . On the test day, weight matched pairs of rats (+ 5%) , unfamiliar to each other, are given identical treatments and returned to their- home cages. Animals are randomly divided into 5 treatment groups, with 5 pairs per group, and are given one of the following i.p. treatments: Test Compound (10, 30 or 100 mg/kg) , vehicle (1 ml/kg) or chlordiazepoxide (5 mg/kg) . Dosing is 1 hour prior to testing. Rats are subsequently placed in a white perspex test box or arena (54 x 37 x 26 cm), whose floor is divided up into 24 equal squares, for 15 minutes. An air conditioner is used to generate background noise and to keep the room at approximately
74°F. All sessions are videotaped using a JVC camcorder
(model GR-SZ1, Elmwood Park, NJ) with either TDK (HG ultimate brand) or Sony 30 minute videocassettes . All sessions are conducted between 1300 - 1630 hours. Active social interaction, defined as grooming, sniffing, biting, boxing, wrestling, following and crawling over or under, is scored using a stopwatch (Sportsline model no. 226, 1/100 sec. discriminability) . The number of episodes of rearing
(animal completely raises up its body on its hind limbs) , grooming (licking, biting, scratching of body) , and face washing (i.e. hands are moved repeatedly over face) , and number of squares crossed are scored. Passive social interaction (animals are lying beside or on top of each other) is not scored. All behaviors are assessed later by an observer who is blind as to the treatment of each pair. At the ' end of each test, the box is thoroughly wiped with moistened paper towels.
Animals
Male albino Sprague-Dawley rats (Taconic Farms, NY) are housed in pairs under a 12 hr light dark cycle (lights on at 0700 hrs.) with free access to food and water.
Drug Administration
Test Compound is dissolved in either 100% DMSO or 5% lactic acid, v/v (Sigma Chemical Co., St. Louis, MO) . Chlordiazepoxide (Sigma Chemical Co., St. Louis, MO) is dissolved in double distilled water. The vehicle consists of 50% DMSO (v/v) or 100% dimethylacetamide (DMA) . All drug solutions are made up 10 minutes prior to injection and the solutions are discarded at the end of the test day. The volume of drug solution administered is 1 ml/kg.
Data Analysis The social interaction data (time interacting, rearing and squares crossed) are subjected to a randomized, oneway ANOVA and post hoc tests conducted using the Student-Newman-Keuls test. The data are subjected to a test of normality (Shapiro-Wilk test) . The data are analyzed using the GBSTAT program, version 6.5 (Dynamics
Microsystems, Inc., Silver Spring, MD, 1997).
In Vivo Models of the Micturition Reflex
The effects of compounds on the micturition reflex were assessed in the "distension-induced rhythmic contraction" (DIRC) , as described in previous publications (e.g. Maggi et al, 1987; Morikawa et al, 1992) , and Continuous Slow Transvesicular Infusion (CSTI) models in rats.
DIRC Model
Female Sprague Dawley rats weighing approximately 300 g were anesthetized with subcutaneous urethane (1.2 g/kg) . The trachea was cannulated with PE240 tubing to provide a clear airway throughout the experiment. A midline abdominal incision was made and the left and right ureters were isolated. The ureters were ligated distally (to prevent escape of fluids from the bladder) and cannulated proximally with PE10 tubing. The incision was closed using 4-0 silk sutures, leaving the PE10 lines routed to the exterior for the elimination of urine. The bladder was' canulated via the transurethral route using PE50 tubing inserted 2.5 cm beyond the urethral opening. This cannula was secured to the tail using tape and connected to a pressure transducer. To prevent leakage from the bladder, the cannula was tied tightly to the exterior urethral opening using 4-0 silk. To initiate the micturition reflex, the bladder was first emptied by applying pressure to the lower abdomen, and then filled with normal saline in 100 increments (maximum = 2 ml) until spontaneous bladder contractions occurred (typically 20-40 mmHg at a rate of one contraction every 2 to 3 minutes. Once a regular rhythm was established, vehicle (saline) or Test
Compounds were administered i.v. or i.p. to explore their effects on bladder activity. The 5-HTιA antagonist WAY-100635 was given as a positive control. Data were expressed as contraction interval (in seconds) before drug application (basal) , or after the application of vehicle or test article.
Continuous Slow Transvesicular Infusion (CSTI) rat Model
Male Sprague Dawley rats weighing approximately 300 g were used for the study. Rats were anaesthetized with pentobarbitone sodium (50 mg/kg, i.p). Through a median abdominal incision, bladder was exposed and a polyethylene cannula (PE 50) was introduced into the bladder through a small cut on the dome of the bladder and the cannula was secured with a purse string suture . The other end of the cannula was exteriorized subcutaneously at the dorsal neck area. Similarly, another cannula (PE 50) was introduced into the stomach through a paramedian abdominal incision with the free end exteriorized subcutaneously to the neck region. The surgical wounds were closed with silk 4-0 suture and the animal was allowed to recover with appropriate post surgical care. On the following day, the animal was placed in a rat restrainer. The open end of the bladder- cannula was connected to a pressure transducer as well as infusion pump through a three-way stopcock. The bladder voiding cycles were initiated by continuous infusion of normal saline at the rate of 100 μl/min. The repetitive voiding contractions were recorded on a Power Lab on-line data acquisition software. After recording the basal voiding pattern for an hour, the test drug or vehicle was administered directly into stomach through the intragastric catheter and the voiding cycles were monitored for 5 hours. Micturition pressure and frequency were calculated before and after the treatment
(at every 30 min interval) for each animal. Bladder capacity was calculated from the micturition frequency, based on the constant infusion of lOOul/min. The effect of the test drug was expressed as a percentage of basal, pre-drug bladder capacity. WAY 100635 was used as positive control for comparison.
In Vivo Results
Table 2
Effect of MCHl antagonist (Example No.) in the following in vivo models: 3-day Body Weight (3D BW) , mouse Sweetened Condensed Milk (mSwCM) , mouse Forced Swim Test (mFST), rat Forced Swim Test (rFST), DIRC model, or CSTI model .
Figure imgf000741_0001
A = Produced a significant reduction in weight gain relative to vehicle-treated controls B = Produced a significant decrease in consumption of milk relative to vehicle- treated controls
C = Produced a significant decrease in immobility relative to vehicle-treated animals when administered orally.
D = Produced a significant decrease in immobility or a significant increase in swimming activity relative to vehicle-treated animals
E = Produced a significant increase in contraction interval relative to pre-drug interval
F = Produced an increase in bladder capacity in rats relative to baseline capacity.
References:
American Psychiatric Association (1994a) , Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association.
American Psychiatric Association (1994b) , American DSM- IV Sourcebook. Washington, DC: American Psychiatric Association.
Auburger, G. , et al . , (1992) Assignment of the second (cuban) locus of autosomal dominant cerebellar ataxia to chromosome 12q23-24.1, between flanking markers D12S58 and PLA2. Cytσgrenet. Cell . Genet. 61:252-256.
Bahjaoui-Bouhaddi, M., et al . , (1994) Insulin treatment stimulates the rat melanin-concentrating hormone- producing neurons. Neuropeptides 24 : 251-258.
Baker, B.I. (1991) Melanin-concentrating hormone: a general vertebrate neuropeptide . Int. Rev. Cytol . 126 : 1- 47.
Baker, B.I. (1994) Melanin-concentrating hormone update: functional consideration. TEM 5: 120-126.
Bassett, A.S., et al . , (.1988) Partial trisomy chromosome 5 cosegregating with schizophrenia. Lancet 1^:799-801.
Bednarek, M.A. , et al . "Synthesis and biological evaluation in vitro of a selective, high potency peptide agonist of human melanin-concentrating hormone action at human melanin- concentrating hormone receptor 1" J Biol Chem 277(16) : 13821-13826 (2002) .
Bittencourt, J.C., et al . , (1992) The melanin- concentrating hormone system of the rat brain: An immuno- and hybridization histochemical characterization J". Comp . Neurol . 319:218-245.
Bobes, J. (1998) J Clin Psychiatry; 59 [suppl 17]:12-16.
Borowsky, B., et al . , Nature Medicine (in press) .
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle or protein-dye binding. Anal. Biochem . 72: 248-254.
Burgaud, J.L., et al . , (1997) Melanin-concentrating hormone binding sites in human SVK14 keratinocytes . Biochem . Biophys . Res . Commun . 241 (3) : 622-629.
Chambers, J., et al . , "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1" Nature 400(6741) : 261-6 (1999) .
Chen, Y., et al, "Targeted disruption of the melanin- concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity" Endocrinology 143(7): 2469-2477(2002).
Craddock, Ν. , et al . , (1993) The gene for Darier's disease maps to chromosome 12q23-q24.1. Hum. Mol . Genet . 2:1941-1943. Dondoni, A., et al . , (1995) T. Synthesis, 181.
Drozdz, R. and Eberle, A.N. (1995) Binding sites for melanin-concentrating hormone (MCH) in brain synaptosomes and membranes from peripheral tissues identified with highly tritiated MCH. J. Recept . Signal . Transduct . Res . 15 (1-4) :487-502.
Drozdz, R. , et al . , (1995) Melanin-concentrating hormone binding to mouse melanoma cells in vitro. FEBS 359 : 199- 202.
Drozdz, R. , et al . , (1998) Characterization of the receptor for melanin-concentrating hormone on melanoma cells by photocrosslinking. Ann. NY" Acad. Sci . 839 (1) :210-213.
Gale Group (2001) Gale Encyclopedia of Psychology, 2nd ed. Gale Group.
Gilliam, T.C., et al . , (1989) Deletion mapping of D A markers to a region of chromosome 5 that cosegregates with schizophrenia. Genomics 5 : 940-944.
Goodman WK, Price LH, Rasmussen SA et al . (1989), The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 46:1006-1011.
Gonzalez, M.I., et al . , (1997) Stimulatory effect of melanin-concentrating hormone on luteinizing hormone release. Neuroendocrinology 6j5_(4) : 254-262.
Gonzalez, M.I., et al., (1996) Behavioral effects of - melanocyte-stimulating hormone (α-MSH) and melanin- concentrating hormone (MCH) after central administration in female rats. Peptides 17 : 171-177.
Grillon, S., et al . , (1997) Exploring the expression of the melanin-concentrating hormone messenger RNA in the rat lateral hypothalamus after goldthioglucose injection. Neuropeptides 3JL(2) : 131-136.
Herve, C. and Fellmann, D. (1997) Changes in rat melanin-concentrating hormone and dynorphin messenger ribonucleic acids induced by food deprivation. Neuropeptides 31(3) : 237-242.
Hervieu, G. , et al . , (1996) Development and stage- dependent expression of melanin-concentrating hormone in mammalian germ cells. Biology of Reproduction 54:1161- 1172.
Kauwachi, H., et al . , (1983) Characterization of melanin-concentrating hormone in chum salmon pituitaries . Nature 305 : 321-333.
Knigge, K.M., et al . , (1996) Melanotropic peptides in the mammalian brain: The melanin-concentrating hormone. Peptides 17:1063-1073.
Knigge, K.M. and Wagner, J.E. (1997) Melanin- concentrating hormone (MCH) involvement in pentylenetetrazole (PTZ) -induced seizure in rat and guinea pig. Peptides 18 (7) : 1095-1097.
Lakaye, B., et al . , "Cloning of the rat brain cDΝA encoding for the SLC-1 G protein-coupled receptor reveals the presence of an intron in the gene"
Biochem Biophys Acta 1401(2) : 216-220 (1998) .
Ludwig, D.S., et al., (1998) Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am. J. Physiol . Endocrinol . Metab . 274 (4) :E627-E633.
MacKenzie, F.J., et al . , (1984) Evidence that the dopaminergic incerto-hypothalamic tract has a stimulatory effect on ovulation and gonadotropin release. Neuroendocrinology 39 : 289-295.
Maggi, C.A., et al . , "Spinal and supraspinal components of GABAergic inhibition of the micturition reflex in rats." J Pharmacol Exp Ther 240: 998-1005 (1987) .
Marsh, D.J., et al, "Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism" Proc Natl Acad Sci U S A 99(5) : 3240-3245 (2002) .
Martin, R. , et al . , (1997) J. Tetrahedron Letters, 38, 1633.
McBride, R.B., et al . , (1994) The actions of melanin- concentrating hormone (MCH) on passive avoidance in rats: A preliminary study. Peptides 15 : 757-759.
Medical Economics Company (2002) , Physicians' Desk Reference, 56th ed. , Montvale, NJ: Medical Economics Company, Inc., pp. 1609-1615, 2751-2756, 3495-3504. Melki, J. , et al . , (1990) Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature
(London) 344:767-768.
Miller, C.L., et al . , (1993) ce-MSH and MCH are functional antagonists in a CΝS auditory paradigm. Peptides 14:1-10.
Morikawa, K., et al . , "Inhibitory effect of inaperisone hydrochloride (inaperisone) , a new centrally acting muscle relaxant, on the micturition reflex." Eur J Pharmacol 213: 409-415 (1992) .
Νahon, J-L. (1994) The melanin-concentrating hormone: from the peptide to the gene. Cri tical Rev. in Neurobiol 221:221-262.
Parkes, D.G. (1996) Diuretic and natriuretic actions of melanin concentrating hormone in conscious sheep. J. Neuroendocrinol . 8 : 57-63.
Pedeutour, F., et al . , (1994) Assignment of the human pro-melanin-concentrating hormone gene (PMCH) to chromosome 12q23-24 and two variant genes (PMCHLl and PMCHL2) to chromosome 5pl4 and 5ql2-ql3. Genomics 19:31-37.
Porsolt, R.D., et al . , "Behavioural despair in rats: a new model sensitive to antidepressant treatments" Eur J Pharmacol 47(4) : 379-391 (1978) .
Presse, P., et al . (1992) Rat melanin-concentrating hormone messenger ribonucleic acid expression: marked changes during development and after stress and glucocorticoid stimuli. Endocrinology 131:1241-1250.
Qu, D., et al . (1996) A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380:243-247.
Rossi, M., et al., (1997) Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 138:351-355.
Sahu, A. (1998) Evidence suggesting that galanin (GAL) , melanin-concentrating hormone (MCH) , neurotensin (NT) , proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology 139 (2) : 795-798.
Sakurai, T., et al . , (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585.
Sanchez, M., et al . , (1997) Melanin-concentrating hormone (MCH) antagonizes the effects of α-MSH and neuropeptide E-I on grooming and locomotor activities in the rat. Peptides 18:393-396.
Saito, Y. , et al . , "Molecular characterization of the melanin-concentrating-hormone receptor" Nature 400 (6741) : 265-269 (1999) .
Schneier FR, Heckelman LR, Garfinkel R, et al . (1994) J Clin Psychiatry 55:322-331. Sherrington, R., et al . , (1988) Localization of a susceptibility locus for schizophrenia on chromosome 5.
Nature (London) 336:164-167.
Srebnik, M., et al . , (1988) J. Org. Chem. , 53, 2916- 2920.
Takekawa, S., et al . , "T-226296 : a novel, orally active and selective melanin-concentrating hormone receptor antagonist" Eur J Pharmacol 438 (3) : 129-35 (2002)
Twells, R. , et al . , (1992) Chromosomal assignment of the locus causing olivo-ponto-cerebellar atrophy (SCA2) in a cuban founder population. Cytogenet . Cell . Genet . 61:262-265.
Westbrook, C.A., et al . , (1992) Report of the second international workshop on human chromosome 5 mapping. Cytogenet . Cell . Genet . 61:225-231.

Claims

What is claimed is :
1. A compound having the structure:
wherein Rx is hydrogen, straight chained or branched Cx- C7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, - N02, -CH3, -CF3, -COCH3, -C02R2, phenyl, phenoxy or straight chained or branched Cχ-C-7 alkyl;
wherein R2 is straight-chained or branched C3-C4 alkyl or cyclopropyl ;
wherein R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more - F, -Cl, -Br, -I, -CN, -N02, straight chained or branched Cι-C7 alkyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, -COR3, -C02R3, straight chained or branched Cχ-C-7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is O or NH; and
wherein n is an integer from 0 to 5 inclusive.
2. The compound of claim 1, wherein Rλ is aryl optionally substituted with one or more -F, -Cl, -Br, - I, -CN, -N02, -COCH3, -C02R2, straight chained or branched Cχ-C-7 alkyl;
wherein R3 is phenyl;
wherein A is H; and
wherein X is O.
3. The compound of claim 2, wherein R2 is isopropyl.
4. The compound of claim 3 , wherein the compound has the structure:
Figure imgf000752_0001
5. The compound of claim 3 , wherein the compound has the structure :
Figure imgf000752_0002
6. The compound of claim 1, wherein Rx is hydrogen, straight chained or branched Cχ-C7 alkyl; and wherein R3 is aryl .
7. The compound of claim 6, wherein R2 is isopropyl; and A is hydrogen-
8. The compound of claim 7, wherein the compound has the structure:
Figure imgf000753_0001
9 . The compound of claim 7, wherein the compound has the structure:
Figure imgf000753_0002
10. A compound having the structure:
Figure imgf000753_0003
wherein Rx is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -OCH3, phenoxy, fused cyclopentanyl, straight chained or branched Cx-C7 alkyl, monofluoroalkyl or polyfluoroalkyl ;
wherein R2 is straight-chained or branched C1-C4 alkyl or cyclopropyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; and
wherein n is an integer from 1 to 5 inclusive.
11. The compound of claim 10, wherein Rx is aryl optionally substituted with one or more -F, -Cl, -Br, -I or straight chained or branched Cι-C4 alkyl; and
wherein A is H.
12. The compound of claim 11, wherein R2 is isopropyl; and
wherein n is 2.
13. The compound of claim 12, wherein the compound has the structure:
Figure imgf000754_0001
14. The compound of claim 12, wherein the compound has the structure:
Figure imgf000755_0001
15. The compound of claim 12, wherein the compound has the structure:
Figure imgf000755_0002
16. The compound of claim 10, wherein Ri is thienyl; and wherein A is H.
17. The compound of claim 16, wherein R2 is isopropyl.
18. The compound of claim 17, wherein the .compound has the structure:
Figure imgf000755_0003
19. A compound having the structure:
Figure imgf000755_0004
wherein W is
Figure imgf000756_0001
wherein each R is independently hydrogen, methyl or ethyl ;
wherein R2 is straight-chained or branched C3-C4 alkyl or cyclopropyl;
wherein R3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, -N0 , straight chained or branched Cχ-C-7 alkyl.
wherein each A is independently -H, -F, -Cl, -Br, -CN, - N02, -C0R3, -C02R3, straight chained or branched Cχ-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
wherein X is O, NR3, CO or may be absent; and
wherein Y is hydrogen, 'aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, straight chained or branched Cχ-C7 alkyl.
20. The compound of claim 19, wherein W is
Figure imgf000757_0001
and wherein X is O or may be absent.
21. The compound of claim 20, wherein R2 is isopropyl,
22. The compound of claim 21, wherein the compound has the structure :
Figure imgf000757_0002
23. The compound of claim 21, wherein the compound has the structure :
Figure imgf000757_0003
24. The compound of claim 19, wherein W is
Figure imgf000757_0004
25. The compound of claim 24, wherein A is -H, -F,
Cl, -Br.
26. The compound of claim 25, wherein R2 is isopropyl; and A is hydrogen.
27. The compound of claim 26, wherein the compound has the structure:
Figure imgf000758_0001
28. A compound having the structure:
Figure imgf000758_0002
wherein W is
Figure imgf000758_0003
wherein Rx is hydrogen, straight chained or branched Cι~ C7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more - F, -Cl, -Br, -CN, -N02, -OCH3, -C02CH3, -CF3, phenyl, straight chained or branched Cι-C7 alkyl; wherein R2 is straight- chained or branched C3-C4 alkyl or cyclopropyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, -CORi, -COzRx, straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl.
wherein each B is independently -H, -F, -Cl, -Br, -I, - CN, -N02, -CORi, -C02Rι, -OCH3, -OCF3, -CF3, straight chained or branched Cχ-C7 alkyl, monofluoroalkyl or polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein the aryl, phenoxy or benzyloxy is optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -CORi, -CO^, -OCH3, -OCF3, -CF3 or straight chained or branched Cχ-C-7 alkyl.
29. The compound of claim 28, wherein W is
Figure imgf000759_0001
30. The compound of claim 29, wherein Ri is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, straight chained or branched Cχ-C7 alkyl.
31. The compound of claim 30, wherein R2 is isopropyl.
32. The compound of claim 31, wherein the compound has the structure :
Figure imgf000760_0001
33. The compound of claim 31, wherein the compound has the structure:
Figure imgf000760_0002
34. A compound having the structure:
Figure imgf000760_0003
wherein Ri is hydrogen, straight chained or branched C - C7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more - F, -Cl, -Br, -CN, -N02, -CF3, -OCH3, straight chained or branched Cι~C3 alkyl;
wherein R2 is straight-chained or branched- C3-C4 alkyl or cyclopropyl ;
wherein R3 is -H, -F, -Cl, -Br, -I, -CN, -N02, -CF3, OCH3, or straight chained or branched C1-C3 alkyl, monofluoroalkyl or polyfluoroalkyl, or a phenyl ring fused to C6 and C7 of the indole moiety;
wherein R4 is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -N02, -CF3, straight chained or branched Cx-C3 alkyl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl ; and
wherein n is an integer from 2 to 4 inclusive.
35. The compound of claim 34, wherein R3 is -H, -F, -Cl, -Br, -I, -CN, -N02, -0CF3 or -OCH3; and
wherein R4 is hydrogen or phenyl optionally substituted with one or more -F, -Cl or -CF3.
36. The compound of claim 35, wherein Rx is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, -N02, -CF3, -OCH3 or straight chained or branched Cχ-C3 alkyl;
37. The compound of claim 36, wherein R2 is isopropyl.
38. The compound of claim 37, wherein the compound has the structure:
Figure imgf000762_0001
39. The compound of claim 37, wherein the compound has the structure:
Figure imgf000762_0002
40. The compound of claim 37, wherein the compound has the structure:
Figure imgf000762_0003
41. A compound having the structure
Figure imgf000762_0004
wherein each Rx is independently hydrogen or CH3;
wherein R2 is- straight-chained or branched Cι-C4 alkyl or cyclopropyl;
wherein R3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenenedioxy group or one or more -F or -Cl;
wherein A is -H, -F, -Cl, -Br, -CN, -N02, straight chained or branched Cι-C7 alkyl, monofluoroalkyl or polyfluoroalkyl ;
wherein X is (CH2)2, C0CH2 or CONH;
42. The compound of claim 41, wherein R3 is phenyl optionally substituted with one or more -F; and
wherein A is hydrogen.
43. The compound of claim 42, wherein X is CONH.
44. The compound of claim 43, wherein R2 is methyl.
45. The compound of claim 44, wherein the compound has the structure:
Figure imgf000764_0001
46. The compound of claim 44, wherein the compound has the structure :
Figure imgf000764_0002
wherein each Y is independently hydrogen or -F
47. The compound of claim 4'6, wherein the compound has the structure :
Figure imgf000764_0003
48. The compound of claim 46, wherein the compound has the structure :
Figure imgf000765_0001
49. The compound of claim 41, wherein R3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl .
50. The compound of claim 49, wherein the compound has the structure :
Figure imgf000765_0002
wherein each Y is independently hydrogen or -F.
51. The compound of claim 50, wherein the compound has the structure:
Figure imgf000766_0001
52. A compound of claims 1 to 51, wherein the compound is enantiomerically pure.
53. A compound of claims 1 to 51, wherein the compound is diastereomerically pure.
54. The compound of claims 52 and 53, wherein the compound is enantiomerically and diastereomerically pure .
55. A pharmaceutical composition comprising a therapeutically amount of a compound of any of claims 1 to 51 and a pharmaceutically acceptable carrier.
56. The pharmaceutical composition of claim 55, wherein the amount of the compound is from about 0. Olmg to about 500mg.
57. The pharmaceutical composition of claim 56, wherein the amount of the compound is from about 0. lmg to about 60mg.
58. The pharmaceutical composition of claim 57, wherein the amount of the compound is from about lmg to about 2Omg.
59. The pharmaceutical composition of claim 55, wherein the carrier is a liquid and the composition is a solution.
60. The pharmaceutical composition of claim 55, wherein the carrier is a solid and the composition is a tablet.
61. The pharmaceutical composition of claim 55, wherein the carrier is a gel and the composition is a suppository.
62. A process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of claims 1 to 51 and a pharmaceutically acceptable carrier.
63. A method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of any of claims 1 to 51.
64. The method of claim 63, wherein the therapeutically effective amount is between about 0.03 and about 1000 mg per day.
65. The method of claim 64, wherein the therapeutically effective amount is between about 0.30 and about 300 mg per day.
66. The method of claim 65, wherein the therapeutically effective amount is between about 1.0 and about 100 mg per day.
67. The method of claim 63, wherein the disorder is depression.
68. The method of claim 63, wherein the disorder is anxiety.
69. The method of claim 63, wherein the disorder is obesity.
70. The method of claim 63, wherein the disorder is urge incontinence.
71. A method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to reduce the body mass of the subject.
72. A method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's depression.
73. A method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of any of .claims 1 to 51 effective to treat the subject's anxiety.
74. A method of alleviating urge urinary incontinence in a subject suffering from an overactive bladder, which comprises administering to the subject an amount of the compound of any of claims 1 to 51 effective to alleviate the subject's urge urinary incontinence.
74. A method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to induce weight loss in the subject.
75. A method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to maintain such weight loss in the subject .
76. A method of treating overactive bladder in a subject, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's overactive bladder.
78. A method of treating a disorder in a subject, wherein the symptoms of the subject can be alleviated by treatment with an MCHl antagonist, wherein the MCHl antagonist is the compound of any of claims 1 to 51.
79. A method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject an amount of an MCHl antagonist- effective to alleviate the symptoms, wherein the MCHl antagonist is the compound of any of claims 1 to 51.
PCT/US2002/021063 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists WO2003004027A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
UA2004010518A UA75416C2 (en) 2002-01-09 2002-03-07 Substituted aniline piperidines as selective antagonists for mch
NZ530221A NZ530221A (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as MCH selective antagonists
KR10-2004-7000087A KR20040027870A (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists
BR0210869-0A BR0210869A (en) 2001-07-05 2002-07-03 Compound, pharmaceutical composition, process of preparing a pharmaceutical composition, methods of treating an individual suffering from a disorder, depression and anxiety, obesity, overactive bladder and a disorder in an individual, reducing an individual's body mass and relieve urinary urge incontinence and the symptoms of a disorder in an individual
IL15969702A IL159697A0 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists
HU0401880A HUP0401880A2 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists, pharmaceutical compositions containing them and their use
JP2003510038A JP2004536104A (en) 2001-07-05 2002-07-03 Substituted aniline-piperidine derivatives as MCH selective antagonists
MXPA03011886A MXPA03011886A (en) 2001-07-05 2002-07-03 Composite dosage forms having an inlaid portion.
CA002454613A CA2454613A1 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists
AU2002316531A AU2002316531B8 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as MCH selective antagonists
EP02746843A EP1411942A4 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists
EA200400146A EA005934B1 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists
US10/345,063 US7105544B2 (en) 2001-07-05 2003-01-14 Substituted alkyl amido piperidines
IS7085A IS7085A (en) 2001-07-05 2003-12-18 Substituted anilinic piperidine as MCH selective antagonist
NO20040028A NO20040028L (en) 2001-07-05 2004-01-05 Substituted aniline piperidines as MCH-selective antagonists
US10/753,057 US7199135B2 (en) 2001-07-05 2004-01-06 Substituted alkyl amido piperidines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89979401A 2001-07-05 2001-07-05
US09/899,794 2001-07-05
US4258202A 2002-01-09 2002-01-09
US10/042,582 2002-01-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/345,063 Continuation-In-Part US7105544B2 (en) 2001-07-05 2003-01-14 Substituted alkyl amido piperidines
US10/753,057 Continuation-In-Part US7199135B2 (en) 2001-07-05 2004-01-06 Substituted alkyl amido piperidines

Publications (1)

Publication Number Publication Date
WO2003004027A1 true WO2003004027A1 (en) 2003-01-16

Family

ID=26719414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021063 WO2003004027A1 (en) 2001-07-05 2002-07-03 Substituted anilinic piperidines as mch selective antagonists

Country Status (15)

Country Link
EP (1) EP1411942A4 (en)
JP (1) JP2004536104A (en)
KR (1) KR20040027870A (en)
CN (1) CN1671386A (en)
CA (1) CA2454613A1 (en)
CO (1) CO5670352A2 (en)
EA (1) EA005934B1 (en)
HU (1) HUP0401880A2 (en)
IL (1) IL159697A0 (en)
IS (1) IS7085A (en)
MX (1) MXPA03011886A (en)
NO (1) NO20040028L (en)
NZ (1) NZ530221A (en)
PL (1) PL366624A1 (en)
WO (1) WO2003004027A1 (en)

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
FR2850379A1 (en) * 2003-01-28 2004-07-30 Aventis Pharma Sa New N-(hetero)aryl-pyrrole and -pyrazole derivatives, are tubulin polymerization inhibitors useful as anticancer medicaments
WO2004069798A1 (en) * 2003-02-10 2004-08-19 Banyu Pharmaceutical Co.,Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
WO2004078732A1 (en) * 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
WO2004064764A3 (en) * 2003-01-14 2005-01-13 Synaptic Pharma Corp Substituted alkyl amido piperidines
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2006010446A2 (en) * 2004-07-27 2006-02-02 7Tm Pharma A/S Medicinal use of receptor ligands
US7067534B1 (en) 2001-07-05 2006-06-27 H. Lundbeck A/S Substituted anilinic piperidines as MCH selective antagonists
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
US7199135B2 (en) 2001-07-05 2007-04-03 H. Lundbeck A/S Substituted alkyl amido piperidines
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7335665B2 (en) 2002-07-03 2008-02-26 H - Lundbeck A/S Spirocyclic piperidines as MCH1 antagonists and uses thereof
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US7378435B2 (en) 2005-10-11 2008-05-27 Hoffmann-La Roche Inc. Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives
US7388025B2 (en) 2005-11-09 2008-06-17 Hoffman-La Roche Inc. 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
US7414061B2 (en) 2005-12-27 2008-08-19 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazole derivatives
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US7473698B2 (en) 2002-07-03 2009-01-06 H. Lunbeck A/S Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof
CN100448870C (en) * 2003-05-21 2009-01-07 万有制药株式会社 2-aminoquinoline derivative
US7541372B2 (en) 2005-12-23 2009-06-02 Hoffman-La Roche Inc. Aryl-isoxazolo-4-yl-oxadiazole derivatives
US7544704B2 (en) 2006-05-31 2009-06-09 Hoffmann-La Roche Inc. Aryl-4-ethynyl-isoxazole derivatives
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7585874B2 (en) 2006-01-17 2009-09-08 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US7851469B2 (en) 2007-06-22 2010-12-14 Hoffmann-La Roche Inc. Isoxazole-imidazole derivatives
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8163728B2 (en) 2009-05-05 2012-04-24 Hoffmann-La Roche Inc. Pyrazoles
US8173652B2 (en) 2009-02-19 2012-05-08 Hoffmann-La Roche Inc. Isoxazole-isoxazoles and isoxazole-isothiazoles
US8178522B2 (en) 2009-05-05 2012-05-15 Hoffmann-La Roche Inc. Thiazoles
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8357703B2 (en) 2009-05-07 2013-01-22 Hoffmann-La Roche Inc. Pyridines
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8410104B2 (en) 2009-05-05 2013-04-02 Hoffmann-La Roche Inc. Pyridazines
US8415379B2 (en) 2009-05-05 2013-04-09 Hoffmann-La Roche Inc. Pyridines
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016016238A1 (en) * 2014-07-29 2016-02-04 Universite De Lille 2 Droit Et Sante 2-oxo-3,4-dihydropyridine-5-carboxylates and their use
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9650349B2 (en) 2007-08-27 2017-05-16 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
CN106986882A (en) * 2017-05-25 2017-07-28 河南省商业科学研究所有限责任公司 The method of the thioxene of one-step synthesis 3,4 [2,3 b] bithiophene
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP2465850B1 (en) * 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
WO2008140239A1 (en) * 2007-05-11 2008-11-20 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
US20100324049A1 (en) * 2007-09-27 2010-12-23 Makoto Ando Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor
MA33416B1 (en) * 2009-07-06 2012-07-03 Syngenta Participations Ag Pesticide compounds
RU2436786C1 (en) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Substituted indoles, antiviral active component, synthesis and application method
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9771316B2 (en) 2013-01-21 2017-09-26 Osaka University Phenoxyalkylamine compound
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
WO2015091939A1 (en) * 2013-12-20 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Piperidine derivatives having multimodal activity against pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059971A1 (en) * 1998-05-18 1999-11-25 Pfizer Inc. Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
WO2002002744A2 (en) * 2000-07-05 2002-01-10 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
US6441000B1 (en) * 1999-05-28 2002-08-27 Pfizer Inc Compounds useful in therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059971A1 (en) * 1998-05-18 1999-11-25 Pfizer Inc. Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
US6441000B1 (en) * 1999-05-28 2002-08-27 Pfizer Inc Compounds useful in therapy
WO2002002744A2 (en) * 2000-07-05 2002-01-10 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1411942A4 *

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067534B1 (en) 2001-07-05 2006-06-27 H. Lundbeck A/S Substituted anilinic piperidines as MCH selective antagonists
US7199135B2 (en) 2001-07-05 2007-04-03 H. Lundbeck A/S Substituted alkyl amido piperidines
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
US7473698B2 (en) 2002-07-03 2009-01-06 H. Lunbeck A/S Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof
US7335665B2 (en) 2002-07-03 2008-02-26 H - Lundbeck A/S Spirocyclic piperidines as MCH1 antagonists and uses thereof
EA009818B1 (en) * 2003-01-14 2008-04-28 Х. Лундбекк А/С Substituted alkyl amido piperidines
WO2004064764A3 (en) * 2003-01-14 2005-01-13 Synaptic Pharma Corp Substituted alkyl amido piperidines
WO2004078732A1 (en) * 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
FR2850379A1 (en) * 2003-01-28 2004-07-30 Aventis Pharma Sa New N-(hetero)aryl-pyrrole and -pyrazole derivatives, are tubulin polymerization inhibitors useful as anticancer medicaments
AU2004209505B2 (en) * 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
JPWO2004069798A1 (en) * 2003-02-10 2006-05-25 萬有製薬株式会社 Melanin-concentrating hormone receptor antagonist containing piperidine derivative as active ingredient
WO2004069798A1 (en) * 2003-02-10 2004-08-19 Banyu Pharmaceutical Co.,Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
CN100448870C (en) * 2003-05-21 2009-01-07 万有制药株式会社 2-aminoquinoline derivative
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2006010446A3 (en) * 2004-07-27 2006-05-18 7Tm Pharma As Medicinal use of receptor ligands
WO2006010446A2 (en) * 2004-07-27 2006-02-02 7Tm Pharma A/S Medicinal use of receptor ligands
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7378435B2 (en) 2005-10-11 2008-05-27 Hoffmann-La Roche Inc. Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
US7388025B2 (en) 2005-11-09 2008-06-17 Hoffman-La Roche Inc. 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US7541372B2 (en) 2005-12-23 2009-06-02 Hoffman-La Roche Inc. Aryl-isoxazolo-4-yl-oxadiazole derivatives
US7956074B2 (en) 2005-12-23 2011-06-07 Hoffman-La Roche Inc. Aryl-isoxazolo-4-yl-oxadiazole derivatives
US7414061B2 (en) 2005-12-27 2008-08-19 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazole derivatives
US7585874B2 (en) 2006-01-17 2009-09-08 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives
US7544704B2 (en) 2006-05-31 2009-06-09 Hoffmann-La Roche Inc. Aryl-4-ethynyl-isoxazole derivatives
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7851469B2 (en) 2007-06-22 2010-12-14 Hoffmann-La Roche Inc. Isoxazole-imidazole derivatives
US9650349B2 (en) 2007-08-27 2017-05-16 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
US10053467B2 (en) 2007-08-27 2018-08-21 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8173652B2 (en) 2009-02-19 2012-05-08 Hoffmann-La Roche Inc. Isoxazole-isoxazoles and isoxazole-isothiazoles
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
US8410104B2 (en) 2009-05-05 2013-04-02 Hoffmann-La Roche Inc. Pyridazines
US8163728B2 (en) 2009-05-05 2012-04-24 Hoffmann-La Roche Inc. Pyrazoles
US8415379B2 (en) 2009-05-05 2013-04-09 Hoffmann-La Roche Inc. Pyridines
US8178522B2 (en) 2009-05-05 2012-05-15 Hoffmann-La Roche Inc. Thiazoles
US8357703B2 (en) 2009-05-07 2013-01-22 Hoffmann-La Roche Inc. Pyridines
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016016238A1 (en) * 2014-07-29 2016-02-04 Universite De Lille 2 Droit Et Sante 2-oxo-3,4-dihydropyridine-5-carboxylates and their use
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN106986882A (en) * 2017-05-25 2017-07-28 河南省商业科学研究所有限责任公司 The method of the thioxene of one-step synthesis 3,4 [2,3 b] bithiophene
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
NO20040028L (en) 2004-03-04
CA2454613A1 (en) 2003-01-16
CO5670352A2 (en) 2006-08-31
CN1671386A (en) 2005-09-21
EP1411942A1 (en) 2004-04-28
EP1411942A4 (en) 2005-01-26
JP2004536104A (en) 2004-12-02
PL366624A1 (en) 2005-02-07
HUP0401880A2 (en) 2005-01-28
AU2002316531B2 (en) 2007-09-13
MXPA03011886A (en) 2005-03-07
IS7085A (en) 2003-12-18
NZ530221A (en) 2006-03-31
EA005934B1 (en) 2005-08-25
IL159697A0 (en) 2004-06-20
KR20040027870A (en) 2004-04-01
EA200400146A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
US6727264B1 (en) Substituted anilinic piperidines as MCH selective antagonists
EP1411942A1 (en) Substituted anilinic piperidines as mch selective antagonists
US5116846A (en) N-aralkyl piperidine derivatives as psychotropic drugs
US7335665B2 (en) Spirocyclic piperidines as MCH1 antagonists and uses thereof
US5864039A (en) Benzoic acid compounds and use thereof as medicaments
KR100384906B1 (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
US7105544B2 (en) Substituted alkyl amido piperidines
US7199135B2 (en) Substituted alkyl amido piperidines
US7473698B2 (en) Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof
AU2002316531B8 (en) Substituted anilinic piperidines as MCH selective antagonists
EP0873990A1 (en) Benzoic acid compounds and medicinal use thereof
AU2002316531A1 (en) Substituted anilinic piperidines as MCH selective antagonists
US20050154020A1 (en) 4-Aryl piperidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 530221

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/09860

Country of ref document: ZA

Ref document number: 200309860

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2454613

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003510038

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002316531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 159697

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020047000087

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002746843

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400146

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 230/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20028172124

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002746843

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500016

Country of ref document: PH

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 530221

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12007501240

Country of ref document: PH